{"text": "A.泌尿生殖道感染由于此类药物促进大量葡萄糖从尿液排出，这就增加了泌尿生殖道局部的葡萄糖浓度，导致发生细菌和霉菌感染的机会增加。临床研究数据显示，SGLT-2抑制剂治疗后生殖道感染发生率为4.8%~5.7%，但多为轻到中度感染，常规抗感染治疗有效；女性较男性生殖道感染发生率稍高；有感染疾病史者感染率升高，且感染后需抗感染治疗。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "生殖道", "subject_type": "患病部位", "object": {"@value": "泌尿生殖道感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "生殖道", "subject_type": "患病部位", "object": {"@value": "生殖道感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "生殖道", "subject_type": "患病部位", "object": {"@value": "生殖道感染"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)二线用药：当二甲双胍最佳有效剂量单药治疗仍无法控糖达标时，需增加其他类型降糖药，磺脲类药物是备选之一。需要指出的是，尽管磺脲类药物可引起患者体重增加，但超重或肥胖并不是其治疗的禁忌证。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "3.胰岛素促泌剂的联合用药原则：2型糖尿病患者，若胰岛素促泌剂单药治疗血糖控制不佳，应与其他降糖药物如双胍类、α-糖苷酶抑制剂或噻唑烷二酮类药物联用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "噻唑烷二酮类药物", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "α-糖苷酶抑制剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "双胍类", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.精神-心理支持：肥胖者常见的心理因素如压力、沮丧、抑郁容易导致过度进食，并引发罪恶感面陷人恶性循环中。精神-心理支持中需要医务人员能识别干扰减重管理成功的心理或精神疾患，并请专科医师进行治疗。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "精神-心理支持", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.二甲双胍在改善血脂方面的作用：二甲双胍能改善脂肪的合成与代谢。多项研究显示，二甲双胍可降低T2DM患者血浆TG、LDL-C及TC水平，但对HDL-C改变不明显。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血浆TG", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "TC", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HDL-C", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "强化血压控制还可使心血管病终点事件的风险下降20%~30%。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "心血管病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "一、2型糖尿病合并慢性肾脏病的流行病学", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "推荐3：在确诊T2DM的同时均应检测患者的空血脂(包括TG、TC、HDL-C和LDL-C)(推荐；E级证据)。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "空血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "TG", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "TC", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HDL-C", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.糖尿病视网膜病变：糖尿病视网膜病变常早于糖尿病肾病发生，大部分糖尿病肾病患者患有糖尿病视网膜病变，但在透析的糖尿病肾病患者中，糖尿病视网膜病变的发病率反而减少，糖尿病视网膜病变被NKF/KDOQI指南作为2型糖尿病患者糖尿病肾病的诊断依据之一。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "透析", "subject_type": "非药治疗", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(4)慢性肾脏病合并HUA：治疗时机及靶目标值同慢性尿酸盐肾病。慢性肾脏病患者的HUA治疗药物根据原发病、并发症及肾功能情况进行选择。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "慢性尿酸盐肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "社会因素是决定血糖控制目标的另一个重要且必须考虑的问题，对美国不同种族的糖尿病患者在降糖治疗过程中的依从性和血糖控制情况的调查表明，那些医疗保障差的患者，治疗的依从性、血糖的自我管理能力和血糖的控制水平明显下降。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "英国国家卫生与临床优化研究所(NICE)指南认为肥胖管理包括节食、运动、行为改变，且需要长期随访并推荐低脂、高纤维饮食，增加体力活动，避免久坐，规律监测体重和腰围变化。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "节食", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "运动", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "行为改变", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "低脂", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "高纤维饮食", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "体力活动", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "避免久坐", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "相较于2011版《专家共识》，本共识中我们对下列内容进行了更新：(1)血脂异常特点及流行病学中补充了中国血脂研究的数据。(2)对于国外指南建议非空腹血脂监测，本共识未做推荐。(3)ASCVD危险度评估和治疗目标中更新危险因素。(4)对T2DM患者的血脂管理的流程图进行合并，更简单明了，易于操作。(5)基于疗效、耐受性及治疗费用的考虑，中国证据显示中等强度他汀类药物治疗适合于我国多数T2DM合并血脂异常患者。(6)经过中等强度的他汀类药物治疗后非高密度脂蛋白胆固醉(non-HDL-C)仍不达标者，特别是三酰甘油(TG)≥2.3mmol/L，可在他汀类药物治疗基础上加用贝特类药物，如非诺贝特或苯扎贝特，或高纯度鱼油。(7)胆固醇吸收抑制剂依折麦布和人类前蛋白转化酶枯草溶菌素9(PCSK9)抑制剂可作为他汀不耐受或单药治疗低密度脂蛋白胆固醇(LDL-C)不能达标时的联合用药。(8)对于T2DM患者特殊情况下的血脂管理，如合并肝病或肝功能异常、合并慢性肾脏病(CKD)、老年T2DM时的处理进行了更新。(9)评价了长期服用他汀类药物对血糖影响和增加新发糖尿病风险的获益和风险。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "中等强度他汀类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "肝病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "肝功能异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "慢性肾脏病(CKD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病(CKD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病(CKD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "新发糖尿病", "subject_type": "不良反应", "object": {"@value": "他汀类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "对血糖影响", "subject_type": "不良反应", "object": {"@value": "他汀类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "二、2型糖尿病合并慢性肾脏病的诊断与分期", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.二甲双胍是否具有心血管保护作用：二甲双胍通过有效改善糖尿病和非糖尿病患者的IR，降低基础和负荷后胰岛素水平，起到直接或间接的心血管保护作用。前瞻性糖尿病研究UKPDS结果显示，使用二甲双胍的肥胖T2DM患者的全因死亡风险相对下降35%、心肌梗死风险下降39%(I级)；UKPDS 10年随访显示，使用二甲双胍治疗带来的大血管并发症及死亡风险的获益具有延续效应，且其降低死亡和心肌梗死的作用优于磺脲类和胰岛素(Ⅰ级)。REACH研究是一项全球、多中心、随机、双盲研究，结果提示二甲双胍治疗2年，全因死亡相对风险下降24%。HOME研究结果提示，二甲双胍联合胰岛素比单用胰岛素可以减少大血管事件风险。意大利多中心队列研究将纳入的T2DM患者(平均67岁)按年龄及eGFR分层，结果提示，与其他降糖药物治疗相比，二甲双胍组心血管事件发生风险降低。SPREAD是一项在中国进行的多中心、随机、双盲、安慰剂对照研究，结果显示，对于有冠心病病史的T2DM患者，与格列吡嗪组相比，二甲双胍组的主要终点事件发生风险降低46%(Ⅰ级)。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "IR", "subject_type": "发病机制", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "IR", "subject_type": "发病机制", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "大血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "eGFR", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列吡嗪", "subject_type": "药品名称", "object": {"@value": "冠心病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "冠心病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列吡嗪", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(4)利尿剂：60%~90%糖尿病肾病合并高血压的患者使用噻嗪类或袢利尿剂。GUARD临床研究表明ACEI与氢氯噻嗪联合用药在降低患者尿蛋白水平方面优于ACEI与CCB组合。对收缩期高血压患者应用联合治疗以预防心血管事件(ACCOMPLISH)临床研究的结果却表明，在糖尿病高血压高危患者中，ACEI与氢氯噻嗪联合用药对减缓患者肾小球滤过率下降的作用不及ACEI与CCB组合。虽然噻嗪类或袢利尿剂作为联合用药是否强于CCB存在争议，多数糖尿病肾病合并高血压的患者，尤其血压高于130/80mmHg者需要一种以上药物控制血压，故推荐噻嗪类或袢利尿剂作为联合用药。氢氯噻嗪促进钾钠排泄，造成低钠血症时可引起反射性肾素和醛固酮分泌，在无尿或肾功能损害患者的效果差，大剂量使用易导致药物蓄积，增加毒性，故其慎用于该类患者，应从小剂量每日25mg开始。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "噻嗪类", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "袢利尿剂", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "噻嗪类", "subject_type": "药品名称", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "袢利尿剂", "subject_type": "药品名称", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "收缩期", "subject_type": "分期分型", "object": {"@value": "收缩期高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ACEI", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "氢氯噻嗪", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ACEI", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "CCB", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肾小球滤过率", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ACEI", "subject_type": "药品名称", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "氢氯噻嗪", "subject_type": "药品名称", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ACEI", "subject_type": "药品名称", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "CCB", "subject_type": "药品名称", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肾小球滤过率", "subject_type": "检查指标", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "噻嗪类", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "袢利尿剂", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "噻嗪类", "subject_type": "药品名称", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "袢利尿剂", "subject_type": "药品名称", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低钠血症", "subject_type": "不良反应", "object": {"@value": "氢氯噻嗪"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "25mg", "subject_type": "用药剂量", "object": {"@value": "氢氯噻嗪"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "氢氯噻嗪", "subject_type": "药品名称", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.5 其他糖尿病心肌病变可在代谢紊乱及微血管病变的基础上引发心肌广泛局灶性坏死，出现亚临床的心功能异常，最终进展为心力衰竭、心律失常及心源性休克，重症患者甚至猝死。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "糖尿病心肌病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "心肌广泛局灶性坏死", "subject_type": "临床表现", "object": {"@value": "糖尿病心肌病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "心功能异常", "subject_type": "临床表现", "object": {"@value": "糖尿病心肌病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "微血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "建议：(1)格列喹酮对2型糖尿病患者各项血糖指标均有很好的控制作用，可作为2型糖尿病降糖选择的一线用药之一；对于主要以PPG升高为主的，或新发2型糖尿病患者，格列喹酮可作为磺脲类药物的优先选择。(2)格列喹酮临床处方剂量范围为15~180mg/d，根据长期临床使用经验，在综合考虑患者耐受程度及经济情况等条件的前提下，推荐使用格列喹酮单药治疗90mg/d(30mg，Tid)能够尽快使血糖达标；若患者控糖效果不理想，可综合考虑患者基本情况增加临床处方剂量，推荐最大剂量180mg/d(60mg，Tid)。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "PPG", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "15~180mg/d", "subject_type": "用药剂量", "object": {"@value": "格列喹酮"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "90mg/d(30mg，Tid)", "subject_type": "用药剂量", "object": {"@value": "格列喹酮"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "180mg/d(60mg，Tid)", "subject_type": "用药剂量", "object": {"@value": "格列喹酮"}, "object_type": {"@value": "药品名称"}}]}
{"text": "血糖波动对于糖尿病慢性并发症的危害甚至比持续性高血糖更为严重，血糖波动通过激活氧化应激通路，损伤内皮细胞功能，加剧慢性炎症状态等造成血管损伤，增加糖尿病并发症的发生风险。血糖波动与糖尿病慢性并发症的发生和发展密切相关：", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病慢性并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病慢性并发症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "胰岛素@观察病情，临床症状缓解，过渡至皮下胰岛素注射，应避免低血糖发生。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "皮下胰岛素注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "糖尿病高危足糖尿病患者未出现足溃疡但存在周围神经病变，不管是否存在足畸形或周围动脉病变或足溃疡史或截肢(趾)史。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "足溃疡", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "足畸形"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围动脉", "subject_type": "患病部位", "object": {"@value": "周围动脉病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "足溃疡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病高危足"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "随着信息化技术和互联网技术的发展，智能化的远程教育服务应用广泛。基于指南及专家共识构建知识库，设置健康评估提醒功能，智能化辅助识别潜在危险因素，在多学科管理患者的同时，将自我管理处方加人大数据和人工智能技术，实现线上线下、院内居家闭环管理的智能化处方系统应运而生。美国移动医疗公司WellDoc研发了首个获美国食品药品监督管理局批准的可帮助医师优化开具处方的手机应用BlueStar。在一项随机对照试验中，验证了其对糖化血红蛋白的降低效果达2.03%。So等开发了交互式虚拟网络平台[亚洲糖尿病联合评估(Joint Asia Diabetes Evaluation，JADE)].并证实亚洲不同国家和地区使用JADE平台的可行性和有效性。随着国内互联网技术的进步及大数据时代的快速发展，智能化处方系统(控糖尿病智能管理网络终端、APP端、微信端)也已在多家医院投人使用，且该系统通过与中国疾病预防控制中心等机构临床研究证实其有助于提高糖尿病患者血糖监测、有效运动及规律服药等行为的依从性.血糖控制效果明显。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖监测", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.了解患者自身糖调节能力：对新就诊的老年糖尿病患者，有条件时可与血糖检测同步测定患者的血浆胰岛素和/或C肽浓度，结合病程、血糖变化情况了解患者胰岛β细胞分泌水平，有助于选择合适的降糖药(IV)。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血浆胰岛素", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "C肽浓度", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "主要降低餐后血糖并且低血糖的风险较低，对于以碳水化合物为主要能量来源的老年糖尿病患者更为适合(B)。目前阿卡波糖是国内唯一说明书中标明有糖尿病前期服用适应证的降糖药物(A)。服药后的胃肠道反应可能会影响这类药物的使用，采用从小剂量开始，逐渐加量可以有效减少不良反应。单独服用本类药物通常不会发生低血糖。合用α-糖苷酶抑制剂的患者如果出现低血糖，治疗时需使用葡萄糖制剂，食用蔗糖或淀粉类食物纠正低血糖的效果差。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "餐后血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿卡波糖", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "α-糖苷酶抑制剂"}, "object_type": {"@value": "药品名称"}}]}
{"text": "1.糖尿病：若有代谢紊乱症状(包括多饮、多尿、多食和不明原因的体重下降)，一次FPG≥7.0mmol/L或2hPG≥11.1mmol/L或随机血糖≥11.1mmol/L，即可诊断糖尿病。无糖尿病症状者，需两次血糖值达到上述诊断标准(表1)。", "spo_list": [{"Combined": false, "predicate": "发病机制", "subject": "代谢紊乱", "subject_type": "发病机制", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "多饮", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "多尿", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "多食", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "体重下降", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "2hPG", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "随机血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.根据患者的BMI和临床情况来判断是否行手术治疗：(1)积极手术：BMl≥32kg/m2，无论是否存在其他合并症(阻塞性睡眠呼吸暂停综合征、非酒精性脂肪性肝炎、高尿酸血症、多囊卵巢综合征、肾功能异常等)；(2)慎重手术：BMI28~32kg/m2，至少符合额外的2个代谢综合征组分，或存在合并症；(3)暂不推荐：BMI25~28kg/m2。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "非酒精性脂肪性肝炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "卵巢", "subject_type": "患病部位", "object": {"@value": "多囊卵巢综合征"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能异常"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "快速建议指南认为DPP-4抑制剂可用于超重/肥胖2型糖尿病患者的降糖治疗，理由是DPP-4抑制剂并不影响患者的体重。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "高TG血症可引发急性胰腺炎，因此若患者TG>5.6mmol/L时，可在生活方式干预的基础上首选降TG药物治疗(如贝特类，或高纯度鱼油0.5~1.0g/次)，以减少发生急性胰腺炎的风险(推荐；C级证据)。", "spo_list": [{"Combined": false, "predicate": "患病病因", "subject": "高TG血症", "subject_type": "患病病因", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "胰腺", "subject_type": "患病部位", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "急性", "subject_type": "分期分型", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "TG", "subject_type": "检查指标", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "降TG药物", "subject_type": "药品名称", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝特类", "subject_type": "药品名称", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "0.5~1.0g/次", "subject_type": "用药剂量", "object": {"@value": "高纯度鱼油"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "高纯度鱼油", "subject_type": "药品名称", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "胰腺", "subject_type": "患病部位", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "急性", "subject_type": "分期分型", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)血压控制：2型糖尿病患者每次随访均需监测血压。对于糖尿病合并高血压的患者，除接受生活方式干预外，需立即行药物治疗，以及时达到血压控制目标，无DKD的糖尿病患者血压控制目标为≤140/90mmHg，有DR、DKD或脑血管损伤患者的血压控制目标为≤130/80mmHg。降压药物的选择如下：血管紧张素转化酶抑制剂/血管紧张素Ⅱ受体拮抗剂(ACEI/ARB)、噻嗪类利尿剂或钙通道阻滞剂(CCB)，通常需联用多种降压药物。对于微量白蛋白/肌酐比值(UACR)≥300mg/g肌酐或30~299mg/g肌酐的糖尿病患者，推荐采用最大可耐受剂量ACEI或ARB作为高血压治疗的一线用药。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "DR"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "DKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脑血管", "subject_type": "患病部位", "object": {"@value": "脑血管损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "脑血管损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ACEI", "subject_type": "药品名称", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ARB", "subject_type": "药品名称", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "微量白蛋白/肌酐比值(UACR)", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "相比于传统磺脲类药物(如氯磺丙脲、格列本脲)，新型磺脲类药物(如格列美脲)和剂型(如格列齐特缓释片)对患者体重影响较小，而且通过与二甲双胍、阿卡波糖、SGLT一2抑制剂等具有减轻体重作用的药物联用，能够减少磺脲类药物的体重增加风险。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "GLP-1受体激动剂禁用于对该类产品活性成分或任何其他辅料过敏者。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "过敏", "subject_type": "不良反应", "object": {"@value": "GLP-1受体激动剂"}, "object_type": {"@value": "药品名称"}}]}
{"text": "神经病变表现：患肢皮肤干而无汗，肢端刺痛、灼痛、麻木、感觉减退或缺失，呈袜套样改变，行走时脚踩棉絮感", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "皮肤干", "subject_type": "临床表现", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "无汗", "subject_type": "临床表现", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "肢端刺痛", "subject_type": "临床表现", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "灼痛", "subject_type": "临床表现", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "麻木", "subject_type": "临床表现", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "感觉减退或缺失", "subject_type": "临床表现", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "呈袜套样改变", "subject_type": "临床表现", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "行走时脚踩棉絮感", "subject_type": "临床表现", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "西洛他唑的推荐剂量为50~100mg/次，2次/d。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "2次/d", "subject_type": "用药频率", "object": {"@value": "西洛他唑"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "50~100mg/次", "subject_type": "用药剂量", "object": {"@value": "西洛他唑"}, "object_type": {"@value": "药品名称"}}]}
{"text": "5.肝功能不全的T2DM患者使用二甲双胍应注意的问题：二甲双胍不经过肝脏代谢，无肝脏毒性。目前，肝功能不全患者使用二甲双胍的临床资料较少。肝功能严重受损会明显限制乳酸的清除能力，建议血清转氨酶超过3倍正常上限或有严重肝功能不全的患者应避免使用二甲双胍。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能严重受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血清转氨酶", "subject_type": "检查指标", "object": {"@value": "肝功能严重受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "严重肝功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "近年来，胰高血糖素样肽1类似物也开始广泛应用于临床，其不规范注射同样影响患者血糖达标情况。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "胰高血糖素样肽1类似物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "痛风@HUA患者突发足第一跖趾、踝、膝等单关节红、肿、热、痛，即应考虑痛风可能，长期反复发作的患者可逐渐累及上肢关节，伴有痛风石形成。根据病程，痛风可分为4期：(1) 无症状HUA期；(2) 痛风性关节炎急性发作期；(3)痛风性关节炎发作间歇期；(4)慢性痛风性关节炎期。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "足第一跖趾、踝、膝等单关节红、肿、热、痛", "subject_type": "临床表现", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足第一跖趾", "subject_type": "患病部位", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "踝", "subject_type": "患病部位", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "膝", "subject_type": "患病部位", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "单关节", "subject_type": "患病部位", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "上肢关节", "subject_type": "患病部位", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "无症状HUA期", "subject_type": "分期分型", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "痛风性关节炎急性发作期", "subject_type": "分期分型", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "痛风性关节炎发作间歇期", "subject_type": "分期分型", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性痛风性关节炎期", "subject_type": "分期分型", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "因此，尿白蛋白作为诊断依据时需进行长期随访、多次检测，结果重复时方可做出判定，且需排除其他可引起白蛋白尿的病因。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "尿白蛋白", "subject_type": "检查指标", "object": {"@value": "白蛋白尿"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "临床应用共识指出西格列汀在上市后发现有严重超敏反应，包括过敏反应、血管性水肿和剥脱性皮肤损害，如怀疑发生超敏反应时应停用；维格列汀尽管在临床中未观察到皮肤损伤发生率升高，但在合并糖尿病皮肤并发症的患者中经验有限，建议观察皮肤病变，如水疱、皮疹或溃疡等情况；阿格列汀在上市后发现严重皮肤不良反应，如怀疑发生严重过敏反应时应停用；沙格列汀上市后有报告严重超敏反应(包括速发过敏反应和血管性水肿)，怀疑时应停用；利格列汀在临床研究中也报告有高敏反应，如荨麻疹、血管性水肿、局部皮肤剥脱或支气管高敏反应。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "超敏反应", "subject_type": "不良反应", "object": {"@value": "西格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "过敏反应", "subject_type": "不良反应", "object": {"@value": "西格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "血管性水肿", "subject_type": "不良反应", "object": {"@value": "西格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "剥脱性皮肤损害", "subject_type": "不良反应", "object": {"@value": "西格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "超敏反应", "subject_type": "不良反应", "object": {"@value": "西格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "皮肤不良反应", "subject_type": "不良反应", "object": {"@value": "阿格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "过敏反应", "subject_type": "不良反应", "object": {"@value": "阿格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "超敏反应", "subject_type": "不良反应", "object": {"@value": "沙格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "速发过敏反应", "subject_type": "不良反应", "object": {"@value": "沙格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "血管性水肿", "subject_type": "不良反应", "object": {"@value": "沙格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "荨麻疹", "subject_type": "不良反应", "object": {"@value": "利格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "高敏反应", "subject_type": "不良反应", "object": {"@value": "利格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "血管性水肿", "subject_type": "不良反应", "object": {"@value": "利格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "局部皮肤剥脱", "subject_type": "不良反应", "object": {"@value": "利格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "支气管高敏反应", "subject_type": "不良反应", "object": {"@value": "利格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "皮肤", "subject_type": "患病部位", "object": {"@value": "糖尿病皮肤并发症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "基于GLP-1类降糖药物的应用是2型糖尿病治疗中的一个重要发展，其药物作用的特点弥补了传统降糖药物治疗中的一些不足之处。多项研究结果显示CLP-1受体激动剂具有葡萄糖浓度依赖性降低血糖作用的特点，低血糖发生率低，还可减轻体重、降低收缩压、减少心血管疾病危险因素。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "GLP-1类降糖药物", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "CLP-1受体激动剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "5.其他糖尿病相关周围神经病：糖尿病前周围神经病是糖耐量异常或空腹血糖受损相关的周围神经病，临床特点和DPN相似。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "糖耐量异常", "subject_type": "发病机制", "object": {"@value": "周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "糖耐量异常", "subject_type": "发病机制", "object": {"@value": "糖尿病前周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "空腹血糖受损", "subject_type": "发病机制", "object": {"@value": "周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "空腹血糖受损", "subject_type": "发病机制", "object": {"@value": "糖尿病前周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "糖尿病前周围神经病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.用化学方法或偏振光显微镜证实痛风石中含尿酸盐结晶。3，具备以下12项(临床、实验室、X线表现)中6项(1)急性关节炎发作>1次；(2)炎症反应在1d内达高峰；(3)单膝关节炎发作；(4)可见关节发红；(5)第一跖趾关节疼痛或肿胀；(6)单侧第一跖趾关节受累；(7)单侧跗骨关节受累；(8)可疑痛风石；(9)高尿酸血症；(10)不对称关节内肿胀(X线证实)；(11)无骨侵蚀的骨皮质下囊肿(X线证实)；(12)关节炎发作时关节液微生物培养阴性。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "关节", "subject_type": "患病部位", "object": {"@value": "急性关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "关节", "subject_type": "患病部位", "object": {"@value": "单膝关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "关节液微生物培养", "subject_type": "检查方法", "object": {"@value": "关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "关节", "subject_type": "患病部位", "object": {"@value": "关节炎"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)对于大多数的非内分泌科住院高血糖患者而言，胰岛素是控制血糖的首选治疗方法。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "因此中国2型糖尿病患者更应关注β细胞胰岛素分泌功能的异常。", "spo_list": [{"Combined": false, "predicate": "发病机制", "subject": "β细胞胰岛素分泌功能的异常", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病肾病的国外诊断标准有美国肾脏基金会(NKF)肾脏病预后质量倡议(K/DOQI)指南标准(2007年)和英国国民医疗服务(NHS)标准(2010年)。我国目前仍无统一的糖尿病肾病诊断标准，本共识推荐采用表3诊断标准，符合任何一项者可考虑为糖尿病肾脏病变(适用于1型及2型糖尿病)：", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "其他降糖药物在心力衰竭患者中应用的安全性尚待进一步评估。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "在胰岛素治疗期间，结合血糖监测结果，适时调整治疗方案和胰岛素剂量，以取得良好的血糖控制。对于不同的预混胰岛素治疗方案，其剂量调整方法有所不同，可参考每日2次预混胰岛素治疗方案(见表5)和1-2-3次预混胰岛素类似物治疗方案的剂量调整方法(见表6)，每3~5天调整1次，每次调整1~4IU，直至血糖达标。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "每日2次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1~4IU", "subject_type": "用药剂量", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1~4IU", "subject_type": "用药剂量", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "如无禁忌症，二甲双胍是T2DM药物治疗的首选药物，且应一直保留在糖尿病治疗方案中。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "自我血糖监测(self-monitoring of blood glucose，SMBG)是糖尿病管理中的重要组成部分，其结果有助于评估降糖治疗的效果并指导治疗方案的调整。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "自我血糖监测(self-monitoring of blood glucose，SMBG)", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "脉岛素@(3)对于急危重症患者，推荐采用持续静脉岛素输注，根据血糖波动情况随时调整胰岛素剂量；在打算改用胰岛素皮下注射时，需在停止胰岛素静脉输注前1~2h接受皮下注射。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "持续静脉岛素输注", "subject_type": "用药方法", "object": {"@value": "脉岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "皮下注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉输注", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "皮下注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "对于2型糖尿病患者而言，尽早启动胰岛素治疗能减轻胰岛β细胞的负荷，尽快纠正高血糖状态，迅速解除高糖毒性，改善胰岛素抵抗，保护甚至逆转残存β细胞功能。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "高糖毒性", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "基础胰岛素是T2DM管理中重要的降糖措施，基础胰岛素的及时起始和合理充分的剂量调整能改善T2DM患者的整体血糖控制，也为之后更复杂的基础联合餐时胰岛素的治疗方案奠定了基础。临床工作中我们需加强对患者的教育和管理，适时起始基础胰岛素治疗并根据血糖水平进行剂量调整，通过适当的血糖监测和随访，实现长期平稳的血糖控制，降低糖尿病并发症发生的风险，改善患者生活质量和延长寿命。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病并发症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "最近关于新诊断2型糖尿病患者的全国多中心研究显示，平均病程为8.1年的2型糖尿病患者神经病变的患病率为15.2%。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病患者的血糖控制可根据自我血糖监测(SMBG)的结果和HbA1c水平综合判断。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "自我血糖监测(SMBG)", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2013年美国关于成年人肥胖管理指南推荐，增加有氧运动(如快走)至每周150min以上(每天30min以上，每周的大多数天)；推荐更高水平的身体活动(每周200-300min)，以维持体重下降及防止减重后的体重反弹(长期，1年以上)", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "增加有氧运动(如快走)", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "身体活动(每周200-300min)", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "有明确大血管粥样硬化斑块形成的患者，尤其是有下肢动脉闭塞症者，可酌情定期静脉输注具有扩张血管、改善微循环、抑制血小板凝聚的药物前列腺素E1制剂(10~40μg/d，连续10~20d为1个疗程)，也可长期口服贝前列腺素钠片(III)。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "大血管粥样硬化斑块"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "前列腺素E1制剂", "subject_type": "药品名称", "object": {"@value": "大血管粥样硬化斑块"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝前列腺素钠片", "subject_type": "药品名称", "object": {"@value": "大血管粥样硬化斑块"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢动脉", "subject_type": "患病部位", "object": {"@value": "下肢动脉闭塞症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "前列腺素E1制剂", "subject_type": "药品名称", "object": {"@value": "下肢动脉闭塞症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝前列腺素钠片", "subject_type": "药品名称", "object": {"@value": "下肢动脉闭塞症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉输注", "subject_type": "用药方法", "object": {"@value": "前列腺素E1制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "10~20d", "subject_type": "持续时间", "object": {"@value": "前列腺素E1制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "10~40μg/d", "subject_type": "用药剂量", "object": {"@value": "前列腺素E1制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "长期", "subject_type": "持续时间", "object": {"@value": "贝前列腺素钠片"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "贝前列腺素钠片"}, "object_type": {"@value": "药品名称"}}]}
{"text": "蜂窝织炎融合形成大脓腔，脓性分泌物及坏死组织增多，足或少数趾干性坏疽，但骨质破坏尚不明显。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "大脓腔", "subject_type": "临床表现", "object": {"@value": "蜂窝织炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "脓性分泌物及坏死组织增多", "subject_type": "临床表现", "object": {"@value": "蜂窝织炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "足或少数趾干性坏疽"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "趾", "subject_type": "患病部位", "object": {"@value": "足或少数趾干性坏疽"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "沙格列汀用于GFR≥50ml/(min·1.73m2)的CKD患者时无需调整剂量，当GFR在30~49ml/(min·1.73m2)时减量；CKD4~5期患者禁用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "沙格列汀", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "4~5期", "subject_type": "分期分型", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "利格列汀用于CKD1~4期患者时无需调整剂量，5期患者用药经验有限。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "利格列汀", "subject_type": "药品名称", "object": {"@value": "CKD1~4期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~4期", "subject_type": "分期分型", "object": {"@value": "CKD1~4期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "5期", "subject_type": "分期分型", "object": {"@value": "CKD1~4期"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病患者中足部溃疡的患病率为4%~10%。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足部", "subject_type": "患病部位", "object": {"@value": "足部溃疡"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.开发针对糖尿病肾病发病机制的药物：如抗AGE药物Pyridorin、抗纤维化类药物舒洛地昔，内皮受体拮抗剂阿曲生坦进入临床试验，但其应用尚缺乏经验。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "抗AGE药物", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "Pyridorin", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "抗纤维化类药物", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "舒洛地昔", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "内皮受体拮抗剂", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿曲生坦", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3. 出现并发症患者管理：(1)一经确诊的HUA患者应积极筛查并发症或合并症，及时制定多学科联合方案；(2)急、慢性尿酸(盐)肾病患者须避免使用损害肾脏损伤药物，监测肾功能并指导药物选择，中重度肾功能不全者痛风急性期治疗首选糖皮质激素；(3)肾石症患者碱化尿液，必要时给予溶石或手术治疗；(4)合并高血糖、血脂紊乱、高血压者须同时积极降糖、调脂、降压治疗，尽量选择有利于尿酸排泄的药物；(5)心肌梗死、心功能不全者痛风急性发作期避免使用环氧化酶2(COX-2)抑制剂。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "急、慢性尿酸(盐)肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "监测肾功能", "subject_type": "检查方法", "object": {"@value": "急、慢性尿酸(盐)肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "中重度肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "糖皮质激素", "subject_type": "药品名称", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾石症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "溶石", "subject_type": "非药治疗", "object": {"@value": "肾石症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心功能不全者"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)需密切监测血糖：同时服用噻嗪类药物或其他利尿剂、糖皮质激素、吩噻嗪、甲状腺制剂、雌激素、口服避孕药、苯妥英、烟碱酸、拟交感神经药、钙离子通道阻滞剂和异烟肼等可引起血糖升高的药物。而在这些药物停用后，要密切注意低血糖的发生；合并服用氯磺丙脲的患者在换用二甲双胍的最初两周要密切监测血糖，氯磺丙脲在体内有较长滞留，易发生低血糖。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "避孕药"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "氯磺丙脲"}, "object_type": {"@value": "药品名称"}}]}
{"text": "d.利格列汀在不同程度肝功能不全的患者中使用，均不需要调整剂量。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "利格列汀", "subject_type": "药品名称", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "急性尿酸性肾病通常可逆，重在预防。高风险患者积极静脉补液，心肾功能允许情况下将尿量维持在80~100ml·m-2·h-1。首选重组尿酸酶，或黄嘌呤氧化酶抑制剂将血尿酸控制在300μmol／L以下；确诊急性尿酸者肾病患者需要紧急处理，及时有效的治疗下肾功能有望恢复正常。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "急性尿酸性肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "急性尿酸者肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.5 患者管理与教育基层医疗卫生机构医师需要为患者建立糖尿病及其并发症相关档案，主要包括患者的基本信息、一般资料、DR、DKD、DPN、自主神经病变筛查记录，具体筛查记录表格见附录1。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "自主神经", "subject_type": "患病部位", "object": {"@value": "自主神经病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "EMPA-REG OUTCOME和LEADER均为大型、多中心、随机、双盲、安慰剂对照的CVOT，这两项研究分别为恩格列净和利拉鲁肽的心血管保护作用提供了可靠证据，对于T2DM合并ASCVD患者的降糖治疗策略制定具有里程碑意义。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "恩格列净", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "恩格列净", "subject_type": "药品名称", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利拉鲁肽", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利拉鲁肽", "subject_type": "药品名称", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "HUA是造影剂相关急性肾损伤的独立危险因素。HUA患者接受冠状动脉CT成像或冠状动脉造影前建议检血尿酸，并进行危险分层，加强水化，避免使用高渗性对比剂，并减少对比剂剂量。", "spo_list": [{"Combined": false, "predicate": "患病病因", "subject": "HUA", "subject_type": "患病病因", "object": {"@value": "造影剂相关急性肾损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "造影剂相关急性肾损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "冠状动脉CT成像", "subject_type": "检查方法", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "冠状动脉造影", "subject_type": "检查方法", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.饮食疗法：糖尿病前期及糖尿病患者应接受个体化的医学营养治疗(MNT)以达到治疗目标。MNT包括对患者进行个体化营养评估诊断，制定相应的营养干预计划，以便在保证儿童青少年正常生长发育的前提下，纠正已发生的代谢紊乱，减轻胰岛β细胞负荷，从而延缓并减轻糖尿病及并发症的发生和发展。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "饮食疗法", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "医学营养治疗(MNT)", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食疗法", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "医学营养治疗(MNT)", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛β细胞负荷", "subject_type": "发病机制", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "有研究认为胰岛素促泌剂可以引起胰岛β细胞凋亡，且促凋亡作用呈时间-剂量依赖性增加。UKPDS的结果显示，无论使用何种降糖治疗，胰岛β细胞功能每年以约7%的速度丧失，使用格列本脲和氯磺丙脲治疗的患者β细胞胰岛素分泌功能有下降趋势，但与采用二甲双胍治疗和单纯饮食控制相似。糖尿病进展试验(ADOPT)对比了3种不同类型降糖药物(罗格列酮、格列本脲和二甲双胍)在新诊断T2DM患者中的疗效，发现格列本脲改善β细胞胰岛素分泌功能明显优于罗格列酮和二甲双胍，并非发现磺脲类药物加重或加速了β细胞的衰竭。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "罗格列酮", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列本脲", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "三、T2DM合并CKD的口服降糖药选择", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "由于糖尿病使心脏病或卒中风险加倍，多数医生和患者非常关注心脑血管疾病，而糖尿病导致死亡的其他因素却较少受到关注。近期的一项研究显示，40%的糖尿病患者死于非心血管疾病，包括肾病、感染、癌症、老年痴呆症、慢性阻塞性肺疾病、神经系统疾病等，提示关注糖尿病患者全因死亡非常重要(2b级)。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心脏", "subject_type": "患病部位", "object": {"@value": "心脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心脑血管", "subject_type": "患病部位", "object": {"@value": "心脑血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性阻塞性", "subject_type": "分期分型", "object": {"@value": "慢性阻塞性肺疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肺", "subject_type": "患病部位", "object": {"@value": "慢性阻塞性肺疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "神经系统疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "这为我国2型糖尿病忠者降糖治疗提供了一种新的选择。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "大多数国内外指南均推荐二甲双胍作为T2DM", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2008年中国糖尿病流行病学调查显示，中国20岁及以上人群2型糖尿病患病率为9.7%。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "目前国内上市的GLP-1受体激动剂为艾塞那肽和利拉鲁肽，均需皮下注射。包括我国2型糖尿病患者在内的临床试验显示艾塞那肽可以使HbA1c降低0.8%，利拉鲁肽的疗效和格列美脲相当。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "皮下注射", "subject_type": "用药方法", "object": {"@value": "艾塞那肽"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "皮下注射", "subject_type": "用药方法", "object": {"@value": "利拉鲁肽"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "艾塞那肽", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利拉鲁肽", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列美脲", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "病理活检被认为是糖尿病肾病诊断的金标准，不能依据临床病史排除其他肾脏疾病时，需考虑进行肾穿刺以确诊。2010年，肾脏病理学会研究委员会首次提出了糖尿病肾病病理分级标准，在1型和2型糖尿病患者中均适用。根据肾脏组织光镜、电镜及免疫荧光染色的改变对肾小球损害和肾小管/肾血管损伤分别进行分级、分度。肾小球损伤分为4级：Ⅰ级：GBM增厚；Ⅱa级：轻度系膜增生；Ⅱb级：重度系膜增生；Ⅲ级：一个以上结节性硬化(K-W结节)；Ⅳ级：晚期糖尿病肾小球硬化。肾小管间质用间质纤维化和肾小管萎缩、间质炎症的程度评分，肾血管损伤按血管透明变性和大血管硬化的程度评分。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾穿刺", "subject_type": "检查方法", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾穿刺", "subject_type": "检查方法", "object": {"@value": "肾脏疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型和2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "1型和2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾脏组织光镜", "subject_type": "检查方法", "object": {"@value": "肾小球损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾脏组织光镜", "subject_type": "检查方法", "object": {"@value": "肾小管/肾血管损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "电镜及免疫荧光染色", "subject_type": "检查方法", "object": {"@value": "肾小球损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "电镜及免疫荧光染色", "subject_type": "检查方法", "object": {"@value": "肾小管/肾血管损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾小球", "subject_type": "患病部位", "object": {"@value": "肾小球损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾小管", "subject_type": "患病部位", "object": {"@value": "肾小管/肾血管损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾血管", "subject_type": "患病部位", "object": {"@value": "肾小管/肾血管损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "Ⅰ级", "subject_type": "分期分型", "object": {"@value": "肾小球损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "Ⅱb级", "subject_type": "分期分型", "object": {"@value": "肾小球损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "Ⅲ级", "subject_type": "分期分型", "object": {"@value": "肾小球损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "Ⅳ级", "subject_type": "分期分型", "object": {"@value": "肾小球损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "GBM增厚", "subject_type": "发病机制", "object": {"@value": "肾小球损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "轻度系膜增生", "subject_type": "发病机制", "object": {"@value": "肾小球损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "重度系膜增生", "subject_type": "发病机制", "object": {"@value": "肾小球损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "一个以上结节性硬化(K-W结节)", "subject_type": "发病机制", "object": {"@value": "肾小球损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "晚期糖尿病肾小球硬化", "subject_type": "发病机制", "object": {"@value": "肾小球损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾小球", "subject_type": "患病部位", "object": {"@value": "肾小球损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾血管", "subject_type": "患病部位", "object": {"@value": "肾血管损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "血管透明变性", "subject_type": "发病机制", "object": {"@value": "肾血管损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "大血管硬化", "subject_type": "发病机制", "object": {"@value": "肾血管损伤"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "除高血糖外，T2DM患者往往合并有高血压、血脂异常、肥胖等多重心血管危险因素。因此，对于大多数T2DM患者，特别是合并ASCVD的患者，应采取综合管理策略，在控制血糖的同时，全面管理好各种心血管危险因素，具体措施包括生活方式干预、降压、调脂、抗血小板治疗、减重等，以期最大程度降低心血管事件和死亡风险。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "5.3 如何看待磺脲类药物增加体重的问题? ", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "增加体重", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "DPP-4i可用于伴有心血管疾病或心血管事件的2型糖尿病患者的降糖治疗。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4i", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3 基层医疗卫生机构糖尿病微血管并发症的筛查、诊断、随访教育及分级诊疗建议 ", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.下肢动脉闭塞：外周动脉疾病(PAD)是糖尿病常见的大血管并发症，老年患者中多发，下肢动脉闭塞最常见(C)。糖尿病合并高血压将增加PAD的发生及靶器官损伤(A)。应用彩色多普勒超声技术筛查下肢动脉病变，可以更早及准确检测血管损伤，并进行危险分层(C)。对出现下肢疼痛症状者，临床上按疼痛程度分级(表2)。治疗上按照病变不同阶段各有侧重，单纯动脉管壁增厚伴散在斑块者，需要加用抗血小板药物，下肢动脉管腔狭窄>50%、足背动脉搏动缺失或有运动后下肢无力等症状，可联合西洛他唑(50~100mg，2次/d)长期服用，下肢动脉管腔狭窄>75%、中重度间歇性跛行伴静息痛患者，有条件需行介入治疗(D)。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "下肢动脉", "subject_type": "患病部位", "object": {"@value": "下肢动脉闭塞"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "外周动脉", "subject_type": "患病部位", "object": {"@value": "外周动脉疾病(PAD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "大血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢动脉", "subject_type": "患病部位", "object": {"@value": "下肢动脉闭塞"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "靶器官", "subject_type": "患病部位", "object": {"@value": "靶器官损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "彩色多普勒超声", "subject_type": "检查方法", "object": {"@value": "下肢动脉病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "彩色多普勒超声", "subject_type": "检查方法", "object": {"@value": "血管损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢动脉", "subject_type": "患病部位", "object": {"@value": "下肢动脉病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "血管", "subject_type": "患病部位", "object": {"@value": "血管损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足背动脉", "subject_type": "患病部位", "object": {"@value": "足背动脉搏动缺失"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "2次/d", "subject_type": "用药频率", "object": {"@value": "西洛他唑"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "50~100mg", "subject_type": "用药剂量", "object": {"@value": "西洛他唑"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "长期", "subject_type": "持续时间", "object": {"@value": "西洛他唑"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢动脉", "subject_type": "患病部位", "object": {"@value": "下肢动脉管腔狭窄"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢动脉管", "subject_type": "患病部位", "object": {"@value": "下肢动脉管腔狭窄"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "二甲双胍改善高血糖的主要机制包括：(1)作用于肝脏，抑制糖异生，减少肝糖输出；(2)作用于外周组织(肌肉、脂肪)，改善肌肉糖原合成，降低游离脂肪酸，提高胰岛素敏感性，增加对葡萄糖的摄取和利用；(3)作用于肠道，抑制肠壁细胞摄取葡萄糖，提高胰高血糖素样肽-1(GLP-1) 水平。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.肾病：白蛋白尿是评估糖尿病肾病的重要指标。TODAY研究发现在633例平均病程7个月的2型糖尿病青少年患者中，6.3%存在微量白蛋白尿，而到病程36个月时，这一比例上升到16.6%。尿白蛋白/肌酐比值在诊断之初检测后，每年应检测1次。糖尿病病程超过5年的患儿，应考虑至少每年筛查尿白蛋白，取随机尿样检测白蛋白/肌酐比值。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "微量白蛋白尿", "subject_type": "临床表现", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿白蛋白", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "白蛋白/肌酐比值", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "事实上在糖尿病诊断前约10~15年，β细胞胰岛素分泌功能已开始逐渐下降(2b级)。", "spo_list": [{"Combined": false, "predicate": "发病机制", "subject": "β细胞胰岛素分泌功能已开始逐渐下降", "subject_type": "发病机制", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)糖尿病病情评估：系统评价血糖控制状况，监测全天血糖谱(三餐前后、睡前血糖)及HbA1c，必要时可进行动态血糖监测系统(CGMS)；全面评估糖尿病慢性并发症状况如糖尿病视网膜病变(DR)、糖尿病肾脏病变(DKD)及糖尿病周围神经病变等，评估可能加重或促使DR、DKD进展的危险因素；根据White分级(表3)评估糖尿病病情与妊娠风险，White分级在F级以下的患者，妊娠后胎儿存活率不到5%，因而应避免妊娠。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变(DR)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "糖尿病肾脏病变(DKD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "糖尿病周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "避免妊娠", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "对于伴有非酒精性脂肪肝的2型糖尿病患者GLP-1RA可降低BMI和ALT水平，建议使用GLP-1RA进行治疗。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "非酒精性脂肪肝"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "GLP-1RA", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "ALT", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(3)联合用药：将该共识的这部分内容概括一句话就是，二甲双胍可以和临床上现有的各种降糖药联用，而且还能减轻某些降糖药的副作用(α-糖苷酶抑制剂除外，两者联用有可能增加胃肠不适)，实现扬长避短的效果。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "胃肠不适", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠不适", "subject_type": "不良反应", "object": {"@value": "α-糖苷酶抑制剂"}, "object_type": {"@value": "药品名称"}}]}
{"text": "14.二甲双胍是否应尽早足量使用以维持更长的达标时间：500~2000mg/d剂量，二甲双胍疗效呈现剂量依赖效应，且相比其他降糖药物，二甲双胍具有更好的成本-效益比。ADOPT研究显示，在新诊断的T2DM患者中，二甲双胍(2000mg/d)单药治疗可以在4年内使受试者平均HbA1c水平维持在7%以下(Ⅰ级)。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "500~2000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "1.老年糖尿病患者：老年糖尿病患者常合并多种疾病，器官功能减退，且低血糖感知性弱、耐受性差，认知能力、自我管理能力下降。因此，老年糖尿病患者血糖控制目标一般较为宽松，HbA1c为7.5%~8.0%，对于出现糖尿病并发症或合并多种疾病的患者，血糖控制目标可进一步放宽。在使用降糖药物控制血糖，预防和减少并发症的同时，需考虑老年患者的肝、肾功能及合并用药的相互作用问题，减少低血糖发生。临床上常采用口服降糖药治疗，需胰岛素治疗情况下通常推荐使用基础胰岛素，尤其是低血糖风险较低的长效胰岛素类似物。除新诊断伴严重高血糖症状及某些特殊情况外，不推荐多次胰岛素注射的方案。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "腹腔镜袖状胃切除术(laparoscopic sleeve gastrectomy，LSG)是中重度T2DM合并肥胖的首选术式；胃旁路术(roux-en-Y gastric、bypass，RYGB)适用于T2DM病程相对较长、需要减重更多的患者。", "spo_list": [{"Combined": false, "predicate": "临床手术", "subject": "腹腔镜袖状胃切除术(laparoscopic sleeve gastrectomy，LSG)", "subject_type": "临床手术", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "腹腔镜袖状胃切除术(laparoscopic sleeve gastrectomy，LSG)", "subject_type": "临床手术", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "胃旁路术(roux-en-Y gastric、bypass，RYGB)", "subject_type": "临床手术", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病足的治疗目标：预防全身动脉粥样硬化疾病的进展，预防心、脑血管事件的发生，降低糖尿病足患者死亡率；预防缺血导致的溃疡和肢端坏疽，预防截肢或降低截肢平面，改善间歇性跛行患者的下肢肤体功能状态。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "全身动脉", "subject_type": "患病部位", "object": {"@value": "全身动脉粥样硬化疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心、脑血管", "subject_type": "患病部位", "object": {"@value": "心、脑血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "缺血", "subject_type": "患病病因", "object": {"@value": "溃疡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "缺血", "subject_type": "患病病因", "object": {"@value": "肢端坏疽"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "截肢", "subject_type": "临床手术", "object": {"@value": "溃疡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肢端", "subject_type": "患病部位", "object": {"@value": "肢端坏疽"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "截肢", "subject_type": "临床手术", "object": {"@value": "肢端坏疽"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢肤体", "subject_type": "患病部位", "object": {"@value": "间歇性跛行"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "对于合并代谢综合征的肥胖患者，临床证据中较为一致的将生活行为方式干预作为减重和改善代谢紊乱的基础治疗措施。同时，对于各种膳食模式的比较发现，在控制总能量摄入的前提下，它们的总体效果相似。需要指出的是，目前的研究样本量均不大，且干预时间较短(12~24周)，尚欠缺长时间干预的研究证据。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "生活行为方式干预", "subject_type": "非药治疗", "object": {"@value": "代谢综合征"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活行为方式干预", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)儿童和青少年T2DM合并CKD患者：在儿童和青少年T2DM合并CKD患者中，缺乏对高血糖、高血压和血脂异常治疗的相关数据。但是生活方式的改变(饮食、锻炼、减肥)对减少以上危险因素有益，因此对高血糖的起始干预应从改变生活方式开始。若生活方式干预不能控制血糖，应考虑降糖药治疗。尽管ADA推荐口服降糖药作为儿童和青少年T2DM患者的一线治疗，但其中仅二甲双胍被FDA批准用于10岁以上的儿童，其使用注意事项与成人相同。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式的改变", "subject_type": "非药治疗", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食", "subject_type": "非药治疗", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "锻炼", "subject_type": "非药治疗", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "减肥", "subject_type": "非药治疗", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "改变生活方式", "subject_type": "非药治疗", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(3)混合性坏疽：混合性坏疽较干性坏疽稍多见，占糖尿病足坏疽的15.2%。肢端局部血供障碍引起干性坏疽，而病变另一部分合并感染。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "足坏疽"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "肢端局部血供障碍", "subject_type": "患病病因", "object": {"@value": "干性坏疽"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "推荐D PP-4i作为2型糖尿病患者的一线治疗选择之一。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "D PP-4i", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "①老年患者：老年糖尿病患者常合并多种疾病，器官功能减退，且低血糖感知性弱、耐受性差，认知能力、自我管理能力下降。因此，老年糖尿病患者血糖控制目标一般较为宽松，在选择降糖药物时，除了控糖达标以预防和减少并发症，更应当考虑其肝、肾功能及合并用药的相互作用，减少低血糖发生。临床上常采用口服降糖药治疗，需胰岛素治疗时通常推荐使用基础胰岛素，尤其是低血糖风险较低的长效胰岛素类似物。除新诊断伴严重高血糖症状及某些特殊情况外，不推荐多次胰岛素注射的方案。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(3)空军总医院分级法：空军总医院内分泌科李仕明主任依据机体组织抗感染能力及坏疽病变的性质、范围、深度作为分级的依据和说明感染严重程度的依据，结合国内外分级标准，将糖尿病足按病变程度划分为0~5级，提出了空军总医院糖尿病足分级方法。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "当血尿酸超过饱和浓度，尿酸盐晶体析出可直接黏附、沉积于关节及周围软组织、肾小管和血管等部位，趋化中性粒细胞、巨噬细胞；细胞与晶体相互作用后释放致炎症因子(如IL-1β、IL-6等)以及金属蛋白酶9、水解酶等，引起关节软骨、骨质、肾脏以及血管内膜等急慢性炎症损伤。", "spo_list": [{"Combined": false, "predicate": "患病病因", "subject": "细胞与晶体相互作用", "subject_type": "患病病因", "object": {"@value": "急慢性炎症损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "关节软骨", "subject_type": "患病部位", "object": {"@value": "急慢性炎症损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "骨质", "subject_type": "患病部位", "object": {"@value": "急慢性炎症损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "急慢性炎症损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "血管内膜", "subject_type": "患病部位", "object": {"@value": "急慢性炎症损伤"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(6)GLP-1：GLP-1半衰期短，GLP-1类似物的半衰期延长，其代表药物有艾塞那肽、利拉鲁肽等。艾塞那肽经肾排泄，GFR低于45ml·min-1·1.73m-2时，其清除率下降36%，GFR低于30ml·min-1·1.73m-2时，其清除率下降64%且透析患者不能耐受胃肠道不良反应，因此艾塞那肽不推荐用于CKD4~5期的患者。利拉鲁肽也仅可用于CKD1~2期患者，在中度肾功能损害患者中的治疗经验有限，不推荐用于包括ESRD患者在内的重度肾功能损害患者。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "胃肠道不良反应", "subject_type": "不良反应", "object": {"@value": "艾塞那肽"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "艾塞那肽", "subject_type": "药品名称", "object": {"@value": "CKD4~5期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "CKD4~5期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "CKD4~5期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "透析", "subject_type": "非药治疗", "object": {"@value": "CKD4~5期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "4~5期", "subject_type": "分期分型", "object": {"@value": "CKD4~5期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利拉鲁肽", "subject_type": "药品名称", "object": {"@value": "CKD1~2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~2期", "subject_type": "分期分型", "object": {"@value": "CKD1~2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "尿微量白蛋白排泄的检测方法包括尿白蛋白/尿肌酐比值(ACR)及尿白蛋白定量等，检测技术已较为成熟，ACR与尿白蛋白定量比较，具有快速、简便、精确等特点。这些检测方法在多数基层医疗卫生机构均能开展或可外送第三方检测机构，因此本项共识建议将尿ACR作为基层医疗卫生机构DKD筛查的首选方法。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "尿ACR", "subject_type": "检查指标", "object": {"@value": "DKD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "心理干预计划：评估负面情绪产生的原因及临床表现，分析情绪因素在糖尿病的发生、发展与转归中的重要作用，提出改善情绪障碍的实用性建议，展开心理问题讨论，配合音乐治疗和放松认练。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "心理干预", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "配合音乐治疗", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "放松认练", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "成人2 型糖尿病基础胰岛素临床应用中国专家指导建议", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2 型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2 型", "subject_type": "分期分型", "object": {"@value": "2 型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.针极肌电图检查：①针极肌电图检查可见异常自发电位，运动单位电位时限增宽、波幅增高，大力收缩时运动单位募集减少。②针极肌电图能够证实运动神经轴索损害，发现亚临床病变，并协助不同神经病变分布类型的定位。③在以自主神经或感觉神经受累为主的周围神经病变，针电极检测的阳性率较低。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "针极肌电图", "subject_type": "检查方法", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "针极肌电图", "subject_type": "检查方法", "object": {"@value": "运动神经轴索损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "运动神经", "subject_type": "患病部位", "object": {"@value": "运动神经轴索损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "轴索", "subject_type": "患病部位", "object": {"@value": "运动神经轴索损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "自主神经", "subject_type": "患病部位", "object": {"@value": "周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "感觉神经", "subject_type": "患病部位", "object": {"@value": "周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "针电极检测", "subject_type": "检查方法", "object": {"@value": "周围神经病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "肥胖与糖尿病存在的其他代谢异常协同作用可进一步加剧T2DM患者慢性并发症的发生。肥胖是糖尿病肾脏病变的独立危险因素，可导致慢性肾脏病的恶化。减轻体重有利于减少慢性肾脏病患者的蛋白尿，延缓肾功能衰退进程。T2DM合并肥胖使心脑血管疾病患病风险升高。因此，针对T2DM合并肥胖患者，在降糖的同时加强体重管理，对于预防糖尿病并发症、提高患者生活质量具有重要意义。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "肥胖", "subject_type": "患病病因", "object": {"@value": "糖尿病肾脏病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "糖尿病肾脏病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "减轻体重", "subject_type": "非药治疗", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能衰退"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心脑血管", "subject_type": "患病部位", "object": {"@value": "心脑血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "降糖", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "体重管理", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "降糖", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "体重管理", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "血糖控制达标的关键仍然是监测碳水化合物的摄入量。推荐每日碳水化合物供能比45%~60%，如碳水化合物的来源为低血糖生成指数(GI)食物，其供能比可达60%。建议碳水化合物来自于低GI，富含膳食纤维的食物，如全麦(全谷)粉、荞麦、粉丝、黑米、粟米等，以及蔬菜、水果、豆类和奶制品。整体应符合中国居民膳食推荐摄入量，应避免含糖饮料的摄入，减少含蔗糖食物。同时，很多研究引入血糖负荷(GL)这一指标。GL是食物GI与其碳水化合物含量的乘积，克服了单纯使用血糖指数或碳水化合物含量评估的不足。研究表明高GL饮食明显增加了2型糖尿病的发病率，同时肥胖成人中，GL与HbA1c呈正相关。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "因此，本共识暂不推荐应用该类药物作为糖尿病肾病的一级预防。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)糖尿病视网膜病变(DR)的诊断：DR依据散瞳后眼底镜检查或眼底照相结果进行诊断与分级诊断与分级标准参照目前全球统一的“糖黄斑水肿疾病严重程度分级标准。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变(DR)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "散瞳后眼底镜检查", "subject_type": "检查方法", "object": {"@value": "DR"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "眼底照相", "subject_type": "检查方法", "object": {"@value": "DR"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "黄斑", "subject_type": "患病部位", "object": {"@value": "糖黄斑水肿"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "此外，饮食和运动不规律、治疗依从性差、情绪应激、睡眠障碍、酣酒、感染、胰岛素不规范注射等多种因素也可增加血糖波动，而应对餐后血糖的药物作用不足也是导致血波动的原因之一。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "胰岛素@(4)血糖管理：①合并急危重症：(a)合并急性并发症：DKA、高血糖高渗状态、乳酸酸中毒伴高血糖。严重糖代谢紊乱伴水、电解质、酸碱平衡紊乱时的降糖治疗：此时患者处于急性糖代谢严重紊乱状态，合并脱水、电解质絮乱甚至酸中毒，危及生命。补液和胰岛素的应用有利于最大限度地逆转病情。在积极补液，有效改善组织灌注的同时，给予小剂量短效胰岛素静脉滴注，开始时按每小时每千克体重计算胰岛素的剂量0.1U·kg-1·h-1，每1小时监测血糖。之后根据血糖下降速度调整胰岛素剂量，血糖下降速度一般控制在每小时降低3.9~6.1mmol/L为宜。如第1个小时血糖下降不明显，且脱水已基本纠正，胰岛素剂量可加倍。当血糖降至13.9mmol/L.时，胰岛素剂量减至0.05~0.1U·kg-1·h-1，使血糖稳定在8.0~13.9mmol/L。观察病情，临床症状缓解，消化道症状基本消失，能少量进食后，需皮下注射基胰岛素(即中效胰岛素或长效胰岛素类似物)1~2h后，方可停止胰岛素静脉滴注。静脉输注胰岛素转皮下胰岛素注射时，可选择每日多次胰岛素皮下注射(MDI)或持续皮下胰岛素输注(CSH)。不能正常进食者，可仅给予基础胰岛素，或CSⅡ的基础量，每4~6h监测血糖。基础胰岛素剂量可参照患者院外基础胰岛素剂量，如果院外没有使用胰岛素者，可按0.2U·kg-1·h-1计算。进食主食量不足25g时，可暂时不给予餐前胰岛素，但要观察餐后血糖变化。进食量增加且能规律，或进食后血糖明显增加时，可在三顿主餐前加用短效胰岛素或速效胰岛素类似物，或CSII的餐前大剂量。使用剂量视者进餐情况并参照院外胰岛素剂量，同时监测7次血糖，每2~3天调整1次胰岛素剂量，逐渐控制血糖达到住院糖尿病患者控制目标。患者病情稳定，血糖控制满意后，调整为院外降糖方案，并至少监测1天的7次血糖。院外降糖方案可依据患者具体情况，选择MDI、CSII、预混胰岛素或预混胰岛素类似物2~3次皮下注射，加用或不加用二甲双胍、α-糖苷酶抑制剂。院外血糖控制目标可参照2011年《中国成人2型糖尿病HbA1c控制目标的专家共识》，血糖监测计", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "静脉滴注", "subject_type": "用药方法", "object": {"@value": "短效胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "0.1U·kg-1·h-1", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "0.05~0.1U·kg-1·h-1", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "皮下注射", "subject_type": "用药方法", "object": {"@value": "基胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉滴注", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉输注", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "持续皮下胰岛素输注(CSH)", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "每日多次胰岛素皮下注射(MDI)", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "T2DM是危害人类健康的主要疾病之一，是ASCVD的独立危险因素。T2DM患者血脂异常的发生率明显高于非糖尿病患者，是T2DM患者心血管并发症发生率增加的重要危险因素。英国前瞻性糖尿病研究(UKPDS)的结果显示，血脂异常是T2DM患者发生致死性和非致死性心肌梗死的首要危险因素。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "致死性和非致死性心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "致死性和非致死性心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "致死性和非致死性", "subject_type": "分期分型", "object": {"@value": "致死性和非致死性心肌梗死"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "二甲双胍是一个在临床上已经应用了60年的老药，曾几经沉浮，目前国内外主要糖尿病指南均认可其核心地位，建议无论超重还是体重正常的2型糖尿病患者，除非存在禁忌证或无法耐受，否则都应从一开始就使用二甲双胍治疗，且联合治疗的方案中都应包括二甲双胍。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.血糖相关检查：对于周围神经病患者，应常规进行空腹血糖、葡萄糖负荷后2h血糖和糖化血红蛋白测定，明确患者有无糖尿病。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "血糖相关检查", "subject_type": "检查方法", "object": {"@value": "周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血糖相关检查", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "空腹血糖", "subject_type": "检查指标", "object": {"@value": "周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "葡萄糖负荷后2h血糖", "subject_type": "检查指标", "object": {"@value": "周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "糖化血红蛋白", "subject_type": "检查指标", "object": {"@value": "周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "空腹血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "葡萄糖负荷后2h血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "糖化血红蛋白", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(四)糖尿病足的分类、分级 ", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "格列喹酮、格列吡嗪普通剂型属于短效制剂，作用时间较短；格列美脲、格列吡嗪控释剂、格列齐特、格列齐特缓释片、格列本脲为中、长效制剂，作用时间较长。短效药物需要每日3次给药，中、长效药物每日给药1~2次即可。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "每日3次", "subject_type": "用药频率", "object": {"@value": "格列喹酮"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日3次", "subject_type": "用药频率", "object": {"@value": "格列吡嗪普通剂型"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日给药1~2次", "subject_type": "用药频率", "object": {"@value": "格列美脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日给药1~2次", "subject_type": "用药频率", "object": {"@value": "格列吡嗪控释剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日给药1~2次", "subject_type": "用药频率", "object": {"@value": "格列齐特"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日给药1~2次", "subject_type": "用药频率", "object": {"@value": "格列齐特缓释片"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日给药1~2次", "subject_type": "用药频率", "object": {"@value": "格列本脲"}, "object_type": {"@value": "药品名称"}}]}
{"text": "①口服降糖药联合基础胰岛素方案：血糖明显增高伴有明显高血糖症状的新诊断糖尿病患者或口服降糖药治疗血糖控制不佳的患者起始基础胰岛素时，可根据体重计算每日起始剂量，通常为0.1~0.3单位/千克体重，肥胖患者或HbA1c>8.0%时，可考虑0.2~0.3单位/千克体重起始。从预混缺岛素治疗转换为基础胰岛素时，可依据血糖水平，按照原预混胰岛素总剂量的60%-80%起始基础胰岛素；如HbA1c≦8.0%，基础胰岛素起始剂量=原预混胰岛素总量x 0.6，HbA1c>8%时，推荐起始剂量=原预混胰岛素总量x0.8。口服药种类和剂量根据患者个体情况酌情选择和调整。此后，根据空腹血糖水平，在避免低血糖的情况下及时调整胰岛素剂量。多数患者长效胰岛素类似物每日剂量达到约0.5单位/千克体重前，可通过继续调整剂量控制血糖，而无需调整治疗方案。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "0.1~0.3单位/千克体重", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "0.2~0.3单位/千克体重", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "0.5单位/千克体重", "subject_type": "用药剂量", "object": {"@value": "长效胰岛素类似物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "糖尿病微血管病变筛查与防治双向转诊流程见图1，具体并发症筛查与防治双向转诊流程见图2一4。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "低血糖对心血管系统具有显著的不良影响.其短期风险包括诱发心律失常、心血管事件，长期风险为认知障碍和痴呆，严重低血糖甚至可导致患者猝死。因此，对于合并ASCVD的T2DM患者，在降糖治疗过程中尤其应尽量避免出现低血糖。胰岛素和胰岛素促泌剂均可引起低血糖，与SUs相比，格列奈类药物的低血糖风险相对较低。二甲双胍、a-糖苷酶抑制剂、TZDs、GLP-1受体激动剂、DPP-4抑制剂以及SGLT-2抑制剂单独使用时通常不会导致低血糖，在接受降糖治疗的患者中，一旦发生低血糖，应迅速补充葡萄糖或含糖食物，以使血糖水平恢复正常，并及时调整降糖治疗方案。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管系统", "subject_type": "患病部位", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "SUs"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列奈类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "a-糖苷酶抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "TZDs"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "GLP-1受体激动剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "DPP-4抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "SGLT-2抑制剂"}, "object_type": {"@value": "药品名称"}}]}
{"text": "③肾功能不全患者：这类患者的肾脏对胰岛素的降解明显减少，同时胰岛素排出速率下降，胰岛素可能在体内蓄积，患者出现氮质血症时[血液中尿素氮超过9毫摩尔/升(mmol/L)、肌酐超过178微摩尔/升(μmol/L)]应根据血糖监测情况及时减少和调整胰岛素用量，使血糖维持在适当范围内，并且优先选择短效或速效胰岛素剂型。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)血糖控制：DCCT、UKPDS、VADT等多项临床研究结果均显示强化血糖控制可以降低糖尿病微血管并发症的发生风险。大多数成人2型糖尿病患者合理的糖化血红蛋白(HbA1c)目标是<7%。研究证明，严格控制血糖，使HbA1c<6.5%，可以更好地预防糖尿病微血管并发症的发生。对于经过生活方式干预和规范口服降糖药治疗3个月血糖仍不能达标的2型糖尿病患者，需及时使用胰岛素治疗。此外，具有降糖之外微血管病变防治效应的降糖药应优先选择。基层医疗卫生机构在使用胰岛素时可优先考虑使用方便、低血糖风险小的胰岛素产品，如基础胰岛素等。目前，国内外指南对糖尿病微血管并发症防治的降糖药物并无特别推荐，但有研究显示，及时开始胰岛素治疗可以延缓糖尿病患者微血管瘤和DR的进展。ORIGIN研究亦显示，甘精胰岛素可延缓糖尿病患者DKD和微量白蛋白尿的进展。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "糖化血红蛋白(HbA1c)", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "微血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "微血管瘤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "微血管瘤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "DR"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "甘精胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "甘精胰岛素", "subject_type": "药品名称", "object": {"@value": "DKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "①口服降糖药联合基础胰岛素方案：高血糖 (FPG>11.1毫摩尔/升，或HbA1c>9%) 伴明显高血糖症状的新诊2型糖尿病患者；1~2种口服降糖药 (超重或肥胖患者1~3种口服降糖药)规范治疗3个月以上血糖控制仍未达标者；正在接受预混胰岛素治疗(低于50单位/天)的患者血糖控制不佳，频繁发作低血糖者，或对每日2次预混胰岛素注射依从性差者。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "低于50单位/天", "subject_type": "用药剂量", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日2次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "3.α-糖苷酶抑制剂：常用药物有阿卡波糖和伏格列波糖，多从小剂量开始应用，而后根据血糖监测结果进行剂量调整。通过抑制碳水化合物在小肠上部的消化和吸收而降低餐后血糖，适用于以碳水化合物为主要食物和餐后血糖升高的患者。α-糖苷酶抑制剂可使HbA1c下降0.5%~0.8%，不增加体重。单独使用时不导致低血糖，但与胰岛素促泌剂或胰岛素合用时需要注意低血糖的防治，纠正低血糖只能使用葡萄糖制剂。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "葡萄糖制剂", "subject_type": "药品名称", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "OGTT方法：(1)空腹至少8h，在次日上午检查前，配制口服葡萄糖溶液(无水葡萄糖粉75g，或国内常用的含1分子结晶水的葡萄糖粉82.5g，溶于300ml水内)备用；(2)第1次抽血应在服糖前，前臂采血标本测定血糖。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "葡萄糖溶液"}, "object_type": {"@value": "药品名称"}}]}
{"text": "血糖控制情况影响心血管疾病(CVD)患者预后。英国前瞻性糖尿病研究(UKPDS)提示，早期严格血糖控制对降低大血管并发症非常重要；但目前还没有足够的临床研究证明，更加严格的血糖控制(如HbA1c<6.5%)可使所有CVD合并糖尿病患者有更进一步的心血管获益。对随机对照研究如退伍军人糖尿病事件研究(VADT)、控制糖尿病患者心血管危险行动(ACCORD)、糖尿病治疗和血管保护行动：百普乐与达美康缓释片对照评估研究(ADVANCE)进行的荟萃分析，也未发现口服降糖药强化治疗可降低心血管事件风险。同时，强化血糖控制会增加低血糖事件发生率，低血糖可诱发合并CVD的糖尿病患者发生心肌梗死及卒中等。因此，重视低血糖的危害、预防低血糖的发生，对心血管疾病合并糖尿病患者尤为重要。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "心血管疾病(CVD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病(CVD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "CVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "CVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "CVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "血管", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "低血糖", "subject_type": "患病病因", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "低血糖", "subject_type": "患病病因", "object": {"@value": "卒中"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "增加磺脲类药物发生低血糖事件的主要因素有：高龄，饮酒，合并肝、肾疾病，药物过量，药物相互作用等。糖尿病患者在使用磺脲类药物时，预防低血糖的措施包括：①年长、体弱的患者建议选用低血糖风险相对低的格列齐特缓释片、格列美脲，或者其他短效制剂；2应从小剂量开始服用，并根据血糖监测结果缓慢加量至最佳剂量；③饮食方面应定食定量，避免餐前剧烈运动。如果出现腹泻、呕吐等症状，应减少药物剂量；④每天的运动量应保持相对稳定。运动量过大也可引起低血糖，在外出旅游、登山时，应适量增加饮食。对于绝大多数可被患者察觉的、有症状的低血糖事件，可通过补充含糖食物或口服/静脉推注20g葡萄糖予以纠正，若15~20min后症状仍不能缓解或血浆葡萄糖水平仍很低可以重复给予葡萄糖。对于发生严重低血糖事件的患者，尤其格列本脲所致者，需在静脉推注葡萄糖后给予较长时间(24~72h)的葡萄糖静脉滴注以防止低血糖的再次发生，并至少观察3d，密切监测血糖水平。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "腹泻", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "呕吐", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列齐特缓释片"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列美脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "葡萄糖"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉推注", "subject_type": "用药方法", "object": {"@value": "葡萄糖"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "20g", "subject_type": "用药剂量", "object": {"@value": "葡萄糖"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列本脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列本脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉推注", "subject_type": "用药方法", "object": {"@value": "葡萄糖"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉滴注", "subject_type": "用药方法", "object": {"@value": "葡萄糖"}, "object_type": {"@value": "药品名称"}}]}
{"text": "血尿酸水平和神经系统疾病的关系复杂，HUA血性卒中的发生及预后不良，生理浓度的血尿酸水平对神经系统有一定的保护作用，血尿酸水平过低有可能增加神经退行性疾病发生的风险，故将血尿酸水平控制在合理范围内有助于整体健康。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血尿酸水平", "subject_type": "检查指标", "object": {"@value": "神经系统疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸水平", "subject_type": "检查指标", "object": {"@value": "神经退行性疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "因此，在患者可以耐受的情况下，使用单药最佳剂量(2000mg/d)的二甲双胍治疗不但可以使血糖控制尽早达标，且可使血糖得到更长时间的良好控制，如果出现可耐受的不良反应时，可适当减量；如果不能耐受，建议尽早更换其他降糖药。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "2000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "二甲双胍通过减少肝脏葡萄糖的输出和改善外周胰岛素抵抗而降低血糖，被多个国家的糖尿病诊治指南推荐为T2DM治疗一线用药。", "spo_list": [{"Combined": false, "predicate": "发病机制", "subject": "外周胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "老年糖尿病患者的知晓率、诊断率、治疗率均不高，老年糖尿病以餐后血糖升高为多见，尤其是新诊断的患者，即使是联合空腹血糖和糖化血红蛋白(HbA1c)做筛查时，仍有1/3比例的餐后高血糖患者漏诊。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "餐后血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "空腹血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "糖化血红蛋白(HbA1c)", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(4)分娩及产料、儿料处理：住院期间如出现母儿并发症，应及时联合产科进病情评估，根据病情决定终止妊娠时机及分娩方式。新生儿出生后易发生低血糖，严密监测其血糖变化及时发现低血糖，提早喂糖水、开奶，必要时进行静脉葡萄滴注。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "提早喂糖水、开奶", "subject_type": "非药治疗", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "⑥维格列汀和沙格列汀在纽约心功能分级(NYHA)为Ⅰ-Ⅱ级的充血性心力衰竭的患者中经验有限，此类患者中慎用；尚未在Ⅲ-Ⅳ级充血性心力衰竭的患者中进行临床试验，不推荐在此类患者中使用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "维格列汀", "subject_type": "药品名称", "object": {"@value": "充血性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "沙格列汀", "subject_type": "药品名称", "object": {"@value": "充血性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "Ⅰ-Ⅱ级", "subject_type": "分期分型", "object": {"@value": "充血性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "充血性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "Ⅲ-Ⅳ级充血性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "Ⅲ-Ⅳ级", "subject_type": "分期分型", "object": {"@value": "Ⅲ-Ⅳ级充血性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "充血性", "subject_type": "分期分型", "object": {"@value": "Ⅲ-Ⅳ级充血性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "充血性", "subject_type": "分期分型", "object": {"@value": "充血性心力衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "①蜜月期：初诊1型糖尿病患者经胰岛素规范治疗后可短期停用胰岛素或每日使用很少量胰岛素治疗，血糖水平就能维持在接近正常或正常的范围内，即1型糖尿病蜜月期。在此阶段根据血糖监测情况，可每日≤3次小剂量胰岛素(包括预混胰岛素)注射，但应以维持血糖达标为准；如出现血糖波动大、血糖不易控制，需频繁调整胰岛素用量等情况，建议及时评估胰岛功能并及时改用胰岛素强化治疗方案。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日≤3次", "subject_type": "用药频率", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日≤3次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "极高危的T2DM患者，除非存在禁忌证，无论", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "如果增加二甲双胍剂量后发生严重胃肠道反应，可以降至之前较低的剂量，耐受后可再尝试增大剂量。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "严重胃肠道反应", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "2.3.3 起始剂量对于(1)情况，早晚餐前等剂量转换，午餐前加2~4IU或每天胰岛素总量的10%，并可能需要减少早餐前的剂量2~4IU；对于(2)情况，临床医生根据具体情况决定。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "2~4IU", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2~4IU", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "针对老年糖尿病患者，实施个体化药物治疗方案控制血糖并避免或最小化药物相关的不良反应是必要的。老年糖尿病患者对低血糖耐受性差，易出现无症状性低血糖和严重低血糖，需要特别关注。因此，在选择降糖药物时，老年患者应着重考虑药物的低血糖风险。若患者既往有严重低血糖史、预期生存期较短、或合并其他严重疾病，如果需要联合磺脲类药物治疗，宜选择降糖作用较温和、作用时间较短、低血糖风险小的磺脲类药物，避免使用格列本脲。无论选择何种磺脲类药物，都应从最小剂量开始，严密监测血糖变化，根据血糖逐步调整至合适剂量，将低血糖的发生风险降至最小。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列本脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(1)2型糖尿病的一线首选和全程用药：在横向对比中，最佳有效剂量(2000毫克/天)二甲双胍治疗的降糖疗效要强于其他口服降糖药；在纵向对比中，与以其他口服降糖药物作为一线药物治疗的患者相比，以二甲双胍作为一线治疗的患者加用第二种口服降糖药或需要联合胰岛素治疗的时间最晚，以后需调整治疗方案的可能性也最低。二甲双胍减轻体重的这个“副作用”令其成为联合治疗中的“百搭药“。此外，二甲双胍还具有心血管保护作用，安全性和耐受性也很好，价格还不算贵。有这么多好处，也难怪该共识给出这样的建议，而且是最高级别的推荐——如无禁忌证，二甲双胍是治疗2型糖尿病的首选药物和联合治疗方案中的基础治疗药物，且应一直保留在糖尿病治疗方案中。记得在2007年版的《中国2型糖尿病防治指南》中还仅建议超重或肥胖的2型糖尿病患者将二甲双胍作为一线药物，此后的研究证据显示二甲双胍在正常体重/超重/肥胖的2型糖尿病患者中的疗效相当，体重并不是能否使用二甲双胍治疗的决定因素，所以早在2010年版的《中国2型糖尿病防治指南》中就已经开始给出与该共识类似的建议。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2000毫克/天", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "减轻体重", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.3 每日3次预混胰岛素类似物治疗的SMBG方案每日3次预混胰岛素类似物治疗的开始阶段应每天监5~7个时间点血糖，包括空腹、三餐前后、睡前，血糖达标后每日监测2~4个时间点血糖(见表4)。3.4 注意事项在胰岛素治疗期间，如有低血糖表现时需随时监测血糖；如出现不可解释的空腹高血糖或夜间低血糖时，应监测夜间血糖(如3am血糖)。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "每日3次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日3次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "高血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "对于计划妊娠的糖尿病患者，应严格控制血糖目标值HbA1c<6.5%，如应用胰岛素可适当放宽HbA1c<7%以防止低血糖发生。不建议HbA1c>8%的患者妊娠，这些患者应首先应控制血糖，因为高血糖会明显增加早期流产和胎儿畸形风险。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "高血糖", "subject_type": "患病病因", "object": {"@value": "早期流产"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "高血糖", "subject_type": "患病病因", "object": {"@value": "胎儿畸形"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "早期", "subject_type": "分期分型", "object": {"@value": "早期流产"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "对于T2DM合并ASCVD患者，应采取综合管理策略，全面控制高血糖、高血压、血脂异常、超重或肥胖等多重心血管危险因素。在血糖管理方面，临床医师应充分考虑降糖药物的疗效与安全性之间的平衡，并且全面了解常用降糖药物的心血管安全性，这样才能熟练掌握其应用原则。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "合理运动可改善胰岛素敏感性、骨酪肌功能、改善代谢紊乱，对改善生活质量有正反馈作用。(1)运动治疗前进行医学评估，严格把握适应证和禁忌证。(2)根据病程、严重程度、并发症等，并综合考虑年龄、家庭状况、运动习惯、文化背景等多种因素，制定个体化运动处方。运动处方应包括运动频率、运动强度、运动时间、运动类型和运动量5大要素。运动类型应以有氧运动为主。(3)注意事项：运动前、后监测血糖以预防低血糖，关键是自我监测与医师指导。如运动前血糖<4.2mmol/L或有低血糖反应，应降低降糖药物的使用剂量。T2DM合并肥胖患者，运动时应注意预防关节疼痛和不适。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "基层糖尿病微血管病变筛查与防治专家共识 ", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "禁忌证：对别嘌醇过敏、严重肝肾功能不全和明显血细胞低下者、孕妇、有可能怀孕妇女以及哺乳期妇女。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肝肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "e.阿格列汀在中度肾功能受损患者中使用剂量为推荐剂量减半，重度肾功能受或终末期肾功能衰竭患者中使用剂量为推荐量的四分之一。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "阿格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能受"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿格列汀", "subject_type": "药品名称", "object": {"@value": "终末期肾功能衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "推荐剂量减半", "subject_type": "用药剂量", "object": {"@value": "阿格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "推荐量的四分之一", "subject_type": "用药剂量", "object": {"@value": "阿格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能受"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "终末期", "subject_type": "分期分型", "object": {"@value": "终末期肾功能衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "终末期肾功能衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)每日多次胰岛素注射方案", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日多次", "subject_type": "用药频率", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(2)预混人胰岛素应在餐前30min皮下注射，预混胰岛素类似物可在餐前即刻注射或餐后立即注射；", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "餐前30min皮下注射", "subject_type": "用药方法", "object": {"@value": "预混人胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "餐前即刻注射", "subject_type": "用药方法", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "餐后立即注射", "subject_type": "用药方法", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "对伴CVD或CVD极高危患者血糖控制目标要适当放宽，治疗过程中要避免血糖下降速度过快和发生低血糖；并且该组患者多同时服用其他干预CVD危险因素的药物，应慎重选择降糖药物，注意药物的禁忌证和药物间的相互作用。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "CVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "CVD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "DPP-4抑制剂均为口服制剂，使用方便，也具有葡萄糖浓度依赖性降低血糖作用，低血糖发生率低，对体重的影响小，已有报告阿格列汀和沙格列汀对CVD的长期安全性良好，胃肠道不良反应少。目前DPP-4抑制剂在国内被批准用于单药或与二甲双胍或与磺脲类联合治疗。综上所述，作为新一类2型糖尿病的治疗药物，基于GLP-1的降糖药物为临床控制糖尿病提供了新的治疗手段。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "DPP-4抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "DPP-4抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿格列汀", "subject_type": "药品名称", "object": {"@value": "CVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道不良反应", "subject_type": "不良反应", "object": {"@value": "阿格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "沙格列汀", "subject_type": "药品名称", "object": {"@value": "CVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道不良反应", "subject_type": "不良反应", "object": {"@value": "沙格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "GLP-1的降糖药物", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "成年人具有下列任何一个及以上危险因素，可被定义为糖尿病高危人群，应进行糖尿病的筛查。(1)有糖调节受损史(定义见诊断标准)；(2)年龄≥40岁；(3)超重(BMI≥24kg/m2)或肥胖(BMI≥28kg/m2)和/或中心性肥胖(男性腰围≥90cm，女性腰围≥85cm)；(4)2型糖尿病患者的一级亲属；(5)高血压(血压≥140/90mmHg，1mmHg=0.133kPa)，或正在接受降压治疗；(6)血脂异常[HDL-C≤0.91mmol/L(35mg/dI)或TG≥2.26mmol/L(200mg/dI)]，或正在接受调脂治疗；(7)动脉粥样硬化性心脑血管疾病患者；(8)其他：①静坐生活方式；2有巨大儿(出生体重≥4kg)生产史，妊娠期糖尿病史；③有一过性类固醇诱导性糖尿病病史者；④多囊卵巢综合征患者；⑤严重精神病和/或长期接受抗抑郁症药物治疗的患者。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "中心性", "subject_type": "分期分型", "object": {"@value": "中心性肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HDL-C", "subject_type": "检查指标", "object": {"@value": "血脂异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "TG", "subject_type": "检查指标", "object": {"@value": "血脂异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "动脉", "subject_type": "患病部位", "object": {"@value": "动脉粥样硬化性心脑血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心脑血管", "subject_type": "患病部位", "object": {"@value": "动脉粥样硬化性心脑血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "妊娠期", "subject_type": "分期分型", "object": {"@value": "妊娠期糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "一过性", "subject_type": "分期分型", "object": {"@value": "一过性类固醇诱导性糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "类固醇诱导性", "subject_type": "分期分型", "object": {"@value": "一过性类固醇诱导性糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "卵巢", "subject_type": "患病部位", "object": {"@value": "多囊卵巢综合征"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.糖尿病足的分级 ", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "5.血管影像检查：包括动脉彩色多普勒超声检查、CT血管造影(CTA) 、磁共振血管造影(MRA) 和数字减影血管造影(DSA)血管彩色多普勒检查具有无创、简便的特点，可以了解动脉硬化斑块状况及有无动脉狭窄或闭塞，适用于血管病变大范围筛查。 CTA和MR A具有成像清晰的特点，可以显示血管有无狭窄或闭塞，但准确率低于DSA。对于肾功能正常者，CTA目前可作为糖尿病足下肢血管病变的首选影像学检查手段。DSA仍是诊断下肢血管病变的金标准，可以准确显示动脉堵塞状况及侧支循环建立情况，对外科治疗方案的选择有重要作用。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "血管影像检查", "subject_type": "检查方法", "object": {"@value": "血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血管影像检查", "subject_type": "检查方法", "object": {"@value": "动脉硬化斑块"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "动脉彩色多普勒超声检查", "subject_type": "检查方法", "object": {"@value": "血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "动脉彩色多普勒超声检查", "subject_type": "检查方法", "object": {"@value": "动脉硬化斑块"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "CT血管造影(CTA)", "subject_type": "检查方法", "object": {"@value": "血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "CT血管造影(CTA)", "subject_type": "检查方法", "object": {"@value": "动脉硬化斑块"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "磁共振血管造影(MRA)", "subject_type": "检查方法", "object": {"@value": "血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "磁共振血管造影(MRA)", "subject_type": "检查方法", "object": {"@value": "动脉硬化斑块"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "数字减影血管造影(DSA)", "subject_type": "检查方法", "object": {"@value": "血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "数字减影血管造影(DSA)", "subject_type": "检查方法", "object": {"@value": "动脉硬化斑块"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血管彩色多普勒检查", "subject_type": "检查方法", "object": {"@value": "血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血管彩色多普勒检查", "subject_type": "检查方法", "object": {"@value": "动脉硬化斑块"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "动脉", "subject_type": "患病部位", "object": {"@value": "动脉硬化斑块"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "动脉狭窄或闭塞", "subject_type": "临床表现", "object": {"@value": "血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "血管", "subject_type": "患病部位", "object": {"@value": "血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "CTA", "subject_type": "检查方法", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "CTA", "subject_type": "检查方法", "object": {"@value": "下肢血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "影像学检查", "subject_type": "检查方法", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢血管", "subject_type": "患病部位", "object": {"@value": "下肢血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "影像学检查", "subject_type": "检查方法", "object": {"@value": "下肢血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "DSA", "subject_type": "检查方法", "object": {"@value": "下肢血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢血管", "subject_type": "患病部位", "object": {"@value": "下肢血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "动脉堵塞", "subject_type": "临床表现", "object": {"@value": "下肢血管病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "福辛普利在肾功能不全患者中应减量或停药，它在透析中不可清除，但在高流量透析膜进行血液透析时较易引起类过敏反应。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "福辛普利", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "由于糖尿病是一种终身性的慢性代谢性疾病，其治疗要求患者具有高度的自我管理能力，DSME/S理论的应用对患者的临床、社会心理和行为等方面均有积极的影响。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "DSME/S", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "7.糖尿病外周神经病变：老年糖尿病患者约半数以上合并外周神经病变(DPN)(C)。以感觉神经、自主神经受损最为常见，临床表现多样(C)。由于老年患者伴存的骨关节病变、精神异常、认知障碍等病变在一些症状的发生中相互影响，诊断DPN时需要综合分析。α-硫辛酸、前列地尔和甲基维生素B12在改善DPN引起的感觉异常、肢体麻木和疼痛方面有一定效果，非麻醉性镇痛药和辣椒辣素对减轻痛性神经病变症状有一定作用(II)。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "外周神经", "subject_type": "患病部位", "object": {"@value": "糖尿病外周神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "外周神经", "subject_type": "患病部位", "object": {"@value": "外周神经病变(DPN)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "骨关节", "subject_type": "患病部位", "object": {"@value": "骨关节病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "α-硫辛酸", "subject_type": "药品名称", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "前列地尔", "subject_type": "药品名称", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "甲基维生素B12", "subject_type": "药品名称", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "感觉异常", "subject_type": "临床表现", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "肢体麻木", "subject_type": "临床表现", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "疼痛", "subject_type": "临床表现", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "辣椒辣素", "subject_type": "药品名称", "object": {"@value": "痛性神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "痛性神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "非麻醉性镇痛药", "subject_type": "药品名称", "object": {"@value": "痛性神经病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "一旦发生足部皮肤溃烂，应尽快到足病专科就诊，接受多学科综合治疗，早期控制感染及损伤，降低截肢风险(B)。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "足部皮肤溃烂", "subject_type": "临床表现", "object": {"@value": "感染"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "住院血糖管理模式是在管理理念指导下建构起来，由管理方法、管理制度、管理工具、管理程序组成的住院血糖管理行为体系结构。虽然我国糖尿病患病率逐年升高，但关于住院患者血糖管理模式的研究报道较少。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.避免术前不必要的长时间禁食，糖尿病患者择期手术应安排在当日第一台进行。禁食期间注意血糖监测，必要时输注含糖液体。由于术前精神紧张应激，手术患者发生低血糖的风险低于普通住院患者。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "禁食", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "输注", "subject_type": "用药方法", "object": {"@value": "含糖液体"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "精神紧张应激", "subject_type": "患病病因", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.运动：体力活动可诱导糖尿病肾病早期的尿蛋白暂时升高，长期规律的运动可通过提高胰岛素敏感性、改善糖耐量，减轻体重，改善脂质代谢，改善内皮功能，控制血糖、血压，，减缓糖尿病及糖尿病肾病的发生发展。糖尿病控制和并发症防治试验(DCCT)的回顾分析却表明运动对1型糖尿病微血管病变的预后无改善作用，但无证据表明运动带来危害，故仍建议1型糖尿病患者运动。FinnDiane研究结果显示，低频率低强度体育锻炼的1型糖尿病患者发生糖尿病肾病的比例更高。因此糖尿病肾病患者运动的频率强度应达到一定的要求。患者每周应至少进行150min以上中等强度的有氧运动(运动时心率达到最高值的50%~70%)，每周至少运动3d，每周至少安排2次对抗性训练。不适当的运动可因胰岛素水平不足诱发酮症，也可因过度耗能诱发低血糖，因而运动强度、持续时间、频率、项目的选择都要个体化，建议糖尿病肾病患者在专业人士的指导下制定合理的运动方案，或参加运动计划，提高依从性，减少运动不良后果的发生。对于进展至ESRD的糖尿病肾病患者，每周2~3次以上的有氧运动、对抗性运动有利于控制血压、减轻炎症、改善生活质量，但证据大多来自小样本试验。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿蛋白", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "糖耐量", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "长期规律的运动", "subject_type": "非药治疗", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "不适当的运动", "subject_type": "患病病因", "object": {"@value": "酮症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素水平不足", "subject_type": "发病机制", "object": {"@value": "酮症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "不适当的运动", "subject_type": "患病病因", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "每周2~3次以上的有氧运动、对抗性运动", "subject_type": "非药治疗", "object": {"@value": "ESRD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "ESRD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "每周2~3次以上的有氧运动、对抗性运动", "subject_type": "非药治疗", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "运动", "subject_type": "非药治疗", "object": {"@value": "1型糖尿病微血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病微血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "1型糖尿病微血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "运动", "subject_type": "非药治疗", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "抑制糖尿病肾病患者体内的肾素活性，可显著降低其血压和蛋白尿水平。2型糖尿病患者中，肾素抑制剂阿利吉仑联合氯沙坦与单用氯沙坦相比，尿蛋白更低。然而，近期一项在2型糖尿病患者中进行的阿利吉仑临床试验却因阿利吉仑与ACEI/ARB的联合应用所导致的严重不良事件所终止，不良反应包括肾功能衰竭、高血钾及低血压等。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "肾功能衰竭", "subject_type": "不良反应", "object": {"@value": "阿利吉仑"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "肾功能衰竭", "subject_type": "不良反应", "object": {"@value": "ACEI"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "肾功能衰竭", "subject_type": "不良反应", "object": {"@value": "ARB"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "高血钾", "subject_type": "不良反应", "object": {"@value": "阿利吉仑"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "高血钾", "subject_type": "不良反应", "object": {"@value": "ACEI"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "高血钾", "subject_type": "不良反应", "object": {"@value": "ARB"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血压", "subject_type": "不良反应", "object": {"@value": "阿利吉仑"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血压", "subject_type": "不良反应", "object": {"@value": "ACEI"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血压", "subject_type": "不良反应", "object": {"@value": "ARB"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "蛋白尿", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "肾素抑制剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿利吉仑", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "氯沙坦", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "氯沙坦", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿蛋白", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿利吉仑", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿利吉仑", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ACEI", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ARB", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "推荐DPP-4i作为2型糖尿病患者的二线治疗之一。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4i", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "DPP-4抑制剂国内注册研究的主要疗效见表1。此外，在以二甲双胍为基础治疗，再加用DPP-4抑制剂与其他多种降糖药物，包括磺脲类、噻唑烷二酮类的许多对比研究中，显示DPP-4抑制剂在降低HbA1c方面，与对照药的疗效相当。在中国2型尿病人群的对比研究中维格列汀与阿卡波糖降低HbA1c的作用相似。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "维格列汀", "subject_type": "药品名称", "object": {"@value": "2型尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿卡波糖", "subject_type": "药品名称", "object": {"@value": "2型尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病肾病是由糖尿病引起的肾脏损伤，以往用DN(diabetic nephropathy)表示，2007年美国肾脏病基金会(NKF)制定了肾脏病生存质量指导指南，简称NKF/KDOQI。该指南建议用DKD(diabetic kidney disease)取代DN。2014年美国糖尿病协会(ADA)与NKF达成共识，认为DKD是指由糖尿病引起的慢性肾病，主要包括肾小球滤过率(GFR)低于60ml·min-1·1.73m-2或尿白蛋白/肌酐比值(ACR)高于30mg/g持续超过3个月。糖尿病性肾小球肾病(diabetic glomerulopathy)专指经肾脏活检证实的由糖尿病引起的肾小球病变。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "糖尿病", "subject_type": "患病病因", "object": {"@value": "慢性肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肾小球滤过率(GFR)", "subject_type": "检查指标", "object": {"@value": "慢性肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿白蛋白/肌酐比值(ACR)", "subject_type": "检查指标", "object": {"@value": "慢性肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "慢性肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾小球", "subject_type": "患病部位", "object": {"@value": "糖尿病性肾小球肾病(diabetic glomerulopathy)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病性肾小球肾病(diabetic glomerulopathy)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "糖尿病", "subject_type": "患病病因", "object": {"@value": "肾小球病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾小球", "subject_type": "患病部位", "object": {"@value": "肾小球病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "推荐7：所有T2DM合并血脂异常患者均应进行生活方式干预，在此基础上血脂仍未达标者接受中等强度的他汀类药物治疗。若他汀类药物不耐受，则换用另一种他汀类药物、减低他汀剂量或给药频次、或小剂量他汀合用胆固醇吸收抑制剂依折麦布或PCSK9抑制剂。若LDL-C未达到预期目标，则进一步强化调整生活方式，并中等强度他汀合用胆固醇吸收抑制剂折麦布或PCSK9抑制剂。若他汀治疗前TG>5.6hmol/L，服用降TG药物(如贝特类或高纯度鱼油)，以减少发生急性胰腺炎的风险；若他汀治疗后TG≥2.3mmol/L，可在他汀类药物治疗基上合用贝特类或高纯度鱼油。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "中等强度的他汀类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "不耐受", "subject_type": "不良反应", "object": {"@value": "他汀类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀", "subject_type": "药品名称", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "TG", "subject_type": "检查指标", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "降TG药物", "subject_type": "药品名称", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝特类", "subject_type": "药品名称", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "高纯度鱼油", "subject_type": "药品名称", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "胰腺", "subject_type": "患病部位", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "急性", "subject_type": "分期分型", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "对于进食差，或无法正常进食的患者，可考虑以基础胰岛素为主，辅以临时短效或速效胰岛素注射；营养摄入充足患者，则推荐基础一餐时胰岛素治疗方案以及必要时临时补充短效或速效胰岛素，有条件的也可考虑胰岛素泵治疗。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "短效或速效胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "磺脲类药物单药治疗可使HbA1c下降1%~2%，降糖作用在常规剂量内呈剂量依赖性，且患者基线HbA1c越高，HbA1c降幅越大。磺脲类药物可以与多种其他降糖药物联合应用，并且可以作为治疗方案的基础用药之一长期使用。长期使用磺脲类药物治疗的患者应严密监测有无低血糖和体重增加。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "1.泌尿生殖道感染：SGLT2i促进大量葡萄糖从尿液中排出，增加了泌尿生殖道局部的葡萄糖浓度，导致发生细菌和霉菌感染的机会增加。临床研究数据显示，SGLT2i治疗后其生殖道感染的发生率为4.8%~5.7%，但多为轻到中度感染，常规抗感染治疗有效：女性较男性生殖道感染发生率稍高，最为常见的生殖道感染疾病在女性中为外阴阴道真菌感染、阴道念珠菌病和外阴阴道炎，在男性中为念珠菌性龟头炎和阴茎包皮炎；有感染疾病史的患者，感染率升高；且发生感染后，需抗感染治疗；女性生殖道感染大部分发生在用药的初始4个月内，而男性则在第一年内。为避免生殖道和泌尿道感染的发生，建议使用前询问病史，半年内反复发生泌尿生殖感染的患者不推荐使用；在使用过程中，如果发生感染并需要抗感染治疗时建议暂停SGLT2i。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "泌尿生殖道", "subject_type": "患病部位", "object": {"@value": "泌尿生殖道感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "阴道", "subject_type": "患病部位", "object": {"@value": "阴道念珠菌病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "外阴阴道", "subject_type": "患病部位", "object": {"@value": "外阴阴道炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "龟头", "subject_type": "患病部位", "object": {"@value": "念珠菌性龟头炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "阴茎包皮", "subject_type": "患病部位", "object": {"@value": "阴茎包皮炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "外阴阴道", "subject_type": "患病部位", "object": {"@value": "外阴阴道真菌感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "生殖道", "subject_type": "患病部位", "object": {"@value": "生殖道感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "生殖道", "subject_type": "患病部位", "object": {"@value": "生殖道感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "生殖道", "subject_type": "患病部位", "object": {"@value": "生殖道感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "生殖道", "subject_type": "患病部位", "object": {"@value": "生殖道感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "泌尿道", "subject_type": "患病部位", "object": {"@value": "泌尿道感染"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.双胍类：常用药物为二甲双胍，起始剂量500mg/d，随餐服用，逐渐加量，最大剂量2000mg/d。主要通过减少肝脏葡萄糖的输出和改善肝脏、肌肉胰岛素抵抗而降低血糖。二甲双胍可以使HbA1c下降1%~2%，并可减轻体重。单独使用二甲双胍极少发生低血糖。常见的副作用为胃肠道反应，绝大多数患者均能耐受；严重的副作用是乳酸性酸中毒。因此，禁用于肾功能不全[血肌酐水平男性>132.6μmol/L(1.5mg/dI)，女性>123.8μmol/L(1.4mg/dI)；或肾小球滤过率<45ml·min-1·1.73m-2]、肝功能不全、严重感染、缺氧或接受大手术的患者。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "500mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血肌酐水平", "subject_type": "检查指标", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肾小球滤过率", "subject_type": "检查指标", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "对于口服降糖药在T2DM合并CKD患者的应用，参考药品说明书、近期国际指南及经典专著，如“The Kidney”，若缺乏用药经验，则依据从严原则，以保护医患利益。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "中国医师协会内分泌代谢科医师分会于2013年组织国内的内分泌科和肾内科领域专家,共同制定了“2型糖尿病合并慢性肾脏病口服降糖药用药原则中国专家共识”。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病微循环障碍在糖尿病肾病、糖尿病视网膜病变、糖尿病神经病变和糖尿病足病的发生发展中发挥着重要作用，是这些糖尿病慢性并发症共同的病因学机制之一。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "糖尿病神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "微循环障碍", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "公认的低血糖发生少的甘精胰岛素的大型研究最新结果显示，甘精胰岛素低血糖发生的风险明显高于口服药。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "甘精胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "甘精胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "血尿酸水平增高不仅增加2型糖尿病的患病风险，而且是非糖尿病人群未来发生2型糖尿病的独立危险因素。HUA还是糖尿病肾病进展和恶化的重要预测因子。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "九、T2DM患者的血脂异常预防策略 ", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "Meta分析证明.烟酸单药或联合他汀治疗可有效改善糖尿病患者的血脂异常，但长期治疗可升高空腹血糖(+0.085mmo/L，P<0.05)。此外，目前没有确切证据证明烟酸用于糖尿病患者中可降低心血管事件风险，而烟酸与他汀联合的终点事件研究——干预对全球卫生健康的影响研究(AIM-HIGH)，因可能增加缺血性卒中风险(1.6%对0.9%)而提前终止。因此，不推荐T2DM合并血脂异常患者使用烟酸。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "他汀", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "烟酸", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "空腹血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "烟酸", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "烟酸", "subject_type": "药品名称", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "缺血性卒中", "subject_type": "不良反应", "object": {"@value": "烟酸"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "缺血性卒中", "subject_type": "不良反应", "object": {"@value": "他汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "烟酸", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病患者血糖波动的主要原因包括胰岛β细胞功能状态、饮食、运动和药物等。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "HUA具有两层含义，一种是理化性质上的定义，另一种流行病学上的定义。既往HUA定义的依据是流行病学数据，即正常嘌呤饮食下，非同日两次空腹血尿酸水平男性>420μmol/L，女性>360μmol/L。而理化性质上的定义，也称为绝对HUA，正常人体血液pH值为7.35~7.45，处于微碱性，而尿酸在这样的酸碱环境下，浓度—H超过420 μmol/L(不分男女)，便会析出尿酸钠结晶而沉积在关节腔和其他组织中，继而引起痛风性关节炎和/或其他相关组织损伤。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "空腹血尿酸", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血液pH", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "尿酸钠结晶而沉积在关节腔和其他组织中", "subject_type": "患病病因", "object": {"@value": "痛风性关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "关节", "subject_type": "患病部位", "object": {"@value": "痛风性关节炎"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "抗体阳性的患儿或合并有Grave病，重症肌无力等自身免疫性疾病者，相对来说更支持1型糖尿病，同时或考虑是否存在自身免疫性多腺体病。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "抗体", "subject_type": "检查指标", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "抗体", "subject_type": "检查指标", "object": {"@value": "自身免疫性多腺体病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "目前T2DM的诊断标准与分型参考WHO 1999年标准；肥胖诊断标准参考《中国成人肥胖症防治专家共识》和《中国2型糖尿病防治指南(2013年)》腹型肥胖的标准。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1. 1 型糖尿病患者", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "1 型", "subject_type": "分期分型", "object": {"@value": "1 型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(4)降纤治疗：糖尿病足患者的纤维蛋白原高于正常者，可给予降纤治疗。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "纤维蛋白原", "subject_type": "检查指标", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(3)联合用药：尽管磺脲类药物理论上可以和各种降糖药联用以获得更好的降糖效果，但正如之前提到的，考虑到磺脲类药物的低血糖和增重副作用，它更适合与二甲双胍、α一糖苷酶抑制剂等低血糖风险低且具有减重作用的药物联用。需要特别指出的是，尽管通常不推荐磺脲类药物联合胰岛素治疗，但胰岛细胞尚有部分分泌功能的2型糖尿病患者可考虑使用磺脲类药物联合基础胰岛素治疗，不过应特别注意饮食和运动量，以及体重增加和低血糖。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "增重", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "注意饮食和运动量", "subject_type": "非药治疗", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "由于慢性肾病患者可能因高蛋白饮食而增加肾脏血流负荷，建议合并慢性肾病患者应慎重选择高蛋白饮食。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "慢性肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "高蛋白饮食", "subject_type": "非药治疗", "object": {"@value": "慢性肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "慢性肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "与2型糖尿病并存的其他疾病比较多，这些情况下血糖控制目标目前缺乏相应的循证医学证据和共识。比如：恶性肿瘤、老年痴呆症、癫痫等。若患者预期寿命<5年者，HbA1c不应超过9%；预期寿命更长者，HbA1c可控制在7%左右。执行治疗方案较困难的情况，如精神或智力障碍者、视力障碍者、老年、高龄及独居者等，其血糖的控制目标应适当放宽，HbA1c不应超过9%，主要防止血糖过高引起的症状、急性代谢紊乱、感染和低血糖的发生。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "恶性", "subject_type": "分期分型", "object": {"@value": "恶性肿瘤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "精神或智力障碍"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "精神或智力障碍"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "视力障碍"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "视力障碍"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "急性", "subject_type": "分期分型", "object": {"@value": "急性代谢紊乱"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.特殊人群的治疗：(1)儿童和青少年2型糖尿病合并慢性肾脏病患者中，缺乏高血糖、高血压和血脂异常治疗方面的相关数据；但是生活方式干预(饮食、锻炼、减肥)是各种治疗的基础，因此对高血糖的控制应从改善生活方式开始。若生活方式干预不能控制血糖，应考虑降糖药治疗。尽管美国糖尿病协会(ADA)推荐口服降糖药作为儿童和青少年2型糖尿病患者的一线治疗，但其中仅二甲双胍被美国食品药品监督管理局(FDA)批准用于10岁以上的儿童，其使用注意事项与成人相同。(2)老年2型糖尿病合并慢性肾脏病患者：老年2型糖尿病患者除合并慢性肾脏病之外，还通常合并其他多种并发症和伴随症，尤其是心血管疾病以及认知功能障碍；因此应加强对多种危险因素的管理。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食", "subject_type": "非药治疗", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "锻炼", "subject_type": "非药治疗", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "减肥", "subject_type": "非药治疗", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "改善生活方式", "subject_type": "非药治疗", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "那格列奈83.0%在尿中排泄，所服药物的6.0%~16.0%以原型在尿中排泄。药代动力学研究显示，中度及重度肾功能损害的糖尿病患者中，包括在血液透析患者，那格列奈暴露无显著变化。有研究显示那格列奈的活性代谢产物在肾功能不全患者中仅少量增加，但降糖效力仅为原药1/5。一项纳人1170例老年糖尿病患者的回顾性研究显示，在合并肾功能不全的老年糖尿病患者中，那格列奈可降低HbA1c1.1%，低血糖发生率仅3.0%。基于以上资料，推荐那格列奈在肾功能损害患者中无需调整剂量：对于起始用药的GFR<30ml.min-1.(1.73m2)-1患者，应从每餐60mg开始。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "中度", "subject_type": "分期分型", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "重度", "subject_type": "分期分型", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "那格列奈", "subject_type": "药品名称", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "那格列奈", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "那格列奈", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "那格列奈", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "那格列奈", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "那格列奈", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "那格列奈"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "那格列奈", "subject_type": "药品名称", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "每餐60mg", "subject_type": "用药剂量", "object": {"@value": "那格列奈"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "不同的自主神经功能有相应的检测方法，如测定卧位和立位或Valsalva试验引起的血压变化和心率变化，可以反映心脏自主神经功能；B超检测膀胱残余尿和尿动力学测定有助于排尿困难的鉴别诊断。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "B超", "subject_type": "检查方法", "object": {"@value": "排尿困难"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "尿动力学测定", "subject_type": "检查方法", "object": {"@value": "排尿困难"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "膀胱残余尿", "subject_type": "检查指标", "object": {"@value": "排尿困难"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "心血管并发症是导致糖尿病患者死亡的最主要原因，因此，在选择糖尿病治疗药物的过程中，药物的心血管安全性是非常重要的考量因素。临床研究的数据汇集分析(pooled analysis)显示，DPP-4抑制剂不增加心血管事件。最新发表的SAVOR-TIMI53研究和EXAMINE研究为评估沙格列汀和阿格列汀心血管安全性的多中心、随机、双盲、对照的前瞻性临床研究。研究纳入未接受过肠促胰素类降糖药物的2型糖尿病(HbA1c≥6.5%)合并心血管高危风险患者，随机分为安慰剂组和治疗组。研究结果显示主要复合终点事件(包括心血管疾病导致的死亡、非致死性心肌梗死、非致死性缺血性脑卒中)发生率与安慰剂组相似，进一步明确了沙格列汀和阿格列汀心血管安全性良好。其他关注DPP-4抑制剂心血管安全性的诸多大型前瞻性临床研究正在进行中，如西格列汀的TECOS研究、利格列汀的CAROLINA，CARMELINA研究等。但现有的研究数据显示DPP-4抑制剂不增加2型糖尿病患者的心血管风险。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "非致死性心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "非致死性", "subject_type": "分期分型", "object": {"@value": "非致死性心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脑", "subject_type": "患病部位", "object": {"@value": "非致死性缺血性脑卒中"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "非致死性", "subject_type": "分期分型", "object": {"@value": "非致死性缺血性脑卒中"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "单中心研究显示60岁以上糖尿病患者下肢动脉病变的比例为3 5.4%。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "下肢动脉", "subject_type": "患病部位", "object": {"@value": "下肢动脉病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "本共识主要描述糖尿病周围神经病变 (diabetic peripheral neuropathy，DPN)。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "糖尿病周围神经病变 (diabetic peripheral neuropathy，DPN)"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "格列喹酮的代谢产物无降糖作用且大部分从粪便排泄，仅5%经肾脏排泄，受肾功能影响较小，但用于CKD患者的临床证据有限，格列喹酮曾用于GFR10~50ml/(min·1.73m2)患者，但试验设计不尽完善。格列喹酮可用于CKD1~3期的患者且无需调整剂量；4期用药经验有限，需谨慎用药；5期禁用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "CKD1~3期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~3期", "subject_type": "分期分型", "object": {"@value": "CKD1~3期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "4期", "subject_type": "分期分型", "object": {"@value": "CKD1~3期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "5期", "subject_type": "分期分型", "object": {"@value": "CKD1~3期"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2012年改善全球肾脏病预后组织(KDIGO)把CKD定义为肾脏出现影响健康的结构或功能异常超过3个月。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(3)预混胰岛素类似物可在餐前即刻注射或餐后立即注射；", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "餐前即刻注射", "subject_type": "用药方法", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "餐后立即注射", "subject_type": "用药方法", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "磺脲类促泌剂可导致低血糖的发生，但剂型改良后的缓释、控释制剂、格列奈类及格列美脲低血糖发生率相对较低。GUIDE研究结果显示，在血糖水平控制相似的情况下，不同磺脲类促泌剂所致低血糖发生风险不同(1b级)。ADVANCE以格列齐特缓释片为基础的降糖治疗严重低血糖年发生率仅为UKPDS采用格列本脲和氯磺丙脲为基础的降糖治疗的1/4(1b级)。因此，应根据不同胰岛素促泌剂的特点及糖尿病患者的血糖谱选择合适的胰岛素促泌剂，从而在保证降糖疗效的同时降低低血糖发生风险。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列美脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "严重低血糖", "subject_type": "不良反应", "object": {"@value": "格列齐特缓释片"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(3)单纯缺血性溃疡：此类患者无周围神经病变，以缺血性改变为主，较少见，需根据症状、体征及相关检查排除周围神经病变后方可诊断。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "缺血性改变为主", "subject_type": "临床表现", "object": {"@value": "单纯缺血性溃疡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "周围神经病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.应重视下肢的感觉障碍和腱反射检查。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "下肢", "subject_type": "患病部位", "object": {"@value": "下肢的感觉障碍"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "而对脑梗死溶栓患者而言，高血尿酸水平与脑梗死容积以及预后良好(改良Rankin量表评分小于2分)相关，较低血尿酸水平与恶性大脑中动脉梗死以及出血转化相关。溶栓患者高血尿酸水平与临床症状改善呈正相关，阿替普酶溶栓同时静脉输注尿酸治疗能够改善女性患者预后，而对于男性患者不明显，可能与女性基础血尿酸水平低于男性有关。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "脑", "subject_type": "患病部位", "object": {"@value": "脑梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脑", "subject_type": "患病部位", "object": {"@value": "脑梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "大脑中动脉", "subject_type": "患病部位", "object": {"@value": "恶性大脑中动脉梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉输注", "subject_type": "用药方法", "object": {"@value": "尿酸"}, "object_type": {"@value": "药品名称"}}]}
{"text": "5.其他：SGLT2i作为新型的口服降糖药物，其长期使用中的安全性也需要关注。在临床试验和药物上市后报告的一些不良事件，如膀胱癌、骨折、足趾截肢风险，以及急性肾损伤风险等需要在更多的临床研究和观察中予以进一步澄清。目前，临床研究数据尚未证实SGLT2i与膀胱癌发生风险间是否存在因果关系，上市后至今尚无相关肿瘤病例的报告.FDA和EMA根据不良事件报告系统的数据.已加强提醒在使用SGLT2i的过程中，注意骨折风险(坎格列净)、足趾截肢风险(坎格列净)及急性肾损伤风险(达格列净，坎格列净)。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "SGLT2i"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "膀胱", "subject_type": "患病部位", "object": {"@value": "膀胱癌"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "急性肾损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "膀胱", "subject_type": "患病部位", "object": {"@value": "膀胱癌"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "骨折", "subject_type": "不良反应", "object": {"@value": "坎格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "足趾截肢", "subject_type": "不良反应", "object": {"@value": "坎格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "急性肾损伤", "subject_type": "不良反应", "object": {"@value": "坎格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "急性肾损伤", "subject_type": "不良反应", "object": {"@value": "达格列净"}, "object_type": {"@value": "药品名称"}}]}
{"text": "格列吡嗪和格列齐特的代谢产物均无降糖活性，虽然主要经肾脏排泄，但低血糖风险小于格列本脲和格列美脲。格列吡嗪用于CKD1~2期患者无需调整剂量；3期减量，4~5期禁用。格列齐特用于CKD1~2期患者无需调整剂量；在3a期减量，3b期用药经验有限，需谨慎用药；4~5期禁用。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列吡嗪"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列齐特"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列本脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列美脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列吡嗪", "subject_type": "药品名称", "object": {"@value": "CKD1~2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "4~5期", "subject_type": "分期分型", "object": {"@value": "CKD1~2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3期", "subject_type": "分期分型", "object": {"@value": "CKD1~2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~2期", "subject_type": "分期分型", "object": {"@value": "CKD1~2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~2期", "subject_type": "分期分型", "object": {"@value": "CKD1~2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3a期", "subject_type": "分期分型", "object": {"@value": "CKD1~2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3b期", "subject_type": "分期分型", "object": {"@value": "CKD1~2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "4~5期", "subject_type": "分期分型", "object": {"@value": "CKD1~2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列齐特", "subject_type": "药品名称", "object": {"@value": "CKD1~2期"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)HbA1c<7.5%：适用于预期生存期>10年、较轻并发症及伴发疾病，有一定低血糖风险，应用胰岛素促泌剂类降糖药物或以胰岛素治疗为主的2型和1型糖尿病患者。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型和1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂类降糖药物", "subject_type": "药品名称", "object": {"@value": "2型和1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型和1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型和1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "2型和1型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.餐后高血糖对机体的其他不良影响：随着病程进展，胰岛β细胞功能减退及餐后血糖逐渐升高，而增高的餐后高血糖及血糖波动可使胰岛β细胞能进一步恶化。此外，有学者发现，餐后高血糖和PPG波动与老年人整体认知、执行和注意力障碍有关。", "spo_list": [{"Combined": false, "predicate": "发病机制", "subject": "胰岛β细胞功能减退", "subject_type": "发病机制", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "餐后血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛β细胞能进一步恶化", "subject_type": "发病机制", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "PPG", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.运动治疗与儿童减肥：一筒纳入了2项Meta分析的系统性综述，均显示体脂率有显著性降低。而其他肥胖指标(BMI、体重、中心性肥胖)则没有显著性差异。一篇纳入40项研究的系统性综述和Meta分析，评价了抗阻训练对肥胖儿童力量、体成分等的影响，显示抗阻运动对体成分有极小影响，且亚组分析显示运动量越大、年龄越小、随机对照设计产生更显著效果。一项纳入15个随机对照试验的系统性综述和Meta分析，比较仅饮食干预与饮食结合运动或仅运动干预对超重儿童减重和降低代谢风险的效果，结果显示，短期干预中仅饮食和饮食结合运动均产生了减重和代谢指标改善的效果，而长期干预显示饮食结合运动干预可以显著改善高密度脂蛋白胆固醇和空腹血糖、空腹胰岛素水平。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "抗阻训练", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食干预", "subject_type": "非药治疗", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "运动干预", "subject_type": "非药治疗", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "高密度脂蛋白胆固醇", "subject_type": "检查指标", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "空腹血糖", "subject_type": "检查指标", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "空腹胰岛素", "subject_type": "检查指标", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食结合运动", "subject_type": "非药治疗", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "此类药物均只需晨服一次即可，达格列净和恩格列净餐前或餐后均可服用。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "一次", "subject_type": "用药频率", "object": {"@value": "达格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "一次", "subject_type": "用药频率", "object": {"@value": "恩格列净"}, "object_type": {"@value": "药品名称"}}]}
{"text": "在我国大型城市住院T2DM患者中，25.1%合并冠心病，17.3%合并脑血管疾病。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脑血管", "subject_type": "患病部位", "object": {"@value": "脑血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "临床上选择他汀类药物剂量，在LDL-C达标的前提下，还需考虑安全性、耐受性和治疗费用。对于绝大多数T2DM患者，中等强度他汀(可使LDL-C水平降低30%~50%)是可选的降胆固醉治疗药物(推荐；A级证据)。中国胆固醇教育计划专家建议中指出：与白种人比较，我国人群平均胆固醇水平较低。中国国家糖尿病和代谢紊乱研究表明，中国居民的平均LDL-C水平为2.68mmol/L，明显低于欧美国家。因此，大多数中国患者经过中等强度他汀类药物治疗即可使LDL-C达标。此外，中国患者对于高强度他汀类药物治疗的耐受性也较差，发生肝毒性、肌肉毒性的风险明显高于欧美患者。基于疗效、耐受性及治疗费用的考虑，中等强度他汀类药物治疗适合于我国多数T2DM合并血脂异常患者，推荐临床选择效价比高的中等强度他汀，如辛伐他汀20~40mg、匹伐他汀2~4mg、阿托伐他汀10~20mg等。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "中等强度他汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "降胆固醉治疗药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C水平", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C水平", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C水平", "subject_type": "检查指标", "object": {"@value": "代谢紊乱"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "肝毒性", "subject_type": "不良反应", "object": {"@value": "高强度他汀类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "肌肉毒性", "subject_type": "不良反应", "object": {"@value": "高强度他汀类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "中等强度他汀类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "中等强度他汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "辛伐他汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "匹伐他汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿托伐他汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "20~40mg", "subject_type": "用药剂量", "object": {"@value": "辛伐他汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2~4mg", "subject_type": "用药剂量", "object": {"@value": "匹伐他汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "10~20mg", "subject_type": "用药剂量", "object": {"@value": "阿托伐他汀"}, "object_type": {"@value": "药品名称"}}]}
{"text": "三、T2DM合并肥胖的管理", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "⑥利拉鲁肽在纽约心脏病学会(NYHA)分级Ⅰ-Ⅱ级的充血性心力衰竭的患者中的治疗经验有限，尚无在Ⅲ-Ⅳ级充血性心力衰竭患者中的应用经验。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "利拉鲁肽", "subject_type": "药品名称", "object": {"@value": "充血性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心脏", "subject_type": "患病部位", "object": {"@value": "心脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "Ⅰ-Ⅱ级", "subject_type": "分期分型", "object": {"@value": "充血性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "Ⅲ-Ⅳ级", "subject_type": "分期分型", "object": {"@value": "充血性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "充血性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "充血性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "充血性", "subject_type": "分期分型", "object": {"@value": "充血性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "充血性", "subject_type": "分期分型", "object": {"@value": "充血性心力衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "恩格列净的心血管结局研究(EMPA-REGOUTCOME)已完成并发布了其研究结果。该研究中患者均为心血管疾病的高危人群。结果显示，恩格列净的治疗与全因死亡、心血管死亡、心血管病变、心力衰竭、肾功能下降和终末期肾病发生的风险下降相关。该研究提示对于糖尿病合并心血管疾病的患者，恩格列净具有心血管及肾脏保护作用。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管死亡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "终末期", "subject_type": "分期分型", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "恩格列净", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "GFR是评价肾脏功能的重要指标之一，我国估算肾小球滤过率(eGFR)课题协作组改良简化MDRD方程，制定了适合我国CKD患者的eGFR的评估公式：eGFR[ml/(min·1.73m2)]=175×Scr-1.234(mg/dL)×年龄-0.179(女性×0.79)。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肾小球滤过率(eGFR)", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "eGFR", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "eGFR", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "当合并CKDI~2期，他汀类药物的使用无须减量(图3)；当合并CKD3期，除普伐他汀限制使用，阿托伐他汀、辛伐他汀、氟伐他汀、瑞舒伐他汀均无须减量；当合并CKD4期，阿托伐他汀可无须减量，辛伐他汀应减量使用，而氟伐他汀、瑞舒伐他汀、普伐他汀均应限制使用；当合并CKD5期，透析前使用他汀治疗的患者.他汀类药物谨慎续用；不推荐在此期起始他汀治疗。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "他汀类药物", "subject_type": "药品名称", "object": {"@value": "CKDI~2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "I~2期", "subject_type": "分期分型", "object": {"@value": "CKDI~2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3期", "subject_type": "分期分型", "object": {"@value": "CKD3期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿托伐他汀", "subject_type": "药品名称", "object": {"@value": "CKD3期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "辛伐他汀", "subject_type": "药品名称", "object": {"@value": "CKD3期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "氟伐他汀", "subject_type": "药品名称", "object": {"@value": "CKD3期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞舒伐他汀", "subject_type": "药品名称", "object": {"@value": "CKD3期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "4期", "subject_type": "分期分型", "object": {"@value": "CKD4期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿托伐他汀", "subject_type": "药品名称", "object": {"@value": "CKD4期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "辛伐他汀", "subject_type": "药品名称", "object": {"@value": "CKD4期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "5期", "subject_type": "分期分型", "object": {"@value": "CKD5期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀", "subject_type": "药品名称", "object": {"@value": "CKD5期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "透析", "subject_type": "非药治疗", "object": {"@value": "CKD5期"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2 糖尿病微循环障碍的定义", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "微循环障碍", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "住院患者发生高血糖非常普通，包括入住内分泌科的成人糖尿病患者，其他内科、外科、急诊、重症监护科室的糖尿病或高血糖患者以及妊娠糖尿病或糖尿病妊娠患者等，针对不同患者的具体血糖控制目标见表1和表2。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "妊娠糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病妊娠"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "②脆性糖尿病：1型糖尿病患病一段时间后由于胰岛功能完全衰竭，出现血糖巨幅波动，高血低与低血糖交替出现，频发不可预知的严重低血糖，即脆性糖尿病。少数进展迅速的患者在确诊时即可进入脆性糖尿病阶段。此类患者建议使用胰岛素泵或速效胰岛素类似物联合长效胰岛素类似物方案。", "spo_list": [{"Combined": false, "predicate": "患病病因", "subject": "胰岛功能完全衰竭", "subject_type": "患病病因", "object": {"@value": "脆性糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "脆性糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "胰岛功能完全衰竭", "subject_type": "患病病因", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "速效胰岛素类似物", "subject_type": "药品名称", "object": {"@value": "脆性糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "长效胰岛素类似物", "subject_type": "药品名称", "object": {"@value": "脆性糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)中长效促泌剂：中长效磺脲类促泌剂半衰期长，作用较持久，明显降低2型糖尿病患者空腹和餐后血糖。包括自身半衰期较长的普通剂型磺脲类促泌剂，如格列本脲和格列美脲，以及剂型改良后的缓控释制剂，如格列齐特缓释片、格列吡嗪控释片。格列本脲与β细胞膜SUR亲和力强，降糖疗效强，但低血糖的发生率高(1a级)。格列美脲与β细胞膜SUR结合及解离的速度较格列本脲为快，低血糖发生率有所降低(2b级)；且在血糖控制相同的情况下格列美脲较格列本脲治疗时的空腹及餐后胰岛素和C肽水平为低(2b级)。格列吡嗪控释片通过胃肠道治疗系统(GITS)技术实现控释，格列齐特缓释片采用以亲水性羟丙甲纤维素为基质的缓释技术，可保持全天血药浓度平稳。其活性成分的释放更符合2型糖尿病患者24h血糖变化特点，低血糖尤其是严重低血糖的发生更少(4级)。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "24h血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "中长效磺脲类促泌剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "空腹和餐后血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列本脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列美脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列本脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "针对神经病变发病机制的治疗包括：①神经修复，常用药物有甲钴胺、神经生长因子等；②神经营养因子、肌醇、神经节苷酯及亚麻酸等。针对神经病变发病机制的治疗包括：①抗氧化应激：通过抑制脂质过氧化，增加神经营养血管的血流量，提高神经Na+-K+-ATP酶活性，保护血管内皮功能，常用药物为硫辛酸；②改善代谢素乱：醛糖还原酶抑制剂，常用依帕司他等；③改善微循环：周围神经血流减少是导致DPN发生的重要因素，通过扩张血管，改善血液高凝状态和微循环，提高神经细胞的血氧供应，可有效改善DPN患者的临床症状，常用药物包括前列地尔、贝前列素钠、西洛他唑、己酮可可碱、胰激肽原酶、CCB及活血化瘀类中药等。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "甲钴胺", "subject_type": "药品名称", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "神经生长因子", "subject_type": "药品名称", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "前列地尔", "subject_type": "药品名称", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝前列素钠", "subject_type": "药品名称", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西洛他唑", "subject_type": "药品名称", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "己酮可可碱", "subject_type": "药品名称", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰激肽原酶", "subject_type": "药品名称", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "CCB", "subject_type": "药品名称", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "周围神经血流减少", "subject_type": "患病病因", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)基层医疗卫生机构糖尿病微血管并发症分级诊疗和双向转诊建议：糖尿病患者适时地双向转诊是为了确保患者得到早期筛查和安全有效的治疗，最大限度地发挥基层医疗卫生机构和专科医疗机构各自的优势；同时也是应对在糖尿病微血管病变筛查中所面临的我国基层医疗卫生机构资源配置不平衡、尤其是筛查设备配备不足问题的有效解决方法之一。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "目前所有磺脲类药物说明书均将重度肝功能不全列为禁忌证。丙氨酸氨基转移酶(alanine transaminase，ALT)>3倍参考值上限可作为肝损害的敏感而特异的指标，若ALT>8~10倍参考值上限或者ALT>3倍参考值上限且血清总胆红素(total bilirubin，TBIL)>2倍参考值上限则是预测重度肝损害的特异指标，表明肝脏实质细胞受到损害，此时应禁用磺脲类药物。在临床使用中，伴有肝性脑病、腹水或凝血障碍的失代偿肝硬化患者应禁用该类药物以防发生低血糖。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "肝损害", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "重度肝损害", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝性脑病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脑", "subject_type": "患病部位", "object": {"@value": "肝性脑病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "腹", "subject_type": "患病部位", "object": {"@value": "腹水"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "失代偿肝硬化"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.心力衰竭：急性心力衰竭伴有缺氧情况，禁用双胍类药物、噻唑烷二酮类药物。对于慢性心力衰竭患者，需根据肾功能、血氧状态以及基础心功能等情况，选择应用口服降糖药物，还应注意监测血清乳酸水平和血气分析指标。心功能NYHAII~IV级的患者，应避免使用噻唑烷二酮类药物。DPP-4抑制剂在心功能NYHAⅡ~Ⅲ级临床经验有限，III~IV级无临床经验，故心力衰竭时应慎用或禁用。目前缺乏其他药物在心力衰竭患者中的用药证据。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "急性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "急性", "subject_type": "分期分型", "object": {"@value": "急性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "缺氧", "subject_type": "临床表现", "object": {"@value": "急性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "慢性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾功能", "subject_type": "检查方法", "object": {"@value": "慢性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血氧", "subject_type": "检查指标", "object": {"@value": "慢性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "基础心功能", "subject_type": "检查方法", "object": {"@value": "慢性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血清乳酸", "subject_type": "检查指标", "object": {"@value": "慢性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血气分析", "subject_type": "检查方法", "object": {"@value": "慢性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心功能NYHAII~IV级"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "II~IV级", "subject_type": "分期分型", "object": {"@value": "心功能NYHAII~IV级"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心功能NYHAⅡ~Ⅲ级"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "Ⅱ~Ⅲ级", "subject_type": "分期分型", "object": {"@value": "心功能NYHAⅡ~Ⅲ级"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "III~IV级", "subject_type": "分期分型", "object": {"@value": "心功能NYHAⅡ~Ⅲ级"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "血尿酸水平过低增加轻度认知功能障碍患者认知功能下降的风险。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血尿酸水平", "subject_type": "检查指标", "object": {"@value": "轻度认知功能障碍"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "根据国际儿科内分泌手术协会(International Pediatric Endo surgery Group)指南，对于接近成人身高的青少年，体质指数(BMI) >40kg/m或BMI>35kg/m并有严重并发症者方考虑手术干预。一项针对严重肥胖青少年的代谢手术指南指出，代谢手术应在发育阶段Tanner 4-5期，接近成人身高，男孩>15岁，女孩>13岁方可进行。新西兰一项研究报告，18岁以下肥胖青少年两种术式的代谢手术后，BMI分别降低11.6kg/m2和16.6kg/m2。美国5家儿童中心联合研究(Teen- LABS study)表明，242例平均BMI为53kg/m2的2型糖尿病患儿手术后，95%2型糖尿病及合并症病情都有好转，同时也能更快达到HbA1c控制目标.传统的Roux-en-Y胃旁路术安全性较差，胃束带和袖管胃切除术等较新的手术较为安全，但对儿童患者，还是不推荐常规应用。代谢手术应该在具有多学科团队的有治疗糖尿病和胃肠外科验的大医院进行，手术后仍要坚持生活方式的干预。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "代谢手术", "subject_type": "临床手术", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "代谢手术", "subject_type": "临床手术", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "代谢手术", "subject_type": "临床手术", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式的干预", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2 基层医疗卫生机构糖尿病微血管并发症管理现状 ", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "目前一般认为磺脲类药物治疗可引起患者体重增加。UKPDS表明，以格列本脲为基础的降糖治疗，患者体重增加1.7kg。Schernthaner等对使用格列齐特和格列美脲治疗的患者行27周的随访发现，其体重增加分别为0.5kg和0.6kg。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "格列本脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "格列齐特"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "格列美脲"}, "object_type": {"@value": "药品名称"}}]}
{"text": "⑤艾塞那肽有罕见肾功能改变报告，不推荐艾塞那肽用于终末期肾病或严重肾功能不全(肌酐清除率<30ml/min)的患者；利拉鲁肽由于经验有限，不推荐利拉鲁肽用于肾脏终末期患者。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "肾功能改变", "subject_type": "不良反应", "object": {"@value": "艾塞那肽"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "终末期", "subject_type": "分期分型", "object": {"@value": "终末期肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "终末期肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "严重肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肌酐清除率", "subject_type": "检查指标", "object": {"@value": "严重肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏终末期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "终末期", "subject_type": "分期分型", "object": {"@value": "肾脏终末期"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)不同类型的抗血小板药：抗血小板的药物甚多，其主要作用是抑制血小板功能。氯吡格雷和噻氯匹定等药物是一类抑制二磷酸腺苷介导的血小板活化的新型抗血小板药。盐酸沙格雷酯是5-羟色胺2(5-hydroxytryptamine 2，5-HT2)受体拮抗剂，对血小板以及对血管平滑肌的5-HT2受体具有特异性拮抗作用，从而抑制5-HT2受体介导的血小板凝聚、抑制血管收缩和平滑肌细胞增殖，改善红细胞的变形能力，改善侧支循环，升高慢性动脉闭塞症患者的经皮氧分压以皮肤表面温度，改善微循环障碍。盐酸沙格雷酯可改善包括糖尿病周围血管病变引起的疼痛、冷感、溃疡等多种症状。一项随机对照研究显示，盐酸沙格雷酯治疗能有效增加糖尿病下肢血管病变患者MWD和PFWD，部分改善足背动脉和胫后动脉的流速、阻力指数和踝肱指数(ankle brachial index，ABI)。一项纳入了9个随机对照研究的荟萃分析结果显示，盐酸沙格雷酯治疗下肢血管病变，能减小患者溃疡面积，增加ABI、足背动脉血流量和PFWD。另一项研究显示，盐酸沙雷酯可降低早期糖尿病肾病患者蛋白尿，延缓肾病发展。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "盐酸沙格雷酯", "subject_type": "药品名称", "object": {"@value": "慢性动脉闭塞症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "5-羟色胺2(5-hydroxytryptamine 2，5-HT2)受体拮抗剂", "subject_type": "药品名称", "object": {"@value": "慢性动脉闭塞症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "动脉", "subject_type": "患病部位", "object": {"@value": "慢性动脉闭塞症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "盐酸沙格雷酯", "subject_type": "药品名称", "object": {"@value": "糖尿病周围血管病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围血管", "subject_type": "患病部位", "object": {"@value": "糖尿病周围血管病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "疼痛", "subject_type": "临床表现", "object": {"@value": "糖尿病周围血管病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "冷感", "subject_type": "临床表现", "object": {"@value": "糖尿病周围血管病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "溃疡", "subject_type": "临床表现", "object": {"@value": "糖尿病周围血管病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "盐酸沙格雷酯", "subject_type": "药品名称", "object": {"@value": "糖尿病下肢血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢血管", "subject_type": "患病部位", "object": {"@value": "糖尿病下肢血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "盐酸沙格雷酯", "subject_type": "药品名称", "object": {"@value": "下肢血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢血管", "subject_type": "患病部位", "object": {"@value": "下肢血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "盐酸沙雷酯", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "早期", "subject_type": "分期分型", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "蛋白尿", "subject_type": "临床表现", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "初始剂量20～40mg／d，2～5周后血尿酸不达标者，逐渐加量，最大剂量80mg／d。因其主要通过肝脏清除，在肾功能不全和肾移植患者中具有较高的安全性，轻中度肾功能不全(G1~3期)患者无需调整剂量，重度肾功能不全(G4~5期)患者慎用。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "轻中度肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "G1~3期", "subject_type": "分期分型", "object": {"@value": "轻中度肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "重度肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "G4~5期", "subject_type": "分期分型", "object": {"@value": "重度肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "国内一项涉及10家医疗机构、2型糖尿病患者的多中心、自身对照临床试验对格列哇喹的量效关系研究显示，2/3的患者使用30-~20mg/d，若血糖控制不佳可增加剂量，平均剂量为112mg/dl即使剂量增加至270mg/d也无更多低血糖反应发生。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列哇喹", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "30-~20mg/d", "subject_type": "用药剂量", "object": {"@value": "格列哇喹"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "112mg/dl", "subject_type": "用药剂量", "object": {"@value": "格列哇喹"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "270mg/d", "subject_type": "用药剂量", "object": {"@value": "格列哇喹"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列哇喹"}, "object_type": {"@value": "药品名称"}}]}
{"text": "②基础胰岛素联合餐时胰岛素方案：对于口服降糖药联合基础胰岛素治疗的患者，基础胰岛素可维持原剂量，开始时可在主餐/早餐前给予餐时胰岛素4-6单位，然后逐步增加餐时胰岛素，根据下一餐前血糖值，每周调整1~2次餐时胰岛素剂量，每次调整1-2单位或10%~15%直至达到下次餐前血糖目标，根据每3~6个月的HbA1c结果，如需要可逐渐增加至每日2~3次餐时胰岛素注射。对于之前使用预混胰岛素的患者，可按照原先预混胰岛素剂量的40%~50% 作为基础胰岛素，剩余量作为餐时胰岛素，三餐平均分配；对于需短时间内纠正高血糖的患者，可根据0.3~0.5单位/千克体重来估算起始胰岛素总量，其中，50%为基础胰岛素，50%为餐时胰岛素，三餐平均分配。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "4-6单位", "subject_type": "用药剂量", "object": {"@value": "餐时胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "餐时胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日2~3次", "subject_type": "用药频率", "object": {"@value": "餐时胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "0.3~0.5单位/千克体重", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "1.心力衰竭患者使用注意事项：需要药物治疗的充血性心力衰竭(CHF)是二甲双胍使用的禁忌证，但回顾性研究显示，二甲双胍本身不会导致心力衰竭，也不会对心力衰竭患者造成不良影响。2014年ADA糖尿病指南也指出，如果肾功能正常，二甲双胍可用于病情稳定的CHF患者(Ⅴ级)。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "充血性心力衰竭(CHF)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "充血性", "subject_type": "分期分型", "object": {"@value": "充血性心力衰竭(CHF)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "CHF"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "血清肌本酐在估算GFR中存在灵敏度不足，受个体肌肉量、蛋白质摄入、体内代谢水平、溶血、脂血等因素干扰等局限性。近年来，胱抑素C(CysC)被认为在预测2型糖尿病肾病进展为ESRD的作用上比血清肌酐更好，CysC是由有核细胞以恒速产生的，可自由滤过，被肾小管上皮细胞重吸收和细胞内降解，但不会被肾小管上皮细胞分泌，可更准确地反映肾功能，但其检测的准确性尚未得到保障。一些学者提出了基于CysC的eGFR计算公式和CKD分期。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血清肌本酐", "subject_type": "检查指标", "object": {"@value": "溶血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "溶血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "胱抑素C(CysC)", "subject_type": "检查指标", "object": {"@value": "2型糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "2型糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血清肌酐", "subject_type": "检查指标", "object": {"@value": "ESRD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "CysC", "subject_type": "检查指标", "object": {"@value": "ESRD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "CysC", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "eGFR", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "荟萃分析结果显示，正确使用磺脲类药物单药及联合治疗的患者，轻、中度低血糖发生率为1.92例/(患者·年)，重度低血糖发生率为0.01例/(患者·年)。不同磺脲类药物的作用机制及剂型存在差异，其低血糖发生率也不同，其中格列本脲导致低血糖的发生风险最高。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "轻、中度低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "重度低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列本脲"}, "object_type": {"@value": "药品名称"}}]}
{"text": "T2DM患者的血糖控制目标因患者的年龄、合并症、并发症等不同而异，临床医生应注意结合患者病情、经济等各方面的因素综合考虑，选择适合患者的治疗方案。对已合并心脑血管疾病或其他危险因素的T2DM患者，在胰岛素治疗治疗时，应当采取稳妥、安全的降糖治疗措施和目标值，尽量避免低血糖的发生。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心脑血管", "subject_type": "患病部位", "object": {"@value": "心脑血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "随着CVOT的广泛开展，其研究结果将陆续公布。最新公布的SUSTAIN-6研究显示，新型长效GLP-1受体激动剂索马鲁肽(semaglutide，尚未被批准上市)同样也可显著降低心血管事件风险。因此，有理由相信未来将会出现越来越多可为T2DM患者带来心血管保护作用的降糖药物，这将推动T2DM(特别是合并ASCVD)患者的治疗策略和理念发生巨大的变革。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "治疗方案需个体化、分层、达标、长程管理，逐步调整剂量，避免短期内血尿酸水平波动过大诱发痛风急性发作。", "spo_list": [{"Combined": false, "predicate": "患病病因", "subject": "短期内血尿酸水平波动过大", "subject_type": "患病病因", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "翟所迪等进行的系统性评价结果提示，PK对糖尿病视网膜病变和糖尿病肾病有一定的疗效。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(3)手术方式的选择：尽可能优先选择简单、维发损伤小的手术方案，争取以简单方法解决复杂问题。①止血带：疑似血运障碍者，建议慎用止血带。②清创术：注意探查深层组织损伤情况，避免肌肉组织夹心样坏死和骨筋膜间室综合征，术后能够通畅引流；建议通过多次清创的手术方式，避免损伤过多健康组织，对无明确坏死表现的骨质应尽可能保全。③缝合术：不推荐清创后一期缝合。④植皮术：创面基底达到植皮条件，应尽早手术封闭创面。建议优先选择刃厚皮植皮，能够选择游离皮片移植的不需选择皮瓣移植。⑤皮瓣移植术：因糖尿病足患者多双下肢同步发生血管缺血性病变，故不推荐皮瓣转移移植手术，以避免出现皮瓣修复失败甚至供瓣区愈合不良。需在术前对术区血管详细检查评估的前提下，制定手术方案，选择皮瓣的优先顺序为邻位、远位、带蒂、游离。⑥截肢/趾术：对坏死肢体感染危及生命、血供无法重建、创面难以愈合、因疼痛难以忍受，患者家庭经济状况难以坚持长期非手术治疗而强烈要求者，可进行截肢治疗。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "深层组织损伤", "subject_type": "临床表现", "object": {"@value": "肌肉组织夹心样坏死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "深层组织损伤", "subject_type": "临床表现", "object": {"@value": "骨筋膜间室综合征"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肌肉组织", "subject_type": "患病部位", "object": {"@value": "肌肉组织夹心样坏死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "骨筋膜间室", "subject_type": "患病部位", "object": {"@value": "骨筋膜间室综合征"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "皮瓣移植术", "subject_type": "临床手术", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "双下肢", "subject_type": "患病部位", "object": {"@value": "双下肢同步发生血管缺血性病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "截肢/趾术", "subject_type": "临床手术", "object": {"@value": "坏死肢体感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肢体", "subject_type": "患病部位", "object": {"@value": "坏死肢体感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "截肢", "subject_type": "临床手术", "object": {"@value": "坏死肢体感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "危及生命", "subject_type": "临床表现", "object": {"@value": "坏死肢体感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "血供无法重建", "subject_type": "临床表现", "object": {"@value": "坏死肢体感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "创面难以愈合", "subject_type": "临床表现", "object": {"@value": "坏死肢体感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "疼痛难以忍受", "subject_type": "临床表现", "object": {"@value": "坏死肢体感染"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "基础胰岛素可通过中效胰岛素、长效胰岛素或长效胰岛素类似物给予，餐时胰岛素可通过短效胰岛或速效胰岛素类似物给予，详见表1。该指南指出与中效胰岛素相比，长效胰岛素类似物空腹血糖控制更好，夜间低血糖发生风险更低。具体用法：①体重在理想体重正负20%以内的成年患者，若无特殊情况每日胰岛素需要总量0.4~0.8单位/千克体重，每日总量也可以最小剂量12~18单位起始；儿童则需根据年龄、体重及血糖情况酌情处理。2每日胰岛素基础=全天胰岛素总量X(40%~60%)，长效胰岛素一般1次注射，中效胰岛素可每日1次或2次注射。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "0.4~0.8单位/千克体重", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "长效胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "1次", "subject_type": "用药频率", "object": {"@value": "长效胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日1次或2次", "subject_type": "用药频率", "object": {"@value": "中效胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "中效胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "老年人低血糖症状多不典型，较多见的是非特异性神经、精神症状，尤其是眩晕、定向障碍、跌倒或突发行为改变。对于存在认知功能障碍的老年人，不能及时识别低血糖，有时会带来严重后果，其危害远高于轻中度高血糖。在老年人出现跌倒、突发行为异常，应该想到低血糖的可能。对用胰岛素促泌剂或胰岛素治疗的老年患者和/或家属，需要在第一时间告知其低血糖的防治措施，有严重低血糖发生经历的老年患者，如不能彻底阻断发生原因，血糖的控制目标需大步放松，以不发生低血糖、又无严重高血糖为目标(C)。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "眩晕", "subject_type": "临床表现", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "定向障碍", "subject_type": "临床表现", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "跌倒", "subject_type": "临床表现", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "突发行为改变", "subject_type": "临床表现", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "跌倒", "subject_type": "临床表现", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "突发行为异常", "subject_type": "临床表现", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "在欧洲，用于临床治疗视网膜病变已多年。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "视网膜病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "一般情况下老年2型糖尿病降糖药物选用路径见图1。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "①基础/餐时胰岛素起始方法：对于口服降糖药联合基础胰岛素治疗的患者，基础胰岛素可维持原剂量，主餐/早餐前给予餐时胰岛素4U；对于之前使用预混胰岛素的患者，可按照原先预混胰岛素剂量的40%~50%作为基础胰岛素，剩余量作为餐时胰岛素，三餐平均分配；对于需短时间内纠正高血糖的患者，可根据0.3~0.5U/(kg·d)估算起始胰岛素总量，其中，50%为基础胰岛素，50%为餐时胰岛素，三餐平均分配。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "4U", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "0.3~0.5U/(kg·d)", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "儿童青少年2型糖尿病诊治中国专家共识 ", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "二、T2DM合并肥胖的诊断标准", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.肾功能不全", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "由于GLP—1RA具有较好的血糖控制效果，在二线治疗时血糖仍控制不佳的患者，推荐GLP-1RA作为2型糖尿病患者的三线治疗选择之一。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "GLP-1RA", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "5.神经病变：2型糖尿病确诊时应该筛查远端对称性多发性神经病变，可使用简单的临床检查手段进行筛查，以后至少每年筛查1次。如果临床特征典型，一般不需要进行电生理学检查或转诊给神经科专家。严格控制糖尿病病情有助于改善神经病变，疼痛明显时可以采用镇痛剂对症治疗。同时应该筛查心血管自主神经病变的症状和体征，但由于不影响治疗或预后，一般不需特殊辅助检查。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "疼痛", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "镇痛剂", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管自主神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "疼痛", "subject_type": "临床表现", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "镇痛剂", "subject_type": "药品名称", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "老年人群中40%~70%患有高血压病，30%~50%患有血脂紊乱，均高于糖尿病的患病率，腹型肥胖比单纯BMI增高在老年患者中更常见。同时合并糖代谢紊乱、高血压、向心性肥胖、高甘油三酯血症(代谢综合征)的老年人高达30%~40%，而无上述各项者不到10%。老年综合征是老年人群中常见的与年龄相关的疾病组合，包括智能和体能的缺陷、自伤和他伤防护能力的下降、跌倒和骨折风险的增加、认知障碍和抑郁、尿失禁、疼痛、用药过多等。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "智能和体能的缺陷", "subject_type": "临床表现", "object": {"@value": "老年综合征"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "自伤和他伤防护能力的下降", "subject_type": "临床表现", "object": {"@value": "老年综合征"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "跌倒和骨折风险的增加", "subject_type": "临床表现", "object": {"@value": "老年综合征"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "认知障碍", "subject_type": "临床表现", "object": {"@value": "老年综合征"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "抑郁", "subject_type": "临床表现", "object": {"@value": "老年综合征"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "尿失禁", "subject_type": "临床表现", "object": {"@value": "老年综合征"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "疼痛", "subject_type": "临床表现", "object": {"@value": "老年综合征"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "用药过多", "subject_type": "临床表现", "object": {"@value": "老年综合征"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "中国2型糖尿病合并血脂异常防治专家共识(2017年修订版)", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.65岁以上老年患者使用注意事项：2013年IDF老年糖尿病指南和中国老年糖尿病诊疗措施专家共识都把二甲双胍作为一线首选用药，对二甲双胍的使用没有具体年龄限制。老年糖尿病患者合理应用二甲双胍治疗可以达到良好的降糖效果，较少的低血糖风险对老年人有一定益处，但需要定期监测肾功能(3~6个月检查1次)。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "临床问题10：在二线治疗控制不佳情况下，GLP-1RA是否可作为2型糖尿病患者的三线治疗选择之一?", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "GLP-1RA", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "临床医师在制定胰岛素方案、剂量调整和设定糖尿病血糖控制目标时，除考虑病理生理因素外，还必须考虑社会经济因素，并统筹考虑安全性、可行性和科学性，制定个体化的血糖控制目标和起始治疗方案。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(一)心血管疾病", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "CKD患者痛风急性发作时应特别重视水化和碱化尿液，并在上述治疗的同时辅以局部NSAIDs药物的使用，改善患者的症状，最大限度减少全身用药的毒副作用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "NSAIDs药物", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "NSAIDs药物", "subject_type": "药品名称", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "水化和碱化尿液", "subject_type": "临床表现", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)肠内或肠外营养：①持续肠内营养，每日1次或2次基础胰岛素；同时，每4h给予短效或速效胰岛素皮下注射；分次肠内营养，维持原基胰岛素治疗方案；如初始治疗，给予10U基础胰岛素。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "每日1次或2次", "subject_type": "用药频率", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每4h", "subject_type": "用药频率", "object": {"@value": "短效或速效胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "皮下注射", "subject_type": "用药方法", "object": {"@value": "短效或速效胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "10U", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "5.二甲双胍单药治疗的降糖疗效：一项随机、双盲、平行对照研究结果显示，在减去安慰剂效应后二甲双胍单药治疗29周可降低FPG3.2mmol/L、PPG4.0mmol/L、HbA1c1.8%(I级)。在中国人群开展的安慰剂对照的临床研究中，1000mg/d或1700mg/d二甲双胍单药治疗可使HbA1c分别降低0.7%和1.0%(去除安慰剂效应后)(I级)。一项前瞻性、随机对照研究显示，在新诊断的曾经接受短期胰岛素治疗后的T2DM患者中，以二甲双胍(2000mg/d)为基础的口服降糖药物组疗效与甘精胰岛素组的降糖疗效相当(I级)。在中国人群中的研究显示，2000mg/d二甲双胍的疗效与1000mg/d二甲双胍联合DPP-4抑制剂的疗效相当(I级)。一项前瞻性、随机对照研究显示，在新诊断的T2DM患者中，二甲双胍(1500mg/d)的降糖疗效和阿卡波糖(300mg/d)相当。", "spo_list": [{"Combined": false, "predicate": "持续时间", "subject": "29周", "subject_type": "持续时间", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1700mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "甘精胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿卡波糖", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1500mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "300mg/d", "subject_type": "用药剂量", "object": {"@value": "阿卡波糖"}, "object_type": {"@value": "药品名称"}}]}
{"text": "1.ASCVD急性期", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "急性期", "subject_type": "分期分型", "object": {"@value": "ASCVD急性期"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.对维生素B12的吸收的影响：已有多项交叉横断面试验及随机对照研究显示，长期服用二甲双胍可引起维生素B12水平的下降。其机制可能与以下因素有关(1)小肠蠕动的改变刺激肠道细菌过度生长，竞争性抑制维生素B12的吸收；(2)维生素B12内因子水平的变化及钴胺素内吞受体的相互作用；(3)二甲双胍可抑制回肠末端维生素B12内因子复合物钙依赖性吸收(这种抑制作用可以通过补充钙剂逆转)。二甲双胍治疗引起巨幼红细胞性贫血罕见，如发生应排除维生素B12缺乏。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "维生素B12水平的下降", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "巨幼红细胞性贫血", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "4.T1DM、儿童青少年、孕妇和哺乳期妇女：目前，SGLT2i均没有在T1DM中使用的适应证。已经完成的探索性研究证实了SGLT2i与胰岛素联合治疗T1DM的疗效与安全性。T1DM患者使用SGLT2i发生DKA的风险可能增加。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T1", "subject_type": "分期分型", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "SGLT2i", "subject_type": "药品名称", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T1", "subject_type": "分期分型", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "SGLT2i", "subject_type": "药品名称", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T1", "subject_type": "分期分型", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T1", "subject_type": "分期分型", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "SGLT2i", "subject_type": "药品名称", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "附录2：糖尿病微血管并发症诊断", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "中或重度肝肾功能不全者不宜使用胰岛素促泌剂。轻中度肾功能不全者若不用胰岛素，需要用胰岛素促泌剂时可考虑瑞格列奈和格列喹酮。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肝肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "此外，研究还发现肠促胰素，尤其是GLP-1可抑制胰腺α细胞分泌胰高糖素，并有减轻体重、改善β细胞功能和在动物模型中增加β细胞量的作用，可对2型糖尿病患者的代谢异常进行多方面的调控。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)抗血管内皮生长因子药：①雷珠单抗，临床上用于各种原因引起的黄斑水肿、视网膜新生血管、视网膜静脉阻塞、新生血管性青光眼等疾病。随机对照研究结果显示，雷珠单抗可显著降低糖尿病黄斑水肿患者硬性渗出区域。此外，存在黄斑水肿、黄斑变性、视网膜内囊肿、玻璃体严重增厚眼病的糖尿病患者使用雷珠单抗治疗可有效减轻黄斑变性。②贝伐单抗可用于治疗视网膜新生血管性疾病。一项随机对照研究结果显示，贝伐单抗联合视网膜光凝术治疗可显著降低高风险糖尿病视网膜病变患者的视敏度恶化程度，减少黄斑中心凹厚度及黄斑体积。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "雷珠单抗", "subject_type": "药品名称", "object": {"@value": "黄斑水肿"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "雷珠单抗", "subject_type": "药品名称", "object": {"@value": "视网膜新生血管"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "雷珠单抗", "subject_type": "药品名称", "object": {"@value": "视网膜静脉阻塞"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "雷珠单抗", "subject_type": "药品名称", "object": {"@value": "新生血管性青光眼"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "黄斑", "subject_type": "患病部位", "object": {"@value": "黄斑水肿"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "视网膜新生血管"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "视网膜静脉阻塞"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "眼", "subject_type": "患病部位", "object": {"@value": "新生血管性青光眼"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "雷珠单抗", "subject_type": "药品名称", "object": {"@value": "糖尿病黄斑水肿"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "雷珠单抗", "subject_type": "药品名称", "object": {"@value": "黄斑水肿"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "黄斑", "subject_type": "患病部位", "object": {"@value": "黄斑水肿"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "黄斑", "subject_type": "患病部位", "object": {"@value": "糖尿病黄斑水肿"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "雷珠单抗", "subject_type": "药品名称", "object": {"@value": "黄斑变性"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "黄斑", "subject_type": "患病部位", "object": {"@value": "黄斑变性"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "雷珠单抗", "subject_type": "药品名称", "object": {"@value": "视网膜内囊肿"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "视网膜内囊肿"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "雷珠单抗", "subject_type": "药品名称", "object": {"@value": "玻璃体严重增厚眼病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "玻璃体", "subject_type": "患病部位", "object": {"@value": "玻璃体严重增厚眼病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "雷珠单抗", "subject_type": "药品名称", "object": {"@value": "黄斑变性"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "黄斑", "subject_type": "患病部位", "object": {"@value": "黄斑变性"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝伐单抗", "subject_type": "药品名称", "object": {"@value": "视网膜新生血管性疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "视网膜新生血管性疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝伐单抗", "subject_type": "药品名称", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "视网膜光凝术治疗", "subject_type": "临床手术", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "二甲双胍在我国已经有近20年的使用经验。1995年，FDA正式批准二甲双胍用于治疗T2DM，2004年欧盟正式批准二甲双胍用于治疗10岁以上的儿童T2DM。国内外主要糖尿病指南均建议：无论患者超重与否，除非有肾损害的证据或风险，否则均应从开始就使用二甲双胍治疗，且联合治疗的方案中都应包括二甲双胍，这体现了二甲双胍在糖尿病治疗中的“基石“地位。然而,在临床工作中，仍有部分医生和患者对二甲双胍的使用(有效性、剂量、用法、安全性、疗效与体重的关系等)存在误区，如因担心胃肠道反应未能发挥二甲双胍的剂量优势：因担心其损害肝肾功能和引起乳酸酸中毒等，使一些原本可从二甲双胍治疗中获益的患者错失治疗良机，为此，我们组织内分泌临床专家、药学专家共同制定《二甲双胍临床应用专家共识》，以指导临床医生和患者正确认识并合理使用二甲双胍。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道反应", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "损害肝肾功能", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "乳酸酸中毒", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾损害"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)苯溴马隆：适用于原发性和继发性高尿酸血症。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "苯溴马隆", "subject_type": "药品名称", "object": {"@value": "继发性高尿酸血症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.二甲双胍被推荐为治疗T2DM的一线首选和全程用药：二甲双胍有可靠的短期和长期降糖疗效，单独使用能有效降低T2DM患者的FPG、PPG，可使HbA1c下降1.0%~2.0%(去除安慰剂效应后)，可使中国新诊断T2DM患者的HbA1c降低1.8%(可能含安慰剂效应)，且不受体重影响。在相似的基线HbA1c条件下，最佳有效剂量(2000mg/d)的二甲双胍的降糖疗效强于其他口服降糖药。数据分析显示，二甲双胍单药治疗疗效不佳的患者，联合其他口服降糖药可进一步获得明显的血糖改善(I级)。与以其他口服降糖药物作为一线药物治疗的患者相比，以二甲双胍作为一线治疗的患者加用第二种口服降糖药或需要联合胰岛素治疗的时间最晚，今后需调整治疗方案的可能性也最低。二甲双胍联合胰岛素可进一步降低HbA1c，减少胰岛素用量、体重增加和低血糖风险。另外，二甲双胍具有心血管保护作用。二甲双胍的长期治疗与新诊断T2DM患者及已经发生心血管疾病的T2DM患者的心血管疾病发生风险下降相关(I级)。二甲双胍具有良好的安全性和耐受性，低血糖发生率低，其胃肠道反应多为一过性，不导致肾脏损害，长期使用不增加高乳酸血症或乳酸酸中毒风险。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "PPG", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道反应", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏损害"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.体重管理：老年人体重的管理以适中为好(BMI20~<25kg/m2) (II)，不建议单纯以体重变化衡量是否管理达标。建议以就诊时的状态为参照，肥胖者适度控制热量的摄入，体瘦者增加热量供给，两种情况均需进行饮食结构的调整，鼓励适度增加运动(IV)。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "进行饮食结构的调整", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "增加运动", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "我国糖尿病患者1年内新发溃疡发生率为8.1%，糖尿病足溃疡患者1年内新发溃疡发生率为31.6%", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "足溃疡"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "临床应用共识指出，DPP-4抑制剂适用于成人2型糖尿病患者的血糖控制。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.对已合并心脑血管疾病或危险因素的2型糖尿病患者，或老年糖尿病患者，过于激进的降糖治疗策略可能产生潜在的风险，进而抵消或掩盖其潜在的心血管获益。由于脑组织代谢的特殊性，卒中患者对低血糖的耐受性更低，在使用胰岛素时，应采取相对宽松的降糖治疗策略与目标值，避免低血糖的发生。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心脑血管", "subject_type": "患病部位", "object": {"@value": "心脑血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "卒中"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "格列奈类药物降糖机制类似磺脲类，但起效更快，改善胰岛素早相分泌更明显，主要降低PPG，括括瑞格列奈、那格列奈和米格列奈，降低HbA1c0.5%~1.0%。瑞格列奈的降糖作用以促进胰岛素第一时相分泌为主。荟萃分析结果显示，在降低HbA1c方面，瑞格列奈优于安慰剂及磺脲类药物。一项随机对照研究显示，单纯饮食治疗血糖控制不佳的新诊断T2DM患者，那格列奈单药治疗12周后HbA1c较基线降低0.9%(可能包括部分安慰剂效应)，2 hPG亦下降。此类药物需在餐前即刻服用，可单独或与其他非促泌剂类降糖药物联合应用。常见不良反应为低血糖和体重增加，但严重程度较磺脲类药物轻。肾功能不全的患者可选择瑞格列奈。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "那格列奈", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "12周后", "subject_type": "持续时间", "object": {"@value": "那格列奈"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "单纯饮食治疗", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "2 hPG", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(4)DKA和糖尿病高渗状态：处理目标包括：纠正血容量、改善组织灌注、纠正高血糖、血电解质紊乱和酮症等。寻找相关诱因非常重要。小剂量胰岛素静脉、肌肉或皮下注射是治疗DKA和高渗状态的安全有效措施。具体治疗方案详见本章节“(一)内分泌科住院糖尿病患者的血糖管理“中“2.内分泌科住院糖尿病患者的血糖管理”部分。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "静脉、肌肉或皮下注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "DKA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "高渗状态"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "心血管疾病和糖尿病患者常合并慢性肾脏病(CKD)，而CKD患者应基于药物的药代动力学特征和患者的肾功能水平综合判断，选择合适的降糖药物，并适当调整剂量，确保在有效降糖的同时不增加低血糖风险。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病(CKD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病(CKD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾功能", "subject_type": "检查方法", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "维生素D的水平与儿童肥胖的负相关也得到了进一步的证实。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "维生素D", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "六、T2DM患者特殊情况下的血脂管理", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "【2型糖尿病的治疗】 ", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "d.利格列汀极少经过肾脏排泄，在不同程度肾功能不全的患者中使用，均不需要调整剂量。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "利格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.不同治疗方案的选择：目前尚无循证医学证据证实何种胰岛素起始治疗方案更优，各权威学术组织推荐的胰岛素启动治疗方案不尽相同。多数国家和地区[美国糖尿病学会(ADA)/欧洲糖尿病研究协会(EASD)联合共识、中国台湾糖尿病临床照护指引、英国国家健康与临床优化研究所(ICE)临床指南、国际糖尿病联盟(IDF)欧洲指南]推荐起始使用基础胰岛素。若血糖控制不达标，可加用餐时胰岛素。美国临床内分泌医师协会(AACE)/美国内分泌学院(ACE)专家共识推荐基础胰岛素、预混胰岛素、基础-餐时胰岛素或餐时胰岛素1日多次注射、餐时胰岛素加二甲双胍这4种胰岛素方案中任一种均可作为起始治疗。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "1日多次", "subject_type": "用药频率", "object": {"@value": "基础胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "基础胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "1日多次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "1日多次", "subject_type": "用药频率", "object": {"@value": "基础-餐时胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "基础-餐时胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "1日多次", "subject_type": "用药频率", "object": {"@value": "餐时胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "餐时胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "由于血脂异常通常没有明显症状，往往通过体检或发生了心脑血管事件后才得以发现，因而及早发现T2DM患者合并血脂异常，并给予早期干预，可防治动脉粥样硬化、减少心脑血管事件、降低死亡率。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心脑血管", "subject_type": "患病部位", "object": {"@value": "心脑血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心脑血管", "subject_type": "患病部位", "object": {"@value": "心脑血管事件"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "三、糖尿病足的临床表现 ", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "20世纪80年代，Vertes等对519例门诊患者进行断食治疗，78%的患者体重下降超过18.2kg，总体减重为每周1.5kg，女性平均每周减重1.3kg，男性每周减重2.1kg，大多数均能接受该方案而无任何严重副作用。一项基于16例肥胖患者的研究显示，在隔日断食法干预8周后，患者体重平均下降(5.6±1.0)kg，腰围平均缩小4.0cm，体脂含量从原来的(45±2)%降到(42±2)%，收缩压由(124±5)mmHg(1mmHg=0.133kPa)降到(116±3)mmHg，总胆固醇、低密度脂蛋白胆固醇和甘油三酯浓度也分别下降(21±4)%、(25±10)%和(32±6)%，而高密度脂蛋白胆固醇水平无变化。Johnson等的研究也发现，在隔日断食法干预8周后，肥胖患者的BMI较基线值下降8%，而低密度脂蛋白胆固醇和甘油三酯分别下降10%和40%。2013年发表的一项基于115例肥胖女性的研究显示，干预3个月后，两日断食法的肥胖患者体重平均下降4kg，而传统能量限制的肥胖患者体重平均下降2.4kg，且前者胰岛素抵抗改善更明显。2014年一项关于2型糖尿病预防的Meta分析发现轻断食可有效减重及预防2型糖尿病，对超重和肥胖患者的血糖、胰岛素及低密度脂蛋白胆固醇、高密度脂蛋白胆固醇等代谢标记物均有改善。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "隔日断食法干预", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "低密度脂蛋白胆固醇", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "甘油三酯", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "两日断食法", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "轻断食", "subject_type": "非药治疗", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "胰岛素", "subject_type": "检查指标", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "低密度脂蛋白胆固醇", "subject_type": "检查指标", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "高密度脂蛋白胆固醇", "subject_type": "检查指标", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "胰岛素", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "低密度脂蛋白胆固醇", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "高密度脂蛋白胆固醇", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)生活方式干预：饮食的质和量均影响PPG。高GI饮食可导致PPG升高，且增加血糖曲线下面积(AUC)。分别摄入低GI饮食与高GI饮食可使HbA1c相差0.5%~0.7%。餐后运动可以降低T2DM患者PPG，降低幅度与运动持续时间和频率密切相关，但较少影响FPG。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "餐后运动", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "PPG", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "不同住院人群的控制目标如表2所示。与非妊娠的糖尿病或高血糖患者相比，妊娠患者由于涉及到母亲和胎儿两方面，其控制目标需要更为严格，具体目标见“糖尿病妊娠及妊娠糖尿病住院患者的血糖管理”章节。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病妊娠"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "妊娠糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(3)药物：应用降糖药物所带来的低血糖也是血糖波动增加的诱因之一。如促进胰岛素分泌的药物或者胰岛素本身等均会增加患者的低血糖风险，增加血糖波动。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "目前关于妊娠期糖尿病或妊娠期显性糖尿病或孕前2型糖尿病患者妊娠期间及哺乳期使用胰岛素促泌剂的临床证据尚不太充分，一般情况下国内不推荐孕妇及哺乳期患者应用胰岛素促泌剂治疗。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "妊娠期", "subject_type": "分期分型", "object": {"@value": "妊娠期糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "妊娠期显性", "subject_type": "分期分型", "object": {"@value": "妊娠期显性糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "孕前2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "HUA在中国呈现高流行、年轻化趋势，同时HUA也是多种心血管事件危险因素及相关疾病的独立危险因素，本共识是我国首个HUA相关疾病的多学科专家共识，强调从系统医学角度全面认识该疾病，结合中国国情和国内诊疗实践特点，多学科协作、内外兼治，连续、全程、系统地管控HUA及其相关疾病，对HUA的诊断标准、药物选择、控制目标及预防的核心策略均给予明确阐述，对中国HUA的规范化管理具有积极的推动意义。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "迄今为止，胰岛素促泌剂在2型糖尿病治疗中仍占据不可或缺的地位，为多数权威2型糖尿病防治指南中的一线降糖药物。中国成人2型糖尿病患者体重指数较低、糖尿病肾病发生率较高且β细胞胰岛素分泌功能比胰岛素敏感性降低更明显，胰岛素促泌剂更符合中国成人2型糖尿病患者特点。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "β细胞胰岛素分泌功能比胰岛素敏感性降低更明显", "subject_type": "发病机制", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(5)糖尿病合并心血管疾病患者：在合并心血管疾病的糖尿病患者中，一旦发生严重低血糖，可能诱发心肌梗死、严重心律失常、卒中、猝死等严重事件，对于这类人群，应尽量在避免低血糖的情况下使血糖控制达标。因此，本共识建议，对于老年、病程长、合并心血管疾病的糖尿病患者，为了避免低血糖带来的风险，HbA1c控制目标应适当宽松(<7.5%-8.0%)。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心律失常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)胰岛β细胞功能：糖尿病患者自身β细胞功能减退甚至衰竭，导致体内胰岛素水平不足，血糖调节能力低下，导致血糖容易波动。", "spo_list": [{"Combined": false, "predicate": "发病机制", "subject": "自身β细胞功能减退", "subject_type": "发病机制", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "随着基因检测技术的提高，单基因糖尿病的诊断率日益增加。典型的单基因糖尿病有：青少年发病的成年型糖尿病(maturity-onset diabetes of the young，MODY)，线粒体基因突变糖尿病(maternally inherited diabetes and deafness，母系遗传的线粒体基因突变伴有多系统的异常)，新生儿糖尿病(neonatal diabetes mellitus)，A型胰岛素抵抗综合征等等。基因检测有助于明确诊断。所有6月龄前发病的糖尿病均应行基因检测。儿童或青年期诊断者，如果不具备1型糖尿病或2型糖尿病的特点，且连续多代有糖尿病(提示常染色体显性遗传模式)，则应考虑MODY基因检测。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "成年型", "subject_type": "分期分型", "object": {"@value": "成年型糖尿病(maturity-onset diabetes of the young，MODY)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "A型", "subject_type": "分期分型", "object": {"@value": "A型胰岛素抵抗综合征"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "基因检测", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "MODY基因检测", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "估算GFR最常用的指标是血清肌酐，基于血清肌酐的肾小球滤过率的常用计算公式有CG(Cockcrofl-Gauh)公式和肾脏饮食修正公式(MDRD)，2009年又提出了CKD-EPI公式，被认为比CG公式和MDRD公式能更准确地估算2型糖尿病患者的GFR，但存在争议。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "对于新诊断的糖化血红蛋白(hemoglobin A1c，HbA1c)>7.5%的T2DM患者，可以选择作用机制互补的两种降糖药物联合应用。结合中国国情和中国T2DM患者的特点，磺脲类药物联合二甲双胍是推荐的联合治疗方案之一。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "糖化血红蛋白(hemoglobin A1c，HbA1c)", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "二甲双胍自1957年问世，应用于临床已有50多年的历史，是当前全球应用最广泛的口服降糖药之一。近年来有许多种新型降糖药物上市，但二甲双胍仍是在全球使用量迅速增加的经典口服降糖药物。二甲双胍具有良好的单药/联合治疗的疗效和安全性证据，以及良好的卫生经济学效益证据。无论对于血糖控制，还是糖尿病心血管并发症的预防，其都有明确的临床证据。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "五、糖尿病周围神经病的治疗", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "糖尿病周围神经病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "肝功能受损的患者对DPP-4抑制剂具有良好的耐受性。肝功能受损基本不会对DPP-4抑制剂产生有临床意义的药代动力学影响，对于大部分DPP-4抑制剂，在轻到中度肝功能受损的患者中均无需调整剂量。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "肝功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "肝功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "轻到中度肝功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "轻到中度肝功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "轻到中度", "subject_type": "分期分型", "object": {"@value": "轻到中度肝功能受损"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)短效促泌剂：短效磺脲类及格列奈类促泌剂半衰期短，作用迅速，主要降低2型糖尿病患者餐后血糖，主要包括：格列喹酮和格列吡嗪、瑞格列奈和那格列奈等。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "短效磺脲类", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列奈类促泌剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "餐后血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "那格列奈", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列吡嗪", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "推荐DPP-4i用于65岁以上的2型糖尿病患者糖治疗。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4i", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "一、心血管疾病患者糖尿病筛查流程及诊断标准", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "临床问题9：在单药治疗血糖控制不佳情况下，GLP-1RA是否可作为2型糖尿病患者的二线治疗选择之一? ", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "GLP-1RA", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.糖尿病患者围术期需要输注葡萄糖者，建议液体中按糖(g)：胰岛素(U)=3~4：1的比例加用胰岛素中和。肠内外营养的患者应注意营养液中的糖负荷，选用糖尿病专用型制剂，适当降低糖与脂肪的比例，缓慢输注，通过降低糖类总量、减慢吸收速度，降低血糖峰值，减少血糖波动。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "葡萄糖", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "输注", "subject_type": "用药方法", "object": {"@value": "葡萄糖"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "3~4：1", "subject_type": "用药剂量", "object": {"@value": "糖(g)：胰岛素(U)"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "正常人的胰岛素分泌包括基础性的持续分泌和外源性刺激后(主要是进餐)的餐时分泌两部分，两者大约各占全天总量的一半。前者的主要作用是调节空腹和餐前血糖，后者的主要作用是控制餐后血糖。餐时胰岛素又可以细分为早相(第一时相)和晚相(第二时相)分泌，其中早相分泌的速度和分泌量是决定餐后血糖升高幅度和持续时间的主要因素。2型糖尿病早期阶段主要是早相分泌减少，同时伴有晚相分泌代偿性增加且分泌高峰后移；随着病情进展，早相分泌进减少甚至消失，而晚相分泌峰值也逐渐下降，最后发展至基础分泌也逐渐减少。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(10)本共识增加T2DM患者常用药物对血脂的影响。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "7.联合噻唑烷二酮类药物的疗效：对于严重IR，二甲双胍联合噻唑烷二酮类药物能更好地降低HbA1c，显著改善胰岛功能和IR，且有剂量依赖性趋势，但不良反应(体重增加、升高LDL-C)高于二甲双胍单用组；罗格列酮/二甲双胍的复合制剂与单用二甲双胍比较，复合制剂降低HbA1c和FPG更显著，故在IR严重，且排除两药的使用禁忌时，可考虑二甲双胍联合噻唑烷二酮类药物的治疗方案(Ⅰ级)。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "升高LDL-C", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "噻唑烷二酮类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "升高LDL-C", "subject_type": "不良反应", "object": {"@value": "噻唑烷二酮类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "升高LDL-C", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "低血糖是磺脲类药物最常见的不良反度。但剂型改良后的格列吡嗪控释片、格列齐特缓释片和格列美脲等中长效制剂及餐时血糖调节药格列奈类，因其较低的血药浓度和依赖葡萄糖的降糖作用，低血糖的发生率低。GUIDE结果显示，在血糖水平控制相似的情况下，不同磺脲类促泌剂所致低血糖发生风险不同。糖尿病和心血管疾病行动研究(ADVANCE)以格列齐特缓释片为基瑞的降糖治疗严重低血糖年发生率仅为英国前瞻性糖尿病研究(UKPDS)采用格列本脲和氯磺丙脲为基碗的降糖治疗的1/4。英国一般实践研究数据库表明，磺脲类药物使用者年低血糖的发生半为1.8%，其中2.0%为年龄>65岁。在磺脲类药物中，格列苯脲的低血糖发生率最高，格列齐特和格列吡嗪的低血糖发生风险比格列苯脲低25%和40%。UKPDS对使用氯磺丙脲、格列苯脲和胰岛素的T2DM患者进行10年的随访表明，其年低血糖的发生率分别为11.0%、17.7%和36.5%。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列吡嗪控释片"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列齐特缓释片"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列美脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列奈类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列齐特缓释片"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列齐特缓释片", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列本脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列本脲", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "氯磺丙脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "氯磺丙脲", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列苯脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列齐特"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列吡嗪"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列苯脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "氯磺丙脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "氯磺丙脲", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列苯脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列苯脲", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "神经痛是影响DPN患者生活质量的主要因素之一，临床有多种药物可以改善患者神经痛的症状，如阿米替林、加巴喷丁、普瑞巴林、度洛西汀、文拉法辛等，具体参见中华医学会神经病学分会制定的痛性周围神经病的诊断和治疗共识。对于自主神经病变引起各系统受累的症状，可根据情况分别治疗，如胃肠道排空功能减退者，可适当选择胃肠动力药物，需注意降糖药的使用，防止低血糖的发生；对于存在明显直立性低血压者，可使用弹力袜，但需注意下肢的血液循环情况。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "神经痛", "subject_type": "临床表现", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿米替林", "subject_type": "药品名称", "object": {"@value": "痛性周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "加巴喷丁", "subject_type": "药品名称", "object": {"@value": "痛性周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "普瑞巴林", "subject_type": "药品名称", "object": {"@value": "痛性周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "度洛西汀", "subject_type": "药品名称", "object": {"@value": "痛性周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "文拉法辛", "subject_type": "药品名称", "object": {"@value": "痛性周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "痛性周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "自主神经", "subject_type": "患病部位", "object": {"@value": "自主神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "胃", "subject_type": "患病部位", "object": {"@value": "胃肠道排空功能减退"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肠道", "subject_type": "患病部位", "object": {"@value": "胃肠道排空功能减退"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "直立性", "subject_type": "分期分型", "object": {"@value": "直立性低血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "弹力袜", "subject_type": "非药治疗", "object": {"@value": "直立性低血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢", "subject_type": "患病部位", "object": {"@value": "直立性低血压"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(5)住院糖尿病患者控制目标：具体请见“二、住院患者的血糖控制目标”章节。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "对于OSAHS伴发2型糖尿病的患者，常用降糖药均可选用，但应尽可能使用不增加体重的药物。由于OSAHS易发生夜间缺氧，对于低氧血症严重者慎用或禁用双胍类药物。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "夜间缺氧", "subject_type": "临床表现", "object": {"@value": "OSAHS"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "从某种程度上讲，上述药物治疗方法仅仅是对于轻至中度的下肢动脉缺血性病变的患者延缓其病变的发展，是糖尿病足治疗的基础；但对于严重下肢缺血(CLI)患者多数并不能达到改善症状、保肢的目的。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "下肢动脉", "subject_type": "患病部位", "object": {"@value": "下肢动脉缺血性病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢", "subject_type": "患病部位", "object": {"@value": "下肢缺血(CLI)"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "临床应用共识指出，GLP-1受体激动剂适用于成人2型糖尿病患者，其中艾塞那肽目前国内适用于单用二甲双胍、磺脲类，以及二甲双胍合用磺脲类，而血糖仍控制不佳的患者，而在国外，艾塞那肽还可与噻唑烷二酮类、二甲双胍合用磺脲类、二甲双胍合用噻唑烷二酮类以及基础胰岛素联合使用等；利拉鲁肽在国内适用于单用二甲双胍或磺脲类药物最大可耐受剂量治疗后血糖仍控制不佳的患者，与二甲双胍或磺脲类药物联合应用，而在国外，利拉鲁肽在此应用基础上还有单药使用，与二甲双胍+磺脲类或与二甲双胍+噻唑烷二酮类或与胰岛素联合应用的适应证等。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "B.低血糖S GLT-2抑制剂单药治疗不增加低血糖风险；与二甲双胍、DPP-4抑制剂、噻唑烷二酮类等药物联用时，低血糖风险也没有明显增加；与胰岛素或磺脲类药物联用时低血糖风险增加。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "S GLT-2抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "餐后血糖高、胰岛功能差、使用胰岛素/胰岛素类似物或胰岛素促泌剂、低血糖风险高、长病程、高龄的糖尿病患者一般血糖波动大，应重点关注，尤其是使用胰岛素/胰岛素类似物或磺脲类药物的患者，因为这两类药物的低血糖风险较高，故更易造成血糖波动。研究提示，在磺脲类促泌剂基础上联合α-糖苷酶抑制剂，可减少低血糖，改善血糖波动；使用胰岛素/胰岛素类似物治疗的患者联合α-糖苷酶抑制剂后MAGE显著改善。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素类似物", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "α-糖苷酶抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素类似物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "1.最小、最大及最佳使用剂量：二甲双胍的降糖效果与剂量(500~2000mg/d)呈正相关。500mg/d二甲双胍可降低HbA1c0.6%(减去安慰剂效应后，以下同)，2000mg/d可降低HbA1c2%，且胃肠道反应与1000或1500mg/d差异无统计学意义(Ⅰ级)。UKPDS研究中二甲双胍强化治疗剂量中位数达到2550mg/d，缓释剂型推荐最大用量为2000mg/d，普通片推荐成人最大剂量为2550mg/d。二甲双胍起效的最小推荐剂量500mg/d，成人最大量2550mg/d，最佳有效剂量2000mg/d。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "500~2000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "500mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1000或1500mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道反应", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2550mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2550mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "500mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2550mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "2型糖尿病青少年过渡到成人期间，医疗卫生人员和家人必须结合他们的特点，从青少年早中期即开始，至少在过渡前1年做好转诊准备。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.2型糖尿病合并肝功能不全患者", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "④1-2-3次方案：使用预混胰岛素类似物，餐后血糖升高明显者选择中预混制剂。每日1次起始剂量一般为10~12单位，晚餐前注射，根据早餐前血糖调整剂量；如HbA1c或餐前血糖不达标，则早餐前增加3~6单位，根据晚餐前和空腹血糖调整早餐前和晚餐前剂量；如HbA1c或午餐后血糖仍不达标，则午餐前加用3位或将早餐前剂量按1：1分配到早、午餐前，根据午餐后或晚餐血糖调整午餐前剂量。预混胰岛素类做物每日1次治疗时可根据具体情况调整口服降糖药；当调整为每日2次或3次时，不建议同时使用胰岛素促泌剂，可继续使用二甲双胍或α-糖苷酶抑制剂，视患者个体情况决定是否停用噻唑烷二酮类药物。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "每日1次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素类做物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "快速建议指南推荐DPP-4抑制剂用于65岁以上的2型糖尿病患者的降糖治疗。其理由是，老年患者常常合并多种并发疾病，而DPP-4抑制剂具有良好的血糖控制效果和安全性，同时也指出，推荐使用常规剂量进行治疗，但如患者伴有肝或肾功能不全，则需要根据说明书进行剂量调整。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝或肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肝或肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "6.规律运动可降低痛风发作次数，减少HUA相关死亡。鼓励HUA患者坚持适量运动。建议每周150min(30min／d×5d／周)中等强度[运动时心率在(220-年龄)×(50％～70％)范围内]的有氧运动。运动中应当避免剧烈运动或突然受凉诱发痛风发作。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "规律运动", "subject_type": "非药治疗", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "坚持适量运动", "subject_type": "非药治疗", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "剧烈运动", "subject_type": "患病病因", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "突然受凉", "subject_type": "患病病因", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "T2DM患者通常合并多项血脂异常，主要表现为TG升高、LDL-C升高及HDL-C降低、三者均与T2DM患者ASCVD发生风险增高相关。T2DM合并ASCVD患者属于极高危人群，调脂治疗的首要干预靶点IDL-C目标值为<1.8mmol/L，次要干预靶点非HDL-C目标值为<2.6mmol/L，为了达到上述目标-应首选他汀类药物。经他汀类治疗后，如非HDL-C仍不能达到目标值.可在他汀类基础上加用贝特类、高纯度鱼油制剂。对于严重高TG血症(空腹TG≥5.7mmol/L)患者，应首先考虑使用贝特类、高纯度鱼油制剂或烟酸类药物治疗，以预防急性胰腺炎的发生。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "TG", "subject_type": "检查指标", "object": {"@value": "血脂异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "血脂异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HDL-C", "subject_type": "检查指标", "object": {"@value": "血脂异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "IDL-C", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "非HDL-C", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "IDL-C", "subject_type": "检查指标", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "非HDL-C", "subject_type": "检查指标", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类药物", "subject_type": "药品名称", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "空腹TG", "subject_type": "检查指标", "object": {"@value": "高TG血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝特类", "subject_type": "药品名称", "object": {"@value": "高TG血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "高纯度鱼油制剂", "subject_type": "药品名称", "object": {"@value": "高TG血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "烟酸类药物", "subject_type": "药品名称", "object": {"@value": "高TG血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "胰腺", "subject_type": "患病部位", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "急性", "subject_type": "分期分型", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "DPP-4抑制剂通过抑制DDP-4酶对GLP-1的降解，提高周围血GLP-1水平2~3倍，进而促进胰岛β细胞分泌胰岛素，抑制胰升血糖素，降低PPG，可降低HbA1c0.4%~0.9%。此类药包括西格列汀、沙格列汀、维格列汀、利格列汀和阿格列汀。中国T2DM患者使用西格列汀单药治疗HbA1c下降0.7%，2 hPG下降2.8mmol/L；单独使用沙格列汀可使HbA1c下降0.5%，以速食面进行混合餐耐量试验(MMTT)可使2 hPG下降1.32mmol/L。同时，二甲双胍单药治疗血糖控不佳的T2DM患者，加用维格列汀后，较安慰剂组HbA1c下降0.51%；2 hPG下降1.53mmol/L。二甲双胍联合磺脲类药物治疗血糖控制不佳的T2DM患者加用利格列汀后，HbA1c较基线下降0.68%。DPP-4酶抑制剂单独使用低血糖风小，对体重的作用为中性或轻度增加。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西格列汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "沙格列汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "2 hPG", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "维格列汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "安慰剂", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "2 hPG", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利格列汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重的作用为中性或轻度增加", "subject_type": "不良反应", "object": {"@value": "DPP-4酶抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "DPP-4酶抑制剂"}, "object_type": {"@value": "药品名称"}}]}
{"text": "7.与非降糖药物的相互作用：(1)使用氨氯吡咪、地高辛、吗啡、普鲁卡因胺、奎尼丁、奎宁、雷尼替丁、氨苯蝶啶、甲氧苄氨嘧啶和万古霉素等经肾小管排泌的阳离子药物，其影响肾功能或二甲双胍分布，应密切监测血糖并调整二甲双胍和/或相互作用的剂量；(2)同时服用噻嗪类药物或其他利尿剂、糖皮质激素、吩噻嗪、甲状腺制剂、雌激素、口服避孕药、苯妥英、烟碱酸、拟交感神经药、钙离子通道阻滞剂和异烟肼等可引起血糖升高的药物需密切监测血糖。而在这些药物停用后，要密切注意低血糖的发生：合并服用氯磺丙脲的患者在换用二甲双胍的最初2周要密切监测血糖，氯磺丙脲在体内有较长潜留，易发生低血糖；(3)二甲双胍有增加华法林的抗凝血倾向；(4)树脂类药物，如苏合香、血竭、乳香等与二甲双胍合用会减少其吸收。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "氯磺丙脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "口服避孕药"}, "object_type": {"@value": "药品名称"}}]}
{"text": "近二十年来，我国超重/肥胖的患病率逐年增长，呈流行态势。中国健康营养调查(China Health and Nutrition Survey，CHNS)的数据显示，从1993年至2009年的17年间，成年人超重/肥胖的患病率从13.4%增加至26.4%，总体呈线性增长；成年人腹型肥胖的患病率从18.6%增长至37.4%，平均年增长1.1%，显著高于超重/肥胖的增长速度。肥胖是糖尿病、心血管疾病及其他代谢性疾病和肿瘤的潜在危险因素。减重治疗包括生活方式(膳食和体育运动)调整、内科药物及外科手术治疗等多种手段。科学合理的营养治疗联合运动干预仍是目前最有效、最安全的基础治疗。近年来，国际上对肥胖/超重的营养管理已经形成了一些共识。然而，以营养和生活方式干预为核心的肥胖/超重管理必须与特定的地域性饮食习惯及社会文化相适应。为更好地发挥医学营养治疗在肥胖防治中的作用，结合国内外发表的诸多证据和专家的集体智慧，特制定本共识，以便使医学减重更加科学、规范和易于实施。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "肿瘤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "营养治疗", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "减重", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "目前，糖尿病自我管理处方的智能平台已经实现多种功能：储存患者健康信息、通过人工智能技术快速辅助分析患者自我管理行为问题、智能生成个性化糖尿病自我管理方案、配合远程糖尿病教育和复诊评估、评估后智能优化自我管理处方，为患者提供连续的DSME/S。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "DSME/S", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "随机对照临床试验已证实，严格的血糖控制可降低糖尿病的微血管并发症，但对大血管并发症的直接获益存在不同观点，有待进一步证实。早期临床研究如UKPDS报道，严格血糖控制可明显降低微血管并发症，心肌梗死风险降低16%(P=0.052)；在延长观察阶段，心肌梗死和全因性死亡的风险减少13%。近年，对于2型糖尿病患者的口服降糖药物强化血糖控制的随机对照研究，如VADT、ACCORD、ADVANCE，均未发现口服降糖药物强化降糖治疗可降低心血管事件风险，但对VADT、ACCORD和ADVANCE的心血管终点事件的综合荟萃分析后，HbA1c每下降1%，非致命性心梗相对风险降低15%，但未降低卒中或全因死亡风险。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "非致命性", "subject_type": "分期分型", "object": {"@value": "非致命性心梗"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "非致命性心梗"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "对于血糖水平显著增高并伴有高血糖症状的新诊断T2DM患者；或在糖尿病治疗过程中，需短时间内纠正高血糖的患者，推荐进行基础-餐时模式的短期胰岛素强化治疗。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "CFDA批准的达格列净说明书上所写的适应证为“在饮食和运动基础上，本品可作为单药治疗用于2型糖尿病成人患者改善血糖控制。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "严重肾功能损害者(eGFR<30ml/min)及有肾结石的患者，孕妇、有可能怀孕妇女以及哺乳期妇女。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "eGFR", "subject_type": "检查指标", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾结石"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "因此，我国临床内分泌学专家根据当前中国T2DM和肥胖患者的流行病学特征及现有的临床证据，制订出本部中国T2DM合并肥胖综合管理专家共识。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.糖尿病足：发生糖尿病足病意味着同时存在全身动脉粥样硬化性改变，是发生心脑血管严重病变的高风险信号，需要对患者进行全面评估，综合治疗(II)。病程长的糖尿病患者，均须注意预防足部皮肤破损，认真处置足癣和甲癣(B)。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "全身动脉粥样硬化性改变", "subject_type": "临床表现", "object": {"@value": "糖尿病足病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心脑血管", "subject_type": "患病部位", "object": {"@value": "心脑血管严重病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "足部皮肤破损", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "足癣", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "甲癣", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.实施高危人群干预，推动关口前移。用好居民健康档案和各类体检信息，开展机会性筛查，发现或识别高危个体。针对糖尿病前期人群和血糖正常性高危人群开展分层干预和管理。对超重、肥胖者以减重为目标强化生活方式干预。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "减重", "subject_type": "非药治疗", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "减重", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "REACH研究结果提示，二甲双胍治疗2年，全因死亡相对风险下降24%，HOME研究结果提示，二甲双胍联合胰岛素比单用胰岛素可以减少大血管事件风险，中国SPREAD研究结果显示，对于有冠心病病史的T2DM患者，与格列吡嗪组相比，二甲双胍组的主要终点事件发生风险降低46%(Ⅰ级)。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "大血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)格列喹酮与二甲双胍联合：一项多中心、随机、开放、平行分组对照研究显示：格列喹酮在单药和(或)联合治疗失败的2型糖尿病患者中与二甲双胍联合治疗14周后，平均HbA1c下降1.7%，HbA1c<6.5%及HbA1c<7.0%的达标率分别为25.71%及42.86%，均高于阿卡波糖联合二甲双胍组；格列喹酮组对PPG降低幅度达4.75mmol/L，是阿卡波糖组的2倍以上：对FPG降低度为1.0mmol/L。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "14周后", "subject_type": "持续时间", "object": {"@value": "格列喹酮"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "14周后", "subject_type": "持续时间", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "大量研究显示，母体孕前及孕期的肥胖均与孕期合并症及不良妊娠结局相关，包括妊娠期糖尿病、妊娠高血压、子痫、早产、死胎、巨大儿、过期产、剖宫产、先天畸形等；远期不良影响包括产后母体及子代肥胖，增加母婴罹患2型糖尿病、高血压及其他代谢综合征的风险。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "二、糖尿病肾病的防治", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "降糖同时增加体重的药物有胰岛素、噻唑烷二酮类(thiazolidinediones，TZDs)、磺脲类药物。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "增加体重", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "增加体重", "subject_type": "不良反应", "object": {"@value": "噻唑烷二酮类(thiazolidinediones，TZDs)"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "增加体重", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "3.3糖尿病微血管并发症的诊断DR的诊断参考2 017年《中国糖尿病视网膜病变防治指南(基层版)》，依据散瞳后眼底镜检查或眼底照相结果进行诊断与分级。DKD的诊断标准参考《美国肾脏基金会肾脏病预后质量倡议(NKF-K/DOQI)指南标准》。DPN的诊断参考《中国2型糖尿病防治指南(2017年版)》的诊断标准(详见附录2 )。如要确诊是否为DKD或糖尿病合并肾脏疾病，需行肾穿刺活检。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "散瞳后眼底镜检查", "subject_type": "检查方法", "object": {"@value": "DR"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "眼底照相", "subject_type": "检查方法", "object": {"@value": "DR"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾穿刺活检", "subject_type": "检查方法", "object": {"@value": "DKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾穿刺活检", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾穿刺活检", "subject_type": "检查方法", "object": {"@value": "肾脏疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "因此，贝前列素钠能有效地改善间歇性行患者的症状。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "贝前列素钠", "subject_type": "药品名称", "object": {"@value": "间歇性行"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "尿酸由饮食摄入和体内分解的嘌呤化合物在肝脏中产生，约2／3尿酸通过肾脏排泄。其余由消化道排泄。尿酸经肾小球滤过、近端肾小管重吸收、分泌后再吸收，未吸收部分从尿液中排出(图2)。正常情况下，体内尿酸产生和排泄保持平衡，凡导致尿酸生成过多和或排泄减少的因素均可导致HUA(附件1)。", "spo_list": [{"Combined": false, "predicate": "患病病因", "subject": "尿酸生成过多和或排泄减少", "subject_type": "患病病因", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "妊娠期间高血糖包括糖尿病妊娠与妊娠糖尿病(GDM)，不论是那种类型高血糖，均可能导致不良妊娠结局，其中需要进行住院血糖管理的患者包括：糖尿病患者计划妊娠或已妊娠时，或GDM患者，经门诊治疗血糖不达标者；合并严重急、慢性并发症者；妊娠期需启动胰岛素治疗者；另外，在产科住院的妊娠高血糖患者，依据血糖情况，必要时也应请内分泌科进行血糖管理。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "不良妊娠", "subject_type": "临床表现", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "妊娠高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "妊娠高血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "无论是直接起始胰岛素泵还是每日多次胰岛素注射方案与胰岛素泵方案的相互转换，都建议住医生指导下完成。具体用法：①初始胰岛素泵方每日胰岛素总量可按0.4~0.5单位/千克体重计算；2每日基础量=全天胰岛素总量X(40%~60%)，常规分为6或更多个时间段，以尽量减少或避免低血糖事件，或根据血糖情况分段设置基础输注率；③餐食追加量=全天胰岛素总量X(40%~60%)，根据早中晚三餐比例一般按1/3、1/3、1/3或1/5、2/5、2/5分配，之后根据血糖监测结果调整。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "每日多次", "subject_type": "用药频率", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "0.4~0.5单位/千克体重", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "T2DM患者的血脂管理需基于其血脂异常情况及心血管危险程度，确定个体化的治疗目标及措施(图2)。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "血管", "subject_type": "患病部位", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)对血糖控制未达标的非内分泌科住院高血糖患者，尤其在合并有糖尿病酮症、DKA和糖尿病高渗状态等急性并发症的患者，建议邀请内分泌专科医生协同诊治。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "推荐使用常规剂量进行治疗，除非伴有肝或肾功能不全，需根据说明书进行剂量调整。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝或肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肝或肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "瑞格列奈及其代谢产物的8.0%经肾脏排泄此药的I期临床试验表明，使用瑞格列奈7d后，与肾功能正常患者相比，不同程度慢性肾脏病患者的血药浓度没有明显差别，提示瑞格列奈在慢性肾脏病患者体内无蓄积。一项以瑞格列奈替换原有降糖治疗、共人组281例伴或不伴肾功能不全2型糖尿病患者的多中心研究显示，不同程度肾功能不全亚组患者(正常、轻、中、重、极重育功能损害)的低血糖发生率均低于2.0%，且瑞格列奈治疗期低血糖发生率与肾功能损害程度无关。推荐瑞格列奈用于慢性肾脏病1~5期的患者无需调整剂量；如系起始用药患者，应0.5mg起始。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "7d", "subject_type": "持续时间", "object": {"@value": "瑞格列奈"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾功能", "subject_type": "检查方法", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "瑞格列奈"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "瑞格列奈"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "0.5mg", "subject_type": "用药剂量", "object": {"@value": "瑞格列奈"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~5期", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.降糖药的选用原则：从病理改变的过程看，2型糖尿病的发展包括早期正常血糖-胰岛素代偿性高分泌阶段、糖尿病前期(血糖轻度升高)、糖尿病胰岛素分泌不足阶段、糖尿病胰岛素分泌缺乏4个代表性阶段(IV)。在选择降糖药的策略上需有所区别。如能在正常血糖-胰岛素高分泌代偿阶段开始TLC干预，消除引起胰岛素抵抗的原因，可预防糖尿病。糖尿病前期的病理特点表现为胰岛素抵抗+相对分泌不足，保护胰岛β细胞、减轻胰岛素抵抗，必要时辅用非胰岛素促泌剂和肠促胰素类药物，可以延缓糖尿病发生(A)。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素分泌不足", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素分泌缺乏", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "TLC", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗+相对分泌不足", "subject_type": "发病机制", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "非胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "肠促胰素类药物", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.脂肪：多项研究证实CRD的脂肪供能比例应与正常膳食(20%~30%)一致，过低或过高都会导致膳食模式的不平衡。在CRD中补充海鱼或鱼油制剂的研究均报道n-3多不饱和脂肪酸(polyunsaturated fatty acids，n-3PUFA)对肥胖者动脉弹性、收缩压、心率、血甘油三酯及炎症指标等均有明显改善，可增强CRD的减重效果。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "CRD", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "收缩压", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "心率", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血甘油三酯", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "A.肾功能不全：西格列汀通过肾脏代谢，用于中、重度肾功能不全及需要透析的终末期肾病患者时需要根据肌酐清除率调整剂量；维格列汀在中度或重度肾功能不全或需要接受血液透析治疗的终末期肾病患者中的应用经验有限，因此不推荐此类患者使用；沙格列汀在轻度肾功能不全的患者中无需调整剂量，中重度肾功能不全的患者应将剂量调整为2.5毫克，每日1次，在重度肾功能不全的患者中临床研究经验有限，因此不推荐使用；利格列汀极少经过肾脏排泄，在不同程度肾功能不全的患者中使用，均不需要调整剂量；阿格列汀在中度肾功能受损患者中使用剂量为推荐剂量减半，重度肾功能受损或终末期肾功能衰竭患者中使用剂量为推荐量的四分之一。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肌酐清除率", "subject_type": "检查指标", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西格列汀", "subject_type": "药品名称", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "终末期", "subject_type": "分期分型", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肌酐清除率", "subject_type": "检查指标", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "透析", "subject_type": "非药治疗", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "终末期", "subject_type": "分期分型", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "血液透析", "subject_type": "非药治疗", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肌酐清除率", "subject_type": "检查指标", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "沙格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "沙格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "终末期", "subject_type": "分期分型", "object": {"@value": "肾功能衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2.5毫克", "subject_type": "用药剂量", "object": {"@value": "沙格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日1次", "subject_type": "用药频率", "object": {"@value": "沙格列汀"}, "object_type": {"@value": "药品名称"}}]}
{"text": "糖尿病患者出现肢体肌肉无力和萎缩通常相对较晚。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "肢体肌肉无力", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "萎缩", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "多数指南并未单独设定老年糖尿病患者(>65岁)的血糖控制目标，这是因为老年患者的身体健康状况、脏器功能、认知功能以及预期寿命差异较大，不能一概而论；同时缺乏相关的循证医学证据指导制定个体化治疗目标。本共识专家认为应该就此特殊人群制定血糖控制目标，本共识专家认为应该就此特殊人群制定血糖控制目标，参考国外文献，建议血糖控制目标：若患者脏器功能和认知能力良好、预期生存期>15年，应严格控制HbA1c<7%；若患者合并其他疾病、预期生存期5~15年，可适当放宽HbA1c<8%；若患者既往有严重低血糖史、合并其他严重疾病、预期生存期<5年，美国退伍军人事务局推荐控制目标可放宽到HbA1c<9%。HbA1c较高者应避免发生高血糖症状、急性代谢紊乱和感染。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "急性代谢紊乱"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "感染"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "注意事项：在服用非布司他的初期，可见痛风发作频率增加。源于血尿酸浓度降低，导致组织中沉积的尿酸盐动员。为预防治疗初期的痛风发作，建议同时服用非甾体类抗炎药或秋水仙碱。在非布司他治疗期间，若痛风发作，无需中止非布司他治疗。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "痛风发作频率增加", "subject_type": "不良反应", "object": {"@value": "非布司他"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "秋水仙碱", "subject_type": "药品名称", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "非甾体类抗炎药", "subject_type": "药品名称", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "非布司他", "subject_type": "药品名称", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.老年T2DM患者：已确诊的老年T2DM患者，且HbA1c>7.0%时，需考虑口服单药或联合降糖药物治疗。二甲双胍是治疗T2DM的基础用药，但以降低FPG为主；α-糖苷酶抑制剂或DPP-4抑制剂主要降低PPG，这两种药物都不增加低血糖发生，且耐受性较好。老年T2DM患者在使用胰岛素促泌剂或胰岛之前应认真考虑低血糖的风险。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛"}, "object_type": {"@value": "药品名称"}}]}
{"text": "不久的将来，通过大数据和云平台，可以将智能硬件(如血糖仪和可穿戴设备)自动连接，甚至可与居民健康档案系统对接，形成区域性疾病管理云平台，最大程度地提升糖尿病教育管理的效益。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "教育管理", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "随着国民寿命的延长，老年期会涉及每个人的20~30个生命年。按现有资料估计，糖代谢异常约影响我国1亿老年人的晚年生活，高龄老人也是多种慢性病的高风险人群，如缺少科学的防病治病行为，糖尿病所致危害不仅减少生存年，还会因失明、致残、智能障碍等使相当一部分老年患者的生活质量大大下降。", "spo_list": [{"Combined": false, "predicate": "发病机制", "subject": "糖代谢异常", "subject_type": "发病机制", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "失明", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "致残", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "智能障碍", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.腱反射检查：通常可出现腱反射减低或消失，尤以跟腱反射为著，是诊断DPN的主要体征之一。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "腱反射检查", "subject_type": "检查方法", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "腱反射减低或消失", "subject_type": "临床表现", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "尤以跟腱反射为著", "subject_type": "临床表现", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "磺脲类药物正式用于糖尿病临床治疗也已经快60年了，目前仍是糖尿病治疗领域应用最为广泛的口服降糖药物之一，并且在国内外2型糖尿病指南中占据着非常重要的治疗地位。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "DPP-4抑制剂可抑制DPP-4活性，有效减少GLP-1的失活，在生理范围内增加有活性的GLP-1水平，以葡萄糖浓度依赖的方式促进胰岛素释放，并降低胰高糖素水平，发挥降低糖化血红蛋白(HbA1c)、空腹血糖及餐后血糖的作用。最近临床试验的研究结果证实了阿格列汀和沙格列汀对心血管疾病(CVD)的长期良好安全性。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "阿格列汀", "subject_type": "药品名称", "object": {"@value": "心血管疾病(CVD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "沙格列汀", "subject_type": "药品名称", "object": {"@value": "心血管疾病(CVD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病(CVD)"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.生活方式的干预：生活方式干预是2型糖尿病的首要治疗手段，要注重全家的参与，同时还应包括营养师，心理医生，社会工作者和运动生理学家等在内的多学科教育和管理。有效的自我管理教育和自我管理支持是近年来糖尿病教育的重点，可以延缓和预防糖尿病并发症的发生。包括参与各种培训计划，心理咨询等，应作为评估、监测和治疗的一部分。患儿对疾病的态度、对治疗和预后的期望值、情感/情绪状态、与糖尿病相关的生活质量、资源(经济、社会和情感方面)以及精神病史等均与糖尿病预后密切相关。对于糖尿病前期和高危患儿，更应强调生活方式干预以有效降低发病率。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式的干预", "subject_type": "非药治疗", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "有效的自我管理教育", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "自我管理支持", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "有效的自我管理教育", "subject_type": "非药治疗", "object": {"@value": "糖尿病并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "自我管理支持", "subject_type": "非药治疗", "object": {"@value": "糖尿病并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "磺脲类药物单药治疗一般可降低HbA1c1%~2%，平均降低1.5%。对于新诊断T2DM患者，格列齐特缓释片单药治疗52周可使HbA1c降低1.28%，安全性良好，治疗期间无严重低血糖事件发生；格列吡嗪控释片单药治疗8周可使HbA1c降低1.12%；格列本脲单药治疗12个月可使HbA1c降低1.26%；格列美脲单药治疗16周可使HbA1c降低2.5%，稳态模型评估的β细胞功能指数(HOMA-β)显著升高，稳态模型评估的胰岛素抵抗指数(HOMA-IR)显著降低，经血糖检测≤3.9mmol/L证实的低血糖发生率为3.8%，总体安全性良好。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "格列齐特缓释片", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列齐特缓释片"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "52周", "subject_type": "持续时间", "object": {"@value": "格列齐特缓释片"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "8周", "subject_type": "持续时间", "object": {"@value": "格列吡嗪控释片"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "12个月", "subject_type": "持续时间", "object": {"@value": "格列本脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "16周", "subject_type": "持续时间", "object": {"@value": "格列美脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "瑞格列奈和利格列汀在CKD1~5期全程均可使用，且无需调整剂量。其他非胰岛素降糖药的使用均可因肾功能不全的不同程度而受到一定的影响。二甲双胍在CKD3a期[eGFR45~59ml/(min.1.73m2)]时应减量，在CKD3b期[eGFR30--45ml/(min.1.73m2)]时证据相对有限，谨慎观察下减量使用，在CKD4期[eGFR<30ml/(min.1.73m2)]时禁用。基于LEADER研究和LIRA-RENAL研究的数据.推荐利拉鲁肽可用于CKD1~3期，从CKD4期开始禁用。根据美国FDA批准的药品说明书，恩格列净可用于CKD1~3a期，从3b期开始不推荐使用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利格列汀", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~5期", "subject_type": "分期分型", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3a期", "subject_type": "分期分型", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "eGFR", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "eGFR", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3b期", "subject_type": "分期分型", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "eGFR", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "4期", "subject_type": "分期分型", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利拉鲁肽", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~3期", "subject_type": "分期分型", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "4期", "subject_type": "分期分型", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "恩格列净", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~3a期", "subject_type": "分期分型", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3b期", "subject_type": "分期分型", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "推荐1：T2DM患者的血脂诸以混合型血脂紊乱多见，其特征性的血脂谱包括：(1)空腹和餐后TG水平升高.即使在空腹血糖和TG水平控制正常后往往还存在餐后高TG血症；(2)HDL-C水平降低；(3)血清总胆固醇(TC)水平和LDL-C正常或轻度升商，且LDL-C发生质变，小而致密的LDL-C水平升高；(4)富含TG脂蛋白的载脂蛋白(apo)B-100和apoB-48水平升高，apo-CⅢ水平升高，apo-CII/apo-CIII以及apo-CIII/apo-E的比值升高。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "空腹和餐后TG水平", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "空腹血糖", "subject_type": "检查指标", "object": {"@value": "高TG血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "TG水平", "subject_type": "检查指标", "object": {"@value": "高TG血症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "HUA的危害性越来越受到重视。当血尿酸超过饱和浓度，尿酸盐晶体析出可直接黏附、沉积于关节及周围软组织、肾小管和血管等部位，趋化中性粒细胞和巨噬细胞；细胞与晶体相互作用后释放致炎因子、金属蛋白酶9、水解酶等，导致关节软骨、骨质、肾脏以及血管内膜等急慢性炎症损伤，故普遍认为HUA是多种心血管危险因素及相关疾病(代谢综合征、2型糖尿病、高血压、心血管事件及死亡、慢性肾病等)的独立危险因素。共识明确指出，HUA是痛风发生的最重要生化基础和最直接的病因，痛风性关节炎患者首先遵循HUA管理原则。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血尿酸", "subject_type": "检查指标", "object": {"@value": "关节软骨、骨质、肾脏以及血管内膜等急慢性炎症损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "致炎因子", "subject_type": "患病病因", "object": {"@value": "关节软骨、骨质、肾脏以及血管内膜等急慢性炎症损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "金属蛋白酶9", "subject_type": "患病病因", "object": {"@value": "关节软骨、骨质、肾脏以及血管内膜等急慢性炎症损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "水解酶", "subject_type": "患病病因", "object": {"@value": "关节软骨、骨质、肾脏以及血管内膜等急慢性炎症损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "关节软骨", "subject_type": "患病部位", "object": {"@value": "关节软骨、骨质、肾脏以及血管内膜等急慢性炎症损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "骨质", "subject_type": "患病部位", "object": {"@value": "关节软骨、骨质、肾脏以及血管内膜等急慢性炎症损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "关节软骨、骨质、肾脏以及血管内膜等急慢性炎症损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "血管内膜", "subject_type": "患病部位", "object": {"@value": "关节软骨、骨质、肾脏以及血管内膜等急慢性炎症损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "HUA", "subject_type": "患病病因", "object": {"@value": "代谢综合征"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "HUA", "subject_type": "患病病因", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "HUA", "subject_type": "患病病因", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "HUA", "subject_type": "患病病因", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "HUA", "subject_type": "患病病因", "object": {"@value": "慢性肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "HUA", "subject_type": "患病病因", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "关节", "subject_type": "患病部位", "object": {"@value": "痛风性关节炎"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "如无禁忌证，二甲双胍是治疗T2DM的首选药物和联合治疗方案中的基础治疗药物，且应一直保留在糖尿病治疗方案中。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.降低PPG为主的注射制剂(表4)：胰岛素是T2DM患者降糖治疗的有效手段，短效人胰岛素和速效胰岛素类似物主要用于控制PPG。短效胰岛素一般在餐前15~30min皮下注射；速效胰岛素类似物可在餐前即刻皮下注射，个别情况，如进餐量无法估计可餐后即刻注射，注射后30~60min作用达到高峰。速效胰岛素类似物降糖能力与短效人胰岛素相当，但在模拟生理性胰岛素分泌、降低PPG幅度和低血糖风险方面优于人胰岛素，且餐前即刻注射更为方便，有助于提高治疗依从性。此外，预混胰岛素制剂包含一定比例的短效/速效胰岛素，同样可降低PPG。胰岛素治疗可引起低血糖，并增加体重。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "PPG", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "短效人胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "速效胰岛素类似物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "餐前15~30min皮下注射", "subject_type": "用药方法", "object": {"@value": "短效胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "餐前即刻皮下注射", "subject_type": "用药方法", "object": {"@value": "速效胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "30~60min", "subject_type": "持续时间", "object": {"@value": "速效胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "速效胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "餐前即刻注射", "subject_type": "用药方法", "object": {"@value": "速效胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "短效人胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "增加体重", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "T2DM患者的高凝血状态是发生心血管事件的重要原因之一。在ASCVD或伴有心血管高危因素的患者中，阿司匹林可有效预防卒中、心肌梗死等心脑血管事件。对于T2DM合并ASCVD患者应常规使用阿司匹林作为二级预防措施，最佳剂量为75~150mg/d；对于阿司匹林过敏或不耐受的患者，可考虑使用氯吡格雷(75mg/d)作为替代治疗。对于急性冠状动脉综合征(ACS)患者，可使用阿司匹林和氯吡格雷双联抗血小板治疗1年。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "高凝血状态", "subject_type": "患病病因", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿司匹林", "subject_type": "药品名称", "object": {"@value": "卒中"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿司匹林", "subject_type": "药品名称", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿司匹林", "subject_type": "药品名称", "object": {"@value": "心脑血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心脑血管", "subject_type": "患病部位", "object": {"@value": "心脑血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿司匹林", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿司匹林", "subject_type": "药品名称", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "75~150mg/d", "subject_type": "用药剂量", "object": {"@value": "阿司匹林"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "过敏", "subject_type": "不良反应", "object": {"@value": "阿司匹林"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "不耐受", "subject_type": "不良反应", "object": {"@value": "阿司匹林"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "75mg/d", "subject_type": "用药剂量", "object": {"@value": "氯吡格雷"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "冠状动脉", "subject_type": "患病部位", "object": {"@value": "急性冠状动脉综合征(ACS)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "急性", "subject_type": "分期分型", "object": {"@value": "急性冠状动脉综合征(ACS)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿司匹林", "subject_type": "药品名称", "object": {"@value": "急性冠状动脉综合征(ACS)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "氯吡格雷", "subject_type": "药品名称", "object": {"@value": "急性冠状动脉综合征(ACS)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "1年", "subject_type": "持续时间", "object": {"@value": "阿司匹林"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "1年", "subject_type": "持续时间", "object": {"@value": "氯吡格雷"}, "object_type": {"@value": "药品名称"}}]}
{"text": "2.二甲双胍的心血管保护作用机制：二甲双胍可能通过减少心血管疾病的风险因素而达到心血管保护作用。心血管疾病的风因素包括血脂异常、IR、肥胖、高血压、NAFLD等。控制风险因素是心血管保护的重要方式之一。二甲双胍目前已经被证实可以降低血糖、改善NAFLD和IR(尤其是肝脏和肌肉)、减轻体重、改善血脂(主要是改善TG、LDL-C及TC水平，对HDL-C改变不明显)和抗凝等。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "NAFLD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "DPP-4抑制剂是一类耐受性良好的降糖药物，单独使用基本无低血糖风险。临床试验显示其不良事件总体水平与安慰剂相当。通常DPP-4抑制剂增加内源性GLP-1 2~3倍，胃肠道反应也较少。既往曾有该类药物在临床使用后发生胰腺炎的病例报道，但大样本的回顾性分析以及新近发布的大型前瞻性研究结果均未显示DPP-4抑制剂增加胰腺炎发生风险。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "胃肠道反应", "subject_type": "不良反应", "object": {"@value": "DPP-4抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "胰腺", "subject_type": "患病部位", "object": {"@value": "胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "胰腺", "subject_type": "患病部位", "object": {"@value": "胰腺炎"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "八、T2DM患者常用药物对血脂的影响", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)HUA与冠心病：血尿酸水平每升高60μmol／L，女性心血管病病死率和缺血性心脏病病死率增加26％和30%;男性增加9％和17％，女性冠心病增加48%。HUA是女性全因死亡和冠心病死亡的独立危险因素，HUA对男性和女性冠心病的发生和预后影响不同，可能与雌激素水平的影响有关。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心脏", "subject_type": "患病部位", "object": {"@value": "缺血性心脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "HUA", "subject_type": "患病病因", "object": {"@value": "冠心病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(3)尿酸性肾石症：随着生活水平的提高和饮食结构改变，尿酸性肾石症发病率呈上升趋势。美国尿酸结石占泌尿系结石8％～14％，我国占5.1％，仅次于草酸钙结石。尿液中尿酸溶解度下降和过饱和是尿酸结石形成的前提。尿酸性肾石症常表现为腰痛和血尿；急性梗阻时可引起急性肾损伤，表现为发热、少尿、无尿、肾积水，血肌酐升高等；慢性梗阻可引起肾积水和肾实质萎缩，甚至发展为终末期肾病。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "尿酸性肾石症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "尿酸性肾石症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "尿液中尿酸溶解度下降和过饱和", "subject_type": "患病病因", "object": {"@value": "尿酸结石"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "尿酸性肾石症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "腰痛", "subject_type": "临床表现", "object": {"@value": "尿酸性肾石症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "血尿", "subject_type": "临床表现", "object": {"@value": "尿酸性肾石症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "急性梗阻", "subject_type": "患病病因", "object": {"@value": "急性肾损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "急性肾损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "发热", "subject_type": "临床表现", "object": {"@value": "急性肾损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "少尿", "subject_type": "临床表现", "object": {"@value": "急性肾损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "无尿", "subject_type": "临床表现", "object": {"@value": "急性肾损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "肾积水", "subject_type": "临床表现", "object": {"@value": "急性肾损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "慢性梗阻", "subject_type": "患病病因", "object": {"@value": "肾积水"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "慢性梗阻", "subject_type": "患病病因", "object": {"@value": "肾实质萎缩"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾积水"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾实质", "subject_type": "患病部位", "object": {"@value": "肾实质萎缩"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "终末期肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "终末期", "subject_type": "分期分型", "object": {"@value": "终末期肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "肥胖和T2DM的共存使糖尿病的治疗变得更为复杂。肥胖和糖尿病的双重压力进一步加重患者的心理负担。对于肥胖或超重的T2DM惠者应该加强心理干预，通过专业心理医生或者糖尿病专科医生的心理指导，帮助患者循序渐进地改善生活方式，建立自信。降低体重不仅会减轻T2DM患者的心理障碍，而且更容易使很多患者从减肥和运动中再次获得自信，提高生活满意度。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "加强心理干预", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "加强心理干预", "subject_type": "非药治疗", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "降低体重", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "15.二甲双胍可否用于胰岛素治疗的T1DM患者：T1DM患者可在胰岛素治疗基础上加用二甲双胍，尤其适用于胰岛素剂量较大、体重增加明显的患者；但DKA、糖尿病高血糖高渗综合征(HHS)、糖尿病乳酸酸中毒患者禁用。临床研究发现，二甲双胍不仅能减少胰岛素用量，还可进一步降低血脂水平(与降低血糖无关)，尤其是LDL-C水平。对于单用胰岛素治疗血糖控制不佳的患者，如果联合二甲双胍，可降低胰岛素用量10%，减少使用胰岛素所带来的体重过度增加。荟萃分析结果显示，二甲双胍能降低T1DM患者的日常胰岛素剂量、体重及血脂水平，且不增加低血糖及DKA的发生风险。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T1", "subject_type": "分期分型", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T1", "subject_type": "分期分型", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加明显", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重过度增加", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T1", "subject_type": "分期分型", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂水平", "subject_type": "检查方法", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "快速建议指南推荐DPP-4抑制剂联合基础胰岛用于2型糖尿病患者的降糖治疗，指出当使用基础胰岛素进行治疗，糖化血红蛋白水平仍控制不佳时，添加DPP-4抑制剂进行联合治疗，并根据糖化血红白水平，调整胰岛素的剂量。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "基础胰岛", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "糖化血红蛋白", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "糖化血红白", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "CFDA批准的恩格列净剂量规格只有10毫克一种，所以10毫克起始，最大剂量可能为20毫克(目前尚未得到恩格列净说明书)。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "10毫克", "subject_type": "用药剂量", "object": {"@value": "恩格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "20毫克", "subject_type": "用药剂量", "object": {"@value": "恩格列净"}, "object_type": {"@value": "药品名称"}}]}
{"text": "4.完善糖尿病防控体系，规范糖尿病患者治疗与管理。落实基层医疗卫生机构、医院、公共卫生机构职责，推进分级诊疗制度，建立协作共享机制，促进防治结合。强化基层卫生服务能力建设，规范基本公共卫生服务糖尿病患者健康管理，对发生并发症、血糖控制效果不佳等符合转诊条件的患者及时转诊，对病情稳定患者强化非药物治疗和自我管理支持。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "国内报道，二甲双胍的胃肠道反应发生率为15%(Ⅰ级)，如果增加剂量后发生严重胃肠道反应，可以降至之前较低的剂量，耐受后可再尝试增大剂量，缓释制剂也可减少患者的胃肠道症状。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "胃肠道反应", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "总体而言，预混胰岛素治疗达标率更高，基础胰岛素治疗低血糖发生率相对较低。亚裔糖尿病患者中以餐后血糖增高更常见，餐后血糖在血糖控制中的作用尤为重要。中国2型糖尿病防治指南(2010年版)指出，每日1次基础胰岛素或每日1~2次预混胰岛素均可作为胰岛素起始治疗方案，如基础胰岛素或预混胰岛素与口服药物联合治疗控制血糖不达标则应将治疗方案调整为多次胰岛素治疗(基础胰岛素加餐时胰岛素或每日3次预混胰岛素。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "基础胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "餐后血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "基础胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "预混胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日1次", "subject_type": "用药频率", "object": {"@value": "基础胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日1~2次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日3次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "中国“3B”研究显示，门诊就诊的T2DM患者中，14.6%合并心血管疾病，10.1%合并包括缺血性卒中在内的脑血管疾病。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脑血管", "subject_type": "患病部位", "object": {"@value": "脑血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)胰激肽原酶(pancreatic kzllidinogenase，PK)：PK可增加毛细血管血流量；能激活纤溶酶，降低血液黏度，改善血流变；促使肾髓质分泌前列腺素E2，改善组织灌注。临床用于治疗各种微循环障碍性疾病，如糖尿病引起的肾病、周围神经病变、视网膜病变。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "视网膜病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "持续20年的UKPDS研究结果表明，磺脲类药物并未加速β细胞功能衰竭。ADOPT研究终点时，格列本脲组β细胞胰岛素分泌功能和罗格列酮组相似。中国一项多中心研究结果显示，格列齐特缓释片强化治疗3个月可使约60%的患者血糖达标，停药2日后复查口服葡萄糖耐量试验，恢复为正常糖耐量或糖耐量受损者占22.83%，这说明磺脲类药物强化治疗显著改善了早相胰岛素分泌功能。", "spo_list": [{"Combined": false, "predicate": "持续时间", "subject": "3个月", "subject_type": "持续时间", "object": {"@value": "格列齐特缓释片"}, "object_type": {"@value": "药品名称"}}]}
{"text": "3.1 每日1次预混胰岛素类似物治疗的SMBG方案每日1次预混胰岛素类似物治疗的患者在血糖达标前每周监测3天空腹、晚餐后和睡前血糖，每2周复诊1次，复诊前1天加测3个时间点血糖；在血糖达标后每周监测3次血糖，即空腹、晚餐后和睡前血糖，每月复诊1次，复诊前1天加测3个时间点血糖(见表2)。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "每日1次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日1次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(3)建议所有糖尿病或高血糖患者在出院1个月后接受内分泌专科医生的评估。糖尿病患者根据出院后的血糖水平，由内分泌专科医生进行降糖方案的调整并制订长期随访方案。对于住院新发现的高血糖患者更有必要在出院后重新进行糖代谢状态的评估。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖水平", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "糖代谢状态的评估", "subject_type": "检查方法", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.血糖>180mg/dl(10.0mmol/L)开始胰岛素治疗。静脉给胰岛素起效快，方便滴定剂量，术中和术后ICU期间适宜静脉给药。持续静脉泵注胰岛素有利于减少血糖波动，糖尿病患者以及术前已经使用静脉胰岛素的患者术中首选持续静脉泵注胰岛素。应激性高血糖的患者可选择单次或间断静脉推注胰岛素，如血糖仍高，则予持续泵注。通常使用短效胰岛素加入生理盐水，浓度1U/ml配泵，参照患者的血糖水平、术前胰岛素用量、手术刺激大小等因素来确定胰岛素的用量，密切监测，根据血糖升降适当调整泵速，注意个体化给药，避免发生低血糖。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "静脉", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉给药", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "持续", "subject_type": "持续时间", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉泵注", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "持续", "subject_type": "持续时间", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉泵注", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "应激性", "subject_type": "分期分型", "object": {"@value": "应激性高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "应激性高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "应激性高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "单次或间断", "subject_type": "用药频率", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉推注", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "持续", "subject_type": "持续时间", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "泵注", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "浓度1U/ml", "subject_type": "用药剂量", "object": {"@value": "短效胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "浓度1U/ml", "subject_type": "用药剂量", "object": {"@value": "生理盐水"}, "object_type": {"@value": "药品名称"}}]}
{"text": "5.2 如何预防磺脲类药物治疗导致的低血糖? ", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "该共识推荐采用胰岛素/口服药联合方案以增加降糖疗效，同时减少胰岛素治疗潜在的低血糖和体重增加的不良反应。二甲双胍与胰岛素联用可减少体重增加，减少外源性胰岛素用量；葡萄糖苷酶抑制剂与胰岛素联用在有效改善血糖的同时，可减少胰岛素用量，减少体重增加的幅度和趋势。因此，在无禁忌证的2型糖尿病患者中均可采用二甲双胍或糖苷酶抑制剂与胰岛素联用。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "糖苷酶抑制剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)DKD：DKD患者需优质低蛋白饮食，戒烟，严格控制血压、血糖、血脂及尿酸水平。肾功能不全患者可优先选择经肾脏排泄较少的降糖药，严重肾功能不全患者应采用胰岛素治疗。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "优质低蛋白饮食", "subject_type": "非药治疗", "object": {"@value": "DKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "戒烟", "subject_type": "非药治疗", "object": {"@value": "DKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "DKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "DKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血脂", "subject_type": "检查指标", "object": {"@value": "DKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "DKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "干细胞治疗和胃肠道手术治疗是近年来在糖尿病治疗领域发展迅速的降血糖治疗方法，目前尚没有在老年糖尿病患者应用的适应证。", "spo_list": [{"Combined": false, "predicate": "临床手术", "subject": "干细胞治疗", "subject_type": "临床手术", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "胃肠道手术", "subject_type": "临床手术", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "推荐9：对于绝大多数T2DM患者，中等强度他汀(可使LDL-C水平降低30%~50%)是可选的降胆固醇治疗药物(推荐；A级证据)。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "中等强度他汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "降胆固醇治疗药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C水平", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2型糖尿病：(《成人2型糖尿病胰岛素临床应用的中国专家共识(2013年版)》)", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "SGLT-2抑制剂：EMPA-REG OUTCOME研究显示，在伴有心血管疾病的T2DM患者中，恩格列净可降低心力衰竭住院风险。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "恩格列净", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "冲击波碎石：排石疗法治疗1～2个月后如效果不佳采用，适用于：①直径<2.0cm的肾盂结石、肾上盏或肾中盏结石；②直径<1.0cm的肾下盏结石，1.0～2.0cm下盏结石根据是否存在不利因素决定；③直径2.0～3.0cm或表面积<500mm2的部分鹿角形结石。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾盂", "subject_type": "患病部位", "object": {"@value": "肾盂结石"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾上盏", "subject_type": "患病部位", "object": {"@value": "肾上盏或肾中盏结石"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾中盏", "subject_type": "患病部位", "object": {"@value": "肾上盏或肾中盏结石"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾下盏", "subject_type": "患病部位", "object": {"@value": "肾下盏结石"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下盏", "subject_type": "患病部位", "object": {"@value": "下盏结石"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.戒烟：吸烟是糖尿病肾病患者蛋白尿及肾功能进展的危险因素，戒烟或减少吸烟是糖尿病患者预防或控制糖尿病肾病进展的重要措施。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "戒烟", "subject_type": "非药治疗", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾功能", "subject_type": "检查方法", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "戒烟或减少吸烟", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "GLP-1受体激动剂：GLP-1受体激动剂以降低餐后血糖为主，低血糖风险较低，经其他降糖药治疗血糖控制不佳、肥胖或贪食者可考虑本药。但是这类药物可能导致恶心等胃肠道不良反应及体重减轻，对于比较瘦弱的老年患者不适合。肾功能不全时药物需要减量。有胰腺炎病史者须慎用。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "GLP-1受体激动剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "胰腺", "subject_type": "患病部位", "object": {"@value": "胰腺炎"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "ACCORD中3或4种降糖药物同时应用力求快速达到控制目标(HbA1c<6.0%)，这明显增加低血糖的发生率和总死亡率。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "一项系统评价纳入了9个RCT研究，荟萃分析结果显示，盐酸沙格雷酯治疗下肢血管病变，能减小患者溃疡面积，增加ABI、足背动脉血流量，无痛行走距离增加200.87m。一项RCT研究显示，盐酸沙格雷酯治疗糖尿病下肢血管病变，能有效增加患者最大行走距离和无痛行走距离，部分改善足背动脉和胫后动脉的流速、阻力指数和ABI指标。因此，盐酸沙格雷酯被推荐治疗慢性动脉闭塞症所引起的溃疡、疼痛以及冷感等缺血性诸症状，尤其对静息痛的疗效显著。盐酸沙格雷酯的推荐剂量为100mg/次，2次/d。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "盐酸沙格雷酯", "subject_type": "药品名称", "object": {"@value": "下肢血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢血管", "subject_type": "患病部位", "object": {"@value": "下肢血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "溃疡", "subject_type": "临床表现", "object": {"@value": "下肢血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "足背动脉血流量", "subject_type": "检查指标", "object": {"@value": "下肢血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "盐酸沙格雷酯", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "盐酸沙格雷酯", "subject_type": "药品名称", "object": {"@value": "下肢血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢血管", "subject_type": "患病部位", "object": {"@value": "下肢血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "盐酸沙格雷酯", "subject_type": "药品名称", "object": {"@value": "慢性动脉闭塞症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "动脉", "subject_type": "患病部位", "object": {"@value": "慢性动脉闭塞症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "溃疡", "subject_type": "临床表现", "object": {"@value": "慢性动脉闭塞症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "疼痛", "subject_type": "临床表现", "object": {"@value": "慢性动脉闭塞症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "冷感", "subject_type": "临床表现", "object": {"@value": "慢性动脉闭塞症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "静息痛", "subject_type": "临床表现", "object": {"@value": "慢性动脉闭塞症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "100mg/次", "subject_type": "用药剂量", "object": {"@value": "盐酸沙格雷酯"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "2次/d", "subject_type": "用药频率", "object": {"@value": "盐酸沙格雷酯"}, "object_type": {"@value": "药品名称"}}]}
{"text": "正常生理情祝下，肾脏每天经过肾小球滤过近160~180g的葡萄糖到肾小管中，但滤过的葡萄糖全部被重吸收。一般情况下，当血糖浓度达到10mmol/L(肾糖阈)时葡萄糖会漏出到尿液中。血糖浓度超过肾糖阈越多，从尿中排出的葡萄糖就越多。在肾小管内的葡萄糖主要通过钠-葡萄糖共转运蛋白(SGLT)重吸收回到血液循环中。人类SGLT家族主要包括SGLT1-SGLT6，在体内广泛分布。其中，SGLT2是该家族中的重要一员，主要分布在近段肾小管的管腔侧细胞膜上，负责肾小管中90%葡萄糖的重吸收，另外，10%的葡萄糖通过分布在远肾小管的SGLT1通道重吸收，出于对肾脏过量葡萄糖排出的适应，T2DM患者肾糖阈较非糖尿病患者高、导致重吸收葡萄糖量增加。SGLT2基因突变导致的SGLT2通道重吸收葡萄糖的能力下降(肾糖阈降低)可导致在正常血糖水平情况下的尿糖排出增多，即肾性尿糖。该类患者无过高的发生低血糖、肾功能受损、电解质系乱等风险未见显著增高。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肾糖阈", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "机体存在多种机制调控能量平衡以维持自身体重相对稳定，通常减重计划结束后一年，大部分人会恢复已减掉体重(复重)的30%~35%，4年内基本恢复到减重前水平。发表于新英格兰医学杂志和美国医学会杂志的2项随机对照试验表明，适当的干预措施可在一定程度上延长减重后体重的维持时间。世界胃肠病学会对肥胖管理制定的全球指南(WGO)强调，为了维持减重效果，医务人员和营养医师应向患者提供面对面或电话随访的减重维持计划，保持与患者的规律接触(每月或更加频繁)，帮助其进行高强度体力活动(如200~300min/周)，规律监测体重变化(如每周或更加频繁)，并保持低能量饮食(维持更低体重所必需)。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "体力活动(如200~300min/周)", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "低能量饮食", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)银杏叶提取物片(EGb761)：该药的多成分之间具有协同作用，主要通过降低血液黏度来改善血液流变学，从而改善血液循环；清除自由基，抑制细胞膜发生脂质过氧化；拮抗血小板活化因子(platelet active factor，PAF)，从而抑制血小板聚集；促进突触重塑，保护神经细胞。临床上主要用于脑动脉硬化导致的脑功能障碍、糖尿病性视网病变以及周围血管病变导致的间歇性跛行。脑部、周围血流循环障碍：包括糖尿病引起的视网膜病变及神经障碍、老年黄斑变性、间歇性跛行症等。一项针对台湾地区居民的研究显示，银杏叶提取物片能够有效地改善2型糖尿病视网膜病变患者的视网膜毛细血管血流量，从而缓解糖尿病视网膜病变。系统性评价结果显示，在常规治疗基础上联合银杏叶提取物片可进一步降低糖尿病肾病患空腹血糖及尿白蛋白排泄率，改善患者血液流变学。国内的研究显示，银杏叶提取物片联合甲钴胺治疗糖尿病周围神经病变，可明显改善糖尿周围神经病变患者的临床症状及神经传导速度，总有效率(显效和有效)达到88.9%。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "脑动脉", "subject_type": "患病部位", "object": {"@value": "脑动脉硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脑", "subject_type": "患病部位", "object": {"@value": "脑功能障碍"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网", "subject_type": "患病部位", "object": {"@value": "糖尿病性视网病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围血管", "subject_type": "患病部位", "object": {"@value": "周围血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "神经障碍"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "黄斑", "subject_type": "患病部位", "object": {"@value": "老年黄斑变性"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "2型糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "银杏叶提取物片", "subject_type": "药品名称", "object": {"@value": "2型糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "空腹血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿白蛋白排泄率", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "银杏叶提取物片", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "糖尿病周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "甲钴胺", "subject_type": "药品名称", "object": {"@value": "糖尿病周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "银杏叶提取物片", "subject_type": "药品名称", "object": {"@value": "糖尿病周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "糖尿周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "视网膜病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(5)在胰岛素制剂的选择上，有短效或速效胰岛素、预混胰岛素、中效或长效胰岛素。速效胰岛素类似物联合长效胰岛素类似物进行基础一餐时胰岛素治疗或者速效胰岛素类似物用于胰岛素泵治疗能够带来更好的血糖控制，降低低血糖的发生风险，血糖达标时间更短，有助于缩短手术前准备时间和住院时间。速效胰岛素类似物可以餐前即刻或餐后立即注射的灵活特点也使其能够更好地满足进食不规律的住院患者的治疗需求。而且，速效胰岛素类似物堵管的发生风险较低，更适合于胰岛素泵治疗。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "速效胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "堵管", "subject_type": "不良反应", "object": {"@value": "速效胰岛素类似物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "中国批准的各种DPP-4抑制剂的说明书的适应证为2型糖尿病患者饮食运动不能控制血糖的单药、联合二甲双胍以及联合二甲双胍和磺脲类药物治疗。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食运动", "subject_type": "非药治疗", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "5.微量营养素摄入与肥胖：研究表明血清维生素B12和叶酸的浓度与青少年BMI值、躯干脂肪面积以及总脂肪面积呈负相关。一项病例对照研究表明，肥胖儿童血清中维生素B12水平为400ng/L，明显低于正常体重的儿童血清中维生素B12的水平(530ng/L)；相对于正常体重儿童，在调整性别和年龄等混杂因素的影响后，肥胖儿童血清中维生素B12偏低的风险比(odds ratio，OR)高达4.33。也有研究发现，肥胖儿童血清中含有更低水平的Zn、Se和Fe，但血清Cu的水平较高；血清Zn的水平和血清中总胆固醇水平有呈明显负相关，而与血清中HDL-C水平正相关。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血清维生素B12", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "叶酸", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "维生素B12", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "维生素B12", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "Zn", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "Se", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "Fe", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血清Cu", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "格列喹酮是具有肾脏保护作用的胰岛素促泌剂，降糖效果明确，低血糖风险低，不影响体重。单药治疗可全面降糖，亦可与其他非胰岛素促泌剂广泛联合，剂量调整方便，利于个体化治疗，价格合理。主要适用人群为2型糖尿病患者，包括：PPG升高为主的2型糖尿病患者、老年患者和CKD各期患者。由此，格列喹酮可作为中国2型糖尿病患者降糖治疗的一线用药。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列喹酮"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "PPG", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "在选择胰岛素促泌剂治疗时，可根据患者血糖选择不同类型胰岛素促泌剂(5级)：(1)以餐后血糖(PPG)升高为主者，宜选择格列吡嗪、格列奈类促泌剂；(2)以空腹血糖(FPG)升高为主者，宜选择依从性好、低血糖发生风险低的中长效磺脲类促泌剂；(3)餐后血糖和空腹血糖均升高者，宜选择依从性好、低血糖发生风险低的中长效磺脲类促泌剂。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "中长效磺脲类促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "中长效磺脲类促泌剂"}, "object_type": {"@value": "药品名称"}}]}
{"text": "导致尿酸升高的药物：阿司匹林(<2g／d)、噻嗪类利尿剂、吡嗪酰胺、环孢素A、细胞毒药物、左旋多巴、果糖，襻利尿剂、乙胺丁醇、他克莫司、烟酸、甲氧氟烷。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "<2g／d", "subject_type": "用药剂量", "object": {"@value": "阿司匹林"}, "object_type": {"@value": "药品名称"}}]}
{"text": "三、2型糖尿病合并慢性肾脏病的口服降糖药选择", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(二)非内分泌科住院的糖尿病或高血糖患者的血糖管理", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病与心血管疾病关系密切，糖尿病是心血管疾病的主要危险因素之一。血糖管理是心血管疾病综合防控的重要内容之一。心血管专科医师应熟练掌握心血管疾病合并糖尿病患者常用口服降糖药物的应用原则。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "糖尿病", "subject_type": "患病病因", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "慢性病的预防则需遵从“治未病”理念，积极进行糖尿病防治知识的学习和宣教，提倡健康生活方式，增加运动。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "健康生活方式", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "增加运动", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)适用人群和使用方案：口服降糖药联合基础胰岛素治疗后，FPG达标，HbA1c仍不达标者，或使用较大剂量基础胰岛素后[如0.6U/(kg·d)]，血糖仍不达标者；使用多次预混胰岛素治疗，血糖控制不佳者或反复发作低血糖者；需短时间内纠正高血糖的糖尿病患者。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "0.6U/(kg·d)", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "预混胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "T2DM和ASCVD患者常合并CKD。当患者存在肾功能不全[eGFR<60ml/(min.1.73m2)]时，大多数非胰岛素降糖药物的药代动力学会发生", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "eGFR", "subject_type": "检查指标", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "◆磺脲类：为胰岛素促泌剂，可降低HbA1c1.0%-2.0%，是目前国内外指南中推荐的控制2型糖尿病患者高血糖的主要用药之一。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "磺脲类", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "⑦药物相互作用：西格列汀在与磺脲类药物合用时低血糖风险增加，需适当减少磺脉类药物的剂量。利格列汀在与胰岛素、磺脲类合用时低血糖风险增加，需适当减少胰岛素和磺脲类药物的剂量。沙格列汀的代谢主要由CYP3A4/5介导。沙格列汀的主要代谢产物也是DPP-4抑制剂，其抑制活性作用是沙格列汀的二分之一。因此，CYP3A4/5强抑制剂和强诱导剂能改变沙格列汀及其代谢物的药代动力学。与强效CYP3A4/5抑制剂(如酮康唑、阿扎那韦、克拉霉素、茚地那韦、伊曲康唑、奈法唑酮、奈非那韦、利托那韦、沙奎那书和泰利霉素)合用时，应将沙格列汀的剂量限制为2.5mg/d。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "西格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "利格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2.5mg/d", "subject_type": "用药剂量", "object": {"@value": "沙格列汀"}, "object_type": {"@value": "药品名称"}}]}
{"text": "3.评估患者是否合并高血压、血脂异常、高尿酸和肥胖：同时测定血液中肝酶和肾功能指标，有条件测定血蛋白质、电解质、同型半胱氨酸水平，有助于评定患者的心血管疾病风险和确定饮食食谱，为患者制定综合治疗方案(IV)。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "肝酶", "subject_type": "检查指标", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肾功能", "subject_type": "检查指标", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血蛋白质", "subject_type": "检查指标", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "电解质", "subject_type": "检查指标", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "同型半胱氨酸水平", "subject_type": "检查指标", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "HUA患者可食用含果糖较少的水果，如樱桃，草莓，菠萝、西瓜、桃子等。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "食用含果糖较少的水果，如樱桃，草莓，菠萝、西瓜、桃子等", "subject_type": "非药治疗", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "考虑到我国目前存在的上述实际状况，以及中国人群中HbA1c诊断糖尿病的切点需要进一步的研究，《中国2型糖尿病防治指南》尚未推荐在我国采用HbA1c诊断糖尿病。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "c.阿格列汀在上市后发现严重皮肤不良反应，如怀疑发生严重过敏反应，停用阿格列汀。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "严重皮肤不良反应", "subject_type": "不良反应", "object": {"@value": "阿格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "严重过敏反应", "subject_type": "不良反应", "object": {"@value": "阿格列汀"}, "object_type": {"@value": "药品名称"}}]}
{"text": "中国慢性肾脏病患者合并高尿酸血症诊治专家共识", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.4 DPP-4抑制剂与胰岛素的联合应用DPP-4抑制剂另一个潜在的应用方法是与胰岛素联合，这种联合可以改善血糖控制，减少血糖波动而不增加低血糖的发生，并且可减少胰岛素的用量。在使用稳定剂量胰岛素治疗的患者中加用DPP-4抑制剂可进一步降低血糖，但不增加低血糖发生风险和体重，甚至降低低血糖发生率和严重程度。目前西格列汀、利格列汀和格列汀在美国FDA和欧洲EMA均获批了与胰岛素的联用适应证。中国尚未批准上述药物与胰岛素的联用。国内外指南推荐在口服药疗效不佳时可联合胰素使用。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "DPP-4抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "DPP-4抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "胰素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "由于各种药物说明书批准的适应证存在一定差异，而且中国大多数医生目前还缺乏实际应用经验，所以为了更好、更合理地应用这类药物，消除可能的误解，造福糖尿病患者，本共识基于国内外药物说明书、临床研究证据、以及国内外2型糖尿病防治指南，对可能出现的超药物说明书用药(药品说明书之外用法)提供参考意见。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "快速建议指南基于证据总结和专家意见，认为DPP-4抑制剂可用于伴有心血管疾病或心血管事件风险的2型糖尿病患者的降糖治疗。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.CKD的诊断标准和分期：CKD的诊断标准：①肾脏损伤(肾脏结构或功能异常)≥3个月，伴或不伴肾小球滤过率(GFR)下降，肾脏病理学检查异常或肾脏损伤(血、尿成分或影像学检查异常)；②GFR<60ml·min-1·1.73m2)-1达到或超过3个月，有或无肾脏损伤证据。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "肾脏病理学检查", "subject_type": "检查方法", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血、尿成分或影像学检查", "subject_type": "检查方法", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肾小球滤过率(GFR)", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肾小球滤过率(GFR)", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾脏病理学检查", "subject_type": "检查方法", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血、尿成分或影像学检查", "subject_type": "检查方法", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病病程>15年、有无感知低血糖病史、有严重伴发病如肝肾功能不全或全天血糖波动较大并反复出现低血糖症状的患者，很难设定其HbA1c的靶目标，最重要的是避免低血糖的发生，也许HbA1c控制在7%~9%是可以接受的。因为Stratton等对4585例2型糖尿病患者10年的随访表明，HbA1c<7%患者慢性并发症的发生和死亡风险最低；HbA1c控制在7%~9%，上述风险虽然增加，但是相对增长缓慢；一旦HbA1c>9%，风险明显增加甚至翻倍。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肝肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.严重高血糖可能造成渗透性利尿，引起高渗性脱水和低钾血症，应注意维持水电解质平衡。术中由于多数患者血糖水平增高，一般输注无糖液体。术后和过长时间的手术当中，为了减少酮体合成和酸中毒风险，在血糖<250mg/dl(13.9mmol/L)的前提下，静脉泵注胰岛素的同时可泵注加入中和比例胰岛素的含糖液体，根据测得的血糖水平调节泵速。胰岛素+糖双泵同时输注有利于减少血糖波动，但可能促使钾向细胞内转移，进一步加重低钾血症。因此，持续静脉泵注胰岛素时应注意监测血钾，可预防性补钾。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "渗透性利尿", "subject_type": "临床表现", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "高渗性", "subject_type": "分期分型", "object": {"@value": "高渗性脱水"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉泵注", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "泵注", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低钾血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "钾向细胞内转移", "subject_type": "发病机制", "object": {"@value": "低钾血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "持续", "subject_type": "持续时间", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉泵注", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "CKD患者HUA的降尿酸治疗，建议根据患者的伴随症状、合并症、并发症、肾功能情况和尿酸水平合理实施。对于伴有痛风的CKD患者，应在早期积极给予非药物治疗及降尿酸治疗。对于无症状的伴有HUA的CKD患者，男性血尿酸>420μmoI/L，女性血尿酸>360μmol/L，建议降尿酸治疗。降尿酸一线药物包括抑制尿酸生成药物(别嘌醇和非布司他)，促进尿酸排泄药物(苯溴马隆和丙磺舒)可为备选药物，治疗的血尿酸水平最低控制目标应<360μmol/L，在伴有严重痛风时建议控制目标<300μmol/L。不推荐长期维持血尿酸水平<180μmol/L。目前，对于无症状的伴有HUA的CKD患者，降尿酸的起始治疗阈值仍有争议，需要未来的进一步研究来确定。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "男性血尿酸", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "女性血尿酸", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "男性血尿酸", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "女性血尿酸", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "别嘌醇", "subject_type": "药品名称", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "非布司他", "subject_type": "药品名称", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "抑制尿酸生成药物", "subject_type": "药品名称", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "促进尿酸排泄药物", "subject_type": "药品名称", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "苯溴马隆", "subject_type": "药品名称", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "丙磺舒", "subject_type": "药品名称", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸", "subject_type": "检查指标", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "应用磺脲类药物治疗的患者需要有一定的胰岛功能。糖尿病病程较短且能够坚持饮食和运动干预的患者使用磺脲类药物治疗可能具有更好的疗效。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食和运动干预", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "在我国，许多改善微循环障碍的药物仍缺乏足够的循证医学证据，今后仍需开展相关大型前瞻性临床研究，为糖尿病患者微循环障碍治疗的安全性、个体化用药提供更多的临床循证依据。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "微循环障碍", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(7)DPP-4抑制剂：DPP-4是GLP-1降解酶，DDP-4抑剂通过减少GLP-1在体内的降解，增加体内GLP-1的水平。这一类降糖药由于上市较晚，缺乏临床用药经验，因此用于糖尿病肾病患者时应酌情减量。DPP-4抑制剂降低HbA1c弱于其他胰岛素促泌剂。目前在国内上市的DPP-4抑制剂为西格列汀、沙格列汀、维格列汀和利格列汀。西格列汀用于GFR>50ml·min-1·1.73m-2的CKD患者时无需调整剂量，当GFR在30~50ml·min-1·1.73m-2时减量至50mg每日1次，GFR<30ml·min-1·1.73m-2或透析的患者可减量至每日25mg，但相关的临床经验尚不丰富。沙格列汀和维格列汀可用于CKD 1~2期患者，用于中重度肾功能不全患者的临床试验数据有限，不推荐用于3~5期患者，仅有利格列汀在CKD 4~5期时无需减量。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西格列汀", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "50mg", "subject_type": "用药剂量", "object": {"@value": "西格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "25mg", "subject_type": "用药剂量", "object": {"@value": "西格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日1次", "subject_type": "用药频率", "object": {"@value": "西格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "透析", "subject_type": "非药治疗", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "沙格列汀", "subject_type": "药品名称", "object": {"@value": "CKD 1~2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "维格列汀", "subject_type": "药品名称", "object": {"@value": "CKD 1~2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~2期", "subject_type": "分期分型", "object": {"@value": "CKD 1~2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3~5期", "subject_type": "分期分型", "object": {"@value": "CKD 1~2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利格列汀", "subject_type": "药品名称", "object": {"@value": "CKD 4~5期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "4~5期", "subject_type": "分期分型", "object": {"@value": "CKD 4~5期"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "七、糖尿病足的治疗 ", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "推荐8：T2DM患者的血脂管理均应以生活方式干预为基础，并贯穿T2DM治疗的全过程(推荐；A级证据)。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病视网膜病变临床表现分为6期(具体分型、分期标准参考相关指南)。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "二甲双胍改善高血糖主要机制包括：(1)作用于肝脏，抑制糖异生，减少肝糖输出；(2)作用于外周组织(肌肉、脂肪)，改善肌肉糖原合成，降低FFA，提高IS，增加对葡萄糖的摄取和利用；(3)作用于肠道，抑制肠壁细胞摄取葡萄糖，提高GLP-1水平。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "c.沙格列汀在轻度肾功能不全的患者中无需调整剂量。中重度肾功能不全的患者应将剂量调整为2.5mg，每日1次。在重度肾功能不全的患者中临床研究经验有限，因此不推荐使用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "沙格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.老年人群：SGLT2i可用于老年T2DM患者。老年患者中，在原有治疗方案疗效不佳的情况下加用SGLT2i，可有效降低血糖、减轻体重和降低血压，且耐受性良好。探讨影响SGLT2i在对老年患者中有效性与安全性的影响因素发现，校正eGFR影响后，年龄并不影响SGLT2i的疗效。当eGFR≥60ml/(min·1.73m2)时，SGLT2i降糖和减重疗效在老年(年龄≥65岁)和非老年(年龄<65岁)人群中相当，且总体不良事件没有增加，泌尿生殖道感染也没有增加，但是，当老年患者eGFR<60ml/(min·1.73m2)时，低血糖风险、低血容量相关事件、肾损伤或肾衰竭风险升高。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "SGLT2i", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "泌尿生殖道", "subject_type": "患病部位", "object": {"@value": "泌尿生殖道感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "指征：如果患儿代谢尚稳定(HbA1c<9%及随机血糖<13.9mmol/L且无症状)，应以二甲双胍开始治疗。剂量：初始剂量500mg/d，x7d，接下的3-4周内每周增加500mg/d，最大不超过2000mg/d。疗效：现认为长期应用二甲双胍后，HbA1c可有1%~2%的降低，也可一定程度上降低体重。但TODAY(treatment options for type 2 diabeles in adolescents and youth)研究表明，仅一半的2型糖尿病患儿通过二甲双胍单药治疗达到持久血糖控制，且其有效性可持续<18个月。注意事项：二甲双胍单用基本无低血糖的风险，产生乳酸酸中毒的风险也极低。可有胃肠道副作用，包括一过性的腹痛，腹泻，恶心等，基本上都可耐受，如严重可暂时停药，采用缓释制剂也可减少胃肠道反应。但在肝肾功能不全，如肝酶升高3倍以上，严重感染，重大手术，或放射检查使用碘化造影剂时禁用。此外长期使用二甲双胍可能与维生素B12缺乏有关。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "乳酸酸中毒", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道副作用", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "一过性的腹痛", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "腹泻", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "恶心", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道反应", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "维生素B12缺乏", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肝酶", "subject_type": "检查指标", "object": {"@value": "肝肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肝肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.二甲双胍可否用于儿童和青少年糖尿病患者：无需以胰岛素作为起始治疗的10岁及以上T2DM患儿，糖尿病得到诊断后可给予生活方式干预，不达标者以二甲双胍为起始治疗药物。二甲双胍可用于10岁及以上的T2DM的儿童或青少年，且最高剂量不超过2000mg/d，不推荐用于10岁以下的患儿。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "低血糖是磺脲类药物治疗最常见的不良反应。为减少低血糖风险，服用磺脲类药物时宜从小剂量开始，根据血糖监测结果逐渐调整用量，一般每1~2周调整一次。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "老年糖尿病患者是高度差异化的人群，常常合并多种疾病，需要服用多种药物。低血糖以及整体安全性考虑在老年人群药物的选择中占有越来越重的地位。DPP-4抑制剂单独或联合使用低血糖风险较低，而且对体重的影响中性，适于在这类人群中使用。临床研究显示DPP-4抑制剂在老年人群中具有良好的有效性及安全性，甚至有荟萃分析提示DPP-4抑制剂在老年患者中的血糖控制效果优于年轻患者。总体而言，这类药物良好的安全性使其适合应用于老年2型糖尿病患者。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "DPP-4抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "患者平素宜慎口节欲，避免饮酒或过食肥甘厚腻，可长期服用能纠正体质偏颇的食疗如薏苡仁、芡实，山药等，同时通过运动，增强体质、调摄精神，起到防病治病作用。HUA无论有无临床症状，健脾泄浊化淤为基本治法，贯穿治疗始终，常用药物有薏苡仁、土茯苓、菝葜，萆薢，虎杖等。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "薏苡仁", "subject_type": "药品名称", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "土茯苓", "subject_type": "药品名称", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "菝葜", "subject_type": "药品名称", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "萆薢", "subject_type": "药品名称", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "虎杖", "subject_type": "药品名称", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "①肥胖患者：共识指出，在积极使用胰岛素同时，还应注意合理使用以避免过度应用，对于肥胖(BMl>28千克/米2)的患者，应在口服药充分治疗的基础上再考虑起始胰岛素治疗。2低血糖风险：对已合并心脑血管疾病或危险因素的2型糖尿病患者，或是老年糖尿病患者，过于激进的降糖治疗可能产生潜在的风险，进而抵消或掩盖其潜在的心血管获益。由于脑组织代谢的特殊性，卒中患者对低血糖的耐受性更低。然而脑血管疾病在我国发病率显著高于西方国家，因此在使用胰岛素时，更加需要注意采取相对宽松的降糖治疗策略与目标值，避免低血糖的发生。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心脑血管", "subject_type": "患病部位", "object": {"@value": "心脑血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脑血管", "subject_type": "患病部位", "object": {"@value": "脑血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "磺脲类药物与二甲双胍联合治疗可同时改善胰岛素分泌不足和胰岛素抵抗，其疗效和安全性已得到长期临床验证，是推荐的联合治疗方案之一。一项系统性评价结果显示，磺脲类药物联合二甲双胍可使HbA1c降低0.47%~1.30%。与二甲双胍单药治疗相比，二甲双胍联合格列齐特或格列美脲治疗3个月均可使患者HbA1c降低1.9%。为期2年的随机对照研究结果显示，T2DM患者起始二甲双胍联合磺脲类药物治疗可降低HbA1c 1.5%；二甲双胍单药治疗血糖控制不佳的患者加用格列吡嗪治疗可使HbA1c进一步降低0.59%。", "spo_list": [{"Combined": false, "predicate": "持续时间", "subject": "3个月", "subject_type": "持续时间", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "3个月", "subject_type": "持续时间", "object": {"@value": "格列齐特"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "3个月", "subject_type": "持续时间", "object": {"@value": "格列美脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "患者采用口服降糖药联合基础胰岛素治疗，FPG已达标，但HbA1c仍未达标时，可逐步增加1~3次餐时胰岛素注射以更好的控制血糖。如果患者在接受较高剂量基础胰岛素治疗后，血糖仍未达标，建议逐步增加餐时胰岛素进行治疗。预混胰岛素由于其短/速效胰岛素和中效胰岛素的比例固定，在提供个体化的胰岛素需求上有一定的局限性。对于每日多次预混胰岛素方案治疗，仍无法满意控制血糖或频发低血糖的患者，可以考虑使用基础联合餐时胰岛素治疗。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "1~3次", "subject_type": "用药频率", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日多次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "1.选药原则：治疗2型糖尿病合并慢性肾脏病的理想降糖策略是在有效降糖的同时，不增加低血糖发生的风险，同时避免诱发乳酸性酸中毒或增加心力衰竭风险。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "乳酸性", "subject_type": "分期分型", "object": {"@value": "乳酸性酸中毒"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "目前动态血糖监测(continuous glucose monitoring，CGM)和自我血糖监测(self-monitoring of blood glucose，SMBG)都可以有效评估血糖波动程度。CGM能够准确、全面地反映血糖波动的特征，但监测成本较高，操作相对复杂，不易在糖尿病人群中普及。SMBG灵活方便、易操作、相对经济、可行性高，通过每日7-8次SMBG值能够较为准确地估计2型糖尿病患者的日内血糖波动，且与CGM有较好的相关性。但SMBG测定的血糖结果变异性大，用以评估血糖波动时所采用的个别指标计算复杂，缺乏正常参考值。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "CGM", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "日内血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "SMBG", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "血压升高不仅是加速糖尿病肾病进展的重要因素，也是决定患者心血管病预后的主要风险因素。在2型糖尿病肾病患者中，血压对肾功能的影响更加突出，收缩压超过140mmHg(1mmHg=0.133kPa)的患者，其肾功能下降速度为每年13.5%，而收缩压<140mmHg者每年肾功能下降的速度是1%。UKPDS研究显示，在处于糖尿病早期的糖尿病患者中采用强化的血压控制，不但可以显著减少糖尿病大血管病变发生的风险，还显著减少了微血管病变发生的风险。大量临床观察也证实，严格控制高血压能明显减少糖尿病肾病患者尿蛋白水平，延缓肾功能损害的进展。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "心血管病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "2型糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "2型糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾功能", "subject_type": "检查方法", "object": {"@value": "2型糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾功能", "subject_type": "检查方法", "object": {"@value": "2型糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾功能", "subject_type": "检查方法", "object": {"@value": "2型糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "收缩压", "subject_type": "检查指标", "object": {"@value": "2型糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "收缩压", "subject_type": "检查指标", "object": {"@value": "2型糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "糖尿病大血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "微血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿蛋白", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "随着经济高速发展、生活方式改变及人口老龄化，我国糖尿病患病率呈快速上升趋势。2007~2008年流行病学调查显示，我国20岁以上成人糖尿病患病率为9.7%。2010年流行病学调查显示，我国18岁以上成人糖尿病患病率为11.6%。在我国糖尿病患者中，90%以上为2型糖尿病(T2DM)。动脉粥样硬化性心血管疾病(ASCVD)包括冠心病、缺血性卒中及外周动脉疾病。T2DM与ASCVD关系密切，两者共存可进一步增加心血管事件和死亡风险，半数以上糖尿病患者的死亡与ASCVD相关。近年来，随着临床研究证据的不断积累和更新，关于降糖药物与T2DM患者心血管结局之间的关系也日益明确。因此，合理规范应用降糖药物对于T2DM合并ASCVD患者显得尤为重要。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病(T2DM)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "2型糖尿病(T2DM)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "动脉", "subject_type": "患病部位", "object": {"@value": "动脉粥样硬化性心血管疾病(ASCVD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "动脉粥样硬化性心血管疾病(ASCVD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "外周动脉", "subject_type": "患病部位", "object": {"@value": "外周动脉疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.根据患者手术类型、术前血糖水平、脏器功能，建立围术期血糖控制的个体化目标。整形手术对伤口愈合要求高，血糖目标降低至108mg/dl(6.0mmol/L)~144mg/dl(8.0mmol/L)有利于减少术后伤口感染。脑血管疾病患者对低血糖耐受差，血糖目标值可适当放宽至≤214mg/dl(12.0mmol/L)。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "脑血管", "subject_type": "患病部位", "object": {"@value": "脑血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "脑血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "国内多中心研究资料显示我国50岁以上糖尿病患者下肢动脉病变的比例为19.5%。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "下肢动脉", "subject_type": "患病部位", "object": {"@value": "下肢动脉病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "磺脲类胰岛素促泌剂是最早发现并使用最广泛的口服降糖药物，《中国2型糖尿病防治指南(2013)》推荐该类药物为中国2型糖尿病患者降糖治疗的一线备选用药。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "磺脲类胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "c.沙格列汀用于中度肝功能不全的患者时需谨慎，不推荐用于重度肝功能不全的患者。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "沙格列汀", "subject_type": "药品名称", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)高血压：大量研究显示HUA是高血压的独立的危险因素。对于HUA合并高血压患者，优先考虑利尿剂以外的降压药物。氯沙坦钾具有促尿酸排泄的作用，并通过降低血尿酸水平使心血管事件减少13％～29％。氨氯地平是具有促尿酸排泄作用的二氢吡啶类钙拮抗剂，推荐用于合并缺血性卒中的高血压患者。", "spo_list": [{"Combined": false, "predicate": "患病病因", "subject": "HUA", "subject_type": "患病病因", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "氨氯地平", "subject_type": "药品名称", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "在CVOT中，包括肾脏不良事件在内的微血管事件通常作为研究的次要终点。在LEADER研究中，24.7%的患者基线时合并CKD3期或以上，利拉鲁肽可使肾脏事件复合终点(包括新发大量蛋白尿、Scr倍增、终末期肾病或肾病导致的死亡)的风险显著降低22%(P=0.003)。在EMPA-REGOUTCOME研究中，25.9%的患者基线时伴有CKD3期，恩格列净可使肾脏事件复合终点(Scr倍增、起始肾脏替代治疗或因肾病死亡)的风险显著降低46%(P<0.001)。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏不良事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "微血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3期", "subject_type": "分期分型", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利拉鲁肽", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "Scr", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "终末期", "subject_type": "分期分型", "object": {"@value": "终末期肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "终末期肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3期", "subject_type": "分期分型", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "恩格列净", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "Scr", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "与发达国家的1型糖尿病人群相比，我国的1型糖尿病人群存在血糖达标率低、急慢性并发症发生率高、寿命短等明显不足。尽管国际上倡导“基础+餐时”胰岛素强化治疗方案，但该方案在我国1型糖尿病人群中的应用率很低，而以每日2次方案者居多。为此，中华医学会糖尿病学分会在2016年发布了《中国1型糖尿病胰岛素治疗指南》，以期规范我国的1型糖尿病胰岛素治疗。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日2次", "subject_type": "用药频率", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "通过详细的病史询问和体格检查，寻找周围神经受累的证据是诊断DPN的第一步。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "体格检查", "subject_type": "检查方法", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "心血管疾病合并糖尿病口服降糖药物应用专家共识", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)老年T2DM合并CKD患者：老年T2DM合并CKD患者通常有多种合并症，尤其是心血管疾病以及认知功能障碍，因此应加强对多种危险因素的管理。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.糖尿病单神经病或多发单神经病：以正中神经、尺神经、腓总神经受累多见，常隐袭发病，也有急性起病者。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "糖尿病单神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "正中神经", "subject_type": "患病部位", "object": {"@value": "糖尿病单神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "尺神经", "subject_type": "患病部位", "object": {"@value": "糖尿病单神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "腓总神经", "subject_type": "患病部位", "object": {"@value": "糖尿病单神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "多发单神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "正中神经", "subject_type": "患病部位", "object": {"@value": "多发单神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "尺神经", "subject_type": "患病部位", "object": {"@value": "多发单神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "腓总神经", "subject_type": "患病部位", "object": {"@value": "多发单神经病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "UKPDS表明，以格列本脲为基础的降糖治疗，患者体重增加1.7kg(1b级)。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "格列本脲"}, "object_type": {"@value": "药品名称"}}]}
{"text": "4.2 糖尿病微血管并发症的治疗对于己合并DR、DKD或DPN的糖尿病患者，延缓并发症进展、及时给予针对性治疗可最大限度地保护靶器官，减少失明、终末期肾病及糖尿病足等事件的发生。积极控制血糖、血压、血脂仍是糖尿病治疗的基础。改善微循环治疗是针对糖尿病微血管病变重要的临床治疗方法，改善糖尿病微循环用药应遵循“早期、个体化、合理联合、重视安全”的原则。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "终末期", "subject_type": "分期分型", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血脂", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "改善微循环治疗", "subject_type": "非药治疗", "object": {"@value": "糖尿病微血管病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "因此，对老年糖尿病患者的血糖控制目标放宽程度应该因人而异，治疗措施应该简单易行，控制高血糖药物选择还需充分考虑患者脏器功能的减退程度。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "因此，在患者可以耐受的情况下，使用单药最佳剂量(2000mg/d)的二甲双胍治疗不但可使血糖控制尽早达标，且可使血糖得到更长时间的良好控制。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "2000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(1)总体治疗原则：①在选择降糖药物时，应优先考虑有利于减轻体重或对体重影响中性的药物；②需要胰岛素治疗的T2DM合并肥胖患者，建议联合使用至少一种其他降糖药物，如二甲双胍、胰升糖素样肽1(glucagon-like peptide-1，GLP-1)受体激动剂(GLP-1RA)、α-糖苷酶抑制剂、二肽基肽酶4(dipeptidyl peptidase 4，DPP-4)抑制剂等，从而减轻因胰岛素剂量过大而引起的体重增加。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "胰岛素剂量过大", "subject_type": "患病病因", "object": {"@value": "体重增加"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "短效GLP-1受体激动剂可刺激胰岛素分泌、抑制胰升血糖素分泌、延缓胃排空、增加饱腹感和减少进食量而降低PPG。目前，我国临床使用的短效制剂艾塞那肽。在二甲双胍治疗的基础上联合短效GLP-1受体激动剂可降低HbA1c0.8%~1.5%。我国新诊断T2DM患者使用艾塞那肽治疗后，HbA1c较基线下降1.8%。其显著的特点是，在降糖同时，大部分患者可减轻体重、降低TG和SBP。常见的不良反应为胃肠道反应，如恶心、呕吐等，但随着治疗时间(约2周)延长逐渐减弱。单用低血糖发生率低，与胰岛素促泌剂合用可增加低血糖发生风险。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "艾塞那肽", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}]}
{"text": "GLP-1除葡萄糖依赖性刺激胰岛素分泌、抑制胰高血糖素分泌外，还具有延缓胃肠排空以及保护β细胞的作用。胰高糖素分泌相对增多也是1型糖尿病血糖升高的主要机制之一。虽然有研究提示1型糖尿病患者使用DPP-4抑制剂可降低患者HbA1c水平，并减少胰岛素的用量，但现有数据并没有显示DPP-4抑制剂具有延缓1型糖尿病进展的作用。", "spo_list": [{"Combined": false, "predicate": "发病机制", "subject": "胰高糖素分泌相对增多", "subject_type": "发病机制", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "GLP-1受体激动剂以葡萄糖浓度依赖的方式促进β细胞分泌胰岛素、降低α细胞分泌胰血高糖素，磺脲类药物联合GLP-1受体激动剂可使HbA1c水平显著降低，且安全耐受性良好。一项为期26周的随机、双盲、对照研究结果显示，无论之前患者接受何种治疗，格列美脲联合利拉鲁肽治疗均可快速降低HbA1c达1.1%，显著优于格列美脲单药治疗或格列美脲联合罗格列酮治疗。格列美脲联合利拉鲁肽1.8mg/d治疗组患者体重降低，<10%的患者发生轻度低血糖。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "体重降低", "subject_type": "不良反应", "object": {"@value": "格列美脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列美脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1.8mg/d", "subject_type": "用药剂量", "object": {"@value": "格列美脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重降低", "subject_type": "不良反应", "object": {"@value": "利拉鲁肽"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "利拉鲁肽"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1.8mg/d", "subject_type": "用药剂量", "object": {"@value": "利拉鲁肽"}, "object_type": {"@value": "药品名称"}}]}
{"text": "糖尿病足的最终结局是：溃疡愈合、截肢和死亡。 ", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "截肢", "subject_type": "临床手术", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "溃疡", "subject_type": "临床表现", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)血糖控制目标和治疗方案：计划妊娠的糖尿病患者应严格控制血糖，餐前血糖控制在3.9-6.5mmol/L，餐后血糖<8.5mmol/L，在避免低血糖的情况下尽量控制HbA1c<6.5%，用胰岛素治疗者控制HbA1c<7.0%。目前我国口服降糖药物均未纳入妊娠期使用适应证，因此孕前正在使用口服降糖药物的2型糖尿病患者应适时停用，并转换为胰岛素控制血糖。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "磺脲类药物改善高血糖的机制包括：①刺激胰岛β细胞分泌胰岛素，其中格列美脲可能具有葡萄糖依赖性的促胰岛素分泌作用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "尽管接受口服药物治疗及生活方式干预，但大部分T2DM患者胰岛β细胞功能仍随病程进展逐渐恶化，故及时启动胰岛素治疗能减轻胰岛β细胞负荷，解除高糖毒性，改善胰岛素抵抗，保护残存的β细胞功能。《中国2型糖尿病防治指南(2013年版)》指出，每日1次基础胰岛素或每日1~2次预混胰岛素均可作为胰岛素起始治疗方案，如基础胰岛素或预混胰岛素与口服降糖药联合治疗控制血糖不达标则应将治疗方案调整为多次胰岛素注射(基础+餐时胰岛素或每日3次预混胰岛素类似物)。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛β细胞功能仍随病程进展逐渐恶化", "subject_type": "发病机制", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛β细胞负荷", "subject_type": "发病机制", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日1次", "subject_type": "用药频率", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日1~2次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日3次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "1.神经传导测定：神经传导测定在DPN的诊断中具有重要作用。感觉和运动神经传导测定应至少包括上、下肢各2条神经。①感觉神经传导测定：主要表现为感觉神经动作电位波幅降低，下肢远端更为明显，传导速度相对正常，符合长度依赖性轴索性周围神经病的特点。当存在嵌压性周围神经病时，跨嵌压部位的感觉神经传导速度可有减慢。在以自主神经表现为主者，感觉传导可以正常。感觉神经传导测定有助于发现亚临床病变。2运动神经传导测定：远端运动潜伏期和神经传导速度早期通常正常，一般无运动神经部分传导阻滞或异常波形离散，后期可出现复合肌肉动作电位波幅降低，传导速度轻度减慢。在单神经病或腰骶丛病变时，受累神经的复合肌肉动作电位波幅可以明显降低，传导速度也可有轻微减慢。在合并嵌压性周围神经病者，跨嵌压部位传导速度可明显减慢。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "神经传导测定", "subject_type": "检查方法", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "神经传导测定", "subject_type": "检查方法", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "感觉神经传导测定", "subject_type": "检查方法", "object": {"@value": "长度依赖性轴索性周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "长度依赖性轴索性", "subject_type": "分期分型", "object": {"@value": "长度依赖性轴索性周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "长度依赖性轴索性周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "感觉神经动作电位", "subject_type": "检查指标", "object": {"@value": "长度依赖性轴索性周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "传导速度", "subject_type": "检查指标", "object": {"@value": "长度依赖性轴索性周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢远端", "subject_type": "患病部位", "object": {"@value": "长度依赖性轴索性周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "嵌压性", "subject_type": "分期分型", "object": {"@value": "嵌压性周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "嵌压性周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "感觉神经传导速度", "subject_type": "检查指标", "object": {"@value": "嵌压性周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "单神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "单神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "复合肌肉动作电位", "subject_type": "检查指标", "object": {"@value": "单神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "传导速度", "subject_type": "检查指标", "object": {"@value": "单神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "腰骶丛", "subject_type": "患病部位", "object": {"@value": "腰骶丛病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "腰骶丛病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "复合肌肉动作电位", "subject_type": "检查指标", "object": {"@value": "腰骶丛病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "传导速度", "subject_type": "检查指标", "object": {"@value": "腰骶丛病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "嵌压性", "subject_type": "分期分型", "object": {"@value": "嵌压性周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "嵌压性周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "传导速度", "subject_type": "检查指标", "object": {"@value": "嵌压性周围神经病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "尿酸来源部分由人体摄入，部分由体内分解代谢的嘌呤化合物在肝脏中产生，三分之二通过肾脏排泄，其余由消化道、皮肤汗腺等排泄。正常情况下，体内尿酸产生和排泄保持动态平衡，凡导致尿酸生成过多和/或排泄减少的因素均可导致HUA。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "尿酸生成过多", "subject_type": "患病病因", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "排泄减少", "subject_type": "患病病因", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.对于慢性疾病终末期患者，如纽约心脏学会(NYHA)心功能Ⅲ-IV级、终末期肾病、恶性肿瘤伴有转移、中重度认知功能障碍等，HbA1c控制目标可适当放宽至<8.5%。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "心功能Ⅲ-IV级"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "Ⅲ-IV级", "subject_type": "分期分型", "object": {"@value": "心功能Ⅲ-IV级"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "终末期肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "终末期", "subject_type": "分期分型", "object": {"@value": "终末期肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "恶性肿瘤伴有转移"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "中重度认知功能障碍"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "中重度", "subject_type": "分期分型", "object": {"@value": "中重度认知功能障碍"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "格列喹酮通过与胰岛β细胞膜上磺脲受体结合促进胰岛素分泌，该结合作用短效可逆，避免了对细胞的持续刺激，降低了发生低血糖的风险。动物试验和床研究均证实，格列喹酮可有效控制餐后血糖(PPG)及血糖波动，促胰岛素分泌的达峰时间为30-~0min，在120~180min后逐渐下降，可见格列喹酮通过促进胰岛素早期时相分泌，较好地模拟生理胰岛素分泌模式，同时降糖作用维持时间适中，可避免下餐前低血糖。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列喹酮"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列喹酮"}, "object_type": {"@value": "药品名称"}}]}
{"text": "2型糖尿病的女孩自诊断起每次随访中都应详细询问月经史，如果存在原发性或继发性闭经，多毛及严重痤疮，需考虑PCOS的存在。PCOS的诊断需基于月经稀少或停经同时有高雄激素血症的临床或生化表现，可以合并或不合并多囊卵巢。控制体重，改善胰岛素抵抗，体育锻炼，口服二甲双胍均能改善卵巢功能，提高日后生育率。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "月经稀少", "subject_type": "临床表现", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "停经", "subject_type": "临床表现", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "卵巢", "subject_type": "患病部位", "object": {"@value": "多囊卵巢"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(1)预混胰岛素每日2次治疗后HbA1c≥7.0%的患者；", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "每日2次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "临床问题2：在单药治疗血糖控制不佳情况下，DPP-4i是否可作为2型糖尿病患者的二线治疗选择之一? ", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "DPP-4i", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "老年患者应根据脏器功能、认知功能以级预期寿命选择不同胰岛素促泌剂治疗，但总体而言，治疗措施应尽量简单易行，并充分考虑肝肾功能减退程度(5级)。若患者既往有严重低血糖史、合并其他严重疾病、预期生存期较短，宜选择作用时间较短的格列奈类促泌剂；若患者脏器功能和认知能力良好、预期生存期较长，可选择低血糖少等安全性较好的磺脲类促泌剂。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类促泌剂"}, "object_type": {"@value": "药品名称"}}]}
{"text": "推荐DPP-4i联合基础胰岛素用于2型糖尿病的降糖治疗。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4i", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "【2型糖尿病并发症和合并症的评估与治疗】 ", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "转诊对象的纳入标准(以糖尿病微血管并发症患者为对象)如下，满足下列任一条件者需进行双向转诊。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.大血管并发症：对新诊断的2型糖尿病患者，UKPDS以格列本脲和氯磺丙脲为基础的降糖治疗，其后续研究5年随访未显示明显的大血管获益，10年随访心肌梗死风险下降15%(P=0.01，1b级)。对病程较长且合并心血管高危因素的患者，ADVANCE发现以格列齐特缓释片为基础的降糖治疗5年，HbA1c降至6.5%时，心血管死亡相对风险下降12%(P=0.12，1b级)。对伴有持续性微量白蛋白尿的非超重2型糖尿病患者，Steno-2研究结果显示，采用以格列齐特为基础的降糖治疗，结合多因素强化干预，心血管疾病相对风险下降53%(P=0.008，1b级)。对UKPDS和ADVANCE等研究的meta分析结果显示，以氯磺丙脲、格列本脲和格列齐特缓释片为基础的降糖治疗可使2型糖尿病患者非致死性心肌梗死风险显著降低17%、冠心病风险显著降低15%(1a级)。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列本脲", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "氯磺丙脲", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "5年", "subject_type": "持续时间", "object": {"@value": "格列齐特缓释片"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列齐特", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "氯磺丙脲", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列本脲", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列齐特缓释片", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "非致死性", "subject_type": "分期分型", "object": {"@value": "非致死性心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "非致死性心肌梗死"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "对老年尤其高龄(>80岁)患者的血糖控制目标总体放宽主要原因是，老年人的神经反应比较迟钝或存在神经病变，容易发生无感知低血糖，患者常常在没有任何征兆的情况下发生低血糖昏迷，这种情况如果发生在夜间非常危险，往往因错过抢救时机导致严重脑损伤甚至死亡；而且老年人多伴有心脑血管动脉粥样硬化，一旦发生低血糖可诱发心肌梗死及脑卒中。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "无感知低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脑", "subject_type": "患病部位", "object": {"@value": "脑损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心脑血管", "subject_type": "患病部位", "object": {"@value": "心脑血管动脉粥样硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "低血糖", "subject_type": "患病病因", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "低血糖", "subject_type": "患病病因", "object": {"@value": "脑卒中"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脑", "subject_type": "患病部位", "object": {"@value": "脑卒中"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "目前，国内临床使用的基础胰岛素主要包括中效胰岛素(NPH，中性鱼精蛋白锌胰岛素)、长效胰岛素(PZI，精蛋白锌胰岛素)和长效人胰岛素类似物(甘精胰岛素，地特胰岛素等)(表1)。NPH是人胰岛素锌晶体与鱼精蛋白结合而制成的基础胰岛素，作用时间13~16h，且具有明显峰值，变异性较大，低血糖发生的风险相对高。长效人胰岛素类似物甘精胰岛素在人胰岛素的基础上经氨基酸序列修饰，能更好地模拟生理性胰岛素分泌，减少低血糖风险，是我国使用最广泛的基础胰岛素。甘精胰岛素在中性pH液中溶解度低，皮下注射后形成细微沉淀物，其中的多聚体在皮下持续缓慢释放，达到24h平稳、无峰的血药浓度。地特胰岛素是另一种长效人胰岛素类似物，在人胰岛素的基础上经分子结构修饰，皮下注射后自我聚集作用增强，同时添加的脂肪酸侧链与白蛋白可逆结合，从而可延长药物的吸收和作用时间，相对长效人胰岛素类似物，中效胰岛素的价格较低。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "NPH"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "皮下注射", "subject_type": "用药方法", "object": {"@value": "甘精胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "皮下注射", "subject_type": "用药方法", "object": {"@value": "人胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "2.早诊断：2型糖尿病的发生有较长的前期过程，包括高胰岛素-正常血糖的代偿期、血糖轻度异常的糖尿病前期[以空腹血糖(FPG)升高为主的空腹血糖受损和以糖负荷后2h血糖(2hPG)升高为主的糖耐量减低，也可两者并存]，直到糖尿病的早期阶段(血糖轻中度升高)。在不能改变遗传现状的情况下，鼓励高危患者定期体检和进行糖尿病筛查，以便早发现潜在的糖尿病威胁，早开始保护自身β细胞功能。联合空腹血糖(FPG)、随机或2hPG和HbA1c(检测方法需经国际化标准认定)，或采用口服葡萄糖(75g)耐量试验(OGTT)进行糖尿病筛查，有助于减少漏诊率(B)。在确定糖尿病诊断时，标准可适当放宽；切勿放松处于糖代谢水平异常人群的前期管理。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "空腹血糖(FPG)", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "糖负荷后2h血糖(2hPG)", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "空腹血糖受损", "subject_type": "临床表现", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "糖耐量减低", "subject_type": "临床表现", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "空腹血糖(FPG)", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "随机或2hPG", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "口服葡萄糖(75g)耐量试验(OGTT)", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "糖代谢水平异常", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "要注意调动儿童的兴趣和积极性，循序渐进，更要长期坚持。需注意若有心肺功能异常或严重高血压者或严重高血糖代谢不稳定者需根据病情在专家指导下运动，或避免剧烈运动。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心肺功能异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肺", "subject_type": "患病部位", "object": {"@value": "心肺功能异常"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)干性坏疽：糖尿病干性坏疽发病人数较少，占糖尿病足坏疽的5.0%。多发生在糖尿病患者肢端动脉及小动脉粥样硬化，致管腔狭窄或闭塞，局部血供障碍，最终导致缺血组织发生干性坏疽。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "足坏疽"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肢端动脉", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "管腔狭窄或闭塞", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "小动脉粥样硬化", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "局部血供障碍", "subject_type": "患病病因", "object": {"@value": "干性坏疽"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "缺血组织", "subject_type": "患病部位", "object": {"@value": "干性坏疽"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "沙格列汀通过肾和肝排泄，此药用于轻度肾功能不全患者时无需调整剂量；中或重度肾功能不全的患者应将剂量调整为2.5mg，qd；在重度肾功能不全的患者中用药经验非常有限，使用应谨慎。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "沙格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "沙格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "沙格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2.5mg", "subject_type": "用药剂量", "object": {"@value": "沙格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "qd", "subject_type": "用药频率", "object": {"@value": "沙格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.并发症评估：急性并发症，如低血糖、酮症酸中毒；慢性并发症，包括视网膜病变、心脑血管病变、糖尿病肾病、糖尿病神经病变、糖尿病足病等评估。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心脑血管", "subject_type": "患病部位", "object": {"@value": "心脑血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "糖尿病神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.二甲双胍使用时的剂量调整：剂量调整原则为“小剂量起始，逐渐加量”。开始时服用500mg/d或<1000 mg/d，1~2周后加量至最大有效剂量2000 mg/d或最大耐受剂量。二甲双胍可在进餐时或餐后立即服用，缓释剂型1次/d，晚餐时或餐后立即服用。考虑药物的临床疗效及患者依从性，可采用简化的剂量方案，建议起始500mg，2次/d，如无明显胃肠道不良反应，随后可逐步增加至1000mg，2次/d。二甲双胍的血浆半衰期为5.1h，但其同时分布于红细胞储藏室，使得全血消除半衰期达17.6h。二甲双胍1000mg，2次/d，可维持24h有效血药浓度。可根据患者状况个体化治疗，通常剂量1500~2000mg/d，分2~3次服用。注意老年人群及肝肾功能不全的患者需调整剂量，具体方法详见“二甲双胍在特殊人群的使用”。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "1次/d", "subject_type": "用药频率", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "进餐时或餐后立即服用", "subject_type": "用药方法", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "晚餐时或餐后立即服用", "subject_type": "用药方法", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1000mg", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "2次/d", "subject_type": "用药频率", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肝肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肝肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.胰岛素促泌剂的适应证：胰岛素促泌剂可作为2型糖尿病患者的一线用药。一般而言，有一定β细胞功能、无胰岛素促泌剂使用禁忌的2型糖尿病患者可考虑选用胰岛素促泌剂，为不适合使用二甲双胍的2型糖尿病患者的治疗首选，或其他口服降糖药物治疗血糖控制不佳的2型糖尿病患者联合用药方案首选(5级)。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.排除导致周围神经病变的其他原因。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "周围神经病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2007~2008年中国糖尿病流行病学调查结果显示，我国20岁以上的人群中糖尿病的患病率为9.7%，而2010年的调查数据显示，我国成人糖尿病患病率高达11.6%。中国糖尿病患者人数已经位居全球首位，并且给社会和家庭带来沉重的经济负担。中国新诊断的2型糖尿病(type 2 diabetesmellius，T2DM)患者以餐后血糖升高为主，这可能与中国患者胰岛β细胞功能的衰退更显著、饮食结构多以碳水化合物为主有关。预混胰岛素能同时提供基础和餐时胰岛素，控制餐后血糖同时兼顾整体血糖。因此，目前多数中国T2DM患者选择预混胰岛素为胰岛素起始治疗方案。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病(type 2 diabetesmellius，T2DM)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "餐后血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病(type 2 diabetesmellius，T2DM)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛β细胞功能的衰退", "subject_type": "发病机制", "object": {"@value": "2型糖尿病(type 2 diabetesmellius，T2DM)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "饮食结构多以碳水化合物为主", "subject_type": "患病病因", "object": {"@value": "2型糖尿病(type 2 diabetesmellius，T2DM)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "预混胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "对伴有中度肾功能不全患者，应首选胰岛素，也可选择经肾排泄少的胰岛素促泌剂，如瑞格列奈或格列喹酮，并根据肾功能水平适当降低胰岛素促泌剂的使用剂量。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "中度肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "中度肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "中度肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "中度肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "中度肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "中度肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3 糖尿病微循环障碍的表现", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "微循环障碍", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "DPP是一项糖尿病预防计划的随机对照研究，该研究结果显示，强化生活方式干预和二甲双胍(850mg，2次/d)治疗，3年内T2DM的发生率分别降低58%和31%(I级)。DPP随访研究显示，以安慰剂为对照，二甲双胍可降低IGT人群糖尿病发生率约13%(I级)。DPP/DPPOS结果显示，与强化生活方式干预相比，二甲双胍能减少糖尿病前期发展为糖尿病的发生率，减少患者体重增加，且10年内花费更低(I级)。印度IDPP研究显示，二甲双胍单独或与强化生活方式干预联合应用均能降低糖尿病的发生风险，分别为26.4%和28.2%(Ⅱ级)。2012年IDF全球T2DM指南推荐，预防糖尿病最好起始生活方式干预；对于IFG、年龄<60岁的肥胖人群，可给予二甲双胍干预。建议糖尿病前期人群应起始生活方式干预，对生活方式不能有效控制血糖的患者，给予二甲双胍可有效预防糖尿病。接受二甲双胍干预的患者应限于有预防糖尿病意愿、有很好的治疗依从性并有条件按照医嘱定期接受糖代谢评估的糖尿病前期个体。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "850mg", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "2次/d", "subject_type": "用药频率", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "IGT"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病前期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "糖尿病前期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "IFG"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "糖尿病前期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "糖代谢评估", "subject_type": "检查方法", "object": {"@value": "糖尿病前期"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "体重增加是T2DM发生的独立危险因素。体重或腰围增加均可加重胰岛素抵抗，增加T2DM的发生风险，以及血糖控制的难度。与单纯肥胖的患者相比，T2DM合并肥胖患者减重并维持体重更加困难。首先，肥胖患者的胰岛素水平显著增高，而胰岛素具有抑制脂肪分解、促进脂肪合成的作用。其次，肥胖本身与糖尿病患者存在的其他代谢异常协同作用可加重T2DM的胰岛素抵抗，而内脏脂肪增加可能是肥胖患者发生胰岛素抵抗的主要原因。减轻体重可以改善胰岛素抵抗、降低血糖和改善心血管疾病的危险因素，超重和肥胖T2DM患者减重3%~5%，即能产生血糖、HbA1c、血压、甘油三酯(triglyceride，TG)均显著降低等具有临床意义的健康获益，并且提高生活质量。", "spo_list": [{"Combined": false, "predicate": "患病病因", "subject": "体重增加", "subject_type": "患病病因", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "体重或腰围增加", "subject_type": "患病病因", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖控制", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "胰岛素水平", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "内脏脂肪增加", "subject_type": "患病病因", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "减轻体重", "subject_type": "非药治疗", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "减轻体重", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "减轻体重", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血压", "subject_type": "检查指标", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "甘油三酯(triglyceride，TG)", "subject_type": "检查指标", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血压", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "甘油三酯(triglyceride，TG)", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血压", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "甘油三酯(triglyceride，TG)", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "近年来2型糖尿病合并慢性肾脏病患者中口服降糖药治疗证据不断丰富,国内外糖尿病及肾脏病权威指南对2型糖尿病合并慢性肾脏病的口服降糖药应用规范也进行了相应更新,加之同时陆续有新的口服降糖药上市。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "快速建议指南推荐DPP-4抑制剂的剂量为说明中规定的常规使用剂量。临床应用共识则给出了更详细的肝肾功能不全患者的用法用量：", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肝肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "初始剂量：每次50~100mg，每日1~3次。2~3周后增至每日300mg，分2~3次服用。肾功能下降时，如eGFR<60ml/min时别嘌醇应减量，推荐剂量为50~100mg/d，eGFR<15ml/min时应禁用。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "50~100mg/d", "subject_type": "用药剂量", "object": {"@value": "别嘌醇"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(2)HbA1c<8.0%：适用于预期生存期>5年、中等程度并发症及伴发疾病，有低血糖风险，应用胰岛素促泌剂类降糖药物或以多次胰岛素注射治疗为主的老年糖尿病患者。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂类降糖药物", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "建议观察皮肤病变，如水疱、皮疹或溃疡等情况。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "皮肤", "subject_type": "患病部位", "object": {"@value": "皮肤病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "为了进一步规范内分泌科住院成人糖尿病患者的血糖管理，制定本共识。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)创面清创手术的适应证：①已发生明确的足趾、足掌、肢体坏疽创面；②坏死性筋膜炎急性炎症期的创面；③形成足底筋膜、肌膜间隙脓肿的创面：④形成感染性窦道的创面；⑤肌腱、骨骼等深部组织外露失活，换药难以去除的创面；⑥残存大量坏死组织的创面；⑦创面基底肉芽组织增生，无深部组织外露，达到植皮条件而通过换药1个月内难以愈合的创面。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "筋膜", "subject_type": "患病部位", "object": {"@value": "坏死性筋膜炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "创面", "subject_type": "临床表现", "object": {"@value": "坏死性筋膜炎"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "综上所述，2型糖尿病的诊断包括糖尿病的诊断和分型。在分型上，糖尿病家族史，自身抗体，胰岛素和C肽释放试验等均可帮助诊断。治疗首先要改变生活方式，包括饮食，运动等。药物治疗包括二甲双胍和胰岛素的单用或联用，治疗要根据高血糖的严重程度，有无酮症和(或)酮症酸中毒来选择。不同于1型糖尿病的是，2型糖尿病在诊断伊始就要进行并发症和合并症的评估，包括肾病，高血压，脂代谢异常，视网膜病变，NAFLD，PCOS，神经病变，阻塞性睡眠呼吸暂停等。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "自身抗体", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "胰岛素", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "C肽", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "视网膜病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "吡格列酮对大血管事件影响的前瞻性临床试验(PROactive)是一项随机、双盲、安慰剂对照的临床研究，在5238例伴有心血管疾病的T2DM患者中评估吡格列酮的心血管安全性。受试者在常规治疗基础上联合吡格列酮或安慰剂治疗，平均随访时间为34.5个月。结果显示，与安慰剂组相比，吡格列酮组的首要复合事件终点(全因死亡、非致死性心肌梗死、卒中、ACS、冠状动脉或下肢动脉的血运重建、踝关节以上的下肢截肢)风险差异无统计学意义(HR 0.90，95%CI 0.80~1.02，P=0.095)，主要次级终点(全因死亡、非致死性心肌梗死或卒中)相对风险下降16%(P=0.027)。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "吡格列酮", "subject_type": "药品名称", "object": {"@value": "大血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "大血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "吡格列酮", "subject_type": "药品名称", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "吡格列酮", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "非致死性", "subject_type": "分期分型", "object": {"@value": "非致死性心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "非致死性心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "非致死性心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "非致死性", "subject_type": "分期分型", "object": {"@value": "非致死性心肌梗死"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "在急性肢体缺血的初期治疗中，起始手术或者溶栓治疗对于30d、6个月或1年的保肢或死亡发生，两者差异无统计学意义；但起始溶栓治疗组(1.3%)30d的卒中发生率较起始手术治疗组(0%)显著增加(OR=6.41，95%CI：1.57~26.22)；30d的大出血发生率分别为8.8%与3.3%(OR=2.80，95%CI：1.70~4.60)，病灶远端的栓塞发生率分别为12.4%与0%(OR=8.35，95%CI：4.47~15.58)；因此，在急性肢体缺血患者，起始手术治疗或者溶栓治疗对于保肢或死亡均无明显差异，但起始溶栓治疗会使肢体缺血与出血并发症风险增加。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肢体", "subject_type": "患病部位", "object": {"@value": "急性肢体缺血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肢体", "subject_type": "患病部位", "object": {"@value": "急性肢体缺血"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2型糖尿病合并动脉粥样硬化性心血管疾病患者降糖药物应用专家共识", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "动脉", "subject_type": "患病部位", "object": {"@value": "动脉粥样硬化性心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "动脉粥样硬化性心血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(3)格列喹酮与α-糖苷酶抑制剂联合：格列喹酮与阿卡波糖联合治疗老年2型糖尿病患者的研究结果显示：联合用药对PPG及FPG的降幅均大于单用阿卡波糖，同时由于药物剂量减少，胃肠道不适等不良反应发生率明显降低，且无一例出现低血糖反应。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道不适", "subject_type": "不良反应", "object": {"@value": "格列喹酮"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿卡波糖", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道不适", "subject_type": "不良反应", "object": {"@value": "阿卡波糖"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "PPG", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "雷米普利在中度肾功能不全患者中需减量，且不能应用于聚丙烯腈或甲基烯丙基硫化钠高通量滤膜或血液透析。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "雷米普利", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "痛风关节炎急性发作期的治疗建议：及早(应在24h内)给予抗炎止痛治疗，推荐的用药包括：非甾体抗炎药(NSAIDs)、糖皮质激素和秋水仙碱。建议使用选择性环氧化酶2(COX-2)抑制剂，该药可针对性地抑制COX-2，减少对CKD患者胃肠道损伤的不良作用。研究显示，依托考昔治疗急性痛风疗效优于吲哚美辛、双氯芬酸、塞来昔布。但CKD患者在使用NSAIDs时应警惕引起急性肾损伤，更应充分水化，密切注意肾功能情况。NSAIDs不耐受或禁忌的患者可考虑用糖皮质激素(如泼尼松30~35mg/d，共3~5d)或秋水仙碱。秋水仙碱最好在症状出现的12~24h内开始使用，但其不能用于重度肾功能或肝功能损害的患者。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "非甾体抗炎药(NSAIDs)", "subject_type": "药品名称", "object": {"@value": "痛风关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "糖皮质激素", "subject_type": "药品名称", "object": {"@value": "痛风关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "秋水仙碱", "subject_type": "药品名称", "object": {"@value": "痛风关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "选择性环氧化酶2(COX-2)抑制剂", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "依托考昔", "subject_type": "药品名称", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "吲哚美辛", "subject_type": "药品名称", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "双氯芬酸", "subject_type": "药品名称", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "塞来昔布", "subject_type": "药品名称", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "NSAIDs", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "急性肾损伤", "subject_type": "不良反应", "object": {"@value": "NSAIDs"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "共3~5d", "subject_type": "持续时间", "object": {"@value": "泼尼松"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "30~35mg/d", "subject_type": "用药剂量", "object": {"@value": "泼尼松"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能或肝功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肾功能或肝功能损害"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "诊断时，出现以下情况之一的应考虑其CKD是由其他原因引起的：(1)无糖尿病视网膜病变；(2)GFR较低或迅速下降；(3)蛋白尿急剧增多或有肾病综合征；(4)顽固性高血压；(5)尿沉渣活动表现；(6)其他系统性疾病的症状或体征；(7)血管紧张素转换酶抑制剂(ACEI)或血管紧张素II受体拮抗剂(ARB)类药物开始治疗后2~3个月内肾小球滤过率下降超过30%。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病综合征"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "顽固性", "subject_type": "分期分型", "object": {"@value": "顽固性高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "2~3个月", "subject_type": "持续时间", "object": {"@value": "血管紧张素转换酶抑制剂(ACEI)"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "2~3个月", "subject_type": "持续时间", "object": {"@value": "血管紧张素II受体拮抗剂(ARB)类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "④GLP-1受体激动剂在与磺脲类药物合用时低血糖发生率升高，适当减少磺脲类药物的剂量可减少低血糖风险。在联合使用GLP-1受体激动剂与磺脲类药物时，应告知患者在驾驶或操作机械时采取必要措施防止发生低血糖。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "GLP-1受体激动剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "GLP-1受体激动剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "【应对】为避免生殖道和泌尿道感染发生，建议使用前询问病史，半年内反复发生泌尿生殖感染的患者不推荐使用；在使用过程中，如发生感染并需要抗感染治疗时建议暂时停药，感染治愈后，可继续使用。使用过程中，尤其是第一个月，需要关注是否出现感染的症状和体征，如出现，应及时就医并作相关检查以明确有无感染。患者在使用此类药物过程中，还应当注意个人外阴部卫生，适量饮水，保持小便通畅，减少感染发生。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "生殖道", "subject_type": "患病部位", "object": {"@value": "生殖道和泌尿道感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "泌尿道", "subject_type": "患病部位", "object": {"@value": "生殖道和泌尿道感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "泌尿", "subject_type": "患病部位", "object": {"@value": "泌尿生殖感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "生殖", "subject_type": "患病部位", "object": {"@value": "泌尿生殖感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "注意个人外阴部卫生", "subject_type": "非药治疗", "object": {"@value": "感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "适量饮水", "subject_type": "非药治疗", "object": {"@value": "感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "保持小便通畅", "subject_type": "非药治疗", "object": {"@value": "感染"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.情绪管理：糖尿病会为患者带来不同程度的情绪反应，如沮丧、易怒、多虑、孤独感、挫败感、内疚感等。研究显示情绪因素可能是导致并发症增多的因素之一，而通过合理的糖尿病教育及心理干预能更好地改善情绪障碍及糖代谢状态。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "情绪管理", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "情绪反应", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "沮丧", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "易怒", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "多虑", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "孤独感", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "挫败感", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "内疚感", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "教育及心理干预", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "情绪障碍", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "糖代谢状态", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4 基层医疗卫生机构糖尿病微血管并发症的预防和治疗 ", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "用法及用量：成人起始剂量为每次口服0.25g，1日2次，1周后可增至每次0.5g，1日2次。根据临床表现及血和尿尿酸水平调整药物用量，原则上以最小有效量维持。丙磺舒的不良反应为肠胃不适、食欲下降、皮肤出疹，泌尿系尿酸结石等；当eGFR<30ml/min时无效，应避免使用。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "肠胃不适", "subject_type": "不良反应", "object": {"@value": "丙磺舒"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "食欲下降", "subject_type": "不良反应", "object": {"@value": "丙磺舒"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "皮肤出疹", "subject_type": "不良反应", "object": {"@value": "丙磺舒"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "泌尿系尿酸结石", "subject_type": "不良反应", "object": {"@value": "丙磺舒"}, "object_type": {"@value": "药品名称"}}]}
{"text": "1.血糖相关指标：在选择HbA1c控制标准的诸多研究中，仅UKPDS和DCCT有长于10年的研究数据，选择HbA1c<7.0%为强化控制目标有远期获益的结果(A)。冠心病和糖尿病等危症的研究经10年观察才得到糖尿病心血管危害的确切数据，提示一般情况下慢性高血糖引起的损害有一定时间效应(A)。HbA1c≥6.5%时已存在高血糖对人体损害，可作为诊断标准的研究结论确实(A)，HbA1c≥6.5%的诊断特异性高，在中老年人群中相同(IV)。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管危害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "二甲双胍被各国指南推荐作为2型糖尿病患者的一线治疗药物。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "共识强调胰岛素促泌剂仍是治疗T2DM的一线药，对于有一定β细胞功能、无胰岛素促泌剂应用禁忌的T2DM患者均可考虑选用胰岛素促泌剂。对无超重和肥胖或二甲双胍不耐受者或其他口服降糖药物治疗血糖控制不佳的T2DM患者促泌剂可作为首选或联合药物。应根据患者血糖谱选择不同类型的胰岛素促泌剂：以餐后血糖(PPG)升高为主者宜选择格列奈类及短效磺脲类促泌剂；以空腹血糖(FPG)升高为主PPG和FPG均升高者宜选择依从性好、低血糖风险低的中长效磺脲类促泌剂。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "中长效磺脲类促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "五、T2DM合并血脂异常患者的血脂管理", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "由此所带来的就是东西方2型糖尿病人群的胰岛素治疗理念也应有所不同：西方2型糖尿病的治疗主要是以改善胰岛素抵抗和补充基础胰岛素为主的起始治疗，例如，多数国家和地区的指南均推荐起始使用基础胰岛素，像美国糖尿病协会(ADA)/欧洲糖尿究学会(EASD)联合共识、中国台湾糖尿病临床照护指引、英国国家健康与临床优化研究所(ICE)临床指南、国际糖尿病联盟(IDF)欧洲指南；而美国内分泌医师协会/美国内分泌学会(AACE/ACE)专家共识则指出基础胰岛素、预混胰岛素、基础-餐时胰岛素或餐时胰岛素一日多次注射、餐时胰岛素加二甲双胍这四种胰岛素方案中任一种均可作为起始治疗。《成人2糖尿病胰岛素临床应用的中国专家共识》的一个主要特点就是提出，中国2型糖尿病患者更需要适时启胰岛素治疗，而且基于餐后血糖更为常见，在干预策略上，应同时针对β细胞功能缺陷和胰岛素作用障碍两个方面，兼顾基础和餐时胰岛素；同时考虑我国2型糖尿病患者的疾病特点和现实社会因素，推荐基础胰岛素和预混胰岛素均可作为口服药失效或血糖较高的新诊断2型糖尿病患者的一线治疗方案。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "一日多次", "subject_type": "用药频率", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "一日多次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "一日多次", "subject_type": "用药频率", "object": {"@value": "基础-餐时胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "基础-餐时胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "一日多次", "subject_type": "用药频率", "object": {"@value": "餐时胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "餐时胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2糖", "subject_type": "分期分型", "object": {"@value": "2糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "餐后血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "β细胞功能缺陷", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素作用障碍", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "餐时胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "预混胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "推荐GLP一1RA作为2型糖尿病患者的三线治疗选择之一。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "GLP一1RA", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "6.糖尿病视网膜病变与失明：老年患者需要定期进行眼底检查。及时发现病变，及早开始治疗获益最大(I)。抗炎、抗血管生成及改善微循环是目前正在使用的治疗方法，激光光凝治疗是预防失明的有效措施(B)。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "眼底检查", "subject_type": "检查方法", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "眼底检查", "subject_type": "检查方法", "object": {"@value": "失明"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "激光光凝治疗", "subject_type": "非药治疗", "object": {"@value": "失明"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "排石疗法：适于结石直径0.5～1.0cm，且未导致尿路梗阻、感染或疼痛等症状的患者，包括一般疗法、中医中药和溶石疗法。一般疗法包括增加液体摄入、限制高嘌呤饮食及适当运动；中药治疗常采用排石颗粒、尿石通等药物；溶石疗法临床上常采用枸橼酸氢钾钠颗粒口服。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "尿路", "subject_type": "患病部位", "object": {"@value": "尿路梗阻"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "枸橼酸氢钾钠颗粒"}, "object_type": {"@value": "药品名称"}}]}
{"text": "基于以上，成人2型糖尿病胰岛素临床应用中国专家共识推荐如下：", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.在改善血脂方面的作用：二甲双胍能够改善脂肪的合成与代谢。多项研究显示，二甲双胍治疗T2DM患者，可降低患者血浆TG、LDL-C及TC水平，但对HDL-C改变不明显。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "TG", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "TC", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HDL-C", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "推荐意见推荐GLP一1RA联合基础胰岛素用于2型糖尿病患者的降糖治疗。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "GLP一1RA", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "CKD是指肾脏结构或功能异常持续超过3个月，其诊断标准见表1。目前国内外大部分指南是根据GFR来进行CKD的肾功能分期。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肾功能", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "8.二甲双胍联合格列奈类药物的疗效：格列奈类药物属于餐时促胰岛素分泌剂，与二甲双胍联用具有协同作用。在新诊断的血糖水平较高(HbA1c水平接近11.0%)的T2DM患者中，瑞格列奈和二甲双胍联合比单用瑞格列奈能更有效降低HbA1c，而低血糖发生风险却未增加。那格列奈联用二甲双胍与格列齐特联用二甲双胍的降糖强度相似，但低血糖发生的风险更小(I级)。故在二甲双胍联合磺脲类药物且低血糖发生风险较高时，可考虑选用二甲双胍联合格列奈类药物。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "瑞格列奈"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "瑞格列奈"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "那格列奈"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列齐特"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(2)非布司他：适用于痛风患者HUA的长期治疗。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "非布司他", "subject_type": "药品名称", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "非布司他", "subject_type": "药品名称", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "与执业营养师一起完成营养控制目标，可改善糖尿病肾病患者的预后。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "妊娠前糖尿病或妊娠期发现的糖尿病在不发生低血糖前提下孕期血糖控制，理想目标值为HbA1c<6%；毛细血管血糖餐前、睡前及夜间不高于5.4mmol/L，餐后峰值不高于7.1mmol/L。GDM毛细血管血糖餐前<5.3mmol/L，餐后1h<7.8mmol/L或2h<6.7mmol/L。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "妊娠前糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "妊娠前糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "妊娠前", "subject_type": "分期分型", "object": {"@value": "妊娠前糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "毛细血管血糖餐前、睡前及夜间", "subject_type": "检查指标", "object": {"@value": "妊娠前糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "餐后峰值", "subject_type": "检查指标", "object": {"@value": "妊娠前糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "毛细血管血糖餐前", "subject_type": "检查指标", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "餐后1h", "subject_type": "检查指标", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "2h", "subject_type": "检查指标", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "众所周知，2型糖尿病患者胰岛β细胞功能随病程进展逐渐恶化。由此推论，随病程进展，为取得血糖最佳控制，大部分2型糖尿病患者似乎最终均需胰岛素治疗。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛β细胞功能随病程进展逐渐恶化", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "赖诺普利在严重的肾功能不全患者中半衰期可达40h以上，可在体内发生蓄积，蓄积的原药可在透析中去除。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "赖诺普利", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病周围神经病有多种分类方法。按照周围神经受累的分布，可以分为多发性对称性周围神经病和局灶性非对称性周围神经病‘。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "糖尿病周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "多发性对称性周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "局灶性非对称性周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "多发性对称性周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "多发性对称性", "subject_type": "分期分型", "object": {"@value": "多发性对称性周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "局灶性非对称性周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "局灶性非对称性", "subject_type": "分期分型", "object": {"@value": "局灶性非对称性周围神经病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.会诊专业管理模式的优势和不足：(1)优势：内分泌科医师通过院内会诊参与非内分泌科住院患者的血糖管理可以提高患者血糖达标率、缩短平均住院日及改善患者临床结局。(2)不足：医疗资源的短缺使内分泌科医护人员不可能参与每个非内分泌科住院患者的血糖管理，更多的住院糖尿病患者血糖管理实际上由所在科室医护人员完成，得到专科医师的指导有限。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "①DPP-4抑制剂不能用于1型糖尿病或糖尿病酮症酸中毒的患者；不推荐用于妊娠期、哺乳期妇女以及儿童。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "利格列汀在肝功能不全患者中无需调整剂量。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "利格列汀", "subject_type": "药品名称", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "上述研究数据表明，罗格列酮、毗格列酮、甘精胰岛素、西格列汀、沙格列汀、阿格列汀及利司那肽的心血管效应为中性，既不增加也不降低心血管事件发生风险。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.二甲双胍是一种胰岛素增敏剂：《Joslin糖尿病学》将二甲双胍归为增敏剂一类。IR是T2DM的主要病理生理特征之一。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "IR", "subject_type": "发病机制", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "由于GLP一1RA具有较好控制血糖和降低体重的作用，在单药治疗血糖控制不佳的情况，推荐GLP—1RA作为2型糖尿病患者的治疗选择。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "GLP—1RA", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "西格列汀用于GFR≥50ml/(min·1.73m2)的CKD患者时无需调整剂量；GFR在30~50ml/(min·1.73m2)时减量至50mg，qd；GFR<30ml/(min·1.73m2)时用药经验有限，减量至25mg，qd。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "西格列汀", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "qd", "subject_type": "用药频率", "object": {"@value": "西格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "50mg", "subject_type": "用药剂量", "object": {"@value": "西格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "25mg", "subject_type": "用药剂量", "object": {"@value": "西格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "qd", "subject_type": "用药频率", "object": {"@value": "西格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.管理方案发生改变时：生活环境改变如住院患者出院、年龄相关因素变化如出现认知功能和自我管理障碍等问题。此时在建立新的管理方案之前，自我管理处方需要包含：与糖尿病管理团队中的其他成员沟通，为患者制定糖尿病管理方案过波计划，后期再制定新的管理方案和教育支持计划。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "制定新的管理方案和教育支持计划", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.入院前长期胰岛素治疗者，方案多为控制基础血糖的中长效胰岛素联合控制餐后血糖的短效胰岛素皮下注射。长时间大手术、术后无法恢复进食的糖尿病患者，手术日换用短效胰岛素持续静脉泵注控制血糖。短小门诊手术者，手术当日可保留中长效胰岛素，剂量不变或减少1/3~1/2，停用餐前短效胰岛素。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "皮下注射", "subject_type": "用药方法", "object": {"@value": "中长效胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "皮下注射", "subject_type": "用药方法", "object": {"@value": "短效胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "短效胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "持续", "subject_type": "持续时间", "object": {"@value": "短效胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉泵注", "subject_type": "用药方法", "object": {"@value": "短效胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "剂量不变或减少1/3~1/2", "subject_type": "用药剂量", "object": {"@value": "中长效胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(3)贝前列素钠：通过作用于血小板和血管平滑肌的前列环素受体，发挥抗血小板和扩张血管作用，从而改善微循环。临床上用于改善慢性动脉闭塞性疾病引起的溃疡、间歇性跛行、疼痛和冷感等症状。一项多中心、随机、双盲、对照研究显示，贝前列素钠治疗3~6个月可以显著改善间歇性跛行患者的PFWD和MWD。另一项随机双盲对照研究证实，慢性糖尿病足溃疡患者接受6周贝前列素钠治疗后，中位创面愈合率较安慰剂组显著提高。中国一项随机对照研究结果显示，前列地尔和前列地尔-贝前列素钠序贯治疗糖尿病肾病患者，均能显著降低尿微量白蛋白及尿总蛋白水平。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "溃疡", "subject_type": "临床表现", "object": {"@value": "慢性动脉闭塞性疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "间歇性跛行", "subject_type": "临床表现", "object": {"@value": "慢性动脉闭塞性疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "疼痛", "subject_type": "临床表现", "object": {"@value": "慢性动脉闭塞性疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "冷感", "subject_type": "临床表现", "object": {"@value": "慢性动脉闭塞性疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝前列素钠", "subject_type": "药品名称", "object": {"@value": "间歇性跛行"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "3~6个月", "subject_type": "持续时间", "object": {"@value": "贝前列素钠"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "足溃疡", "subject_type": "临床表现", "object": {"@value": "慢性糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝前列素钠", "subject_type": "药品名称", "object": {"@value": "慢性糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "6周", "subject_type": "持续时间", "object": {"@value": "贝前列素钠"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "前列地尔", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "微量白蛋白", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿总蛋白", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "前列地尔", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝前列素钠", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "老年糖尿病的预防已经明确了饮食与运动干预的有效性。但对于老年患者而言，尚需注意一些特殊问题。人体进入老年阶段后，代谢水平随着年龄的增长而逐渐下降，同时运动机能也逐渐降低，导致瘦体质量逐年减少。一部分老年患者存在长期能量摄入超标的现象，表现为内脏脂肪存储过多、肌肉存量衰减型肥胖；另有部分老年患者因多种原因合并食欲减退、味觉或嗅觉异常、吞咽困难、口腔或牙齿等问题以及各种可能影响消化食物过程的功能障碍，导致体重过低和/或少肌症的发生。不良的饮食习惯(饮食结构单一、进食方式欠合理)是促成血糖波动大的重要影响因素，而不恰当的限制饮食也会给老年糖尿病患者带来额外的风险。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "饮食与运动", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "长期能量摄入超标", "subject_type": "患病病因", "object": {"@value": "内脏脂肪存储过多"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "长期能量摄入超标", "subject_type": "患病病因", "object": {"@value": "肌肉存量衰减型肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "内脏", "subject_type": "患病部位", "object": {"@value": "内脏脂肪存储过多"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "食欲减退", "subject_type": "患病病因", "object": {"@value": "体重过低"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "食欲减退", "subject_type": "患病病因", "object": {"@value": "少肌症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "味觉或嗅觉异常", "subject_type": "患病病因", "object": {"@value": "体重过低"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "味觉或嗅觉异常", "subject_type": "患病病因", "object": {"@value": "少肌症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "吞咽困难", "subject_type": "患病病因", "object": {"@value": "体重过低"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "吞咽困难", "subject_type": "患病病因", "object": {"@value": "少肌症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "口腔或牙齿等问题", "subject_type": "患病病因", "object": {"@value": "体重过低"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "各种可能影响消化食物过程的功能障碍", "subject_type": "患病病因", "object": {"@value": "体重过低"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "口腔或牙齿等问题", "subject_type": "患病病因", "object": {"@value": "少肌症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "各种可能影响消化食物过程的功能障碍", "subject_type": "患病病因", "object": {"@value": "少肌症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "不良的饮食习惯(饮食结构单一、进食方式欠合理)", "subject_type": "患病病因", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "不恰当的限制饮食", "subject_type": "患病病因", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)血管保护药：①羟苯磺酸钙通过抗氧化应激作用，减轻炎症改善血管内皮功能紊乱，减轻微血管渗漏，改善微循环；减少血管内皮生长因子(vascular endothelial growth factor，VEGF)与受体结合，抑制新生血管生成。临床用于治疗糖尿病视网膜病变及糖尿病肾病。一项多中心、随机双盲对照研究证实，伴有早期视网膜病变的2型糖尿病患者使用羟苯磺酸钙治疗24个月，后玻璃体穿透率(posterior vitreous penetration ratio，PVPR)较基线进行性降低(降幅13.2%)，且不同血糖控制水平的亚组中PVPR均有显著改善，微动脉瘤及出血进展平均值均显著低于安慰剂组。一项纳入221项研究的荟萃分析显示，羟苯磺酸钙可显著改善非增殖期视网膜病变患者微动脉瘤、眼底渗出和眼底出血。对于较晚期的视网膜病变患者，羟苯磺酸钙可作为激光治疗的辅助手段，进一步提高激光治疗疗效。中国一项随机临床试验也显示，较单纯视网膜激光治疗组，羟苯磺酸钙联合视网膜激光治疗组能更明显减少糖尿病患者的黄斑中心凹厚度。一项针对糖尿病肾脏病变的观察性研究显示，羟苯磺酸治疗3个月可使90%的糖尿病肾脏病患者微量蛋白尿下降至正常。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "羟苯磺酸钙", "subject_type": "药品名称", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "羟苯磺酸钙", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "羟苯磺酸钙", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "24个月", "subject_type": "持续时间", "object": {"@value": "羟苯磺酸钙"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "早期视网膜病变", "subject_type": "临床表现", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "玻璃体穿透率(posterior vitreous penetration ratio，PVPR)", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "羟苯磺酸钙", "subject_type": "药品名称", "object": {"@value": "视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "非增殖期", "subject_type": "分期分型", "object": {"@value": "视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "微动脉瘤", "subject_type": "临床表现", "object": {"@value": "视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "眼底渗出", "subject_type": "临床表现", "object": {"@value": "视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "眼底出血", "subject_type": "临床表现", "object": {"@value": "视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "晚期", "subject_type": "分期分型", "object": {"@value": "视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "羟苯磺酸钙", "subject_type": "药品名称", "object": {"@value": "视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "激光治疗", "subject_type": "非药治疗", "object": {"@value": "视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "激光治疗", "subject_type": "非药治疗", "object": {"@value": "视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "视网膜激光治疗", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "羟苯磺酸钙", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "黄斑中心凹厚度", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "糖尿病肾脏病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "羟苯磺酸", "subject_type": "药品名称", "object": {"@value": "糖尿病肾脏病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "3个月", "subject_type": "持续时间", "object": {"@value": "羟苯磺酸"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "糖尿病肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "蛋白尿", "subject_type": "检查指标", "object": {"@value": "糖尿病肾脏病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.酒精摄入可增加HUA患者痛风发作风险，酒精摄入量与痛风的发病风险呈剂量效应关系。HUA患者当限制酒精摄入，禁饮黄酒、啤酒和白酒。", "spo_list": [{"Combined": false, "predicate": "患病病因", "subject": "酒精摄入", "subject_type": "患病病因", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "限制酒精摄入", "subject_type": "非药治疗", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "禁饮黄酒、啤酒和白酒", "subject_type": "非药治疗", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "阿格列汀的适应证适用于治疗2型糖尿病：单药或联合二甲双胍用于成人2型糖尿病患者的血糖控制。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "阿格列汀", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "8.老年骨质疏松症与关节病变：骨质疏松症好发于绝经后妇女及老年人，适量补充维生素D3和钙剂、及时启用二膦酸盐制剂等抗骨质疏松药物是常规治疗措施(I)，预防跌倒、骨折是目标。老年糖尿病患者伴存的多种疾病均可导致跌倒及骨折的风险增高，对老年人定期进行跌倒风险及身体功能评估非常必要，同时应避免严重高血糖及低血糖导致跌倒风险的增加(B)。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "关节", "subject_type": "患病部位", "object": {"@value": "关节病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "维生素D3", "subject_type": "药品名称", "object": {"@value": "骨质疏松症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "钙剂", "subject_type": "药品名称", "object": {"@value": "骨质疏松症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二膦酸盐制剂", "subject_type": "药品名称", "object": {"@value": "骨质疏松症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "跌倒", "subject_type": "临床表现", "object": {"@value": "骨质疏松症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "伴存的多种疾病", "subject_type": "患病病因", "object": {"@value": "骨折"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "跌倒", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "跌倒", "subject_type": "临床表现", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "跌倒", "subject_type": "临床表现", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "空腹血糖受损和糖耐量受损为糖尿病前期。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "空腹血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "糖耐量", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "快速建议指南推荐DPP-4抑制剂作为2型糖尿病患者的一线治疗选择之一，认为在二甲双胍不耐受或存在使用禁忌等情况下，DPP-4抑制剂可以作为一线的替代治疗药物。在刚刚结束的2017年CDS年会上，贾伟平教授简单介绍了即将发布的《中国2型糖尿病防治指南(2017年版)》(简称2017版指南)的一些内容，在高血糖治疗流程上一个主要变化是把原来的一线、二线、三线药物改为单药、二联和三联治疗，这相当于进一步强调了二甲双胍的重要地位，因为二联和三联治疗均推荐在二甲双胍基础上加用其他药物，而且在单药治疗中，二甲双胍不耐受或存在禁忌时的备选药物给出的是α一糖苷酶抑制剂和胰岛素促泌剂。个人认为，推荐α一糖苷酶抑制剂是考虑到餐后高血糖(尤其是单纯餐后高血糖)在国内很常见，推荐胰岛素促泌剂则是因为其降糖效力和二甲双胍相当，而未推荐DPP-4抑制剂一方面可能是从经济和可获得性角度考虑，另一方面可能是其降糖效力略弱。碰巧在2017年CDS年会上，纪立农教授题为《血糖达标的策略：2型糖尿病起始治疗》的报告中，恰巧也分析了起始单药治疗时，二甲双胍与DPP-4抑制剂的对比情况。2016—2017年发表的比较二甲双胍和西格列汀、阿格列汀、利格列汀的三项中国研究均发现，无论是低剂量还是高剂量(1700或2000毫克/天)的二甲双胍治疗，其降糖疗效都要优于DPP-4抑制剂。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1700或2000毫克/天", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "附件5慢性肾脏病(CKD)定义及分期", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病(CKD)"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "在一项长达104周的对照临床研究中，与西格列汀(100mg/d)单药治疗相比，二甲双胍(2000mg/d)单药治疗使受试者平均HbA1c水平维持在7%以下的时间增加了约24周(I级)。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "100mg/d", "subject_type": "用药剂量", "object": {"@value": "西格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "3.脂代谢异常：TODAY研究发现诊断数月后的2型糖尿病青少年患者中，79.8%存在低高密度脂蛋白血症，10.2%存在高甘油三酯血症。所有大于2岁的儿童在诊断糖尿病后，如有高胆固醇血症家族史、家族在55岁前出现心血管事件或家族史不明，应考虑检查空腹血脂谱(在血糖得到控制后)。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "空腹血脂谱", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.肥胖女性妊娠期体重管理：在一项1777例妊娠妇女队列研究中，用替代健康饮食指数(the alternative healthy eating index，AHEI)进行膳食评价，发现肥胖孕妇AHEI分数更低。另一项2247例妊娠妇女队列研究也发现，高能量、低营养素含量的食物(如碳酸饮料、果汁饮料、精制面粉)也是过高能量摄入的主要贡献者，同时此类膳食富含饱和脂肪酸。小样本研究显示：当肥胖合并妊娠期糖尿病的孕妇能量限制在1800kcal左右时，孕妇体重能够得到控制且不出现酮症，也能够改善孕妇血糖水平并对新生儿出生体重无不良影响。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "妊娠期糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "基于现有的循证医学证据，本共识推荐T2DM合并ASCVD患者的血控制目标如下：", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.医学营养治疗：医学营养治疗应强调饮食结构合理，包括对碳水化合物、蛋白质、脂肪、钠、钾、磷等营养素的管理。每日摄入的总热量应使患者维持接近理想体重，肥胖者可适当减少热量，消瘦者可适当增加热量。高蛋白摄入(超过总热量20%)与轻度肾损伤糖尿病患者中肾功能的下降、糖尿病合并高血压患者中微量白蛋白尿的发展相关联。因此糖尿病肾病患者应避免高蛋白饮食，严格控制蛋白质每日摄入量，不超过总热量的15%，微量白蛋白尿者每千克体重应控制在0.8~1.0g，显性蛋白尿者及肾功能损害者应控制在0.6~0.8g。有随机对照试验的meta分析表明，低蛋白饮食治疗对蛋白尿的控制有益，但对GFR或内生肌酐清除率(Ccr)的改善无显著作用。由于蛋白质的摄入减少，摄入的蛋白质应以生物学效价高的优质蛋白质为主，可从家禽、鱼、大豆及植物蛋白等中获得。有研究表明，ARB/ACEI类药物在低钠饮食下对糖尿病。肾病及心血管疾病的改善作用更明显，但在高钠饮食下则可能存在危害，此应限制钠盐摄入，每日摄入量控制在2000~2400mg，高血压者可配合降压药物治疗。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "高蛋白摄入", "subject_type": "非药治疗", "object": {"@value": "肾损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "高蛋白摄入", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "高蛋白摄入", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "高蛋白摄入", "subject_type": "非药治疗", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "高蛋白摄入", "subject_type": "非药治疗", "object": {"@value": "白蛋白尿"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "轻度", "subject_type": "分期分型", "object": {"@value": "肾损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾功能", "subject_type": "检查方法", "object": {"@value": "肾损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾功能", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "低蛋白饮食治疗", "subject_type": "非药治疗", "object": {"@value": "蛋白尿"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "蛋白尿"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "内生肌酐清除率(Ccr)", "subject_type": "检查指标", "object": {"@value": "蛋白尿"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ARB/ACEI类药物", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "限制钠盐摄入", "subject_type": "非药治疗", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "限制钠盐摄入", "subject_type": "非药治疗", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "近来，发现一些因子对糖尿病肾病的诊断有价值，如转化生长因子β1(TGF-β1)、免疫球蛋白G(IgG)、转铁蛋白(TRF)、细胞外基质(ECM)、肾损伤分子1(Kim-1)及中性粒细胞明胶酶相关脂质运载蛋白(NGAL)。利用糖尿病肾病的患者血清蛋白质指纹图谱的比较中筛选到22个上调、24个下调的蛋白质或多肽，并建立诊断决策树模型，盲法验证模型的敏感性90.9%，特异性89.3%。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "转化生长因子β1(TGF-β1)", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "免疫球蛋白G(IgG)", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "转铁蛋白(TRF)", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "细胞外基质(ECM)", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肾损伤分子1(Kim-1)", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "中性粒细胞明胶酶", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "脂质运载蛋白(NGAL)", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血清蛋白质", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.检测方法：需要监测PPG的糖尿病患者除3~6个月检测1次HbA1c外，还应通过自我血糖监测(SMBG)监测PPG。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "监测PPG", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "自我血糖监测(SMBG)", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "监测PPG", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "肠促胰素引起的胰岛素分泌能力约占全部胰岛素分泌量的50%-70%，而且肠促素刺激胰岛素分泌的作用具有葡萄糖浓度依赖的特点，故在调节血糖的同时，引起低血糖的风险很低。GIP是人17号常染色体长臂基因编码的具有42个氨基酸的肽类物质，在碳水化合物和脂类刺激下，主要由十二指肠和空肠近端的K细胞分泌。GIP与胰腺β细胞上的特异性受体结合，促进胰岛素分泌。但2型糖尿病患者的循环CIP水平正常或升高，同时GIP对β细胞的促胰岛素分泌作用显著降低，对a细胞也没有作用，因而限制了其临床应用。GLP-1是人2号常染色体长臂的胰高血糖素原基因编码，而后经修饰的具有30个氨基酸的肠肽类激素，在食物的刺激下由回肠和结肠的L细胞分泌释放入血，从而发挥葡萄糖依赖性促进胰岛素的合成和分泌、抑制β细胞凋亡、抑制胰高糖素分泌等生理作用。1993年，在Nauck等发表的文章中，提示对磺脲类药物不能有效控制的2型糖尿病患者，持续静脉输注CLP-1后，能够显著降低血糖；当血糖达到正常水平时，持续输注GLP-1并未继续刺激胰岛素分泌、血糖呈稳定状态，进一步表明了GLP-1的葡萄糖浓度依赖性降糖的特征。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "胰岛素：胰岛素治疗不增加心力衰竭患者的死亡风险。ORIGIN研究显示，在有心血管高危因素的糖代谢异常患者中，与二甲双胍或SUs相比，甘精膝岛素治疗不增加心力衰竭住院风险。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.控制餐后高血糖与心血管获益：针对性的控制餐后高血糖是否会使T2DM患者心血管疾病发生的风险下降尚无临床证据。HEART2D研究比较了胰岛素治疗控制空腹高血糖或餐后高血糖对急性心肌梗死后心血管终点的影响，结果显示，两组HbA1c水平比较，差异无统计学意义；FPG和PPG比较差异有统计学意义，但与降低FPG为主比较，降低餐后高血糖未能进一步降低复合心血管终点事件的风险。对该研究的亚组分析发现，在老年糖尿病患者中，控制餐后高血糖可降低心血管风险。对短期评价血糖控制的临床试验的荟萃分析(MeR-IA-7)结果显示，与安慰剂比较，降低PPG的药物，如阿卡波糖的治疗与心血管事件风险下降相关(心肌梗死的风险降低64%、任何心血管事件的风险降低35%)。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "空腹高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "PPG", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "复合心血管终点事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "PPG", "subject_type": "检查指标", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿卡波糖", "subject_type": "药品名称", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.低血糖：SGLT2i单药治疗不增加低血糖发生风险。与二甲双胍、二肽基肽酶-4抑制剂(DPP-4i)、TZDs等药物联合使用时，低血糖发生的风险也没有明显增加；与胰岛素或磺脲类药物联合使用时低血糖发生风险增加。建议与胰岛素或磺类药物联合使用时，注意调整胰岛素或磺脲类药物的剂量，避免低血糖发生。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "中国建议指出，SGLT-2抑制剂可应用于成人2型糖尿病，当饮食和运动不能使血糖得到满意控制或二甲双胍不能耐受时，可单独使用，也可与其他口服降糖药物及胰岛素联合使用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "SGLT-2抑制剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "通过控制T2DM患者多种代谢异常和高血压，预防和延缓糖尿病的大血管病变和微血管病变、提高患者生活质量，延长患者寿命是治疗T2DM的目标。当前，T2DM的控制还面临巨大的挑战，在糖尿病患者的血糖控制上仍需更有效的新型降糖药物来满足传统降糖药物未能满足的治疗需求。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "大血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "微血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "13.新诊断T2DM患者胰岛素短期强化治疗的后续治疗：对于有明显高血糖临床症状的新诊断T2DM患者可实施短期胰岛素治疗。在高血糖得到控制和症状缓解后可根据病情调整治疗方案，如改用口服降糖药物或医学营养和运动治疗。一项中国的研究将经短期胰岛素强化治疗后的T2DM患者随机分为甘精胰岛素治疗组和以二甲双胍为基础的口服降糖药治疗组，治疗24周的结果显示，两组降糖疗效相当，且以二甲双胍为基础的口服降糖药治疗方案简单易行、依从性好，较好地控制体重，成本-效益比更佳。因此，建议接受胰岛素短期治疗的新诊断T2DM患者可在高血糖症状得到改善后可考虑改成以二甲双胍为起始的口服降糖药物治疗方案。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "甘精胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "·利拉鲁肽不得用于有甲状腺髓样癌(MTC)既往史或家族史患者以及2型多发性内分泌肿瘤综合征患者。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "甲状腺", "subject_type": "患病部位", "object": {"@value": "甲状腺髓样癌(MTC)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型多发性内分泌肿瘤综合征"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)出院时向患者及家属交代清楚治疗方案，确保新处方的安全性；正确使用并处置胰岛素皮下注射针头和注射器；提供购买相关医疗设备或耗材的信息(如胰岛素笔、便携式血糖仪)；对药物的服用方法、药品的管理、血糖监测、高低血糖的识别、预防和应急处理进行宣传教育。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "皮下注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "糖尿病@有效的糖尿病自我管理教育和支持(diabetes self-management education/support，DSME/S)是协助糖尿病思者管理和维持自身健康行为的基础。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "糖尿病自我管理教育和支持(diabetes self-management education/support，DSME/S)", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "另1/5已有严重并发症或合并脏器功能异常或是患有其他病变、恶性疾病不宜严格控制血糖者。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "脏器功能异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脏器", "subject_type": "患病部位", "object": {"@value": "脏器功能异常"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "成人2型糖尿病胰岛素临床应用的中国专家共识", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "◆双胍类：此药的主要作用是通过减少肝糖输出和改善外周胰岛素抵抗而降低血糖，可使HbA1c降低1.0%-2.0%，同时减轻体重且不增加低血糖风险。英国前瞻性糖尿病研究(UKPDS)显示，二甲双胍可降低肥胖2型糖尿病患者心血管事件和死亡风险，目前国内外指南均推荐二甲双胍作为2型糖尿病控制血糖的一线用药。研究显示，二甲双胍以原形经肾脏直接排泄，当肾功能严重损害时二甲双胍与乳酸易在体内蓄积,从而增加乳酸性酸中毒的风险。因此,二甲双胍用于慢性肾脏病3a期患者时减量，当GFR<45ml.min-1(1.73m2)-1不推荐使用，当GFR<30ml.min-1.(1.73m2)-1禁用。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "双胍类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾功能", "subject_type": "检查方法", "object": {"@value": "乳酸性酸中毒"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "乳酸性酸中毒"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "乳酸性", "subject_type": "分期分型", "object": {"@value": "乳酸性酸中毒"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "慢性肾脏病3a期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病3a期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3a期", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病3a期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病3a期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "慢性肾脏病3a期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "慢性肾脏病3a期"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.选药原则：T2DM合并CKD的理想降糖治疗策略是在有效降糖的同时，不增加低血糖发生的风险，也应避免诱发乳酸性酸中毒或增加心力衰竭风险。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "如疾病进展为肾病综合征或尿毒症，还需配合肾病科医生的专科治疗(I)。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病综合征"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.综合管理：超重/肥胖PCOS的综合管理应包括持续的社会、家庭支持和教育，个体化方案、密切随访、医师监督以及医师、家庭、配偶和同事的支持都会促进体重达标与维持。PCOS患者记录饮食运动日记有利于长期坚持，以减轻体重并维持长期疗效。强化运动管理可降低并维持体重、改善心血管危险因素，且可改善排卵及胰岛素感性。国内研究显示，超重及肥胖的PCOS患者采用饮食联合运动治疗，可改善其内分泌激素及糖脂代谢紊乱。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "饮食联合运动治疗", "subject_type": "非药治疗", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖代谢异常患者血尿酸>480μmol／L应立即起始降尿酸药物治疗。现有的临床资料没有显示降糖药物水平具有不良影响。磺脲类药物可促进尿酸的排出。α糖苷酶抑制剂阿卡波糖可减轻因蔗糖分解导致的血尿酸水平的升高，噻唑烷二酮类药物可能通过减轻胰岛素抵抗而降低血尿酸水平，达格列净、卡格列净等钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂能降低血尿酸水平。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血尿酸", "subject_type": "检查指标", "object": {"@value": "糖代谢异常"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "上海市区30岁以上T2DM患者CKD患病率可达63.9%。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.明确诊断为1型糖尿病的患者。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "随着生活方式的改变及人口老龄化的加速，2型尿病(type 2 diabetes mellitus，T2DM)和肥胖的患病率呈快速上升趋势，并且已经成为全球性公共卫生问题。2010年中国糖尿病流行病学调查[以糖化血红蛋白(hemoglobin A1c，HbA1c)≥6.5%作为诊断标准之一]数据显示，中国成人糖尿病患病率高达11.6%，糖尿病患者人数居全球首位。肥胖和T2DM关系密切，中国超重与肥胖人群的糖尿病患病率分别为12.8%和18.5%；而在糖尿病患者中超重比例为41%、肥胖比例为24.3%、腹型肥胖[腰围≥90cm(男)或≥85cm(女)]患者高达45.4%。与白种人相比，中国人肥胖程度较轻，而体脂分布趋向于腹腔内积聚，更易形成腹型肥胖。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型尿病(type 2 diabetes mellitus，T2DM)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "糖化血红蛋白(hemoglobin A1c，HbA1c)", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "腹腔", "subject_type": "患病部位", "object": {"@value": "腹型肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "CFDA批准的达格列净剂量规格为5毫克和10毫克两种，说明书给出的用量是，推荐起始剂量为5毫克每日一次，对于需加强血糖控制且耐受5毫克每日一次的患者，可增加至10毫克每日一次。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "5毫克", "subject_type": "用药剂量", "object": {"@value": "达格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "5毫克", "subject_type": "用药剂量", "object": {"@value": "达格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "10毫克", "subject_type": "用药剂量", "object": {"@value": "达格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日一次", "subject_type": "用药频率", "object": {"@value": "达格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日一次", "subject_type": "用药频率", "object": {"@value": "达格列净"}, "object_type": {"@value": "药品名称"}}]}
{"text": "由于中国建议发布时，此类药物尚未在国内上市，所以仅介绍了国外的使用情况，美国药品食品监督管理局(FDA)批准达格列净和恩格列净的起始剂量分别为5毫克和10毫克，根据血糖控制的需求和是否耐受可调整至最大剂量10毫克和25毫克，每日一次口服。与FDA不同的是，欧洲药物机构(EMA)推荐达格列净的起始剂量为10毫克，对于重度肝功能不全的患者可从5毫克起始。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "5毫克", "subject_type": "用药剂量", "object": {"@value": "达格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "10毫克", "subject_type": "用药剂量", "object": {"@value": "达格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日一次", "subject_type": "用药频率", "object": {"@value": "达格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "达格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "10毫克", "subject_type": "用药剂量", "object": {"@value": "恩格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "25毫克", "subject_type": "用药剂量", "object": {"@value": "恩格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日一次", "subject_type": "用药频率", "object": {"@value": "恩格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "恩格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "10毫克", "subject_type": "用药剂量", "object": {"@value": "达格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "5毫克", "subject_type": "用药剂量", "object": {"@value": "达格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "达格列净", "subject_type": "药品名称", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.二甲双胍是否具有抗肿瘤作用：糖尿病可能是多种肿瘤，如乳腺癌、胰腺癌、结直肠癌、子宫内膜癌等的风险因素。多项研究显示，二甲双胍可激活AMP激活的蛋白激酶(AMPK)通路，而AMPK通路的激活除了影响代谢外，还可能抑制肿瘤的发生和发展。英国一项大型病例对照研究显示，二甲双胍治疗与癌症的发生风险下降具有相关性，并观察到随着使用时间的延长和使用次数的增加，二甲双胍的保护效应具有逐渐增强的趋势。多项荟萃分析结果显示，二甲双胍治疗与肺癌、前列腺癌、直肠癌等癌症风险降低相关。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "乳腺", "subject_type": "患病部位", "object": {"@value": "乳腺癌"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "胰腺", "subject_type": "患病部位", "object": {"@value": "胰腺癌"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "结直肠", "subject_type": "患病部位", "object": {"@value": "结直肠癌"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "子宫内膜", "subject_type": "患病部位", "object": {"@value": "子宫内膜癌"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肺癌"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "前列腺癌"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "直肠癌"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肺", "subject_type": "患病部位", "object": {"@value": "肺癌"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "前列腺", "subject_type": "患病部位", "object": {"@value": "前列腺癌"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "直肠", "subject_type": "患病部位", "object": {"@value": "直肠癌"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.在治疗PCOS方面的作用：PCOS不是二甲双胍的适应证，但国内外应用二甲双胍治疗PCOS已有十余年的历史。美国内分泌学会推荐二甲双胍可作为PCOS合并T2DM/IGT患者，生活方式干预(一线治疗)失败或月经不规则且无法应用避孕药(二线治疗)的情况下的一种治疗药物。循证医学证据表明二甲双胍可降低血浆胰岛素水平，增加IS，降低雄激素水平，提高雌二醇水平，改善PCOS患者的多毛症，使月经规律，诱导排卵，PCOS患者可从500mg/d开始，每周加量500mg，直到2000mg/d(分二次餐时或餐后服用)，维持数月，直至排卵，恢复月经，待发现怀孕时停药。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "IGT"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "IGT"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "500mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "每周加量500mg", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "直到2000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "分二次", "subject_type": "用药频率", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "餐时或餐后服用", "subject_type": "用药方法", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "糖尿病肾病是糖尿病最主要的微血管并发症之一，是目前引起终末期肾病(end-stage renal disease，ESRD)的首要原因。国外研究资料显示，20年以上病程的糖尿病肾病患者发展为ESRD的发生率为40.8/1000人年，需要进行透析或移植等肾脏替代治疗。我国糖尿病肾病的患病率亦呈快速增长趋势，2009至2012年我国2型糖尿病患者的糖尿病肾病患病率在社区患者中为30%~50%，在住院患者中为40%左右。糖尿病肾病起病隐匿，一旦进入大量蛋白尿期后，进展至ESRD的速度大约为其他肾脏病变的14倍，因此早期诊断、预防与延缓糖尿病肾病的发生发展对提高糖尿病患者存活率，改善其生活质量具有重要意义。为规范糖尿病肾病的诊断和治疗，中华医学会糖尿病学分会微血管并发症学组组织国内的内分泌和肾内科领域专家共同制定本共识。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "终末期", "subject_type": "分期分型", "object": {"@value": "终末期肾病(end-stage renal disease，ESRD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "终末期肾病(end-stage renal disease，ESRD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "透析", "subject_type": "非药治疗", "object": {"@value": "ESRD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "移植", "subject_type": "临床手术", "object": {"@value": "ESRD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "餐后高血糖的定义为摄食后1~2 hPG>7.8mmol/L。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "1~2 hPG", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "·糖尿病患者围手术期血糖不达标者；", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "围手术期血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "在我国，很多糖尿病患者居住在县以下及农村地区，家庭收入和受教育程度较低、医疗保障及医疗条件差，他们对糖尿病相关知识知之甚少，对糖尿病的危险性认识不够、依从性差、几乎不能进行血糖自我监测(SMBG)，这类患者的血糖控制目标应依据患者的病情综合考虑，适当放宽，尽量避免因严重的低血糖或高血糖发生，加重患者病情和经济负担。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖自我监测(SMBG)", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)ARB：ARB通过双重方式降低血压：其一是阻断血管紧张素Ⅱ(AngⅡ)与血管紧张素II 1型受体(AT1R)结合，从而直接或间接抑制血管收缩，减少血管加压素和醛固酮释放，减少肾脏水钠重吸收；其二是促使AngⅡ与AT2R结合，使血管舒张，抑制细胞分化生长，抑制钠水重吸收和交感神经活性。氯沙坦在肾功能不全患者中无需调整剂量，缬沙坦在肾功能减退的大部分患者中都无需调整用药，但在严重肾功能不全患者中用药经验不足，应谨慎用药。替米沙坦及坎地沙坦在轻中度。肾功能不全患者中无需调整用量，重度肾功能不全患者禁用。厄贝沙坦在肾功能不全及血液透析的患者中可能需要调整剂量。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "氯沙坦", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "缬沙坦", "subject_type": "药品名称", "object": {"@value": "肾功能减退"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能减退"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "厄贝沙坦", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "血液透析", "subject_type": "非药治疗", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "前瞻性流行病学研究和meta分析均证实，高TG水平与ASCVD发生相关，与T2DM患者的大血管和微血管事件的剩留风险相关。多项RCT也检验了此类药物预防CHD的作用。非诺贝特干预及减少糖尿病心脏事件研究(FIELD)和糖尿病患者心血管风险干预研究(ACCORD)的亚组分析均提示在高TG/低HDL-C的糖尿病患者中，非诺贝特治疗可使ASCVD风险减少30%左右。Meta分析表明，贝特类药物可使CHD风险降低约25%，CHD死亡率降低约10%。苯扎贝特心肌梗死预防研究(BIP)和苯扎贝特冠状动脉粥样硬化干预研究(BECAIT)证实，苯扎贝特治疗可以缓解ASCVD的进展。因此，经过中等强度的他汀类药物治疗后non-HDL-C仍不达标者，特别是TG≥2.3mmol/L，可在他汀类药物治疗基础上加用贝特类药物(建议；B级证据)，如非诺贝特或苯扎贝特，或高纯度鱼油。但在老年、严重肝肾疾病、甲状腺功能减退等特殊情况者，应慎用他汀联合贝特类药物，并严密监测和随访，一旦出现异常，及时停药。", "spo_list": [{"Combined": false, "predicate": "患病病因", "subject": "高TG水平", "subject_type": "患病病因", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "高TG水平", "subject_type": "患病病因", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "大血管和微血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "大血管和微血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "高TG水平", "subject_type": "患病病因", "object": {"@value": "大血管和微血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "非诺贝特", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心脏", "subject_type": "患病部位", "object": {"@value": "心脏事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "非诺贝特", "subject_type": "药品名称", "object": {"@value": "心脏事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "TG", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HDL-C", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "非诺贝特", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "非诺贝特", "subject_type": "药品名称", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝特类药物", "subject_type": "药品名称", "object": {"@value": "CHD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "苯扎贝特", "subject_type": "药品名称", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "苯扎贝特", "subject_type": "药品名称", "object": {"@value": "冠状动脉粥样硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "冠状动脉", "subject_type": "患病部位", "object": {"@value": "冠状动脉粥样硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "苯扎贝特", "subject_type": "药品名称", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀", "subject_type": "药品名称", "object": {"@value": "老年、严重肝肾疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝特类药物", "subject_type": "药品名称", "object": {"@value": "老年、严重肝肾疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "老年、严重肝肾疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "老年、严重肝肾疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "甲状腺", "subject_type": "患病部位", "object": {"@value": "甲状腺功能减退"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀", "subject_type": "药品名称", "object": {"@value": "甲状腺功能减退"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝特类药物", "subject_type": "药品名称", "object": {"@value": "甲状腺功能减退"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(8)胰岛素：胰岛素是糖尿病的基础用药，适用于1型糖尿病、有急性并发症或严重合并症或处于应激状态或口服降糖药物疗效不佳或有口服降糖药禁忌的2型糖尿病、妊娠糖尿病、继发于严重胰腺疾病的糖尿病、严重营养不良等。不良反应主要有低血糖发作、体重增加、治疗初期的外周组织水肿、过敏反应等。肾功能受损者胰岛素的排泄减少，故CKD3期以上的患者胰岛素用量需减少。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "严重胰腺疾病", "subject_type": "患病病因", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "肾功能受损者胰岛素的排泄减少", "subject_type": "发病机制", "object": {"@value": "CKD3期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3期", "subject_type": "分期分型", "object": {"@value": "CKD3期"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2013年版《中国2型糖尿病防治指南》推荐磺脲类药物为重要的一线备选和二线降糖药物，可作为二甲双胍不耐受或存在禁忌证者的起始治疗或二甲双胍治疗血糖控制不佳时的联合用药之一。2014年国际糖尿病联盟(International Diabetes Federation，IDF)全球T2DM指南同样将磺脲类药物作为不适合二甲双胍治疗的患者的一线备选和二线首选药物。2016年美国临床内分泌医师协会(American Association of Clinical Endocrinologists，AACE)和美国内分泌学会(American College of Endocrinology，ACE)指南将磺脲类药物列为T2DM的一线治疗药物之一，但给予谨慎使用的标识。2016年美国糖尿病学会(American Diabetes Association，ADA)指南则推荐磺脲类药物为T2DM患者二甲双胍治疗后的二线药物。因此，磺脲类药物目前仍是临床上治疗T2DM的常用口服药物之一，具有相当重要的临床地位。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.检测对象：对于以下临床状态的患者，可通过监测PPG评价疗效、低血糖风险和指导药物剂量调整。(1)任何HbA1c不达标的T2DM患者，尤其是FPG达标，而HbA1c不达标，如FPG<6.0mmol/L，但HbA1c>7.0%；(2)低血糖风险较高的患者，如使用促泌剂或胰岛素治疗、进餐不规律或餐后剧烈运动者；(3)使用降糖药物，尤其是降低PPG的药物时。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "监测PPG", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "随着社会经济发展，人们生活方式及饮食结国高尿酸血症(hyperuricemia，HUA)的患病率逐年增高，并呈年轻化趋势，已成为仅次于糖尿病的第二大代谢疾病。血尿酸升高除可引起痛风之外，还与肾脏、内分泌代谢，心脑血管等系统疾病的发生和发展有关。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血尿酸", "subject_type": "检查指标", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心脑血管", "subject_type": "患病部位", "object": {"@value": "心脑血管等系统疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(一)糖尿病周围神经病诊断的基本条件", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "糖尿病周围神经病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(三)糖尿病肾病临床诊断标准", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.餐后高血糖与糖尿病大血管并发症发生的风险增高相关：流行病学研究显示，餐后或糖负荷后血糖与心血管风险及其结局相关。PPG预测心血管事件的作用优于FPG。多项流行病学观察性研究发现，2 hPG是全因死亡和心血管死亡的独立危险因素，也是心血管疾病和全因死亡的预测因素。餐后高血糖与心血管疾病风险增加相关的机制可能与血糖波动有关。急性血糖升高会快速抑制内皮型一氧化氮(NO)释放及内皮依赖性血管扩张，增加可溶性黏附分子水平，并可能激活血栓形成。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "血管", "subject_type": "患病部位", "object": {"@value": "糖尿病大血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "PPG", "subject_type": "检查指标", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "2 hPG", "subject_type": "检查指标", "object": {"@value": "心血管死亡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "2 hPG", "subject_type": "检查指标", "object": {"@value": "全因死亡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管死亡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "血栓"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病皮肤病变的发病机理是以微血管病变为主，晚期糖基化终产物蓄积、炎性反应、生长因子改变等参与的多因素的病变过程。临床可表现为胫前色素斑、类脂质渐进性坏死、糖尿病性水疱病、硬肿病和皮肤感染。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "皮肤", "subject_type": "患病部位", "object": {"@value": "皮肤病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "胫前色素斑", "subject_type": "临床表现", "object": {"@value": "皮肤病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "类脂质渐进性坏死", "subject_type": "临床表现", "object": {"@value": "皮肤病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "糖尿病性水疱病", "subject_type": "临床表现", "object": {"@value": "皮肤病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "硬肿病", "subject_type": "临床表现", "object": {"@value": "皮肤病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "皮肤感染", "subject_type": "临床表现", "object": {"@value": "皮肤病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "微血管病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "16.二甲双胍的减重效果：二甲双胍具有减轻体重的作用，其减轻体重的机制可能包括抑制食欲，减少热量摄入；改善高胰岛素血症，降低基础胰岛和负荷后胰岛素水平；增加瘦素敏感性。一项前瞻性、开放标签研究表明，新诊断T2DM患者经二甲双胍单药治疗16周，正常(BMI 18.5~23.9kg/m2)、超重(BMI 24.0~27.9kg/m2)、肥胖(BMI≥28.0kg/m2)患者的体重分别下降(可能包含部分安慰剂效应)1.47、2.81、2.92kg，患者不同基线BMI水平不会造成二甲双胍单药对血糖控制的差异(Ⅰ级)。在中国T2DM人群中开展的另外一项研究结果提示，接受二甲双胍(最大剂量1500mg/d)治疗48周后，体重降低1.88kg(可能包含部分安慰剂效应)。磺脲类、格列酮类和胰岛素治疗伴有体重增加，联用二甲双胍可减轻上述药物对体重增加的影响；HOME研究显示，与单用胰岛素组相比，二甲双胍联合胰岛素治疗组体重少增加2.28~3.85kg(I级)。由于不同研究的入组人群及试验方法存在一定的差异，其结果可能有所不同。荟萃分析显示，体重降幅最大的常用口服降糖药为二甲双胍，可使体重降低1.1kg。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "高胰岛素血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1500mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "磺脲类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "格列酮类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "术前住院时间超过3天的患者可在入院后即换用短效胰岛素皮下注射控制血糖，术前调整到适合的剂量。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "皮下注射", "subject_type": "用药方法", "object": {"@value": "短效胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "2011年国际糖尿病联盟(IDF)的2型糖尿病治疗路径、2013年中华医学会糖尿病分会的中国2型糖尿病防治指南、美国糖尿病协会(ADA)/欧洲糖尿病研究协会(EASD)和美国临床内分泌协会(AACE)制定的2型糖尿病治疗流程均认可DPP-4抑制剂可与多种传统降糖药物联合或单药治疗，即在二甲双胍或其他药物联合治疗不能达标加用(联用)，或不能耐受二甲双胍时选择(单药)。IDF指南和中国2型糖尿病防治指南建议在选择二甲双胍、磺脲类药物、α-糖苷酶抑制剂控制不佳后加用；AACE 治疗流程和ADA/EASD专家共识认为二甲双胍治疗不能达标或不能耐受时即可选用，也可与多种降糖药联合使用，包括胰岛素。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "α-糖苷酶抑制剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.一般将HbA1c控制于<6.5%，若降糖治疗无低血糖或体重增加等不良反应者可使HbA1c<6%。目前，新诊断糖尿病患者的人数逐年增加，越来越年轻化，尤其是30—39岁比例增加引起了临床医生的关注。这些患者绝大多数除糖尿病外并无并发症和其他疾病，考虑对患者预期寿命和生活质量的影响，应该严格控制血糖，目标值HbA1c<6.5%，我们也同意并推荐IDF的建议，对于年轻、病程较短、治疗后无低血糖或体重增加等不良反应发生的患者，血糖控制目标值应该尽量使HbAIc<6%。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbAIc", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)双胍类：目前，二甲双胍被推荐作为2型糖尿病控制血糖的一线用药，首选用于单纯饮食控制或体育锻炼无效的2型糖尿病，尤其适用于肥胖患者，也与胰岛素联合用于1型和2型糖尿病。其主要药理作用是通过减少肝糖输出和改善外周胰岛素抵抗而降低血糖，二甲双胍可以使HbA1c降低1%~2%，并可减轻体重且不增加低血糖风险。UKPDS研究显示，二甲双胍可降低伴有肥胖的2型糖尿病患者的心血管事件和死亡风险。糖尿病结果预防试验(ADOPT)研究显示，二甲双胍可延缓糖尿病患者微量白蛋白尿的进展。二甲双胍不经肝脏代谢，直接以原形经肾脏排泄，当肾功能受损时，易发生二甲双胍和乳酸在体内堆积，增加乳酸性酸中毒风险。因此二甲双胍用于CKD3a期以上的患者时应减少剂量，eGFR<45ml·min-1·1.73m-2时停用。肾功能受损的患者应用二甲双胍时应注意肾功能变化，每年至少检查一次肾功能。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "1型和2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "单纯饮食控制", "subject_type": "非药治疗", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "体育锻炼", "subject_type": "非药治疗", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "1型和2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型和2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "1型和2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "乳酸性酸中毒", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "CKD3a期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3a期", "subject_type": "分期分型", "object": {"@value": "CKD3a期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "eGFR", "subject_type": "检查指标", "object": {"@value": "CKD3a期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾功能", "subject_type": "检查方法", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾功能", "subject_type": "检查方法", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病@通常，教育团队由内分泌科医师、营养师、糖尿病专科护士组成，共同为患者提供DSME。不同成员的角色分工不同，美国糖尿病学会建议所有糖尿病患者都需要做以下三个方面的评估和转诊：(1)营养教育：由注册营养师提供医学营养评估与治疗；(2)糖尿病教育：在4个关键时机由糖尿病教育护士对患者进行评估、提供和调整DSME/S；(3)心理健康咨询：必要情况下转诊至专业心理医师。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "DSME", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "营养教育", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "糖尿病教育", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "心理健康咨询", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "DSME/S", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2. 痛风石：未经治疗的患者首发症状20年后约70%可出现痛风石，常出现于第一跖趾、耳郭、前臂伸面、指关节、肘关节等部位。痛风石可小如芝麻，大如鸡蛋或更大，受挤压后可破溃或形成瘘管，有白色豆腐渣样排出物。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "第一跖趾", "subject_type": "患病部位", "object": {"@value": "痛风石"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "耳郭", "subject_type": "患病部位", "object": {"@value": "痛风石"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "前臂伸面", "subject_type": "患病部位", "object": {"@value": "痛风石"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "指关节", "subject_type": "患病部位", "object": {"@value": "痛风石"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肘关节", "subject_type": "患病部位", "object": {"@value": "痛风石"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "破溃", "subject_type": "临床表现", "object": {"@value": "痛风石"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "瘘管", "subject_type": "临床表现", "object": {"@value": "痛风石"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "白色豆腐渣样排出物", "subject_type": "临床表现", "object": {"@value": "痛风石"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "借鉴最新“美国糖尿病学会(ADA)/欧洲糖尿病研究协会(EASD)立场声明”中推荐在制定个性化HbA1c控制标准时需对患者的预期寿命、降糖药治疗风险(β细胞功能、低血糖发生、体重增加)、治疗获益程度(已有合并症、脏器功能异常程度)、患者承受治疗能力(自我管理水平、医疗条件)等进行综合评估(A)。根据现有研究结果，权衡利弊，预期寿命长于10年、低血糖风险小、预计治疗获益大、有较好医疗支持的老年糖尿病患者HbA1c控制标准以<7.0%为佳，相应FPG<7.0mmol/L和2hPG<10.0mmol/L，且减少血糖波动，并长期保持上述血糖水平(C)。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "2hPG", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(3)经上述评估后分类：①合并急危重症者：(a)合并急性并发症：包括糖尿病酮症、DKA、高血糖高渗状态、乳酸酸中毒伴高血糖；(b)低血糖昏迷：(c)合并感染：包括糖尿病足或不明原因发热。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.4 心血管风险 ", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管风险"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "10.联合DPP-4抑制剂的疗效：二甲双胍联合DPP-4抑制剂在降低FPG、HbA1c、体重的幅度均强于两药单用，但是对心血管危险因素、低血糖、胃肠道作用差异无统计学意义，二甲双胍联合DPP-4抑制剂的疗效与二甲双胍联合磺脲类药物的疗效相当，但体重增加和低血糖发生的风险低于二甲双胍联合磺脲类药物，由于DPP-4抑制剂上市时间较短，关于二甲双胍和DPP-4抑制剂的联合用药的疗效和安全性，还需要更多的研究验证。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道作用", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "DPP-4抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道作用", "subject_type": "不良反应", "object": {"@value": "DPP-4抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "DPP-4抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "DPP-4抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "老年糖尿病患者不仅会有与糖尿病相关的合并症，也有其他心血管危险因素所致脏器损害，治疗原则为早期评估、综合分析、因人施治、权衡效益风险，全面控制危险因素。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "脏器", "subject_type": "患病部位", "object": {"@value": "脏器损害"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)肾损伤标志：白蛋白尿[尿白蛋白排泄率(AER)≥30mg／24h；尿白蛋白肌酐比值(ACR)≥3mg／mmol]；尿沉渣异常；肾小管相关病变；组织学异常；影像学所见结构异常；肾移植病史。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾小管", "subject_type": "患病部位", "object": {"@value": "肾小管相关病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "多次胰岛素注射(强化治疗)：遇到新诊断老年糖尿病伴存高血糖(HbA1c>9.0%)、合并感染或急性并发症、处于手术或应激状态、应用拮抗胰岛素作用的药物(如糖皮质激素)等特殊情况时，因存在明显的胰岛素抵抗、高糖毒性、高脂毒性等加重胰岛β细胞损伤的因素，需积极采用短期一天多次胰岛素强化治疗模式，解除β细胞毒性，尽早纠正高血糖(C)。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "糖皮质激素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "糖皮质激素", "subject_type": "药品名称", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胰岛素抵抗", "subject_type": "不良反应", "object": {"@value": "糖皮质激素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "高糖毒性", "subject_type": "不良反应", "object": {"@value": "糖皮质激素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "高脂毒性", "subject_type": "不良反应", "object": {"@value": "糖皮质激素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "加重胰岛β细胞损伤", "subject_type": "不良反应", "object": {"@value": "糖皮质激素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "一天多次", "subject_type": "用药频率", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(2)常用降糖药物对血糖、体重的影响：各种降糖药物的作用机制不同，对体重的影响也存在差异。T2DM合并肥胖患者在选择降糖药物时，应兼顾血糖和体重，尽可能选择降效果肯定同时不增加体重的药物。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "③DPP-4抑制剂在肝功能不全患者中的应用", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "格列喹酮口服吸收迅速完全，血药浓度2~3h达峰值，平均半衰期1.5h，降糖持续时间为5~8h；其代谢途径95%经粪便排泄，仅5%经肾脏排泄；格列喹酮在肝脏中经羟基化被代谢为大量非活性代谢产物，该代谢过程在肝功能不全患者体内仍可进行，且长期应用亦不影响肝胆疾病患者的肝功能；由于代谢产物无活性，不易产生药物蓄积作用，具有很高的安全性。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "格列喹酮"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "5~8h", "subject_type": "持续时间", "object": {"@value": "格列喹酮"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝胆", "subject_type": "患病部位", "object": {"@value": "肝胆疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "胰岛素可快速改善代谢异常并能保护胰岛β细胞功能。用于随机血糖>13.9mmol/L和(或) bA1c>9%，糖尿病酮症酸中毒或代谢不稳定的患儿。剂量：1天1次中性鱼精蛋白锌胰岛素或基础胰岛素(0.25~0.5U/kg起)往往已能有效控制代谢异常。如果患儿代谢不稳定但无酸中毒，可联用二甲双胍。如果二甲双胍和基础量胰岛素(最高至1.2U/kg)联用仍不能达到目标，需要逐渐加用餐前胰岛素，直到血糖正常。病情稳定后胰岛素每次减量30%-50%，过渡到单用二甲双胍，过渡期往往需要2~6周。疗效：胰岛素控制血糖起效快，疗效肯定。但据统计，90%的青少年2型糖尿病患儿在起始治疗时单用二甲双胍即可控制病情。注意事项：如果经过以上治疗，血糖仍然不能控制，要重新考虑2型糖尿病的诊断或者加强生活方式的改变。胰岛素的不良反应主要是低血糖，也要注意体重增加的风险。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "代谢异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "中性鱼精蛋白锌胰岛素", "subject_type": "药品名称", "object": {"@value": "代谢异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "1天1次", "subject_type": "用药频率", "object": {"@value": "中性鱼精蛋白锌胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "基础胰岛素", "subject_type": "药品名称", "object": {"@value": "代谢异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "0.25~0.5U/kg起", "subject_type": "用药剂量", "object": {"@value": "基础胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "最高至1.2U/kg", "subject_type": "用药剂量", "object": {"@value": "基础量胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "减量30%-50%", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "随机血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病酮症酸中毒"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "随机血糖", "subject_type": "检查指标", "object": {"@value": "代谢不稳定"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "bA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病酮症酸中毒"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "bA1c", "subject_type": "检查指标", "object": {"@value": "代谢不稳定"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式的改变", "subject_type": "非药治疗", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "对中国成人2型糖尿病HbA1c目标值的适用人群以HbA1c水平分层，总结于表1。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "推荐10：如果患者TG>5.6mmol/L时，可在生活方式干预的基础上首选隆TG药物治疗(如贝特类，或高纯度鱼油)，以减少发生急性胰腺炎的风险(推荐；C级证据)。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "TG", "subject_type": "检查指标", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "隆TG药物", "subject_type": "药品名称", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝特类", "subject_type": "药品名称", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "高纯度鱼油", "subject_type": "药品名称", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "胰腺", "subject_type": "患病部位", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "急性", "subject_type": "分期分型", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "C.DKA SGLT-2抑制剂在上市前研究和上市后应用过程中，都有过糖尿病酮症酸中毒(DKA)及酮症的病例报告，但非常少见。发生者大多存在手术、过度运动、心肌梗死、卒中、严重感染、长时间禁食或极低碳水化合物摄入量和其他生理及病理应激等诱因，部分联用胰岛素的患者胰岛素减量过快。使用此类药物发生DKA及酮症的患者症状不典型，血糖通常不超过13.9毫摩尔/升，被称为“血糖不高的DKA”，往往不易被诊断。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "DKA"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.2 糖尿病微循环障碍由糖尿病相关因素导致的微循环障碍称之为糖尿病微循环障碍。它不仅在糖尿病血管并发症的发生中起着重要作用，而且参与了胰岛素抵抗及糖尿病的发生发展。目前糖尿病微循环障碍的确切发病机制尚未被完全阐明，主要涉及血管内皮受损及一氧化氮合成减少、多元醇通路激活、蛋白质非酶糖化、氧化应激、蛋白激酶C激活等多个方面的功能和代谢异常，进而出现微循环自律运动障碍，微血管血流量增加，压力增高。持续的血流动力学异常可致微血管结构损伤，通透性增加，毛细血管渗出，基底膜增厚，血管腔狭窄甚至闭塞，微血栓形成，发生微循环缺血、缺氧，进而导致器官功能障碍。微循环障碍可发生于糖尿病期及糖尿病前期，早期对其进行干预有助于糖尿病及其血管并发症的防治。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "微循环障碍", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "微循环障碍", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "微循环障碍", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "微循环障碍", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "微循环障碍", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "微循环障碍", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "血管内皮受损", "subject_type": "发病机制", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "一氧化氮合成减少", "subject_type": "发病机制", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "多元醇通路激活", "subject_type": "发病机制", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "蛋白质非酶糖化", "subject_type": "发病机制", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "氧化应激", "subject_type": "发病机制", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "蛋白激酶C激活", "subject_type": "发病机制", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "肢体麻木、疼痛等感觉异常为DPN的常见主诉。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "肢体麻木", "subject_type": "临床表现", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "疼痛", "subject_type": "临床表现", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "感觉异常", "subject_type": "临床表现", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "因此低血糖高危人群的个体化血糖控制格外重要。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "格列奈类药物也与胰岛β细胞膜SUR结合，与磺脲类药物相比，促胰岛素分泌作用起效快、作用持续时间短，有效降低餐后血糖，同时不增加胰岛素分泌总量，不加重β细胞负荷，低血糖的发生率低。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列奈类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(5)若低预混人胰岛素每日2次治疗的患者餐后血糖≥11.1mmol/L，临床医生可依据具体情况考虑等剂量改为低预混胰岛素类似物或中预混胰岛素类似物。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "每日2次", "subject_type": "用药频率", "object": {"@value": "预混人胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(1)新诊断T2DM患者，HbA1c≥9.0%同时合并明显临床症状；", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "不难看出，胰岛素促泌剂增加体重，但胰岛素体重增加更明显。表明超重和肥胖的糖尿病患者选用降药时一般也应是胰岛素促泌剂优于胰岛素。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "增加体重", "subject_type": "不良反应", "object": {"@value": "胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "衷心希望《基层糖尿病微血管病变筛查与防治专家共识》的发布能够为推动我国基层糖尿病防控的发展贡献力量，希望基层医疗卫生机构能在微血管并发症筛查和管理方面多方联动，逐步完善，真正有效地预防和控制糖尿病微血管并发症的发生发展，改善患者生存质量，减轻患者家庭和社会卫生经济负担。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "微血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.3 磺脲类药物可否用于超重或肥胖的T2DM患者? ", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.体检：通过触诊，扪及股、腘、足背动脉和 (或) 胫后动脉搏动了解下肢血管病变；通过Buerger 试验了解下肢缺血情况。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "体检", "subject_type": "检查方法", "object": {"@value": "下肢血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "触诊", "subject_type": "检查方法", "object": {"@value": "下肢血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢血管", "subject_type": "患病部位", "object": {"@value": "下肢血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "Buerger 试验", "subject_type": "检查方法", "object": {"@value": "下肢缺血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢", "subject_type": "患病部位", "object": {"@value": "下肢缺血"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "对于其基线LDL-C水平如何，均应在生活方式干预的基础上使用中等强度他汀(推荐；B级证据)。对于无ASCVD，且不合并其他心血管危险因素的T2DM患者，如果LDL-C≥2.6mmo/L，也应在生活方式干预的基础上使用中等强度他汀(推荐；A级证据)。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "中等强度他汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "鉴于此，中国微循环学会糖尿病与微循环专业委员会制订此共识，以期为临床合理选择改善糖尿病微循环障碍药物提供参考。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "微循环障碍", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "①? 基础胰岛素起始方法：血糖明显增高伴有明显高血糖症状的新诊断糖尿病患者或口服降糖药治疗血糖控制不佳的患者起始基础胰岛素时，可根据体重计算起始剂量，通常为0.1~0.3U/(kg·d)，肥胖患者或HbA1c>8.0%时，可考虑0.2~0.3U/(kg·d)起始。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "0.1~0.3U/(kg·d)", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "0.2~0.3U/(kg·d)", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "首先要估算初始的胰岛素每日总剂量：在保持相对恒定的饮食及活动量的情况下，需要根据患者的体重、病情、生理需要量等进行估算，一般情况下，1型糖尿病患者可按0.4~0.5单位仟克体重计算，2型糖尿病病患者可按0.5~1.0单位/千克体重计算。然后根据治疗方案的不同计算出餐时胰岛素的用量并合理分配至三餐：采用基础-餐时方案时，餐时胰岛素约占每日总量的40%~60%，再按1/3、1/3、1/3或1/5、2/5、2/5的比例分配至早午晚三餐前注射；采用胰岛素泵治疗时，餐时胰岛素约占每日总量的50%，按1/3、1/3、1/3的比例分配至三餐前大剂量。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "0.4~0.5单位仟克体重", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "0.5~1.0单位/千克", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "磺脲类药物仍是目前糖尿病治疗领域应用最为广泛的口服降糖药物之一，并且在国内外2型糖尿病(type 2 diabetes mellitus，T2DM)指南中占据着非常重要的治疗地位。长期的临床应用和大量的循证医学证据均表明，磺脲类药物不仅降糖作用强，还可减少或延缓T2DM慢性并发症的发生，特别是微血管并发症。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "微血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病(type 2 diabetes mellitus，T2DM)"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "治疗性生活方式改变不仅是治疗T2DM患者血脂异常的基础，更是预防T2DM患者血脂异常的根本手段。因此，应教育患者调整饮食结构，并提倡健康生活方式。调整饮食结构包括控制总热量、减少饱和脂肪酸的摄入、增加不饱和脂肪酸的摄入、控制胆固醇的摄入、增加富含维生素、纤维等食物。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "治疗性生活方式改变", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "临床问题3：在二线治疗控制不佳情况下，DPP-4i是否可作为2型糖尿病患者的三线治疗", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4i", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "而胰岛素促泌剂也潜在有低血糖和体重增加的不良反应，所以除基础胰岛素外，不建议其与胰岛素联用。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}]}
{"text": "明确的糖尿病病史；在诊断糖尿病时或之后出现的神经病变；临床症状和体征与DPN的表现相符；以下5项检查中如果有2项或2项以上异常则诊断为DPN：(1) 温度觉异常； (2) 尼龙丝检查，足部感觉减退或消失；(3)振动觉异常；(4)踝反射消失； (5) NCV有2项或2项以上减慢。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.痛风急性发作期的药物治疗：急性发作期治疗目的是迅速控制关节炎症状。急性期应卧床休息，抬高患肢，局部冷敷。尽早给予药物控制急性发作，越早治疗效果越佳。秋水仙碱或非甾体类消炎药(NSAIDs)是急性关节发作的一线治疗药物，上述药物有禁忌或效果不佳时可选择糖皮质激素控制炎症。急性发作累及1～2个大关节，全身治疗效果不佳者，可考虑关节内注射短效糖皮质激素，避免短期内重复使用。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "关节", "subject_type": "患病部位", "object": {"@value": "关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "关节内注射", "subject_type": "用药方法", "object": {"@value": "短效糖皮质激素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "使用SGLT2i时发生DKA及酮症的患者症状不典型，血糖通常不超13.9mmol/L，被称之为“血糖不高的DKA”，往往不易被诊断。专家建议在使用SGLT2i期间，如果患者出现和DKA相关的症状如腹痛、恶心、呕吐、乏力、呼吸困难、需要考虑患者是否出现DKA并检测血酮体和动脉血酸碱度以明确诊断。明确诊断为DKA的患者，应立即停用SGLT2i，并按照传统的DKA治疗程序进行治疗。为减少患者在使用SGLT2i期间发生DKA的风险，建议在择期手术、剧烈体力活动，如马拉松比赛前24h停用SGLT2i，同时注意停药后的后续效应；避免停用胰岛素或过度减量；对于紧急手术或大的应激状态，需立即停用SGLT2i，采用其他合适降糖措施；口服SGLT2i期间避免过多饮酒及极低碳水化合物饮食。目前，SGLT-2i未被批准用于T1DM。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "腹痛", "subject_type": "临床表现", "object": {"@value": "DKA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "恶心", "subject_type": "临床表现", "object": {"@value": "DKA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "呕吐", "subject_type": "临床表现", "object": {"@value": "DKA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "乏力", "subject_type": "临床表现", "object": {"@value": "DKA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "呼吸困难", "subject_type": "临床表现", "object": {"@value": "DKA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血酮体", "subject_type": "检查指标", "object": {"@value": "DKA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "动脉血酸碱度", "subject_type": "检查指标", "object": {"@value": "DKA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "SGLT2i"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T1", "subject_type": "分期分型", "object": {"@value": "T1DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.二甲双胍的禁忌证：(1)中度(3b级)和严重肾衰竭或肾功能不全[Cr<45ml/min或eGFR<45ml/(min·1.73m2)]；(2)可造成组织缺氧的疾病(尤其是急性疾病或慢性疾病的恶化)，如失代偿性心力衰竭、呼吸衰竭、近期发作的心肌梗死、休克；(3)严重感染和外伤、外科大手术、临床有低血压等；(4)已知对盐酸二甲双胍过敏者；(5)急性或慢性代谢性酸中毒，包括有或无昏迷的DKA(DKA需要用胰岛素治疗)；(6)酗酒者；(7)接受血管内注射碘化造影剂者，可以暂时停用本品；(8)维生素B12、叶酸缺乏未纠正者。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "中度(3b级)和严重肾衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "中度(3b级)和严重", "subject_type": "分期分型", "object": {"@value": "中度(3b级)和严重肾衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "Cr", "subject_type": "检查指标", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "eGFR", "subject_type": "检查指标", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "失代偿性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "过敏", "subject_type": "不良反应", "object": {"@value": "盐酸二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "DKA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "血管内注射", "subject_type": "用药方法", "object": {"@value": "碘化造影剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "昏迷", "subject_type": "临床表现", "object": {"@value": "DKA"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "对于eGFR<30ml/(min·1.73m2) 的DKD患者应请肾脏专科医师治疗；若eGFR<15ml/(min·1.73m2) ，需考虑替代治疗，如进行血液透析治疗等。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "eGFR", "subject_type": "检查指标", "object": {"@value": "DKD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "12.联合胰岛素的疗效：二甲双胍可增强肝脏和肌肉组织的IR，因此在开始胰岛素治疗的同时应该继续维持二甲双胍治疗。与胰岛素单药治疗相比，二甲双胍联合胰岛素可进一步降低HbA1c，减少胰岛素用量，还可减少使用胰岛素之后出现的体重增加(Ⅰ级)，一项随机对照研究人组了接受胰岛素单药治疗但HbA1c≥7.0%的T2DM患者，受试者随机接受胰岛素单药(n=31)或胰岛素联合二甲双胍(n=27)治疗4个月。结果显示，二甲双胍联合胰岛素治疗，在保证相同降精疗效的同时，可减少胰岛素用量，从而降低低血糖的发生风险。Yki-Jarvinen等将96例接受磺脲类药物治疗血糖控制不佳的T2DM患者，随机分为睡前胰岛素+二甲双胍+安慰剂组、睡前胰岛素+格列本脲+安慰剂组、睡前胰岛素+二甲双胍+格列本脲和睡前胰岛素+清晨胰岛素组。治疗1年后，睡前胰岛素+二甲双胍组体重无明显变化，而其他组的体重均有所增加，且与其他组相比，睡前胰岛素+二甲双胍组HbA1c降幅最大，每日胰岛素用量最少，低血糖的发生率最低。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列本脲", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列本脲", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "二、T2DM患者中ASCVD危险因素的综合管理", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "贝那普利的药代动力学和生物利用度在轻中度肾功能不全中不受影响，重度肾功能不全患者需减量，透析对贝那普利的浓度无影响，透析后无需补充药物。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "贝那普利", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝那普利", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病足：糖尿病患者因下肢远端神经异常和不同程度的血管病变导致的足部感染、溃疡和(或) 深层组织破坏。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "下肢远端神经异常", "subject_type": "患病病因", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "不同程度的血管病变", "subject_type": "患病病因", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢远端神经", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足部", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(3)烟酸：烟酸的降脂作用机制尚不明确，可能与抑制脂肪组织中的脂解和减少肝脏中VLDL合成和分泌有关，此外，烟酸还具有促进脂蛋白酶的活性，加速脂蛋白中TG的水解的作用，因而其降低TG的作用明显。但烟酸可导致糖代谢异常或糖耐量恶化，一般不推荐在糖尿病患者中使用，若必须使用，应该定期监测血糖水平。烟酸和阿昔莫司在。肾功能减退患者中应用证据有限，应谨慎或减量使用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "烟酸", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "糖代谢异常", "subject_type": "不良反应", "object": {"@value": "烟酸"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "糖耐量恶化", "subject_type": "不良反应", "object": {"@value": "烟酸"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能减退"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "无论对于超重/肥胖或体重正常的患者，国内外主要糖尿病指南均推荐二甲双胍为治疗T2DM的首选用药。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.治疗T2DM的一线首选用药：二甲双胍具有可靠的短期和长期降糖疗效，单独使用可有效降低T2DM患者的FPG、PPG，可使HbA1c下降1%~2%，可使中国新诊断T2DM患者的HbA1c降低1.8%(可能含安慰剂效应)，且不受体重影响。在相似的基线HbA1c条件下，最佳有效剂量(2000mg/d)的降糖疗效显著强于其他口服降糖药。二甲双胍单药治疗疗效不佳的患者，联合其他口服降糖药可进一步获得明显的血糖改善(Ⅰ级)。联合胰岛素可降低血糖、改善血脂，同时减轻胰岛素引起的体重增加，减少胰岛素用量。该药具有心血管保护作用，是目前唯一被糖尿病指南推荐为有明确心血管获益证据的降糖药物。二甲双胍的长期治疗与新诊断的T2DM患者及已经发生了心血管疾病的T2DM患者的心血管疾病发生风险下降相关(Ⅰ级)。二甲双胍具有良好的安全性和耐受性，低血糖的发生率低，胃肠道反应多为一过性，不导致肾脏损害，长期使用不增加高乳酸血症和乳酸酸中毒的风险。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "PPG", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道反应", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病周围神经病诊断和治疗共识", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "糖尿病周围神经病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(3)CCB：非二氢吡啶类钙拮抗剂地尔硫?和维拉帕米能够减少蛋白尿；二氢吡啶类钙拮抗剂能维持和增加肾血流量，改善Ccr和GFR；可以抑制内皮素对肾脏的影响以及预防肾脏肥大。国际拜新同抗高血压干预研究(INSIGHT)证明，与利尿剂相比，硝苯地平胃肠控释系统能显著提高肾小球滤过率，保护肾功能。一般认为，CCB延缓高血压患者的肾功能进展的机制，主要是通过降低血压减轻了体循环对肾小球内压力的传导，从而改善肾小球内高滤过、高灌注状态。在肾功能受损时，长效钙通道阻滞剂无需减低剂量，尤其适用于合并冠心病、肾动脉狭窄、重度肾功能不全、存在ACEI或ARB使用禁忌的患者。CCB是治疗CKD合并高血压最常用的选择之一，但若尿蛋白持续增多，需加用ACEI或ARB药物才能达到保护肾功能的作用。有临床研究表明，二氢吡啶类CCB氨氯地平联合贝那普利在降低糖尿病患者心血管事件及延缓肾病进展方面优于贝那普利与噻嗪类利尿剂组合，非二氢吡啶CCB类药物在降低糖尿病肾病患者尿蛋白水平，延缓肾病进程方面明显优于ACEI及β受体阻滞剂，且不受血压控制的影响。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "非二氢吡啶类钙拮抗剂", "subject_type": "药品名称", "object": {"@value": "蛋白尿"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "地尔硫?", "subject_type": "药品名称", "object": {"@value": "蛋白尿"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "维拉帕米", "subject_type": "药品名称", "object": {"@value": "蛋白尿"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二氢吡啶类钙拮抗剂", "subject_type": "药品名称", "object": {"@value": "肾脏肥大"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏肥大"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "拜新同", "subject_type": "药品名称", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利尿剂", "subject_type": "药品名称", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "硝苯地平", "subject_type": "药品名称", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肾小球滤过率", "subject_type": "检查指标", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "CCB", "subject_type": "药品名称", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "长效钙通道阻滞剂", "subject_type": "药品名称", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "长效钙通道阻滞剂", "subject_type": "药品名称", "object": {"@value": "冠心病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "长效钙通道阻滞剂", "subject_type": "药品名称", "object": {"@value": "肾动脉狭窄"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "长效钙通道阻滞剂", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "冠心病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾动脉", "subject_type": "患病部位", "object": {"@value": "肾动脉狭窄"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "CCB", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "CCB", "subject_type": "药品名称", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ACEI", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ARB", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿蛋白", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ACEI", "subject_type": "药品名称", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ARB", "subject_type": "药品名称", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿蛋白", "subject_type": "检查指标", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二氢吡啶类", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "CCB", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "氨氯地平", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝那普利", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝那普利", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "噻嗪类利尿剂", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "非二氢吡啶CCB类药物", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ACEI", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "β受体阻滞剂", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿蛋白", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "在目前临床常用的降胆固醇治疗药物中，他汀类药物是具有最充分随机化临床研究(RCT)证据的显著改善患者预后的词脂药物。特别是，斯堪地那维亚辛伐他汀生存研究(4S)、心脏保护研究(HPS)、协作阿托伐他汀糖尿病研究(CARDS)、CTT协作组进行的一项meta分析等多项研究均证实他汀拥有充分的循证证据证明可显著降低T2DM患者心血管疾病风险(附表2)，被各糖尿病指南推荐为首选的降胆固醇治疗药物。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "阿托伐他汀", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "辛伐他汀", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀", "subject_type": "药品名称", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "降胆固醇治疗药物", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.心力衰竭是否是二甲双胍的绝对禁忌证：需要药物治疗的充血性心力衰竭(CHF)是二甲双胍使用的禁忌证。但回顾性研究显示，二甲双胍本身不会导致心力衰竭，也不会对心力衰竭患者造成不良影响。而且多项研究显示，二甲双胍的治疗可能与糖尿病患者心力衰竭和死亡发生风险的减少有关，可能与伴心力衰竭的糖尿病患者的存活率提高相关。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "充血性心力衰竭(CHF)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "充血性", "subject_type": "分期分型", "object": {"@value": "充血性心力衰竭(CHF)"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "应激情况下可出现暂时性血糖升高，对于既往没有糖尿病病史(特别是HbA1c在正常范围者)，不能以此血糖值诊断糖尿病，须在应激消除后复查，必要时行OGTT明确。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "OGTT", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.PPG与血糖波动：血糖波动包括日间血糖波动和日内血糖波动，需要连续监测血糖来计算波动的大小。PPG升高和低血糖构成日内血糖波动，但餐后高血糖是日内血糖波动的主要原因。进餐引起的血糖波动与饮食习惯密切相关，如饮食量、食物种类[不同升糖指数(GI)的食物]及进食次数等。T2DM患者日内血糖波动高于非糖尿病人群，主原因在于餐后高血糖。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "PPG", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "日内血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "日内血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "日内血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "美国大学组糖尿病研究项目(UGDP)研究提出，甲苯磺丁脲可能增加T2DM患者心血管死亡风险。UKPDS随机给予新发T2DM患者胰岛素注射或口服降糖药治疗，以了解不同治疗方式对心血管并发症的影响。结果显示，磺脲类药物未增加心血管并发症发生；相反，其后续研究发现磺脲类可减少心血管事件发生。ADVANCE对病程较长，合并心血管高危因素的T2DM患者采用以格列齐特缓释片为基础的降糖治疗，主要微血管事件减少14%。Meta分析结果显示，以氯磺丙脲、格列本脲和格列齐特缓释片为基础的降糖治疗可使T2DM患者非致死性心肌梗死风险降低17%、冠心病风险降低15%。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "甲苯磺丁脲", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列齐特缓释片", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM患者"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "氯磺丙脲", "subject_type": "药品名称", "object": {"@value": "T2DM患者"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列本脲", "subject_type": "药品名称", "object": {"@value": "T2DM患者"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列齐特缓释片", "subject_type": "药品名称", "object": {"@value": "T2DM患者"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "心血管死亡", "subject_type": "不良反应", "object": {"@value": "甲苯磺丁脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "心血管并发症", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "对于所有T2DM合并ASCVD患者，生活方式干预应作为综合管理策略的基础性措施，并贯穿于综合治疗的全过程。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "众所周知，肥胖的发生常常是由遗传、少动以及摄入过多能量共同导致的结果。从代谢研究角度看则是基于代谢紊乱(metabolic disorders) ，代谢紊乱是肥胖从基因到临床表现的中心环节。肥胖者多存在脂类代谢紊乱，脂肪合成过多，而脂肪水解和脂肪分解氧化无明显异常。血浆甘油三酯、游离脂肪酸和胆固醇一般高于正常水平。应用低能量饮食治疗肥胖症时，血浆酮体增加或酮血症倾向往往低于正常人。", "spo_list": [{"Combined": false, "predicate": "患病病因", "subject": "遗传", "subject_type": "患病病因", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "少动", "subject_type": "患病病因", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "摄入过多能量", "subject_type": "患病病因", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "代谢紊乱(metabolic disorders)", "subject_type": "患病病因", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "代谢紊乱", "subject_type": "患病病因", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "脂肪合成过多", "subject_type": "患病病因", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "脂类代谢紊乱", "subject_type": "患病病因", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "低能量饮食", "subject_type": "非药治疗", "object": {"@value": "肥胖症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "酮体", "subject_type": "检查指标", "object": {"@value": "酮血症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "据美国儿科协会2型糖尿病的指南，6~12岁儿童每日热量需控制在3765.6-5020.8kJ(900-1200kcal)为宜，13~18岁则需要每日5020.8kJ(1200kal)以上。目前糖尿病患者并没有一个完全相同、理想的碳水化合物、蛋白质和脂肪的热量比例；所以宏量营养素的分配应根据总热量摄入和代谢控制目标进行个体化评估。许多饮食方式利于管理2型糖尿病和糖尿病前期，包括地中海饮食、高血压控制饮食(dietary approaches to stop hypertension)和素食。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "地中海饮食", "subject_type": "非药治疗", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "高血压控制饮食(dietary approaches to stop hypertension)", "subject_type": "非药治疗", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "素食", "subject_type": "非药治疗", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "地中海饮食", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "高血压控制饮食(dietary approaches to stop hypertension)", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "素食", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "本共识不主张在临床使用DPP-4抑制剂治疗1型糖尿病患者。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(5)格列喹酮与噻唑烷二酮类(TZDs)联合：格列喹酮等磺脲类药物与罗格列酮联合应用治疗2型糖尿病患者的研究结果显示，可有效降低HbA1c、PPG及FPG(P<0.05)，改善胰岛素抵抗及高胰岛素血症，且未监测到低血糖发生。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "罗格列酮", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "PPG", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.饮食控制和体育锻炼：一篇纳入了从1984年至2007年间42项随机对照试验的系统性综述认为，生活方式和行为干预措施[包括饮食控制和(或)代餐、体育锻炼、保持减重小组间人员交流等]配合一定的药物治疗，对减少减重后复重有效型。Dombrowski等对非手术干预成人肥胖者减重后的长期维持进行了系统回顾和Mela分析，包含45项研究的7788例患者，结果显示包括食物摄取和体力活动在内的行为干预可以使患者较对照组复重减少1.56kg。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "食物摄取", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "体力活动", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "行为干预", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "用药过程仅有血CK升高而不伴肌痛或肌无力等其他肌损伤证据，则不考虑他汀所致肌损伤。在服用他汀类药物期间出现肌肉不适或无力症状以及排褐色尿时，应及时检测CK，注意排除甲状腺功能低下、过度运动等导致的肌肉症状和(或)肌酶升高。如果发生或高度怀疑肌炎，应立即停止他汀治疗。如果患者有肌肉触痛、压痛或疼痛，CK不升高或中度升高(3~10xULN)，应进行随访、每周检测CK水平，直至排除了药物作用；如肌肉症状恶化，应及时停药。如果患者有肌肉触痛、压痛或疼痛，且连续检测CK呈进行性升高，应慎重考虑减少他汀剂量或暂时停药。然后决定是否或何时再开始他汀类药物治疗。一旦患者发生横纹肌溶解，应停止他汀类药物治疗，必要时住院进行静脉内水化治疗。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "肌损伤", "subject_type": "不良反应", "object": {"@value": "他汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "肌肉不适", "subject_type": "不良反应", "object": {"@value": "他汀类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "无力", "subject_type": "不良反应", "object": {"@value": "他汀类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "排褐色尿", "subject_type": "不良反应", "object": {"@value": "他汀类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "甲状腺", "subject_type": "患病部位", "object": {"@value": "甲状腺功能低下"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肌肉", "subject_type": "患病部位", "object": {"@value": "甲状腺功能低下"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肌酶", "subject_type": "检查指标", "object": {"@value": "甲状腺功能低下"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "肌炎", "subject_type": "不良反应", "object": {"@value": "他汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "肌肉触痛", "subject_type": "不良反应", "object": {"@value": "他汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "压痛", "subject_type": "不良反应", "object": {"@value": "他汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "疼痛", "subject_type": "不良反应", "object": {"@value": "他汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "横纹肌溶解", "subject_type": "不良反应", "object": {"@value": "他汀类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "尽管近年来新型降糖药物不断问世，但磺脲类药物因临床应用时间长、疗效确切，仍被多个国内外成人T2DM防治指南推荐为一线备选或二线降糖用药。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "【2型糖尿病定义和诊断】 ", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "②每日2次方案：对于新诊患者或预混胰岛素起始的患者，一般起始用量为0.2~0.4单位/千克体重或10~12单位/天，按1：1分配到早餐前和晚餐前；对于基础胰岛素联合口服药方案转预混胰岛素方案者，一般以基础胰岛素与预混胰岛素以1：1.3的比例进行剂量转换，按1：1分配到早餐前和晚餐前。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "每日2次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "0.2~0.4单位/千克体重", "subject_type": "用药剂量", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "10~12单位/天", "subject_type": "用药剂量", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "首先来说，东西方2型糖尿病人群的病生理特点及血糖特点有所不同：西方白种人的日常饮食中脂肪含量较高，胰岛素抵抗和腹型肥胖尤为突出，空腹血糖升高更为明显；而中国人群的饮食以碳水化合物为主，β细胞功能缺陷相对更为明显，胰岛素分泌和储备能力低，尤其是胰岛素早相分泌减退更严重，餐后血糖升高显著，不仅如此，体质指数(BMI)虽然相对较低但腹部脂肪蓄积较多，高糖高脂毒性及氧化应激等对β细胞的伤害更明显。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "空腹血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "饮食中脂肪含量较高", "subject_type": "患病病因", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.糖尿病合并心血管疾病者：T2DM是心血管疾病的等危症，控制糖尿病患者的各种代谢危险因素如血压、血脂等可有效降低心血管疾病的发生风险。研究表明，SGLT2i除有效降糖外，还可减轻体重，降低血压，降低血尿酸浓度，减少蛋白尿等与心血管疾病相关的危险因素。针对已经完成的达格列净和坎格列净3期临床随机对照研究中的心血管终点的汇总分析，结果显示，这两类药物均不增加心血管事件风险，然而，上述两种药物对心血管的影响需要正在进行中的心血管结局研究DE-CLARE和CANVAS、CANVAS-R和CREDENCE验证。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血压", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血脂", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "减轻体重", "subject_type": "不良反应", "object": {"@value": "SGLT2i"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "降低血压", "subject_type": "不良反应", "object": {"@value": "SGLT2i"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "降低血尿酸浓度", "subject_type": "不良反应", "object": {"@value": "SGLT2i"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "减少蛋白尿", "subject_type": "不良反应", "object": {"@value": "SGLT2i"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.健康饮食：饮食治疗在伴有HUA的CKD患者治疗中占有非常重要的地位，研究显示饮食治疗可以降低10%~18%的血尿酸水平或使血尿酸降低70~90μmol/L。推荐患者的饮食应以低嘌呤食物为主，具体建议详见表1。对于患者正在接受非透析治疗的CKD患者，应结合低蛋白饮食营养方案。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "健康饮食", "subject_type": "非药治疗", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "健康饮食", "subject_type": "非药治疗", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食治疗", "subject_type": "非药治疗", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食治疗", "subject_type": "非药治疗", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食治疗", "subject_type": "非药治疗", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食治疗", "subject_type": "非药治疗", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "低蛋白饮食", "subject_type": "非药治疗", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.1 基本配置建议(参考附录1)我国2017年发布的《中国糖尿病视网膜病变防治指南(基层版)》和同年美国糖尿病学会(American Diabetes Assoc- iation，ADA) 发布的DR指南中都强调了2型糖尿病患者应在诊断后进行眼底筛查，并明确了眼底照相在DR筛查和诊断中的地位与意义。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "眼底筛查", "subject_type": "检查方法", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "眼底照相", "subject_type": "检查方法", "object": {"@value": "DR"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "心血管疾病与糖尿病关系密切。2006年的”中国心脏调查”发现，慢性稳定性心绞痛和急性冠状动脉综合征(ACS)的住院患者中，约80%存在不同程度的糖代谢异常，其中糖尿病占52.9%，糖尿病前期占26.4%。中国医院门诊高血压患者中，糖尿病患病率为24.3%。中华医学会糖尿病学分会慢性并发症调查组报告，1991—2000年部分三级甲等医院住院的2型糖尿病患者合并高血压者占34.2%，合并其他心血管疾病者占17.1%。荟萃分析表明，糖化血红蛋白(HbA1c)在5%以上的患者，HbA1c每增加1%，心血管事件风险增加21%。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "慢性稳定性心绞痛"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性稳定性心绞痛"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "稳定性", "subject_type": "分期分型", "object": {"@value": "慢性稳定性心绞痛"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "急性", "subject_type": "分期分型", "object": {"@value": "急性冠状动脉综合征(ACS)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "冠状动脉", "subject_type": "患病部位", "object": {"@value": "急性冠状动脉综合征(ACS)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "前期", "subject_type": "分期分型", "object": {"@value": "糖尿病前期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "糖化血红蛋白(HbA1c)", "subject_type": "检查指标", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)管理方案：①饮食与运动方案：饮食与运动干预是妊娠期高血糖管理的基础，在孕妇身体条件允许的情况下，住院期间也应进行合理的饮食、运动干预。饮食应控制总能量摄入，并保证营养均衡，可请营养科进行指导。②胰岛素治疗方案：糖尿病患者妊娠时，血糖水平波动较大，血糖较难控制，均需要使用胰岛素控制血糖。而通过生活方式干预血糖不能达标的GDM孕妇应首先推荐应用胰岛素控制血糖。虽然国外有研究证实了口服降糖药物二甲双胍等在GDM孕妇中应用的安全性和有效性，但我国尚缺乏相关研究，且口服降糖药在我国均无妊娠期间使用的适应证。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "饮食与运动干预", "subject_type": "非药治疗", "object": {"@value": "妊娠期高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖水平", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "慢性肾脏病患者的降尿酸治疗可以降低肾小球尿酸荷，延缓慢性肾脏病进展，依据个体化治疗原则选择抑制尿酸生成药物和／或促尿酸排泄药物。肾功能受损可能增加别嘌醇的毒性，治疗需要从低剂量起始并小心滴定(详见药物治疗部分)。非布司他在轻中度肾功能不全患者(G1～3期)和轻中度肝损伤患者(Child—Pugh分级A／B)中应用无需调整剂量，G4～5期患者谨慎使用。非布司他超敏反应综合征发生率低于别嘌醇；促尿酸排泄药物苯溴马隆可用于轻中度肾功能不全(eGFR20～60ml·min-1·1.73m-2。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "非布司他", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "非布司他", "subject_type": "药品名称", "object": {"@value": "肝损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "G1～3期", "subject_type": "分期分型", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "G4～5期", "subject_type": "分期分型", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "Child—Pugh分级A／B", "subject_type": "分期分型", "object": {"@value": "肝损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "苯溴马隆", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "围术期血糖管理的要点围术期血糖管理的要点在于控制高血糖，同时避免发生低血糖，维持血糖平稳。因禁食、降糖方案未及时调整或降糖治疗中断等因素造成的围术期血糖波动比稳定的高血糖危害更大。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "禁食", "subject_type": "非药治疗", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(3)基础加餐时胰岛素替代治疗方法包括每日多次胰岛素注射和持续皮下胰岛素输注。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日多次", "subject_type": "用药频率", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "皮下", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日多次", "subject_type": "用药频率", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "1.已证实HbA1c<7.0%可减少糖尿病患者微血管并发症，故推荐血糖控制目标：HbA1c<7.0%，FPG<7.0mmol/L，2hPG<10.0mmol/L。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "2hPG", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "这些均可以有效预防T2DM患者的血脂异常。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(一)T2DM患者的血脂管理流程", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.对于年龄较大、糖尿病病程较长、存在低血糖高危因素的患者，HbA1c目标应控制在<7.5%或<8.0%.", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "二肽基肽酶-4(dipeptidyl peptidase-4，DPP-4)抑制剂通过降低DPP-4酶的催化活性，抑制胰高血糖素样肽-1(glucagon-like peptide-1，GLP-1)降解，提升GLP-1在血液中的浓度，刺激胰岛素和抑制胰高血糖素分泌，从而达到控制血糖的目的。磺脲类药物单药治疗血糖控制不佳时，联合DPP-4抑制剂可更好地控制血糖。一项为期24周的多中心、随机、双盲、安慰剂对照研究结果显示，格列美脲联合维格列汀50mg/d或100mg/d不但有效降低患者的HbA1c水平，同时改善患者β细胞功能和餐后血糖水平，且对于年龄≥65岁的老年患者同样安全、有效。磺脲类药物联合DPP-4抑制剂会增加低血糖的发生风险。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "50mg/d", "subject_type": "用药剂量", "object": {"@value": "维格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "100mg/d", "subject_type": "用药剂量", "object": {"@value": "维格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "DPP-4抑制剂"}, "object_type": {"@value": "药品名称"}}]}
{"text": "2.3 DPP-4抑制剂与磺脲类药物的联合应用磺脲类药物是我国使用最广泛的口服降糖药物之一，通过刺激内源性胰岛素分泌从而降低血糖。许多患者需要在磺脲类药物治疗效果不满意或药物继发失效的基础上添加其他口服药物。众多临床研究均显示在使用磺脲类单药治疗血糖控制不良的患者中加用DPP-4抑制剂可进一步改善血糖，提高HbA1c的达标率。但需要注意的是DPP-4抑制剂自身单独使用并不引起低血糖，但与磺脲类药物联合使用时发生低血糖的风险增加。FDA已经批准西格列汀、利格列汀和沙格列汀与磺脲类药联合使用，但是上述药物尚未在中国申请与磺脲类的联合使用。从血糖控制以及低血糖风险等综合因素来看，目前的临床证据支持DPP-4抑制剂与磺脲类药物联用，指南也推荐二甲双胍不能耐受时两者的联用。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "DPP-4抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "不能耐受", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "对于糖尿病足合并高血压者，应将血压控制在140/85mmHg以下；糖尿病足合并脂代谢患者，应给予他汀类药物治疗，将低密度脂蛋白胆固醇水平控制在2.1mmol/L以下，若患者同时合并下肢动脉病变，则应将低密度脂蛋白胆固醇水平控制在1 .7mmol/L以下；若无临床禁忌，应该给予小剂量阿司匹林(75~150mg/d)。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类药物", "subject_type": "药品名称", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢动脉", "subject_type": "患病部位", "object": {"@value": "下肢动脉病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿司匹林", "subject_type": "药品名称", "object": {"@value": "下肢动脉病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "低密度脂蛋白胆固醇水平", "subject_type": "检查指标", "object": {"@value": "下肢动脉病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "75~150mg/d", "subject_type": "用药频率", "object": {"@value": "阿司匹林"}, "object_type": {"@value": "药品名称"}}]}
{"text": "当前临床工作中，对于微循环障碍在糖尿病慢性并发症发生发展中的作用及机制，认识尚不充分，相关药物的选择与使用欠规范。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "微循环障碍", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)磺脲类：为胰岛素促泌剂，主要药理作用是通过刺激胰岛β细胞释放胰岛素，增加体内的胰岛素水平而降低血糖。磺脲类药物可降低HbA1c1%~2%，是目前国内外指南中推荐的控制T2DM患者高血糖的主要用药。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "5.肥胖增加HUA患者发生痛风的风险、减轻体重可有效降低血尿酸水平。建议HUA患者将体重控制正常范围(BMI18.5—23.9kg／m2)。", "spo_list": [{"Combined": false, "predicate": "患病病因", "subject": "肥胖", "subject_type": "患病病因", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "体重控制正常范围(BMI18.5—23.9kg／m2)", "subject_type": "非药治疗", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "一、T2DM合并肥胖管理的意义", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.互联网系统管理模式定义：利用住院患者互联网管理系统，与患者血糖监测数据管理系统相结合，使院内任一科室糖尿病患者都能及时接受糖尿病医护的远程系统管理，包括糖尿病教育、监测及治疗方案制定与调整。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖监测", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "本共识从微循环障碍在糖尿病慢性并发症发生中的机制入手，分析其临床表现及药物治疗原则，以期帮助临床医生提高对糖尿病患者微循环障碍的重视程度，在临床实践中实现早期识别、早期诊断、早期预防和治疗，改善糖尿病患者的预后。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "微循环障碍", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "微循环障碍", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.二甲双胍的常见不良反应：常见不良反应包括腹泻、恶心、呕吐、胃胀、乏力、消化不良、腹部不适及头痛。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "腹泻", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "恶心", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "呕吐", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃胀", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "乏力", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "消化不良", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "腹部不适", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "头痛", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(b)低血糖昏迷：停止全部降糖治疗药物。静脉推注50%葡萄糖液60ml，继而5%~10%葡萄糖液持续静脉滴注，至意识恢复并保持。监测血糖，至少观察3d。抢救参照《内科学》第八版，以及2013年《中国2型糖尿病防治指南》、2012年《中国糖尿病患者低血糖管理的专家共识》。通常血糖在3~7d后逐渐增高，依据血糖水平和病情及本次低血糖昏迷的诱发因素综合分析，重新选择较为安全的降糖策略。(c)合并感染：包括糖尿病足或不明原因发热。感染可导致难以控制的高血糖，高血糖不利于感染的控制，如患者存在糖尿病足或不明原因发热，严格控制血糖为首要措施，胰岛素治疗为首选，如无严重糖代谢紊乱伴水、电解质酸碱平衡紊乱，应采用CSII或MDI治疗。基础胰岛素剂量可参照患者院外基础胰岛素剂量，如果院外没有使用胰岛素者，可按0.2U·kg1·d1计算。三餐前餐时胰岛素或餐前大剂量视患者进餐情况并参照院外胰岛素剂量，同时监测7次血糖，每2~3天调整1次胰岛素剂量，逐渐控制血糖达到住院糖尿病患者控制目标。如存在严重糖代谢紊乱伴水、电解质酸碱平衡紊乱，应积极补液及静脉胰岛素治疗，具体静脉使用胰岛素的方法与前述“(a)合并急性并发症”部分相同，使血糖稳定在8.0~13.9mmol/L。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "静脉推注", "subject_type": "用药方法", "object": {"@value": "50%葡萄糖液"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "60ml", "subject_type": "用药剂量", "object": {"@value": "50%葡萄糖液"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "持续静脉滴注", "subject_type": "用药方法", "object": {"@value": "5%~10%葡萄糖液"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖昏迷"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "感染", "subject_type": "患病病因", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "发热"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "发热"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "CSII", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "MDI", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "0.2U·kg1·d1", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "补液", "subject_type": "非药治疗", "object": {"@value": "糖代谢紊乱"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "糖代谢紊乱"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "补液", "subject_type": "非药治疗", "object": {"@value": "水、电解质酸碱平衡紊乱"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "水、电解质酸碱平衡紊乱"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(3)DPN：积极严格地控制高血糖并保持血糖稳定是预防和治疗DPN最重要的措施，", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "HUA患者出现尿酸盐结晶沉积，导致关节炎(痛风性关节炎)、尿酸性肾病和肾结石称为痛风，也有学者仅将痛风性关节炎称为痛风。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "尿酸盐结晶沉积", "subject_type": "临床表现", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "关节", "subject_type": "患病部位", "object": {"@value": "关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "关节", "subject_type": "患病部位", "object": {"@value": "痛风性关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "尿酸性肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾结石"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "关节", "subject_type": "患病部位", "object": {"@value": "痛风性关节炎"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "另外，根据降糖作用时间长短，可以把GPL-I受体激动剂分为短效和长效制剂，短效制剂对延迟胃排空作用较强，餐后血糖降低明显，长效制剂对延迟胃排空作用较弱，但通过刺激胰岛素分泌和抑制胰高糖素分泌，对空腹血糖降低明显。短效制剂有艾塞那肽，每天注射两次；利司那肽(lixisenatide)，每天一次。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "每天注射两次", "subject_type": "用药频率", "object": {"@value": "艾塞那肽"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每天一次", "subject_type": "用药频率", "object": {"@value": "利司那肽(lixisenatide)"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(一)? 糖尿病足的治疗目标及治疗策略 ", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "·对于伴有非酒精性脂肪肝的2型糖尿病患者，GL-1受体激动剂可降低体质指数(BMl)和转氨酶ALT水平，建议使用GLP-1受体激动剂进行治疗。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "GL-1受体激动剂", "subject_type": "药品名称", "object": {"@value": "非酒精性脂肪肝"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "GL-1受体激动剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "转氨酶ALT", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "第一步：糖尿病的诊断。糖尿病的诊断基于症状和血浆葡萄糖检测。目前我们仍然依据美国糖尿病协会和国际儿童青少年糖尿病协会共同制定的诊断标准，符合该标准以下4条中的1条即可诊断糖尿病。(1)空腹血糖≥7.0mmol/L(126mg/dl)，(2)糖耐量试验(用1.75g/kg无水葡萄糖溶于水作为糖负荷，最大不超过75g)2h血糖≥11.1mmol/L(200mg/dl)，(3)有糖尿病的三多一少症状且随机血糖≥11.1mmol/L(200mg/dl)，(4)糖化血红蛋白(HbA1c) >6.5%。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血浆葡萄糖检测", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "随机血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "糖化血红蛋白(HbA1c)", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "5级：足的大部分或足的全部感染或缺血，导致严重的湿性或干性坏疽，肢端变黑，尸干，常波及踝关节及小腿。一般多采取大截肢。", "spo_list": [{"Combined": false, "predicate": "患病病因", "subject": "足的大部分或足的全部感染或缺血", "subject_type": "患病病因", "object": {"@value": "湿性或干性坏疽"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "肢端变黑", "subject_type": "临床表现", "object": {"@value": "湿性或干性坏疽"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "尸干", "subject_type": "临床表现", "object": {"@value": "湿性或干性坏疽"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "踝关节", "subject_type": "患病部位", "object": {"@value": "湿性或干性坏疽"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "小腿", "subject_type": "患病部位", "object": {"@value": "湿性或干性坏疽"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "近年来，随着检查技术的进步，DPN的诊断率有所提高。目前的评估主要依据患者临床症状和体征。5项检查(踝反射、针刺痛觉、震动觉、压力觉、温度觉)等方法半定量评估患者的神经病变程度。本共识建议基层医疗卫生机构配置神经病变筛查工具，条件允许的情况下可考虑配备感觉阈值测定仪，用以评估DPN。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "踝反射", "subject_type": "检查方法", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "针刺痛觉", "subject_type": "检查方法", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "震动觉", "subject_type": "检查方法", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "压力觉", "subject_type": "检查方法", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "温度觉", "subject_type": "检查方法", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)采用预混胰岛素每日2次治疗方案时，不建议同时使用胰岛素促泌剂(主要不良反应与胰岛素一致，为低血糖和体重增加)；", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "每日2次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "超重或肥胖、腹型肥胖可增加胰岛素抵抗(IR)，使ASCVD发生风险显著增加。体重控制目标包括体重指数(BMI)<24kg/m2和腰围(WC)达标(男<90cm，女<85cm)。不同降糖药对体重和内脏脂肪的影响存在差异，胰岛素、磺脲类药物(SUs)及噻唑烷二酮类(TZDs)可导致体重增加；二甲双胍可减轻体重，对内脏脂肪的影响尚不明确；胰升糖素样肽1(GLP-1)受体激动剂和钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂既可减轻体重，又可减少内脏脂肪。因此，对于合并超重或肥胖(尤其是腹型肥胖)的T2DM患者，应优先考虑使用兼具减轻体重和减少内脏脂防的降糖药物。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "腹型", "subject_type": "分期分型", "object": {"@value": "腹型肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "超重", "subject_type": "患病病因", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "肥胖", "subject_type": "患病病因", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗(IR)", "subject_type": "发病机制", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "磺脲类药物(SUs)"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "噻唑烷二酮类(TZDs)"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "腹型", "subject_type": "分期分型", "object": {"@value": "腹型肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "由于儿童青少年肥胖日益增多，临床表现的重叠，区分1型糖尿病或2型糖尿病变得越来越困难，同时全国各地儿童青少年2型糖尿病的发病特征、诊疗经验及统计数据各有不同，儿童青少年2型糖尿病诊治、管理面临众多挑战。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.促进尿酸排泄药物：若使用促排尿酸药物(包括苯溴马隆、丙磺舒)降低患者血尿酸水平，在治疗开始前和治疗过程中，要特别注意多饮水和使用碱化尿液的药物。若患者24h尿尿酸的排出量已经增加(>3.54mmol)或有泌尿系尿酸结石则应禁用此类药物，在溃疡病或肾功能不全者慎用。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "泌尿系", "subject_type": "患病部位", "object": {"@value": "泌尿系尿酸结石"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "五、糖尿病足的诊断 ", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.超重或肥胖T2DM患者的首选用药：回顾性和前瞻性的临床研究结果均显示，二甲双胍在正常体重、超重、肥胖的T2DM患者中的疗效相当，", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(4)特殊情况：①目前所有磺脲类药物说明书均将重度肝功能不全列为禁忌证。丙氨酸氨基转移酶(ALT)>8~10倍参考值上限或ALT>3倍参考值上限且血清总胆红素(TBIL)>2倍参考值上限提示重度肝损害，应禁用磺脲类药物。②肾功能不全者禁用格列本脲，格列吡嗪、格列齐特、格列美脲可用于轻度肾功能不全患者，格列喹酮则可用于轻、中度肾功能不全患者。医生需要根据肾功能情况来确定如何调整治疗，见表2。③老年患者应重点考虑药物的低血糖风险，若既往有严重低血糖史、预期生存期较短或合并其他严重疾病，宜选择降糖作用较温和、作用时间较短、低血糖风险小的磺脲类药物，避免使用格列本脲。无论选择何种磺脲类药物，都应从最小剂量开始，严密监测血糖变化，根据血糖逐步调整至合适剂量，将低血糖发生风险降至最小。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "丙氨酸氨基转移酶(ALT)", "subject_type": "检查指标", "object": {"@value": "肝损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "ALT", "subject_type": "检查指标", "object": {"@value": "肝损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血清总胆红素(TBIL)", "subject_type": "检查指标", "object": {"@value": "肝损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列吡嗪", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列齐特", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列美脲", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "高脂血症不仅直接参与糖尿病胰岛素抵抗和心血管并发症的发生，低密度脂蛋白胆固醇(LDL-C)还可以通过作用于肾小球系膜细胞上的LDL受体，导致系膜细胞和足细胞的损伤，加重蛋白尿和肾小球及肾小管间质纤维化的进展。糖尿病患者出现肾病综合征和肾功能不全，又会进一步加重高脂血症。因此，积极纠正糖尿病肾病患者体内脂代谢紊乱，亦对糖尿病肾病具有重要意义。", "spo_list": [{"Combined": false, "predicate": "发病机制", "subject": "低密度脂蛋白胆固醇(LDL-C)还可以通过作用于肾小球系膜细胞上的LDL受体", "subject_type": "发病机制", "object": {"@value": "高脂血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "系膜细胞和足细胞的损伤", "subject_type": "发病机制", "object": {"@value": "高脂血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "加重蛋白尿和肾小球及肾小管间质纤维化的进展", "subject_type": "发病机制", "object": {"@value": "高脂血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病综合征"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "推荐2：中国T2DM患者合并血脂异常的比例高，治疗率、达标率低，临床上应加强对T2DM患者的血脂管理。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "优化的降糖治疗不仅只针对胰岛素分泌缺陷，还应同时关注其他发病机制(如胰岛素抵抗、能量摄取等)。胰岛素促泌剂与其他作用机制互补的药物联用，可多方面干预糖尿病发病环节，使患者血糖得到长期、有效、平稳及安全的控制。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "对于合并HUA的心衰患者，首选非噻嗪类利尿剂，同时摄取适量的水分并碱化尿液；另外，因噻嗪类利尿剂可能增加别嘌醇发生超敏反应的风险，尽量避免二者同时使用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "非噻嗪类利尿剂", "subject_type": "药品名称", "object": {"@value": "心衰"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心衰"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "超敏反应", "subject_type": "不良反应", "object": {"@value": "别嘌醇"}, "object_type": {"@value": "药品名称"}}]}
{"text": "3.对于糖尿病的预防作用：二甲双胍是第一个被证明能预防糖尿病或延缓糖尿病发生的药物。二甲双胍能有效地降低糖尿病前期人群发生T2DM的风险，且具有良好的耐受性和长期的有效性。但在我国预防糖尿病尚不是二甲双胍的适应证。DPP研究显示，二甲双胍干预治疗3年可使糖尿病的发生率降低31%，且在中年腹型肥胖的患者中干预效果最佳(Ⅰ级)。IDPP研究显示，二甲双胍单独或与强化生活方式干预联合应用均能降低发生糖尿病的危险(Ⅱ级)。2012年IDF全球T2DM指南推荐，预防糖尿病最好选择生活方式干预，对于IFG、年龄<60岁的肥胖人群，可给予二甲双胍干预。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病前期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "腹型肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "腹型", "subject_type": "分期分型", "object": {"@value": "腹型肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "IFG"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "前期", "subject_type": "分期分型", "object": {"@value": "糖尿病前期"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.HUA与代谢综合征：代谢综合征是以肥胖高血压，高血糖、血脂异常等多种心血管疾病的危险因素同时存在于一个体的临床症候群，是一组在代谢上相互关险因素的组合，这些因素直接促进了动脉粥样硬化性血管疾病的发生，也增加了发生2型糖尿病的风险。多项研究显示，HUA与代谢综合征存在密切的联系，亦有学者将HUA作为代谢综合征的组分之一。胰岛素抵抗是代谢综合征的共同病理生理基础。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "动脉", "subject_type": "患病部位", "object": {"@value": "动脉粥样硬化性血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "代谢综合征"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2016年6月，美国FDA修改坎格列净和达格列净的药物说明书，新增急性肾损伤风险的标签警示信息，建议处方这两种药物之前全面考虑增加急性肾损伤风险的各种因素，并在服药期间监测肾功能的动态变化。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "急性肾损伤", "subject_type": "不良反应", "object": {"@value": "坎格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "急性肾损伤", "subject_type": "不良反应", "object": {"@value": "达格列净"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "急性肾损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "急性", "subject_type": "分期分型", "object": {"@value": "急性肾损伤"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "6.肾功能不全的T2DM患者使用注意事项：二甲双胍本身不会对肾功能有影响，但临床存在仅根据蛋白尿就停用二甲双胍的使用误区。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(4)苯氧芳酸类：能增强脂蛋白酯酶的活性，加速VLDL分解代谢，并能抑制肝脏中VLDL的合成与分泌，可降低TG22%~43%、TC6%~15%，并有不同程度升高高密度脂蛋白胆固醇(HDL-C)的作用。有证据显示贝特类药物将会升高增加心血管事件风险的血清肌酐和同源半胱氨酸(Hcy)水平。肾功能减退的糖尿病患者应根据其GFR水平减少非诺贝特、吉非贝齐及苯扎贝特等贝特类药物，并在严重的肾功能不全患者中禁用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "贝特类药物", "subject_type": "药品名称", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血清肌酐", "subject_type": "检查指标", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "同源半胱氨酸(Hcy)", "subject_type": "检查指标", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾功能", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "非诺贝特", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "吉非贝齐", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "苯扎贝特", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝特类药物", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.2.4 中药制剂一些具有活血化瘀作用的植物药及中药制剂也常被用于糖尿病微循环障碍的治疗，如银杏叶制剂、复方丹参滴丸、三七制剂等。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "银杏叶制剂", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "复方丹参滴丸", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "三七制剂", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "微循环障碍", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "◆糖苷醇抑制剂：此类药物可降低HbA1c，0.5%~0.8%。同时，此类药物不增加体重且有减轻体重的趋势。主要代表药物有阿卡波糖、伏格列波糖和米格列醇。阿卡波糖口服后很少部分被吸收，随着肾功能的降低，药物本身及其代谢产物的血药浓度增加显著。阿卡波糖可用于慢性肾脏病1~3期患者：4~5期禁用。伏格列波糖可用于慢性肾脏病1~3期患者；4~5期慎用。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "阿卡波糖"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿卡波糖", "subject_type": "药品名称", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~3期", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "4~5期", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "伏格列波糖", "subject_type": "药品名称", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~3期", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "4~5期", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "衰弱、严重感染、肝肾功能不全的患者低血糖风险增加。长期未得到有效控制的糖尿病患者可能在正常的血糖水平即发生低血糖反应。脑损伤患者难以耐受100mg/dl(5.6mmol/L)以下的血糖水平。", "spo_list": [{"Combined": false, "predicate": "患病病因", "subject": "衰弱", "subject_type": "患病病因", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "严重感染", "subject_type": "患病病因", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "肝肾功能不全", "subject_type": "患病病因", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "脑损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脑", "subject_type": "患病部位", "object": {"@value": "脑损伤"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.血糖控制目标值：对T2DM合并CKD患者的血糖控制目标应遵循个体化原则，尽量避免低血糖的发生。《中国成人2型糖尿病HbA1c控制目标的专家共识》建议对T2DM合并CKD患者的HbA1c可适当放宽控制在7%~9%，一方面避免血糖水平控制过低而出现低血糖，另一方面避免血糖水平过高而出现代谢异常及感染。当CKD导致红细胞寿命缩短时，HbA1c检测结果可能被低估。在晚期CKD患者，使用糖化血清蛋白反映血糖控制水平可能更可靠。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "红细胞寿命缩短", "subject_type": "发病机制", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "晚期", "subject_type": "分期分型", "object": {"@value": "晚期CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "糖化血清蛋白", "subject_type": "检查指标", "object": {"@value": "晚期CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "晚期CKD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.HUA与肾脏疾病：HUA时尿酸盐沉积在肾脏导致慢性尿酸盐肾病、急性尿酸性肾病和尿酸性肾石症；另一方面，肾脏疾病影响尿酸的排泄，发生继发性HUA，HUA又可导致／加重肾脏疾病。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "慢性尿酸盐肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "尿酸盐沉积在肾脏", "subject_type": "发病机制", "object": {"@value": "慢性尿酸盐肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "急性尿酸性肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "尿酸性肾石症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "肾脏疾病", "subject_type": "患病病因", "object": {"@value": "继发性HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "影响尿酸的排泄", "subject_type": "发病机制", "object": {"@value": "继发性HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "HUA", "subject_type": "患病病因", "object": {"@value": "肾脏疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "现有的证据表明，胰岛素促泌剂中的磺脲类药物有利于保护T2DM的心血管，没有随机双盲前瞻性长时间研究发现它增加心血管风险。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "尿酸排泄减少：特发性、肾功能不全、多囊肾病、糖尿病、尿崩症、高血压、饥饿性酮症、酸中毒(乳酸酸中毒、糖尿病酮症酸中毒)、铅中毒、铍中毒、甲状腺功能减退，甲状腺功能亢进、妊娠中毒症、巴特综合征、唐氏综合征，肉状瘤病。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "特发性、肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "多囊肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "甲状腺", "subject_type": "患病部位", "object": {"@value": "甲状腺功能减退"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "甲状腺", "subject_type": "患病部位", "object": {"@value": "甲状腺功能亢进"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.踝反射、痛觉、温度觉：这3种检查方法，也可以应用于糖尿病周围神经病变的诊断。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "踝反射", "subject_type": "检查方法", "object": {"@value": "糖尿病周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "痛觉", "subject_type": "检查方法", "object": {"@value": "糖尿病周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "温度觉", "subject_type": "检查方法", "object": {"@value": "糖尿病周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "糖尿病周围神经病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "另一方面，即使是很典型的2型糖尿病，也有可能存在胰岛细胞的自身免疫，在美国和欧洲国家，临床诊断为2型糖尿病的患者，也可有15%~40%出现自身抗体阳性。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "自身抗体", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "我国糖尿病患病率逐年升高，目前糖尿病患者约9240万，其中T2DM占90%以上。糖尿病与CKD关系密切。糖尿病患者CKD发生风险较非糖尿病者增加2.6倍。近年，各地CKD流行病学调查成年人CKD的患病率存在一定差异，为9%~14%。近期全国CKD流行病学调查显示，我国成年人中CKD患病率为10.8%，据此估算18岁以上人群CKD患者人数约1.195亿。在发达国家，糖尿病已是导致CKD的主要病因，而且在发展中国家，糖尿病正逐渐成为CKD的主要致病原因。美国流行病学调查显示，年龄≥20岁的T2DM患者有39.7%合并CKD。对我国住院糖尿病患者的回顾性研究表明，33.6%的糖尿病患者合并肾脏并发症。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "糖尿病", "subject_type": "患病病因", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "糖尿病", "subject_type": "患病病因", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "儿童青少年2型糖尿病既不同于成人2型糖尿病，也不同于儿童青少年1型糖尿病(type 1 diubetes mellitus)，有其特征：胰岛β细胞功能快速衰竭，快速出现并发症并发展迅速。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病(type 1 diubetes mellitus)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "type 1", "subject_type": "分期分型", "object": {"@value": "1型糖尿病(type 1 diubetes mellitus)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛β细胞功能快速衰竭", "subject_type": "发病机制", "object": {"@value": "1型糖尿病(type 1 diubetes mellitus)"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "②胰岛素治疗方案和剂量调整：逐步增加餐时胰岛素的治疗方案中，主餐/早餐起始4~6U餐时胰岛素后，根据下一餐前血糖值，每周调整1~2次餐时胰岛素剂量，每次调整1~2U或10%~15%直至达到下次餐前血糖目标；根据每3~6个月HbA1c结果，如需要可逐渐增加至2~3次餐时胰岛素治疗。采用基础-三餐前胰岛素治疗方案时，如果血糖水平整体偏高，可先调整基础胰岛素剂量，对于需尽快解除高血糖状态的情况，则可同时调整基础和餐时的剂量。条件允许时，在起始胰岛素治疗的早期可通过住院密切监测血糖每天调整胰岛素剂量。根据FPG，调整基础胰岛素剂量1~4U或10%~20%；根据下一餐前血糖值，调整餐时胰岛素剂量1~2U或10%。如果出现空腹或夜间低血糖(<3.9mmol/L)或低血糖症状，则可减少基础胰岛素和/或晚餐前的餐时胰岛素剂量10%~20%；如果日间两餐间出现低血糖，则减少上一餐的餐时胰岛素剂量10%~20%；如出现需他人协助的严重低血糖或随机血糖<2.2mmol/L，则减少20%~40%胰岛素剂量。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "4~6U", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "1~2次", "subject_type": "用药频率", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1~2U", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "2~3次", "subject_type": "用药频率", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1~4U", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1~2U", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "以最大限度降低患者心血管事件和死亡的风险。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "5.5 磺脲类药物会加速β细胞功能衰退吗? ", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "β细胞功能衰退", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "3.降低PPG与改善心血管疾病危险因素相关：控制PPG与改善多种心血管疾病危险因素有关，如TC、TG、LDL-C降低和HDL-C升高；血压、高凝状态及炎症因子均降低；CIMT进展减慢等。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "PPG", "subject_type": "检查指标", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "PPG", "subject_type": "检查指标", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "TC", "subject_type": "检查指标", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "TG", "subject_type": "检查指标", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HDL-C", "subject_type": "检查指标", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "高凝状态", "subject_type": "检查指标", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "炎症因子", "subject_type": "检查指标", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(二)糖尿病周围神经病的分类", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "糖尿病周围神经病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "相当，达标率相当。阿卡波糖降低餐后2h血糖的作用显著优于二甲双胍，其降低餐后胰岛素、减轻体重和降低三酰甘油的作用也优于二甲双胍。二甲双胍是新诊断2型糖尿病患者药物治疗的一线选择，但如果患者以餐后血糖升高为主要特点时，可考虑首选阿卡波糖。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "餐后血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿卡波糖", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.1 糖尿病微血管并发症的筛查与预防 ", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "对于处在ASCVD急性期(如ACS、缺血性卒中急性期、冠状动脉血运重建围手术期等)的T2DM患者，其降糖治疗方案需要充分考虑疾病特点、机体应激状况以及严格降糖治疗的获益/风险比。对于合并ACS的患者，若血糖>10.0mmol/L，可采用以胰岛素为基础的降糖治疗方案，使血糖水平控制在7.8~10.0mmol/L，同时注意避免发生低血糖。对于接受经皮冠状动脉介人治疗(PCI)的患者，使用对比剂前可以不停用二甲双胍，但应密切监测肾功能，造影后应连续两日检验血清肌酐(Scr)。若Scr值比造影前上升26.5μmol/L，则应考虑对比剂肾病发生，应立即停用二甲双胍，直至肾功能恢复至基础水平，方可重新开始二甲双胍治疗。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "急性期", "subject_type": "分期分型", "object": {"@value": "ASCVD急性期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "冠状动脉血运重建", "subject_type": "临床手术", "object": {"@value": "ASCVD急性期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "急性期", "subject_type": "分期分型", "object": {"@value": "缺血性卒中急性期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "ACS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "ACS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "ACS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "Scr", "subject_type": "检查指标", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "造影", "subject_type": "检查方法", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "对比剂", "subject_type": "药品名称", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾功能", "subject_type": "检查方法", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "中国成人2型糖尿病胰岛素促泌剂应用的专家共识", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "目前肝功能不全患者使用二甲双胍的临床资料较少。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "格列喹酮对胰岛β细胞具高度选择性，对心肌细胞、血管平滑肌细胞亲和力弱，因此安全性更高。动物研究显示，格列喹酮具有抗血小板聚集的活性，抗动脉粥样硬化，改善血脂指标，对体重无影响。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "动脉粥样硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血脂", "subject_type": "检查指标", "object": {"@value": "动脉粥样硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "动脉", "subject_type": "患病部位", "object": {"@value": "动脉粥样硬化"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "②基础胰岛素联合餐时胰岛素方案：口服降糖药联合基础胰岛素治疗后，空腹血糖达标，HbA1c仍不达标者，或使用较大剂量基础胰岛素后[如0.6单位/ (千克·天)]，血糖仍不达标者；使用多次预混胰岛素治疗，血糖控制不佳者或反复发作低血糖者；需短时间内纠正高血糖的糖尿病患者。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "0.6单位/ (千克·天", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "糖尿病患者在经住院短期优化血糖控制，完善相关检查和缓解应激状态和病情之后，可在出院前修改为出院可维持的方案或维持住院治疗的方案门诊治疗。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(一)T2DM合并肥胖患者的综合控制目标见表3", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)DR：改善微循环治疗可能延缓DR的进展。①胰激肽原酶，可增加毛细血管血流量，激活纤溶酶，降低血液黏度，改善血流变；②羟苯磺酸钙，可抗氧化应激和炎症，维护视网膜屏障完整性，抑制新生血管生成，延缓DR进展；③抗血管内皮生长因子药物，包括雷珠单抗和贝伐单抗，可用于各种原因引起的黄斑水肿、视网膜新生血管等。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "改善微循环治疗", "subject_type": "非药治疗", "object": {"@value": "DR"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "羟苯磺酸钙", "subject_type": "药品名称", "object": {"@value": "DR"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "黄斑", "subject_type": "患病部位", "object": {"@value": "黄斑水肿"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "抗血管内皮生长因子药物", "subject_type": "药品名称", "object": {"@value": "黄斑水肿"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "雷珠单抗", "subject_type": "药品名称", "object": {"@value": "黄斑水肿"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝伐单抗", "subject_type": "药品名称", "object": {"@value": "黄斑水肿"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "视网膜新生血管"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "抗血管内皮生长因子药物", "subject_type": "药品名称", "object": {"@value": "视网膜新生血管"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "雷珠单抗", "subject_type": "药品名称", "object": {"@value": "视网膜新生血管"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝伐单抗", "subject_type": "药品名称", "object": {"@value": "视网膜新生血管"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "SGLT-2抑制剂在中度肾功能不全患者可减量使用，起始治疗前需检测肾功能，根据肾功能确认是否可以起始，治疗中每年至少监测一次肾功能，如同时予以影响肾功能的药物，起始前也需监测肾功能，当肾功能逐渐下降并趋向于中度肾功能不全时，则需每年监测2~4次肾功能。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "SGLT-2抑制剂", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "检测肾功能", "subject_type": "检查方法", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "监测2~4次肾功能", "subject_type": "检查方法", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "家进行的一项443例T2DM患者参加的多中心、随机、对照研究显示，对于既往未接受胰岛素治疗的T2DM患者，格列美脲联合甘精胰岛素可进一步降低HbA1c达0.99%，HbA1c达标率为38.1%，空腹血糖降低幅度为5.89mmol/L，与格列美脲联合重组人胰岛素(NPH)组无差异，平均日间血糖降低幅度优于NPH组(-5.22mmol/L vs -4.44mmol/L)，总体低血糖发生682/220(次数/例数)，症状性低血糖为515/220(次数/例数)，严重低血糖为5/220(次数/例数)。接受磺脲类药物联合基础胰岛素治疗的患者应特别注意饮食和运动量，以及体重增加和低血糖。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "格列美脲", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列美脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "症状性低血糖", "subject_type": "不良反应", "object": {"@value": "格列美脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "严重低血糖", "subject_type": "不良反应", "object": {"@value": "格列美脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "甘精胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "甘精胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "症状性低血糖", "subject_type": "不良反应", "object": {"@value": "甘精胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "严重低血糖", "subject_type": "不良反应", "object": {"@value": "甘精胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "基础胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "基础胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "促进尿酸排泄的药物：醋酸己脲、促肾上腺皮质激素、维生素C、尿苷、甲氯芬那酸、酚红、苯基丁氮酮、丙磺舒，射线造影剂、阿司匹林(>2g／d)、磺吡酮、糖皮质激素、愈创木酚甘油醚、格隆溴铵、降脂酰胺、氯沙坦、降钙素、利血平、枸襻酸、双香豆素、二氟尼柳、雌激素、非诺贝特、氯苯锉胺。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": ">2g／d", "subject_type": "用药剂量", "object": {"@value": "阿司匹林"}, "object_type": {"@value": "药品名称"}}]}
{"text": "近年来，T2DM合并CKD患者中口服降糖药治疗证据不断丰富，国外糖尿病及肾脏病权威指南规范了口服降糖药的应用，但我国尚缺乏T2DM合并CKD用药指南或共识。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "必须注意：作为诊断的HbA1c检测应该采用美国HbA1c标准化计划组织(NGSP)或糖尿病控制和并发症研究(DCCT)认证的方法进行。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "尿酸性肾石症患者尿液pH值常低于6.0，尿沉渣检查可见尿酸盐结晶。肾脏B超可见高回声区伴声影。尿酸性结石X线摄片不显影(阴性结石)，阴性结石需与肾脏黄嘌呤、次黄嘌呤结石鉴别，后两者在碱性环境中不能溶解。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "肾脏B超", "subject_type": "检查方法", "object": {"@value": "尿酸性肾石症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏黄嘌呤、次黄嘌呤结石"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2型糖尿病患者的糖尿病肾病可参考以上标准分期。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.1 肝功能不全的T2DM患者是否可以使用磺脲类药物? ", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "自身抗体是区分1型糖尿病和2型糖尿病较为准确的方法，但由于检测方法不一，不同人群抗体谱不一，不能检测到所有参与自身免疫的抗体等因素，使其临床价值受限。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "自身抗体", "subject_type": "检查指标", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "自身抗体", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "建议：格列喹酮治疗老年2型糖尿病患者低血糖发生率较低，且调整剂量方便，推荐作为老年2型糖尿病患者磺脲类药物的优先选择之一。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列喹酮"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.口服降糖药的选择：口服降糖药是临床最常用的降糖手段，对于2型糖尿病合并慢性肾脏病患者的血糖控制不可或缺。然而,口服降糖药种类繁多，各类药物的药代动力学差异显著，加之慢性肾脏病患者对经肾排泄的药物或其活性代谢产物的清除能力下降，这使得对口服降糖药物使用不当将不同程度地增加低血糖以及其它不良事件的风险。因此临床工作中，必须充分了解各种降糖药物的药代和药效动力学特点，结合患者肾功能情况进行个体化选择，确保有效降糖的同时不增加低血糖风险。一般而言，当GFR低于60ml.min-1.(1.73m2)-1时大多数口服降糖药物需酌情减量或停药。常用口服降糖药的药代动力学特征、其在2型糖尿病合并慢性肾脏病人群中应用的临床证据以及适用人群见图1及表3。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "慢性肾脏病是严重威胁人类健康的常见慢性病，病因多种多样，由糖尿病所引发的慢性肾脏病称为糖尿病肾脏病变。2型糖尿病常合并慢性肾脏病，高血糖是慢性肾脏病发生和发展的主要原因之一.因此良好控制血糖至关重要。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "糖尿病", "subject_type": "患病病因", "object": {"@value": "糖尿病肾脏病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "糖尿病", "subject_type": "患病病因", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "糖尿病肾脏病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "高血糖", "subject_type": "患病病因", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.通过眼底检查、尿液白蛋白/肌酐比值测定、颈动脉B超检查等进行糖尿病合并症的早期筛查：了解是否存在糖尿病的血管并发症，评估心脑血管病变风险。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "眼底检查", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿液白蛋白/肌酐比值", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "颈动脉B超", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "血管", "subject_type": "患病部位", "object": {"@value": "血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心脑血管", "subject_type": "患病部位", "object": {"@value": "心脑血管病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "第二步：糖尿病分型。儿童糖尿病中1型糖尿病占89.6%，2型糖尿病仅占7.4%，因此，儿童在糖尿病分型时，首先考虑为1型糖尿病，有如下线索者提示为2型糖尿病：明确的2型糖尿病家族史、肥胖、起病缓慢、症状不明显、发病年龄较大、无需使用胰岛素治疗，或存在和胰岛素抵抗相关的表现，如黑棘皮病、高血压、血脂异常、PCOS等。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血脂", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.视网膜病变：儿童青春期开始或≥10岁，一旦糖尿病病程3~5年，应该考虑进行首次扩瞳后综合性眼科检查。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "视网膜病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "评中国成人2型糖尿病胰岛素促泌剂应用专家共识 ", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.静脉输注胰岛素的患者血糖≤100mg/dl(5.6mmol/L)应重新评估，调整泵速。血糖≤70mg/dl(3.9mmol/L)立即停用胰岛素，开始升血糖处理。可进食的清醒患者立即口服10~25g快速吸收的碳水化合物(如含糖饮料)，不能口服的静脉推注50%葡萄糖20~50rnl，之后持续静脉点滴5%或10%葡萄糖维持血糖，每5~15分钟监测一次直至血糖≥100mg/dl(5.6mmol/L)。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "静脉输注", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "20~50rnl", "subject_type": "用药剂量", "object": {"@value": "50%葡萄糖"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "持续", "subject_type": "持续时间", "object": {"@value": "5%或10%葡萄糖"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉点滴", "subject_type": "用药方法", "object": {"@value": "5%或10%葡萄糖"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(三)老年T2DM", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "老年T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "基础胰岛素： 《成人2型糖尿病基础胰岛素临床应用中国专家指导建议》 ", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.儿童和青少年糖尿病及糖尿病前期患儿使用注意事项：无需以胰岛素作为起始治疗的10岁及以上T2DM患儿，应立即开始给予生活方式干预，不达标者以二甲双胍作为起始治疗药物。10岁及以上的糖尿病前期(IFG或lGT)患儿经3个月有效的生活方式干预(饮食控制、150min/周运动，减轻体重5%~10%)后，代谢异常指标仍无法逆转，建议使用二甲双胍治疗，起始剂量500mg，3次/d，最大剂量2000mg/d(V级)。二甲双胍可用于10岁及以上的T2DM的儿童或青少年，且最高剂量不超过2000mg/d，不推荐用于10岁以下的儿童。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食控制", "subject_type": "非药治疗", "object": {"@value": "糖尿病前期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "150min/周运动", "subject_type": "非药治疗", "object": {"@value": "糖尿病前期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "减轻体重5%~10%", "subject_type": "非药治疗", "object": {"@value": "糖尿病前期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病前期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "糖尿病前期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食控制", "subject_type": "非药治疗", "object": {"@value": "IFG"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食控制", "subject_type": "非药治疗", "object": {"@value": "lGT"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "150min/周运动", "subject_type": "非药治疗", "object": {"@value": "IFG"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "150min/周运动", "subject_type": "非药治疗", "object": {"@value": "lGT"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "减轻体重5%~10%", "subject_type": "非药治疗", "object": {"@value": "IFG"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "减轻体重5%~10%", "subject_type": "非药治疗", "object": {"@value": "lGT"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "3次/d", "subject_type": "用药频率", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "IFG"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "lGT"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "500mg", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "IFG"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "lGT"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "格列吡嗪和格列齐特的代谢产物均无降糖活性，虽然主要经肾脏排泄，但低血糖风险小于格列本脲和格列美脲。推荐格列吡嗪用于慢性肾脏病1~2期患者无需调整剂量；3期减量，4~5期禁用。格列齐特用于慢性肾脏病1~2期患者无需调整剂量；在3a期减量，3b期需谨慎用药；4~5期禁用。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列吡嗪"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列齐特"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列本脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列美脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列吡嗪", "subject_type": "药品名称", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~2期", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3期", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "4~5期", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列齐特", "subject_type": "药品名称", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~2期", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3a期", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3b期", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "4~5期", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.糖化血红蛋白HbA1c反映采血前三个月的平均血糖水平，可用于术前筛查糖尿病和评价血糖控制效果。对既往无糖尿病病史者，如果年龄≥45岁或体重指数BMI≥25kg/m2，同时合并高血压、高血脂、心血管疾病、糖尿病家族史等高危因素，行心脏外科、神经外科、骨科、创伤外科、器官移植等高危手术者，推荐术前筛查HbA1c；HbA1c≥6.5%即可诊断糖尿病。既往已有明确糖尿病病史的患者，HbA1c≤7%提示血糖控制满意，围术期风险较低；HbA1c>8.5%者建议考虑推迟择期手术。单纯应激性高血糖者HbA1c正常。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "糖化血红蛋白HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "采血", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "器官移植", "subject_type": "临床手术", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "应激性", "subject_type": "分期分型", "object": {"@value": "应激性高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "应激性高血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "◆噻唑烷二酮类：此药为胰岛素增敏剂，可降低HbA1c1.0%~1.5%。此类药物包括毗格列酮和罗格列酮；二者均经肝脏代谢，不增加低血糖风险。此类药物的常见不良反应是体重增加、水钠潴留和心力衰竭[纽约心脏学会(NYHA)功能分级2级以上]患者禁用。此外，绝经后妇女服用该类药物增加骨折和骨质疏松风险，因此慎用于潜在骨疾病的患者(如肾性骨营养不良)。吡格列酮用于慢性肾脏病1~3a期患者时，无需调整剂量；3b~5期患者用药经验有限，需谨慎用药。肾功能损伤的患者可以单用罗格列酮，无需调整剂量。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "肾性", "subject_type": "分期分型", "object": {"@value": "肾性骨营养不良"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "骨", "subject_type": "患病部位", "object": {"@value": "肾性骨营养不良"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "吡格列酮", "subject_type": "药品名称", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~3a", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3b~5期", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "罗格列酮", "subject_type": "药品名称", "object": {"@value": "肾功能损伤"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "速效胰岛素类似物常与基础胰岛素联合使用，较少单独三餐前皮下注射，除非患者空腹血糖不高而餐后血糖明显升高，而且必须使用胰岛素治疗，如妊娠糖尿病患者或严重肝肾功能异常的糖尿病患者。此外，胰岛素泵只能采用速效胰岛素类似物或短效人胰岛素；速效胰岛素类似物静脉使用没有优势，故不推荐。三种速效胰岛素类似物尽管在药代动力学和药效学方面有一定的差别，但在对餐后血糖的总体控制、严重低血糖发生率等方面并没有显著差别，三种速效胰岛素类似物在胰岛素泵中的应用优势也类似。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "皮下注射", "subject_type": "用药方法", "object": {"@value": "速效胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "皮下注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "妊娠糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉", "subject_type": "用药方法", "object": {"@value": "速效胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "速效胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "速效胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝肾功能异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肝肾功能异常"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.门诊手术术后监测直至排除低血糖风险后方可离院。皮下注射速效胰岛素1.5小时内、常规胰岛素3~4小时内有发生低血糖的危险。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "皮下注射", "subject_type": "用药方法", "object": {"@value": "速效胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "皮下注射", "subject_type": "用药方法", "object": {"@value": "常规胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "速效胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "1.5小时", "subject_type": "持续时间", "object": {"@value": "速效胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "常规胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "3~4小时", "subject_type": "持续时间", "object": {"@value": "常规胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "帕金森病是好发于中老年人的一种常见中枢神经系统退行性疾病，血尿酸水平高的人群发生帕金森病风险较低。血尿酸水平升高有助于减少帕金森病率和延缓其进展。伴血尿酸水平高或痛风的男性患者发生帕金森病的风险相对较低，女性则无明显相关性。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血尿酸水平", "subject_type": "检查指标", "object": {"@value": "帕金森病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸水平", "subject_type": "检查指标", "object": {"@value": "帕金森病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸水平", "subject_type": "检查指标", "object": {"@value": "帕金森病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "钠-葡萄糖共转运蛋白2抑制剂是一种非常特殊的口服降糖药物，说它特殊是因为，与其他降糖药物都不同的是，它并没有从胰腺、胃肠道等调节血糖的内分泌器官入手，而是作用于葡萄糖的排泄器官一肾脏，通过让更多葡萄糖经肾脏从尿液排出体外来达到降低血糖的效果。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "钠-葡萄糖共转运蛋白2抑制剂"}, "object_type": {"@value": "药品名称"}}]}
{"text": "SGLT2i是一类全新的口服降糖药物。该类药物降糖疗效确切，无低血糖风险，减轻体重、降低血压，可能有心血管及DN保护作用，满足了当前糖尿病治疗中部分未被满足的需求。未来几年内.目前正在进行中的CANVAS、CANVAS-R、CRE-DENCE、DECLARE-TIMI等大规模长期临床研究將提供更多的数据。我们希望临床医师在使用SGLT2i治疗T2DM前充分了解该类药物的特性，在临床应用中尚需根据每个患者的情况，平衡获益与风险，遵照说明书正确使用.确保给患者带来最大程度的治疗获益。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "SGLT2i"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "前者包括主观症状的改善，如疼痛缓解或减轻程度，肢体发冷感觉改善情况等；后者包括ABI，溃疡面愈合情况，截肢平面的降低等。对于糖尿病下肢缺血患者，只要有一项指标得到改善就视为临床成功。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "下肢", "subject_type": "患病部位", "object": {"@value": "下肢缺血"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "由于尿白蛋白和GFR对糖尿病肾病的重要性，对这两项的检测是目前糖尿病肾病的筛检项目，一旦确诊糖尿病，应每年都进行筛检：(1)所有2型糖尿病患者应从确诊时和1型糖尿病患者病程超过5年时每年检查1次以评估UAE/AER。(2)所有成人糖尿病患者，不管UAE/AER如何，每年应至少检查1次血清肌酐，并用血清肌酐估计GFR。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "尿白蛋白", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "UAE/AER", "subject_type": "检查指标", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "UAE/AER", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血清肌酐", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血清肌酐", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病及其慢性并发症可导致患者肾功能衰竭、失明、截肢和心脑血管事件，致残率和致死率高，给患者的健康和生命造成了严重威胁。微障碍是糖尿病慢性并发症发生的重要病理生理基础之一，在控制血糖的同时改善微循环障碍，对于预防、延缓、治疗糖尿病各种慢性并发症具有十分重要的意义。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心脑血管", "subject_type": "患病部位", "object": {"@value": "心脑血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "微障碍", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(3)HUA与心衰：血尿酸水平增高与慢性心衰严重程度相关，并随纽约心脏病学会心功能分级(NYHA分级)加重而增加，血尿酸水平增高是慢性心衰患者预后不佳的独立预测因子。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心衰"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸水平", "subject_type": "检查指标", "object": {"@value": "慢性心衰"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "慢性心衰"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸水平", "subject_type": "检查指标", "object": {"@value": "慢性心衰"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "慢性心衰"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "苯溴马隆：成人起始剂量25～50mg／d，2～5周后根据血尿酸水平调整剂量至75mg／d或100mg／d，早餐后服用；可用于轻中度肾功能异常或肾移植患者，eGFR20～60ml·min-1·1.73m-2患者推荐50mg／d；eGFR<20~60ml·min-1·1.73m-2或尿酸性肾石症患者禁用。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "25～50mg／d", "subject_type": "用药剂量", "object": {"@value": "苯溴马隆"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "75mg／d", "subject_type": "用药剂量", "object": {"@value": "苯溴马隆"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "100mg／d", "subject_type": "用药剂量", "object": {"@value": "苯溴马隆"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "轻中度肾功能异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "尿酸性肾石症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.4 糖尿病足糖尿病患者因周围神经病变与外周血管疾病合并过高的机械压力，可引起足部过高的机械压力，从而导致足部软组织及骨关节系统的破坏与畸形形成。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足部软组织", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "骨关节", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足部", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "外周血管", "subject_type": "患病部位", "object": {"@value": "外周血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "对于噻唑烷二酮类与α-葡萄糖苷酶抑制剂这两类口服降糖药物，目前国内糖尿病相关专业组织尚未发布专门的临床指南或共识，不过据悉，吡格列酮临床应用的专家共识很快将会发布，届时我们再进行介绍。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "噻唑烷二酮类", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "噻唑烷二酮类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "α-葡萄糖苷酶抑制剂", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "α-葡萄糖苷酶抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "吡格列酮", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "贝特类最常见的不良反应为胃肠道不适，多为轻微的恶心、腹泻和腹胀等。另外，偶见皮肤强痒、荨麻疹、皮疹、脱发、头痛、失眠和性欲减退等。长期服用贝特类时，需要警惕药物引起的肝、肾功能损害，因此在治疗开始后半个月应该监测肝、肾功能；个别患者服药后可能发生药物性横纹肌溶解症，若有上述症状，则应该立即检测血CK水平。另外，贝特类可使胆结石的发生率升高，个别患者服药后白细胞、红细胞和嗜酸性粒细胞可能减少，因此若有相应的症状和体征，应该进行相应的监测。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "胃肠道不适", "subject_type": "不良反应", "object": {"@value": "贝特类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "轻微的恶心", "subject_type": "不良反应", "object": {"@value": "贝特类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "腹泻", "subject_type": "不良反应", "object": {"@value": "贝特类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "腹胀", "subject_type": "不良反应", "object": {"@value": "贝特类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "肝、肾功能损害", "subject_type": "不良反应", "object": {"@value": "贝特类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "半个月", "subject_type": "持续时间", "object": {"@value": "贝特类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "药物性横纹肌溶解症", "subject_type": "不良反应", "object": {"@value": "贝特类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胆结石的发生率升高", "subject_type": "不良反应", "object": {"@value": "贝特类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "白细胞、红细胞和嗜酸性粒细胞可能减少", "subject_type": "不良反应", "object": {"@value": "贝特类"}, "object_type": {"@value": "药品名称"}}]}
{"text": "6.肾功能不全的T2DM患者使用二甲双胍应注意的问题：二甲双胍本身不会对肾功能有影响，但临床存在仅根据蛋白尿就停用二甲双胍的使用误区。建议根据患者eGFR水平调整二甲双胍剂量。eGFR≥60ml/(min·1.73m2)无需调整剂量，eGFR 45~59ml/(min·1.73m2)减量，eGFR<45ml/(min·1.73m2)禁用(V级)。2015年，ADA/EASD立场声明，建议放宽二甲双胍用于中度肾功能不全T2DM患者的限制，仅在eGFR<30ml/(min·1.73m2)患者中禁用。2016年，ADA糖尿病指南指出，已有累积观察性数据显示，二甲双胍用于eGFR在30~45ml/(min·1.73m2)的患者依然安全。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "中度肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "中度肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "eGFR", "subject_type": "检查指标", "object": {"@value": "中度肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "eGFR", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "eGFR", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "应对患者表达充分尊重，仔细倾听并建立信任，通过健康教育提高其对肥胖加重疾病危险性的认识，不应忽略任何细微进步，给予及时、适当的奖励和称赞，这对于肥胖儿童的管理尤其重要。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "健康教育", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "在本世纪初的住院患者血糖管理中，重点关注降低高血糖，倾向于较低的血糖控制目标，而这种治疗模式导致低血糖的风险明显增加。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "欧洲版二甲双胍说明书中已删除慢性心力衰竭的禁忌证。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "慢性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "慢性心力衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.口服降糖药的选择：口服降糖药作为临床最常用的降糖手段，对于T2DM合并CKD患者的血糖控制具有重要意义。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "UKPDS的结果显示，接受格列本脲和氯磺丙脲治疗的患者β细胞胰岛素分泌功能有下降趋势，但与采用二甲双胍治疗和单纯饮食控制相似(2b级)。糖尿病进展实验(ADOPT)对比了3种不同类型降糖药物(罗格列酮、格列本脲和二甲双胍)在新诊断2型糖尿病患者中的疗效，对该研究分析发现，格列本脲组在治疗早期对β细胞胰岛素分泌功能显著优于罗格列酮和二甲双胍(2b级)。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "罗格列酮", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列本脲", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "三、T2DM者血脂检测时机及监测频率", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "血脂检测", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "推荐17：长期服用他汀类药物可能引起血糖异常和增加新发糖尿病的风险。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "血糖异常", "subject_type": "不良反应", "object": {"@value": "他汀类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "新发糖尿病", "subject_type": "不良反应", "object": {"@value": "他汀类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "T2DM患者的血脂管理均应以生活方式干预为基础(表2)，并贯穿T2DM治疗的全过程(推荐；A级证据)。生活方式干预不仅有助于降低胆固醇水平，还可对血压、血糖以及整体心血管健康状况产生有益的影响，因此是糖尿病患者血脂管理的基础。一些轻度血脂异常的T2DM患者，经有效生活方式干预可将其血脂参数控制在理想范围。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "胆固醇水平", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血压", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂参数", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "上述检测方法被认为比微量白蛋白尿能更早地发现糖尿病肾病，可能作为糖尿病肾病早期诊断的工具，但其可靠性、特异性、敏感性仍需更多研究证实，目前尚未作为诊断依据。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "由于老年患者常常合并多种并发疾病，DPP-4i具有良好的血糖控制效果和安全性，推荐DPP-4i用于老年2型糖尿病患者的降糖治疗。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "DPP-4i", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)糖皮质激素的使用：糖皮质激素在使用时需考虑其在体内作用时间对高血糖的影响。可使用中效或长效胰岛素控制血糖。同样床旁血糖监测非常重要，根据血精监测结果调整胰岛素的使用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "糖皮质激素", "subject_type": "药品名称", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "①GLP-1受体激动剂不能替代胰岛素，不适用于1型糖尿病患者或糖尿病酮症酸中毒的治疗。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病酮症酸中毒"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.术后因疼痛应激、感染、肠内外营养液输注，是血糖波动的高危时期，也是血糖管理的重要时期。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "输注", "subject_type": "用药方法", "object": {"@value": "肠内外营养液"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(3)急、危重症的处理：①妊娠期低血糖：常见诱因包括：早孕反应(如晨起恶心)引起的摄食异常；运动量过大；胰岛素剂量过大；围产期能量清耗过大。治疗原则：迅速给予糖水或碳水化合物食物；重症者需用50%葡萄糖静脉注射；如需要，可为糖尿病孕妇提供胰升糖素；寻找诱因，及时调整药物治疗。②妊娠期DKA：孕期血糖控制不良容易并发酮症甚至DKA，常见诱因包括：妊娠期间漏诊、未及时诊断或治疗的糖尿病：胰岛素治疗不规范；饮食控制不合理；产程中和手术前后应激状态；合并感染；使用糖皮质激素等。", "spo_list": [{"Combined": false, "predicate": "患病病因", "subject": "早孕反应(如晨起恶心)引起的摄食异常", "subject_type": "患病病因", "object": {"@value": "妊娠期低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "运动量过大", "subject_type": "患病病因", "object": {"@value": "妊娠期低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "胰岛素剂量过大", "subject_type": "患病病因", "object": {"@value": "妊娠期低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "围产期能量清耗过大", "subject_type": "患病病因", "object": {"@value": "妊娠期低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉注射", "subject_type": "用药方法", "object": {"@value": "50%葡萄糖"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰升糖素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "妊娠期间漏诊、未及时诊断或治疗的糖尿病", "subject_type": "患病病因", "object": {"@value": "妊娠期DKA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "胰岛素治疗不规范", "subject_type": "患病病因", "object": {"@value": "妊娠期DKA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "饮食控制不合理", "subject_type": "患病病因", "object": {"@value": "妊娠期DKA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "产程中和手术前后应激状态", "subject_type": "患病病因", "object": {"@value": "妊娠期DKA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "合并感染", "subject_type": "患病病因", "object": {"@value": "妊娠期DKA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "使用糖皮质激素", "subject_type": "患病病因", "object": {"@value": "妊娠期DKA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "酮症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "DKA"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "高龄、有严重合并症、频繁发作低血糖的患者，血糖目标值也可适当放宽。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "维格列汀用于GFR≥50ml/(min·1.73m2)的CKD患者时无需调整剂量，当GFR<50ml/(min·1.73m2)时禁用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "维格列汀", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)ACEI：ACEI主要药理作用是抑制血浆及组织中的血管紧张素转换酶，减少血管紧张素II的生成，减少血管收缩和醛固酮的分泌。在用药过程中需要注意观察患者肾功能及血钾的变化，对伴有肾动脉狭窄的患者要慎用或禁用。有报道显示该药物在妊娠早期可能对胎儿有害(新生儿急性肾损伤、肺毒性作用、先天心血管系统畸形、中枢神经系统畸形、肾脏畸形、头颅发育不全等)。培哚普利在糖尿病及肾功能减退患者中无不良代谢作用，但在透析中可被清除，中重度肾功能损害患者应根据肾小球滤过率变化调整剂量，起始剂量2mg/d，最大剂量不超过8mg/d，在透析患者中培哚普利清除率同肾功能正常患者。卡托普利在肾功能严重减退患者中应谨慎使用。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾动脉", "subject_type": "患病部位", "object": {"@value": "肾动脉狭窄"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "培哚普利", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "培哚普利", "subject_type": "药品名称", "object": {"@value": "肾功能减退"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能减退"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肾小球滤过率", "subject_type": "检查指标", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "卡托普利", "subject_type": "药品名称", "object": {"@value": "肾功能严重减退"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能严重减退"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(三)糖尿病足感染 ", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足感染"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "◆格列奈类：格列奈类降糖药为非磺脲类胰岛素促泌剂，可降低HbA1c0.5%~2.0%，其导致低血的风险和程度低于磺脲类。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血", "subject_type": "不良反应", "object": {"@value": "格列奈类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血", "subject_type": "不良反应", "object": {"@value": "格列奈类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血", "subject_type": "不良反应", "object": {"@value": "非磺脲类胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血", "subject_type": "不良反应", "object": {"@value": "磺脲类"}, "object_type": {"@value": "药品名称"}}]}
{"text": "除维格列汀未在美国上市外，美国FDA批准上述药物的适应证均为饮食运动不能控制血糖的2型糖尿病患者，药物说明书提供单药以及多种联合治疗方案的详细资料。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "维格列汀", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食运动", "subject_type": "非药治疗", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "5.血管活性药物：半数以上的老年糖尿病患者合并动脉粥样硬化症，阿司匹林是首选，为公认对心血管有保护作用的抗血小板制剂，使用方便，每日100(75~150)mg(I)，避免空腹服用。如有纤维蛋白原增高、存在高凝状态者，或对阿司匹林不耐受者，可用硫酸氢氯吡格雷(50~75mg，1次/d)或西洛他唑(50~100mg，2次/d，下肢病变者优选)(II)。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "阿司匹林", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "动脉", "subject_type": "患病部位", "object": {"@value": "动脉粥样硬化症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿司匹林", "subject_type": "药品名称", "object": {"@value": "动脉粥样硬化症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "每日100(75~150)mg", "subject_type": "用药剂量", "object": {"@value": "阿司匹林"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿司匹林", "subject_type": "药品名称", "object": {"@value": "下肢病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "硫酸氢氯吡格雷", "subject_type": "药品名称", "object": {"@value": "下肢病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "50~75mg", "subject_type": "用药剂量", "object": {"@value": "硫酸氢氯吡格雷"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "1次/d", "subject_type": "用药频率", "object": {"@value": "硫酸氢氯吡格雷"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西洛他唑", "subject_type": "药品名称", "object": {"@value": "下肢病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "50~100mg", "subject_type": "用药剂量", "object": {"@value": "西洛他唑"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "2次/d", "subject_type": "用药频率", "object": {"@value": "西洛他唑"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢", "subject_type": "患病部位", "object": {"@value": "下肢病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2006年中国心脏调查发现，52.9%的冠心病住院患者合并糖尿病。另一方面，在全国三甲医院住院T2DM患者中，17.1%合并心血管疾病，13.2%合并脑血管疾病。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脑血管", "subject_type": "患病部位", "object": {"@value": "脑血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.病情稳定后过渡到皮下注射胰岛素。根据过渡前静脉泵速推算皮下胰岛素剂量。皮下注射和静脉泵注应有2小时左右的重叠，便于平稳过渡。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "皮下注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉泵", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "对于孕前已使用二甲双胍的多囊卵巢综合征(PCOS)患者，应权衡药物的潜在风险和可能获益，在知情同意的基础上可以考虑妊娠期间继续使用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "多囊卵巢综合征(PCOS)"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "流行病学研究显示，餐后或负荷后高血糖与多种疾病相关，但目前尚无十分充足的临床证据支持在糖尿病患者中特异性的干预餐后高血糖比干预整体血糖有更多的临床收益。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.存在周围神经病变的临床和(或)电生理的证据。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "周围神经病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.经皮氧分压(transcutaneous oxygenpressure，TcPO2)：正常人足背TcPO2>40 mmHg；如<30mmHg提示周围血液供应不足，足部易发生溃疡，或已有的溃疡难以愈合；如TcPO2<20mmHg，足溃疡几乎没有愈合的可能。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "溃疡", "subject_type": "临床表现", "object": {"@value": "周围血液供应不足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "溃疡难以愈合", "subject_type": "临床表现", "object": {"@value": "周围血液供应不足"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "在全球范围内，已完成的SGLT2i多项临床研究对该类药物的有效性与安全性进行了评价。SGLT2i降低HbA1c幅度大，约0.5%~1.0%，减轻体重1.5~3.5kg，降低SBP3~5mmHg与胰岛素联合使用时，还可减少每日胰岛素用量大约5.9~8.7U/d。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "5.9~8.7U/d", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "格列喹酮的代谢产物无降糖作用且大部分从粪便排泄，仅5.0%经肾脏排泄，受肾功能影响较小，但用于慢性肾脏病患者的大型临床研究有限。曾有研究观察格列喹酮用于GFR10~50mlmin-1.(1.73m2)-1患者，但试验设计不尽完善。格列喹酮可用于慢性肾脏病1~3期的患者且无需调整剂量；4期需谨慎用药；5期禁用。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~3期", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "4期", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "5期", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "T2DM是慢性进展性疾病，随着自然病程的进展，胰岛β细胞功能进行性减退，胰岛素补充或替代治疗成为控制T2DM患者高血糖的有效手段。基础胰岛素是常用的胰岛素治疗方案，具有低血糖风险低，使用简单方便等优点，国内外指南均推荐，口服降糖药治疗血糖控制不佳时即可起始基础胰岛素与口服药联合治疗。但临床研究显示，中国T2DM患者起始基础胰岛素治疗较晚(起始胰岛素时HbA1c已达9.6 %)，起始剂量偏低且在起始治疗后剂量调整不足，是导致起始胰岛素治疗后血糖控制不满意的重要原因。为规范基础胰岛素在临床中的合理使用，我国内分泌临床专家基于循证医学依据，共同制定了《成人2 型糖尿病基础胰岛素临床应用中国专家指导建议》，以供临床参考。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛β细胞功能进行性减退", "subject_type": "发病机制", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2 型", "subject_type": "分期分型", "object": {"@value": "2 型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2 型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "血糖波动是评价血糖控制的重要指标之一。糖化血红蛋白(hemoglobin Alc，HbA1c)虽能反映3个月内血糖的平均水平，但无法反映血糖波动的情况，HbA1c控制相似的糖尿病患者可能因血糖波动的程度不同，发生并发症的风险也不相同。糖尿病患者理想的血糖控制不仅要HbA1c达标，还应尽可能减少血糖波动的幅度。目前，针对血糖波动相关指标的评估方法较为复杂、可操作性差，不利于临床医生对血糖波动进行有效的管理，因此，中华医学会内分泌学分会组织部分临床内分泌学领域专家，通过系统性回顾分析现有循证医学证据并结合专家临床经验，制定了《糖尿病患者血糖波动管理专家共识》。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "糖化血红蛋白(hemoglobin Alc，HbA1c)", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "对非内分泌科住院的糖尿病或高血糖患者的管理流程同样参见图1，如下详细阐述了其中血糖管理部分。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "推荐复方制剂(DPP-4i和二甲双胍)用于2型糖病患者的起始降糖治疗。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4i", "subject_type": "药品名称", "object": {"@value": "2型糖病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)既往有糖尿病史患者，既往3个月内如未行HbA1c检测，入院后则需进行HbA1c检测；", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "对于神经根或丛病变者，可选择影像学检查排除脊柱与椎管内病变和盆腔内占位性病变。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "神经根或丛", "subject_type": "患病部位", "object": {"@value": "神经根或丛病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "影像学检查", "subject_type": "检查方法", "object": {"@value": "神经根或丛病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "影像学检查", "subject_type": "检查方法", "object": {"@value": "脊柱与椎管内病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "影像学检查", "subject_type": "检查方法", "object": {"@value": "盆腔内占位性病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脊柱", "subject_type": "患病部位", "object": {"@value": "脊柱与椎管内病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "椎管内", "subject_type": "患病部位", "object": {"@value": "脊柱与椎管内病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "盆腔内", "subject_type": "患病部位", "object": {"@value": "盆腔内占位性病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "③每日3次方案：建议使用预混胰岛素类似物。当预混胰岛素每日2次转为3次时，早晚餐前可等剂量转换，午餐前加2-4单位或每天胰岛素总量的10%，并可能需要减少早餐前的剂量2~4单位；当替代基础+餐时方案进行强化治疗时，医生需要根据具体情况制定方案。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "每日3次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日2次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2-4单位", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2~4单位", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "因此，规范胰岛素治疗对于改善糖尿病管理、提高广大医护人员的临床实践水平具有重要意义。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)抗凝血药：包括抗凝血因子、抗血小板因子及新型的Xa因子和Ⅱa抑制剂。抗凝血因子又分为非肠道用药及肠道用药，临床常用的肝素(多用低分子肝素)为非肠道用药。新型抗凝血药指新研发上市的口服Xa因子和Ⅱa直接抑制剂，前者包括阿哌沙班、利伐沙班、依度沙班等，后者有达比加群。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "Xa因子和Ⅱa直接抑制剂"}, "object_type": {"@value": "药品名称"}}]}
{"text": "别嘌醇：成人初始剂量50～100mg／d，每2～5周测血尿酸水平1次，未达标患者每次可递增50～100mg，最大剂量600mg／d。肾功能不全患者起始剂量每日不超过1.5mg／eGFR(估算的肾小球滤过率)。G3—4期患者推荐剂量为50～100mg／d；G5期患者禁用。别嘌醇可引皮呋过敏反应及肝肾功能损伤，严重者可发生致死性剥脱性皮炎等超敏反应综合征。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "50～100mg／d", "subject_type": "用药剂量", "object": {"@value": "别嘌醇"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "50～100mg", "subject_type": "用药剂量", "object": {"@value": "别嘌醇"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "600mg／d", "subject_type": "用药剂量", "object": {"@value": "别嘌醇"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "皮呋过敏反应", "subject_type": "不良反应", "object": {"@value": "别嘌醇"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "肝肾功能损伤", "subject_type": "不良反应", "object": {"@value": "别嘌醇"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "致死性剥脱性皮炎", "subject_type": "不良反应", "object": {"@value": "别嘌醇"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "超敏反应综合征", "subject_type": "不良反应", "object": {"@value": "别嘌醇"}, "object_type": {"@value": "药品名称"}}]}
{"text": "床疾患等进行综合评估，并根据评估结果制定相应的血脂管理目标和治疗措施(推荐；C级证据)。值得关注的是，虽然T2DM患者的血脂谱特征是LDL-C正常或轻度升高，但小而致密的LDL颗粒数量增加。事实上，小而密LDL颗粒更容易被氧化形成过氧化脂质，易通过非受体通路摄取，被单核-巨噬细胞的清道夫受体识别、吞噬，形成泡沫细胞，促进ASCVD的发生，具有很强的致ASCVD作用。UKPDS研究结果也显示，LDL-C是T2DM患者发生冠心病和心肌梗死的首要预测因素，LDL-C每上升1mmo/L，冠脉事件发生率增加57%。胆固醇治疗试验(CTT)协作组的meta分析结果也显示，LDL-C每降低1.0mmol/L分别显著下降主要血管事件、血管性死亡和缺血性卒中事件风险达21%、13%和21%。由此证明，T2DM患者降低LDL-C心血管获益确切。低HDL-C水平往往与TG水平升高相关，也是T2DM患者常见的血脂异常。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "血脂谱", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "小而致密的LDL颗粒数量", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "小而密LDL颗粒更容易被氧化形成过氧化脂质", "subject_type": "发病机制", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "易通过非受体通路摄取", "subject_type": "发病机制", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "被单核-巨噬细胞的清道夫受体识别、吞噬，形成泡沫细胞", "subject_type": "发病机制", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "冠心病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "冠脉事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "冠脉", "subject_type": "患病部位", "object": {"@value": "冠脉事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "血管性死亡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "缺血性卒中"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HDL-C水平", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "TG水平", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "血管", "subject_type": "患病部位", "object": {"@value": "血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "血管性", "subject_type": "分期分型", "object": {"@value": "血管性死亡"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "血尿酸水平受年龄、性别、种族、遗传、饮食习惯、药物、环境等多种因素影响，我国目前尚缺乏全国范围的HUA流行病学调查资料。来自不同时间、地区的资料显示，目前我国HUA呈现高流行、年轻化、男性高于女性、沿海高于内陆的流行趋势，原因可能与人群饮食结构、平均寿命的延长和医疗保健水平的不断提高有关。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血尿酸", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "人群饮食结构", "subject_type": "患病病因", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "平均寿命的延长", "subject_type": "患病病因", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "医疗保健水平的不断提高", "subject_type": "患病病因", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.妊娠期糖尿病(GDM)患者使用注意事项：有GDM史的患者发现为糖尿病前期时，应接受生活方式干预或二甲双胍以预防糖尿病。患者一旦妊娠，建议改用胰岛素治疗(V级)。二甲双胍可降低PCOS患者妊娠早期的流产率和GDM的发生率。在控制孕妇体重和治疗IR方面有优势，孕早期口服二甲双胍没有增加胎儿重大畸形和新生儿并发症的风险，二甲双胍在FDA妊娠期用药分级中为B类药物。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "糖尿病前期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病前期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "妊娠期", "subject_type": "分期分型", "object": {"@value": "妊娠期糖尿病(GDM)"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "那格列奈和缬沙坦在IGT人群中的结局研究(NAVIGATOR)显示，在有心血管事件病史或心血管危险因素的IGT患者中，与安慰剂相比，那格列奈治疗5年后，首要心血管事件复合终点(3终点MACE+心力衰竭住院)风险差异无统计学意义( HR 0.94，95%CI 0.82~1.09，P=0.43)。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "那格列奈", "subject_type": "药品名称", "object": {"@value": "IGT"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "缬沙坦", "subject_type": "药品名称", "object": {"@value": "IGT"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "5年", "subject_type": "持续时间", "object": {"@value": "那格列奈"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "7.造影或全麻术前患者使用注意事项：肾功能正常患者，造影前不必停用二甲双胍，但使用对比剂后应在医生的指导下停用48~72h，复查肾功能正常后可继续用药；而对于肾功能异常的患者，使用对比剂及全身麻醉术前48h应当暂时停用二甲双胍，之后还需停药48~72h，复查肾功能结果正常后可继续用药(V级)。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "全身麻醉术", "subject_type": "临床手术", "object": {"@value": "肾功能异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肾功能异常"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.中枢神经系统感觉通路病变、功能性疾病或内外科相关疾病也可有感觉异常或某些自主神经症状(如性功能障碍、便秘、排尿困难等)，详细的病史询问和体格检查是鉴别DPN与其他疾病的关键。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "感觉异常", "subject_type": "临床表现", "object": {"@value": "中枢神经系统感觉通路病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "自主神经症状", "subject_type": "临床表现", "object": {"@value": "中枢神经系统感觉通路病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "性功能障碍", "subject_type": "临床表现", "object": {"@value": "中枢神经系统感觉通路病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "便秘", "subject_type": "临床表现", "object": {"@value": "中枢神经系统感觉通路病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "排尿困难", "subject_type": "临床表现", "object": {"@value": "中枢神经系统感觉通路病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "感觉异常", "subject_type": "临床表现", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "自主神经症状", "subject_type": "临床表现", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "性功能障碍", "subject_type": "临床表现", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "便秘", "subject_type": "临床表现", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "排尿困难", "subject_type": "临床表现", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "第一代磺脲类药物(如甲苯磺丁脲等)目前临床上已基本被淘汰。第二代磺脲类药物中，格列本脲的半衰期较长，其活性代谢产物约50.0%经肾脏排泄，故其易在慢性肾脏病患者体内积聚，从而可能引起严重的低血糖，且低血糖的持续时间可超过24h。故仅推荐格列本脲用于慢性肾脏病1~2期的患者；3~5期禁用。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列本脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列本脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列本脲", "subject_type": "药品名称", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列本脲", "subject_type": "药品名称", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~2期", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3~5期", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.抗肿瘤作用：糖尿病可能是多种肿瘤，如乳腺癌、胰腺癌、结直肠癌、子宫内膜癌等的危险因素。多项研究显示，二甲双胍可激活AMP激活的蛋白激(AMPK)通路。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "乳腺", "subject_type": "患病部位", "object": {"@value": "乳腺癌"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "胰腺", "subject_type": "患病部位", "object": {"@value": "胰腺癌"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "结直肠", "subject_type": "患病部位", "object": {"@value": "结直肠癌"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "子宫内膜", "subject_type": "患病部位", "object": {"@value": "子宫内膜癌"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(3)糖尿病患者，询问既往有无低血糖事件，评判发生低血糖的风险程度。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "低血糖事件", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(一)? 糖尿病下肢血管病变的诊断", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "下肢血管", "subject_type": "患病部位", "object": {"@value": "下肢血管病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "依据不同的病变程度需要对糖尿病足进行分级，目前临床上广为接受的分级方法主要有Wagner 分级、Texas分级，但因为糖尿病足病情复杂，血管病变、神经病变、感染的程度、软组织及骨质破坏情况等差异大，所以任何一种分级方法都不可能做到十全十美。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "血管", "subject_type": "患病部位", "object": {"@value": "血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "软组织", "subject_type": "患病部位", "object": {"@value": "软组织及骨质破坏"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "我国一项使用格列哇喹4.5年的同回性分析结果显示：格列喹酮单药治疗2型糖尿病，HbA1c降幅1.31%，PPG降幅4.88mmol/L，空腹血糖(FPG)降3幅.88mmol/L。而格列喹酮早期的队列研究结果显示：服用格列哇喹的患者仅有0.13%发生轻度低血糖事件，无严重低血糖发生。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "PPG", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "空腹血糖(FPG)", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列哇喹"}, "object_type": {"@value": "药品名称"}}]}
{"text": "皮肤活体组织检查有助于小纤维神经病的诊断，在糖尿病自主神经病的诊断中具有一定价值。神经活体组织检查主要用于鉴别其他疾病，并非诊断DPN的常规手段，仅在病因诊断困难的情况下根据病情选择。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "皮肤活体组织检查", "subject_type": "检查方法", "object": {"@value": "小纤维神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "皮肤活体组织检查", "subject_type": "检查方法", "object": {"@value": "糖尿病自主神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "小纤维神经", "subject_type": "患病部位", "object": {"@value": "小纤维神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "自主神经", "subject_type": "患病部位", "object": {"@value": "糖尿病自主神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "神经活体组织检查", "subject_type": "检查方法", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "烟酸可导致糖代谢异常或糖耐量恶化，一般不推荐在糖尿病患者中使用。若必须使用，应该定期监测血糖水平。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "糖代谢异常", "subject_type": "不良反应", "object": {"@value": "烟酸"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "糖耐量恶化", "subject_type": "不良反应", "object": {"@value": "烟酸"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.良好的代谢管理：对于糖尿病足患者，应积极进行血糖控制，首选胰岛素控制血糖，同时对患者进行充分地血糖控制[糖化血红蛋白 (HbA1c)<7%] ，同时尽可能减少低血糖的发生以降低足溃疡和感染的发生率，继而降低患者的截肢风险。但由于糖尿病足患者常常年龄较大，合并症及并发症较多，因此不能一味地强调将患者的H bA1c控制在7%以下，此时应该参照中华医学会内分泌学分会制定的《中国成人2型糖尿病HbA1c控制目标的专家共识》推荐的个体化控制目标. ", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "糖化血红蛋白 (HbA1c)", "subject_type": "检查指标", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "足溃疡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "H bA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.血脂控制目标值：糖尿病肾病患者血脂干预治疗切点：血LDL-C>3.38mmol/L(130mg/d1)，甘油三酯(TG)>2.26(200mg/d1)。治疗目标：LDL-C水平降至2.6mmol/L以下(并发冠心病将至1.86mmol/L以下)，TG降至1.5mmol/L以下。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血LDL-C", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "甘油三酯(TG)", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "冠心病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "TG", "subject_type": "检查指标", "object": {"@value": "冠心病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.控制高血压：根据目前多个国内外心血管专业指南推荐，老年糖尿病合并高血压者血压控制目标＜140／80mmHg(1mmHg=0．133kPa)(B)。可根据患者糖尿病病程、一般健康状况、有无心脑血管病变及尿蛋白情况设置不同血压控制目标。糖尿病患者降压治疗应积极，掌握“越早越好”的原则，血压处于130~140／80～90mmHg水平，经3个月以上生活方式干预无效时可开始药物治疗。血管紧张素转换酶抑制剂(ACEI)或血管紧张素Ⅱ受体拮抗剂(ARB)类降压药是老年糖尿病患者首选和基用药(Ⅱ)，次选为长效钙离子拮抗剂(CCB)和／或选择性β受体阻断剂，慎用利尿剂，尤其是合并高尿酸血症者。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血压", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血压", "subject_type": "检查指标", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿蛋白", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血压", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心脑血管", "subject_type": "患病部位", "object": {"@value": "心脑血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿蛋白", "subject_type": "检查指标", "object": {"@value": "心脑血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血压", "subject_type": "检查指标", "object": {"@value": "心脑血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血压", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "血管紧张素转换酶抑制剂(ACEI)", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "血管紧张素转换酶抑制剂(ACEI)", "subject_type": "药品名称", "object": {"@value": "高尿酸血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "血管紧张素Ⅱ受体拮抗剂(ARB)类降压药", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "血管紧张素Ⅱ受体拮抗剂(ARB)类降压药", "subject_type": "药品名称", "object": {"@value": "高尿酸血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "长效钙离子拮抗剂(CCB)", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "选择性β受体阻断剂", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利尿剂", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "长效钙离子拮抗剂(CCB)", "subject_type": "药品名称", "object": {"@value": "高尿酸血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "选择性β受体阻断剂", "subject_type": "药品名称", "object": {"@value": "高尿酸血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利尿剂", "subject_type": "药品名称", "object": {"@value": "高尿酸血症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "尿酸生成过多：特发性、富含嘌呤饮食，次黄嘌呤-鸟嘌呤磷酸核糖基转移酶(HPRT)缺乏症、5-磷酸核糖-1-焦磷酸(PRPP)合成酶亢进症、溶血、淋巴增生性疾病、骨髓增生性疾病、真红细胞增多症、银屑病、Paget’s病、糖员贮积症(III、IV、VII型)、横纹肌溶解、运动、饮酒、肥胖。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "骨髓", "subject_type": "患病部位", "object": {"@value": "骨髓增生性疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "III、IV、VII型", "subject_type": "分期分型", "object": {"@value": "糖员贮积症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "共识分别对目前临床上使用的两类降尿酸药物：抑制尿酸合成的药物和促进尿酸排泄的药物进行了详细的介绍，包括起始剂量、最大剂量以及在肾功能不全患者中的使用情况。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.互联网系统管理模式的优势和不足：(1)优势：①国内外互联网系统管理模式系统有所不同，对住院患者血糖控制改善率不一.但均能提高住院患者血糖达标率，降低低血糖发生率及平均住院日，改善预后；②提高患者糖尿病知识的知晓率，提高医护人员工作效率，同时提升患者满意度；③管理系统通过对患者连续的、主动的个性化服务与管理，实现了院内“分泌科-非内分泌科“血糖管理无缝衔接。(2)不足：①护理人员的工作量繁重、交互界面操作困难、内置提醒设置不充足及对错误的关注不足是互联网系统管理模式实施的主要困难；2低血糖发生在系统中被过分关注，导致护士为避免低血糖发生而不完全执行系统推荐的胰岛素注射剂量，增加血糖达标难度：③互联网系统管理模式所有信息建立在电子病历基础上，不能完全替代面对面的内分泌医师会诊评估。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖达标率", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "因此，本共识将血尿酸水平>420μmol/L定义为HUA，更具有临床意义。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血尿酸", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "包括UKPDS和ADVANCE等多项大型临床研究结果均证实了磺脲类药物在降糖治疗中的心血管安全性。荟萃分析结果发现，与格列本脲相比，格列齐特和格列美脲可降低T2DM患者的全因死亡风险，而格列吡嗪、甲苯磺丁脲及氯磺丙脲则无此差异。一项为期5年的大样本观察性研究发现，使用格列齐特治疗的患者总病死率和心血管事件死亡率均低于格列本脲，这可能与格列齐特能选择性激活胰岛β细胞的磺脲类受体1(sulfonylurea receptor，SUR1)，而对心肌细胞上的SUR2A和血管平滑肌细胞上的SUR2B无活化作用有关。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "格列齐特", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列美脲", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "心血管事件", "subject_type": "不良反应", "object": {"@value": "格列齐特"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "心血管事件", "subject_type": "不良反应", "object": {"@value": "格列本脲"}, "object_type": {"@value": "药品名称"}}]}
{"text": "即使是轻微的低血糖也可能引起患者摔伤、骨折等机体损伤，导致患者入院，增加心理和经济负担。", "spo_list": [{"Combined": false, "predicate": "患病病因", "subject": "轻微的低血糖", "subject_type": "患病病因", "object": {"@value": "摔伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "轻微的低血糖", "subject_type": "患病病因", "object": {"@value": "骨折"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)前列地尔：即前列腺素E1(prostaglandin1，PGE1)，增加血管平滑肌细胞内环磷酸腺苷(cyclic adenosine monophosphate，cAMP)含量，舒张血管平滑肌，发挥强大的扩血管作用，尤其对阻塞部位的血管作用显著。通过降低血液黏度，改善红细胞变形能力从而改善微循环。临床上用于治疗慢性动脉闭塞症引起的四肢溃疡及微小血管循环障碍引起的四肢静息疼痛。荟萃分析显示，PGE1可以缓解疼痛，增加无痛行走距离(pain-free walking distance，PFWD)和最大行走距离(maximum walking distance，MWD)且效果持续，促进溃疡愈合，降低截肢率。对于糖尿病神经病变的患者，荟萃分析结果显示，PGE1联合甲钴胺对糖尿病周围神经病变症状和体征改善的总有效率和对平均运动神经传导速度(motor nerve conduction velocity，MNCV)的改善优于单用甲钴胺。对于糖尿病合并肾功能不全的患者，荟萃分析结果显示，PGE1联合常规治疗，可显著降低尿白蛋白排出率(urinary albumin excretion rate，UAER)。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "四肢溃疡", "subject_type": "临床表现", "object": {"@value": "慢性动脉闭塞症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "微小血管循环障碍", "subject_type": "临床表现", "object": {"@value": "慢性动脉闭塞症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "四肢静息疼痛", "subject_type": "临床表现", "object": {"@value": "慢性动脉闭塞症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "糖尿病神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "PGE1", "subject_type": "药品名称", "object": {"@value": "糖尿病周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "甲钴胺", "subject_type": "药品名称", "object": {"@value": "糖尿病周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "糖尿病周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "PGE1", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿白蛋白排出率(urinary albumin excretion rate，UAER)", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "PGE1", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿白蛋白排出率(urinary albumin excretion rate，UAER)", "subject_type": "检查指标", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(3)格列奈类：格列奈类药物是非磺脲类胰岛素促泌剂，其具有葡萄糖依赖性，需餐前服用。由于其对基础胰岛素分泌物无明显刺激作用，其引起低血糖的风险和程度较磺脲类药物轻。其他不良反应有过敏反应、胃肠道不适、眼睛异常、肝功能损害等，均较罕见。格列奈类的主要代表药物有那格列奈和瑞格列奈。瑞格列奈及其代谢产物主要经肝脏代谢，仅<8%经肾排泄。瑞格列奈I期临床试验表明，使用瑞格列奈7d后，肾功能正常患者与不同程度的CKD患者相比，血药浓度没有明显差异，提示瑞格列奈在CKD患者体内无蓄积。一项入选281例伴或不伴肾功能不全2型糖尿病患者的多中心研究提示，使用瑞格列奈替换原有降糖治疗，不同程度肾功能不全亚组患者(正常、轻、中、重、极重肾功能损伤)低血糖发生率均低于2%，且瑞格列奈治疗期低血糖发生率与肾功能损伤程度无关。因此瑞格列奈应用于CKD3、4期或肾脏移植、透析者，均无需调整剂量。在Ccr15~50ml·min-1·1.73m-2的糖尿病患者中，那格列奈的生物利用度和半衰期与健康人相比其差别未达到具有临床意义的程度，但随着肾功能的下降，那格列奈的活性代谢产物水平增加。有观点认为那格列奈应用于肾功能不全的糖尿病患者时无需调整剂量，但ADA仍建议CKD4期应从小剂量每次餐前60mg开始。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "7d", "subject_type": "持续时间", "object": {"@value": "瑞格列奈"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "血药浓度", "subject_type": "发病机制", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "瑞格列奈"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "瑞格列奈"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "CKD3、4期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3、4期", "subject_type": "分期分型", "object": {"@value": "CKD3、4期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "肾脏移植", "subject_type": "临床手术", "object": {"@value": "CKD3、4期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "透析", "subject_type": "非药治疗", "object": {"@value": "CKD3、4期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "Ccr", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "那格列奈", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾功能", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "那格列奈", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "那格列奈", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "那格列奈", "subject_type": "药品名称", "object": {"@value": "CKD4期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "餐前60mg", "subject_type": "用药剂量", "object": {"@value": "那格列奈"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "4期", "subject_type": "分期分型", "object": {"@value": "CKD4期"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "值得注意的是，由于2型糖尿病是一种进行性疾病，大多数患者最终仍需要胰岛素治疗。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "降糖治疗中血糖波动是不可避免的现象，过度的血糖波动是加重血管损伤和发生低血糖的危险因素(B)。告诫患者在日常生活中注意调整降糖药与进食量和运动量的三点平衡，有利于促进有效、平稳降糖。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "血管损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "血管", "subject_type": "患病部位", "object": {"@value": "血管损伤"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(5)α-糖苷酶抑制剂：α-糖苷酶抑制剂适用于饮食结构以碳水化合物为主且餐后血糖升高的患者，可将HbA1c降低0.5%~0.8%，其主要药理作用是抑制碳水化合物在小肠上段的吸收而降低餐后血糖，不增加体重且有减轻体重的趋势。该类药物口服后被胃肠道吸收不到1%，故全身性不良反应不多见，主要不良反应是胃肠道不适，表现为腹胀、腹泻等，其主要代表药物有阿卡波糖、伏格列波糖等。随肾功能的降低，阿卡波糖及其代谢产物的血药浓度显著增加，Ccr低于25ml·min-1·1.73m-2者禁用。伏格列波糖仅微量被吸收，分布于肠黏膜和肾脏，可用于CKD 1~3期患者，慎用于CKD4~5期患者，不必调整剂量。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "胃肠道不适", "subject_type": "不良反应", "object": {"@value": "阿卡波糖"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道不适", "subject_type": "不良反应", "object": {"@value": "伏格列波糖"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "腹胀", "subject_type": "不良反应", "object": {"@value": "阿卡波糖"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "腹胀", "subject_type": "不良反应", "object": {"@value": "伏格列波糖"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "腹泻", "subject_type": "不良反应", "object": {"@value": "阿卡波糖"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "腹泻", "subject_type": "不良反应", "object": {"@value": "伏格列波糖"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "伏格列波糖", "subject_type": "药品名称", "object": {"@value": "CKD 1~3期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "4~5期", "subject_type": "分期分型", "object": {"@value": "CKD4~5期"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "研究显示，相比于短效人胰岛素，门冬胰岛素在改善母婴预后方面更具优势。②儿童和青少年：门冬胰岛素已被CFDA批准用于2岁以上儿童及青少年糖尿病患者；我国的《儿童及青少年糖尿病患者的胰岛素治疗指南》建议赖脯胰岛素的使用年龄为12 岁以上。③肝、肾功能不全：糖尿病合并肾功能不全患者的胰岛素治疗应优先选择短效胰岛素威速效胰岛素类似物。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "门冬胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "赖脯胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "短效胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "速效胰岛素类似物", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "ADVANCE与ACCORD不同，其血糖控制力求平稳，低血糖发生率较低，效果也更好，至少没有增加CVD事件和死亡率。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "临床问题8：复方制剂(DPP-4i和二甲双胍)是否可用于2型糖尿病患者的起始降糖治疗? ", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4i", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.GDM患者能否使用二甲双胍：虽然国际多个学术组织推荐二甲双胍可用于GDM患者，但基于目前国内证据缺乏，暂不推荐(V级)。二甲双胍在FDA妊娠期用药分级中为B类药物。2013年，《糖尿病和妊娠：美国内分泌学会临床实践指南》建议，在妊娠前3个月内医学营养治疗血糖控制不佳，以及拒绝和不适合使用胰岛素和格列本脲的GDM患者可使用二甲双胍治疗。2015年，NICE《妊娠糖尿病及其并发症的管理指南》建议，饮食和运动1~2周血糖未达标的GDM患者，可使用二甲双胍治疗。但我国药监部门尚未批准二甲双胍用于妊娠妇女。对于有糖尿病病史的产妇，二甲双胍干预可以有效减缓10年随访期中糖尿病的发展。二甲双胍可降低PCOS患者妊娠早期的流产率和GDM的发生率，在控制孕妇体重和治疗IR方面有优势。在有效控制血糖的前提下，二甲双胍较胰岛素更有益于产妇健康。一项前瞻性随机对照临床试验结果显示，二甲双胍或二甲双胍联用胰岛素治疗GDM在体重、先兆子痫、新生儿死亡率等方面优于胰岛素单药治疗。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食", "subject_type": "非药治疗", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "运动", "subject_type": "非药治疗", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "IR", "subject_type": "发病机制", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "IR", "subject_type": "发病机制", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(3)妊娠期的糖尿病忠者：糖尿病合并妊娠、妊娠期糖尿病患者的血糖控制目标在餐前及餐后2h分别为≤5.3mmol/L、6.7mmol/L，特殊情况下可测定餐后1h血糖，其控制目标是≤7.8mmol/L；但夜间血糖不低于3.3mmol/L。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "餐后1h血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "夜间血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1型糖尿病：(《中国1型糖尿病胰岛素治疗指南》)", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "③艾塞那肽和利拉鲁肽使用中有少数急性胰腺炎病例报道，应当告知患者急性胰腺炎的特征性症状。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "急性胰腺炎", "subject_type": "不良反应", "object": {"@value": "艾塞那肽"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "急性胰腺炎", "subject_type": "不良反应", "object": {"@value": "利拉鲁肽"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "胰腺", "subject_type": "患病部位", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.控制血脂异常：血清LDL-C是老年糖尿病患者必须关注的指标。对仅有大血管粥样硬化相关检测指标异常者，LDL-C也需要降低至<2.6mmol/L，有其他心脑血管病变风险因素存在者LDL-C<1.8mmol/L(II)，未能达此标准者在除外肾脏病和甲状腺功能减退症的影响后，应该长期服用他汀类药物。有对他汀类药物不耐受者(出现肝酶、肌酶异常)需酌情调整治疗。如他汀类单药不能使LDL-C达标时，推荐联合服用胆固醇吸收抑制剂(II)。合并单纯高甘油三酯血症者(LDL-C正常)，首先控制脂肪的摄入量，如血清TG≥3.5mmol/L可加用贝特类降脂药，无高尿酸血症者可选用烟酸制剂(II)。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血清LDL-C", "subject_type": "检查指标", "object": {"@value": "血脂异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血清LDL-C", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "大血管粥样硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "大血管粥样硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类药物", "subject_type": "药品名称", "object": {"@value": "大血管粥样硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "心脑血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "甲状腺功能减退症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类药物", "subject_type": "药品名称", "object": {"@value": "肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "甲状腺", "subject_type": "患病部位", "object": {"@value": "甲状腺功能减退症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类药物", "subject_type": "药品名称", "object": {"@value": "甲状腺功能减退症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类药物", "subject_type": "药品名称", "object": {"@value": "心脑血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "单纯高甘油三酯血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血清TG", "subject_type": "检查指标", "object": {"@value": "单纯高甘油三酯血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝特类降脂药", "subject_type": "药品名称", "object": {"@value": "单纯高甘油三酯血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "烟酸制剂", "subject_type": "药品名称", "object": {"@value": "单纯高甘油三酯血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "高尿酸血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝特类降脂药", "subject_type": "药品名称", "object": {"@value": "高尿酸血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血清TG", "subject_type": "检查指标", "object": {"@value": "高尿酸血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "烟酸制剂", "subject_type": "药品名称", "object": {"@value": "高尿酸血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心脑血管", "subject_type": "患病部位", "object": {"@value": "心脑血管病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(二)T2DM合并CKD", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "总之，胰岛素促泌剂符合中国2型糖尿病的特点，是多数权威指南推荐的治疗2型糖尿病的一线药物。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "艾塞那肽和利拉鲁肽使用中有少数急性胰腺炎病例报道，因此临床应用共识建议医生应当告知患者急性胰腺炎的特征性症状，如怀疑发生了胰腺炎。应该立即停用。此外，GLP-1受体激动剂与磺脲类药物合用时低血糖发生率升高，建议适当减少磺脲类药物剂量以减少低血糖风险，当联合使用GLP-1受体激动剂与磺脲类药物时，医生应告知患者在驾驶或操作机械时采取必要措施以防止发生低血糖。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "艾塞那肽", "subject_type": "药品名称", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利拉鲁肽", "subject_type": "药品名称", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "GLP-1受体激动剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "GLP-1受体激动剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "胰腺", "subject_type": "患病部位", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "胰腺", "subject_type": "患病部位", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "胰腺", "subject_type": "患病部位", "object": {"@value": "胰腺炎"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病病史长，已患CVD或处于CVD极高危，我们推荐HbA1c≤7.5%，因为他们发生或再次发生CVD风险明显增加，低血糖风险较高，目前还没有足够的证据证明HbA1c控制在7%以下对大血管的益处。大规模随机对照试验，如ACCORD、VADT和ADVANCE的结果表明，强化降糖5年内并未发现大血管受益，ACCORD甚至显示总死亡风险反而有所增加。分析ACCORD的研究资料发现对病情较重的入组患者(平均年龄62岁，病程10年，伴CVD占35%)进行强化降糖，可能是主要原因之一。对这些年龄大、病程长、并发症和伴发疾病多的患者严格控制血糖，若发生低血糖可能诱发CVD，增加患者的死亡风险。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "CVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "CVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "CVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "CVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "CVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "CVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "CVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "低血糖", "subject_type": "患病病因", "object": {"@value": "CVD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(4)噻唑烷二酮类：该类药物的常见不良反应是液体潴留，因而对于重度心衰患者应慎用。使用该类药物发生骨折及骨质疏松的风险增加，需慎用于潜在骨疾病的患者(如肾性骨营养不良)，尤其是绝经后女性；其他不良反应包括肝酶升高、体重增加等。该类药物不刺激内源性胰岛素分泌，单独使用低血糖风险低(1%~2%)。该类药物主要代表为吡格列酮和罗格列酮。由于其经过肝脏代谢，吡格列酮用于肾功能不全无需调整剂量；罗格列酮因增加心血管风险的安全性问题引起了国内外的警惕，美国食品药品监督管理局(FDA)和欧洲药品管理局建议在心功能不全和严重骨质疏松患者慎用已限制其使用(图1)。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "噻唑烷二酮类", "subject_type": "药品名称", "object": {"@value": "重度心衰"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "重度", "subject_type": "分期分型", "object": {"@value": "重度心衰"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "重度心衰"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "骨", "subject_type": "患病部位", "object": {"@value": "骨疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "骨", "subject_type": "患病部位", "object": {"@value": "肾性骨营养不良"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "肾性", "subject_type": "分期分型", "object": {"@value": "肾性骨营养不良"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "吡格列酮", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "罗格列酮", "subject_type": "药品名称", "object": {"@value": "心血管风险"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "液体潴留", "subject_type": "不良反应", "object": {"@value": "噻唑烷二酮类"}, "object_type": {"@value": "药品名称"}}]}
{"text": "②每日2次方案：新诊2型糖尿病患者，HbA1c≥9.0%同时合并明显临床症状；生活方式干预及两种或两种以上口服降糖药最大有效剂量治疗后HbA1c≥9.0% 的患者；口服降糖药物联合基础胰岛素治疗以后，HbA1c≥7%，而空腹血糖已达标的患者。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病患者"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病患者"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "8.联合格列奈类药物的疗效：格列奈类药物属于短效促胰岛素分泌剂，与二甲双胍联用具有协同作用。在新诊断的血糖水平较高(HbA1c水平接近11.0%)的T2DM患者中瑞格列奈和二甲双胍联合比单用瑞格列奈能更有效降低HbA1c，而低血糖发生率差异无统计学意义。那格列奈联用二甲双胍和格列齐特联用二甲双胍的降糖强度差异无统计学意义，但低血糖事件更少(Ⅰ级)。故在二甲双胍联合磺脲类且低血糖发生风险较高时，可考虑选用二甲双胍联合格列奈类药物。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞格列奈", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "瑞格列奈"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "瑞格列奈"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "那格列奈"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列齐特"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列奈类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "一、糖尿病肾病的定义与诊断", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "7.患者造影或全身麻醉术前停用二甲双胍的时间，以及再行启用的时间：肾功能正常的糖尿病患者，造影前不必停用二甲双胍，但使用造影剂后应在医生的指导下停用48~72h，复查肾功能正常后可继续用药；而对于肾功能异常的患者，使用造影剂及全身麻醉术前48h应当暂时停用二甲双胍，之后还需停药48~72h，复查肾功能结果正常后可继续用药(V级)。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "肾功能", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "造影", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "造影剂", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾功能", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾功能", "subject_type": "检查方法", "object": {"@value": "肾功能异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "造影剂", "subject_type": "药品名称", "object": {"@value": "肾功能异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "全身麻醉术", "subject_type": "临床手术", "object": {"@value": "肾功能异常"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)应尽可能在避免低血糖的前提下使血糖达标，以降低远期并发症的发生风险，因此建议胰岛治疗方案必须个体化，制订方案时要兼顾胰岛功能血糖控制目标、血糖波动幅度、低血糖发生风险等。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "中国大规模横断面调查研究发现，口服降糖药治疗仍是治疗T2DM的主要降糖方案。虽然二甲双胍被多数指南推荐为治疗T2DM的一线用药，但对于二甲双胍不耐受或存在禁忌证的患者，可以考虑将磺脲类药物作为一线用药。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病肾病防治专家共识(2014年版)", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.抗高血糖药物的选择：包括双胍类、磺脲类、格列奈类、噻唑烷二酮类、α-糖苷酶抑制剂、二肽基肽酶IV(DPP-4)抑制剂、胰高血糖素样肽1(GLP-1)类似物及胰岛素。某些在肾脏代谢或排泄的药物，在糖尿病肾病尤其是肾功能不全的患者中，经肾排泄减少或其活性代谢产物的清除减少，可引起低血糖等不良反应，这些药物在GFR低于60ml·min·-1·1.73m-2时需酌情减量或停药(图1)。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "格列美脲的代谢产物仍有降糖活性，其代谢产物及原型的60.0%经肾脏排泄。格列美脲用于慢性肾脏病1~2期患者无需调整剂量；3a期减量；3b~5期禁用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "格列美脲", "subject_type": "药品名称", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~2期", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3a期", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3b~5期", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.缺血性脑梗死：糖尿病合并的脑血管病变90％以上是缺血性脑梗死(A)，近1／3卒中患者的病因与颈动脉狭窄有关。老年糖尿病患者脑梗死的一级预防包括积极控制血压、血糖、LDL-C在理想水平，并戒烟(I)。对心脑血管高危患者，应该定期检测颈动脉B超，如发现小斑块形成或颅脑CT或MRI发现小缺血灶，即要开始抗血小板药物治疗(I)。已发生脑梗死者，重在防止再发(D)。LDL-C控制在<2.0mmol／L，HbA1c<7.0％，血压不宜控制过严，<150/85mmHg即可(I)。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "脑", "subject_type": "患病部位", "object": {"@value": "缺血性脑梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脑血管", "subject_type": "患病部位", "object": {"@value": "脑血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脑", "subject_type": "患病部位", "object": {"@value": "缺血性脑梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "颈动脉狭窄", "subject_type": "患病病因", "object": {"@value": "卒中"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脑", "subject_type": "患病部位", "object": {"@value": "脑梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "脑梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "脑梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "脑梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脑", "subject_type": "患病部位", "object": {"@value": "脑梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "脑梗死"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "日常饮食下，非同日两次空腹血尿酸水平＞420μmol/L即可诊断HUA。血液系统肿瘤、慢性肾功能不全、先天性代谢异常、中毒、药物等因素可引起血尿酸水平升高(附件1，2)。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "空腹血尿酸水平", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "慢性肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "中预混胰岛素(赖朋胰岛素50、门冬胰岛素50)主要针对餐后血糖升高明显或者血糖波动较大的患者(如口服降糖药失效后，早餐后血糖≥13.5毫摩尔/升或早餐前后血糖波动≥4.4毫摩尔/升，以及饮食中碳水化合物比例较高的患者；若低预混人胰岛素每日2次治疗的患者餐后血糖≥11.1毫摩尔/升，临床医生可依据具体情况考虑等剂量改为低预混胰岛素类似物(赖脯胰岛素7 5/25、门冬胰岛素30)或中预混胰岛素类似物。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "每日2次", "subject_type": "用药频率", "object": {"@value": "预混人胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "妊娠期高血糖包括糖尿病合并妊娠(妊娠前糖尿病)、妊娠期发现的糖尿病(overt diabetes，指妊娠期HbA1c或血糖达到糖尿病诊断标准)和妊娠糖尿病(GDM)三种情况。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "妊娠期", "subject_type": "分期分型", "object": {"@value": "妊娠期高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "妊娠前", "subject_type": "分期分型", "object": {"@value": "妊娠前糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "妊娠", "subject_type": "分期分型", "object": {"@value": "妊娠糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2009年国际专家委员会和2010年美国糖尿病学会(ADA)指南均提出，将HbA1c作为糖尿病的诊断标准之一，诊断糖尿病的切点为≥6.5%，糖尿病高危状态的切点介于5.7%~6.4%。目前美国和欧洲已认可HbA1c在糖尿病诊断和监测中的作用。由于HbA1c检测在我国尚未实现全国标准化，并且部分医院HbA1c的检测方法未通过美国国家糖化血红蛋白标准化计划(NGSP)标准体系的认证，故HbA1c目前在我国主要用于血糖监测。WHO的意见是，如果HbA1c检测方法通过NGSP认证，可将HbA1c作为糖尿病的诊断指标之一，以6.5%做为糖尿病的诊断切点。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.禁忌证：(1)血清肌酐水平，男≥132μmol/L(1.5mg/dl)女≥124μmol/L(1.4mg/dl)，或eGFR<45ml/(min·1.73m2)禁用；(2)需要药物治疗的CHF和其他严重心、肺疾患；(3)严重感染和外伤、外科大手术、临床有低血压和缺氧等；(4)已知对盐酸二甲双胍过敏；(5)急、慢性代谢性酸中毒，包括有或无昏迷的糖尿病酮症酸中毒；(6)酗酒者；(7)接受血管内注射碘化对比剂者，应暂时停用；(8)维生素B12、叶酸缺乏未纠正者。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "急、慢性", "subject_type": "分期分型", "object": {"@value": "急、慢性代谢性酸中毒"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "代谢性", "subject_type": "分期分型", "object": {"@value": "急、慢性代谢性酸中毒"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "过敏", "subject_type": "不良反应", "object": {"@value": "盐酸二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心、肺疾患"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肺", "subject_type": "患病部位", "object": {"@value": "心、肺疾患"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "血管内注射", "subject_type": "用药方法", "object": {"@value": "碘化对比剂"}, "object_type": {"@value": "药品名称"}}]}
{"text": "临床问题7：DPP-4i是否可用于伴有心血管疾病或心血管事件风险的2型糖尿病患者的降糖治疗? 推荐意见", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4i", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "包括ESRD患者在内的重度肾功能损害患者。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "自从2005年国际上第一个肠促胰素类药上市以来，此类药物的研究和临床应用有了飞速的发展。目前在我国已经上市2种胰高血糖素样肽1(GLP-1)受体激动剂和5种二肽基肽酶Ⅳ(DPP-4)抑制剂，为了便于使用者全面和快速地了解此类药物的基本知识以及在我国的临床研究和应用情况，中华医学会糖尿病学分会达成以下共识。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "胰高血糖素样肽1(GLP-1)受体激动剂", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二肽基肽酶Ⅳ(DPP-4)抑制剂", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "我国的糖尿病教育管理起步于20世纪90年代中期，最初是医护人员组织住院糖尿病患者进行授课，模式单一，患者学习比较被动。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "教育管理", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "我国CKD患者中的高尿酸血症(hyperuricemia，HUA)患病率为36.6%~50.0%，随CKD的进展其患病率明显升高。在IgA肾病患者队列中的研究显示，HUA是肾功能进展的独立危险因素，且该作用独立于患者的基线eGFR水平。维持性腹膜透析(腹透)患者的队列研究显示，血尿酸水平与腹透患者的全因死亡及心血管疾病(cardiovascular disease，CVD)死亡均独立相关。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "IgA肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "eGFR", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸", "subject_type": "检查指标", "object": {"@value": "心血管疾病(cardiovascular disease，CVD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病(cardiovascular disease，CVD)"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.剂量调整原则：二甲双胍的剂量调整原则为“小剂量起始，逐渐加量”。开始时服用500mg/d或<1000mg/d，1~2周后加量至1000mg/d，继续1~2周加量1次。最佳剂量为2000mg/d(1000mg，2次/d或2000mg/d，3次/d)。二甲双胍可在进餐时或餐后立即服用，缓释剂型1次/d，晚餐时或餐后立即服用。考虑药物的临床疗效及患者依从性，可采用简化的剂量方案：建议起始500mg，2次/d，如无明显胃肠道不良反应，2周后可增加至1000mg，2次/d可根据患者状况个体化治疗，每日总剂量1500~2550mg，分2~3次服用。老年人及肝肾功能不全的患者需要调整剂量，具体调整方法详见“四”中，二甲双胍在特殊人群的使用。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "进餐时或餐后立即服用", "subject_type": "用药方法", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "晚餐时或餐后立即服用", "subject_type": "用药方法", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "1次/d", "subject_type": "用药频率", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肝肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "·糖尿病血糖控制差或不稳定，经门诊调整治疗不达标；", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.口服降糖药联合基础胰岛素方案", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "虽然视网膜照片可以作为视网膜病变的一个筛查工具，但不能替代综合性眼科检查。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "视网膜病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "建议：2015年《2型糖尿病合并慢性肾脏病口服降糖药用药原则中国专家共识(2015)》建议格列喹酮在2型糖尿病合并CKD1~3b期(GFR≥30ml/min)患者中可用，GFR<60ml/min时只有格列喹酮是唯一无需调整剂量的口服磺脲类降糖药；2010年《美国综合临床肾脏病学》推荐格列喹酮在CKD~-5期全程均可使用；2015年欧洲肾脏最佳临床实践(European Renal Best Practice，ERBP)颁布了《糖尿病合并慢性肾脏病3b期或以上(DM-CKD3b~5)患者的诊疗指南》，建议格列喹酮用于CKD1~5期，全程均不需要剂量调整；格列喹酮可有效降低蛋白尿水平，延缓或逆转糖尿病肾病的进一步进展；格列喹酮在老年2型糖尿病合并肾病患者中降糖安全有效。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "磺脲类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "高于正常体重的T2DM患者，推荐按照25~30kcal/(kg标准体重·d)计算，再根据患者身高、体重、性别、年龄、活动量、应激状况等调整为个体化能量标准。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "排除其他病变如颈腰椎病变(神经根压迫、椎管狭窄、颈腰椎退行性变)、脑梗死、格林-巴利综合征、严重动静脉血管性病变(静脉栓塞、淋巴管炎)等，尚需鉴别药物尤其是化疗药物引起的神经毒性作用以及肾功能不全引起的代谢毒物对神经的损伤。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "神经根", "subject_type": "患病部位", "object": {"@value": "神经根压迫"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "椎管", "subject_type": "患病部位", "object": {"@value": "椎管狭窄"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "颈腰椎", "subject_type": "患病部位", "object": {"@value": "颈腰椎退行性变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脑", "subject_type": "患病部位", "object": {"@value": "脑梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "动静脉", "subject_type": "患病部位", "object": {"@value": "动静脉血管性病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "静脉", "subject_type": "患病部位", "object": {"@value": "静脉栓塞"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "淋巴管", "subject_type": "患病部位", "object": {"@value": "淋巴管炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "识别围术期血糖异常的高危人群围术期血糖异常以高血糖为主，可分为合并糖尿病的高血糖和应激性高血糖两类(stress-induced hyperglycemia)。一般手术围术期高血糖以合并糖尿病者居多。目前我国糖尿病患病率逐年增高，合并糖尿病的外科手术患者也日趋增多，其中相当比例的患者术前并未得到正确诊断和有效控制。有国外研究报道，择期手术中10%以上的患者合并隐匿性糖尿病。与普通人群相比，合并糖尿病尤其是未发现、未治疗的糖尿病患者血糖升高更加显著，围术期死亡率和并发症发生率更高，应当在术前加以识别。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "应激性高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "stress-induced hyperglycemia"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "应激性", "subject_type": "分期分型", "object": {"@value": "应激性高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "围术期", "subject_type": "分期分型", "object": {"@value": "围术期高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "隐匿性", "subject_type": "分期分型", "object": {"@value": "隐匿性糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.血糖控制目标：糖尿病肾病患者的血糖控制应遵循个体化原则。血糖控制目标：糖化血红蛋白(HbA1c)不超过7%。对中老年患者，HbA1c控制目标适当放宽至不超过7%~9%。由于CKD患者的红细胞寿命缩短，HbA1c可能被低估。在CKD4~5期的患者中，用果糖胺或糖化血清白蛋白反映血糖控制水平更可靠一。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "红细胞寿命缩短", "subject_type": "发病机制", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "4~5期", "subject_type": "分期分型", "object": {"@value": "CKD4~5期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "果糖胺", "subject_type": "检查指标", "object": {"@value": "CKD4~5期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "糖化血清白蛋白", "subject_type": "检查指标", "object": {"@value": "CKD4~5期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "CKD4~5期"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.胰岛素促分泌剂：(1)磺脲类：常用药物有格列吡嗪、格列齐特、格列喹酮及格列美脲。多从小剂量开始应用，而后根据血糖监测结果进行剂量调整。主要通过刺激胰岛β细胞分泌胰岛素，增加体内的胰岛素水平而降低血糖。磺脲类药物可以使HbA1c降低1%~2%。磺脲类药物如果使用不当可以导致低血糖，特别是老年患者和肝、肾功能不全者。磺脲类会增加体重。轻度、中度肾功能不全的患者，宜选择格列喹酮。(2)格列奈类：常用药物有瑞格列奈和那格列奈。多从小剂量开始应用，而后根据血糖监测结果进行剂量调整。主要通过刺激胰岛素的早时相分泌而降低餐后血糖，具有吸收快、起效快和作用时间短的特点，可降低HbA1c0.3%~1.5%。常见副作用是低血糖和体重增加，但与磺脲类药物相比，发生频率较低、程度较轻。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类", "subject_type": "药品名称", "object": {"@value": "肝、肾功能不全者"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝、肾功能不全者"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肝、肾功能不全者"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "增加体重", "subject_type": "不良反应", "object": {"@value": "磺脲类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "磺脲类"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(6)其他肾素-血管紧张素系统(RAS)阻断剂：ACEI或ARB类药物可以降低患者血浆醛固酮水平，但有研究发现有40%服用上述药物的患者其血浆醛固酮水平并未下降，反而升高到了其治疗前的浓度水平，称之为“醛固酮逃避”现象，这可能与肾病进展过程有关，具体机制尚不明确。早期一些短期临床研究表明，ACEI/ARB与醛固酮受体拮抗剂(MRA)联合治疗在降低1型DN患者尿白蛋白水平方面的益处，但是需要更多临床研究证实。赖诺普利联合螺内酯组与赖诺普利+安慰剂组患者相比，其尿白蛋白水平明显降低。因螺内酯可使血钾升高的风险增高，应用时需监测血钾。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "ACEI", "subject_type": "药品名称", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ARB类药物", "subject_type": "药品名称", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血浆醛固酮", "subject_type": "检查指标", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血浆醛固酮水平", "subject_type": "检查指标", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ACEI/ARB", "subject_type": "药品名称", "object": {"@value": "1型DN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "醛固酮受体拮抗剂(MRA)", "subject_type": "药品名称", "object": {"@value": "1型DN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型DN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿白蛋白", "subject_type": "检查指标", "object": {"@value": "1型DN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "血钾升高", "subject_type": "不良反应", "object": {"@value": "螺内酯"}, "object_type": {"@value": "药品名称"}}]}
{"text": "中国成人糖尿病患病率高达9.7%，患者人数居全球首位。糖尿病防治的关键在于积极预防、早期诊断及尽早规范化干预。糖尿病管理的最终目标是防治糖尿病慢性并发症，包括微血管并发症和动脉粥样硬化性血管病(ASVD)，以提高患者生活质量、延长寿命。研究显示，我国门诊T2DM患者血糖达标率仅32.6%；在心血管风险因素控制方面，我国T2DM患者血糖、血压、血脂达标率分别为47.7%、28.4%和36.1%，仅5.6%的患者3项指标均达标。目前，我国糖尿病患者血糖控制现状及临床合理用药情况不容乐观。大部分中国T2DM患者伴有餐后血糖(PPG)升高。流行病学筛查诊断的糖尿病患者中，单纯PPG升高患者的比例达50%，糖尿病前期中约70%为单纯性IGT。PPG增高是导致HbA1c升高的主要原因之一，PPG升高与糖尿病慢性并发症发生发展有相关性。因此，控制PPG是促使HbA1c控制达标以防治糖尿病慢性发症的重要策略。糖尿病的管理中，控制PPG的手段与控制FPG的策略和手段有明显不同。为使广大从事糖尿病防治的医务人员更全面了解餐后高血糖的病理生理特征、临床意义和更好地应用针对餐后高血糖的控制措施，国内部分专家基于国内外临床证据及临床经验，制订了《中国2型糖尿病患者餐后高血糖管理专家共识》，以期为临床医生更好地管理糖尿病提供参考。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血脂", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "餐后血糖(PPG)", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "PPG", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "PPG", "subject_type": "检查指标", "object": {"@value": "糖尿病慢性并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "PPG", "subject_type": "检查指标", "object": {"@value": "糖尿病慢性发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病慢性发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "PPG", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "对于重度非增殖型糖尿病视网膜病变(non-proli- ferative diabetic retinopathy，NPDR) 及增殖型糖尿病视网膜病变(proliferative diabetic retinopathy，PDR) 的糖尿病患者需请眼科医师会诊。高危PDR和部分严重NPDR患者可行激光光凝术。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "增殖型", "subject_type": "分期分型", "object": {"@value": "增殖型糖尿病视网膜病变(proliferative diabetic retinopathy，PDR)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "非增殖型", "subject_type": "分期分型", "object": {"@value": "非增殖型糖尿病视网膜病变(non-proli- ferative diabetic retinopathy，NPDR)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "激光光凝术", "subject_type": "非药治疗", "object": {"@value": "PDR"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "激光光凝术", "subject_type": "非药治疗", "object": {"@value": "NPDR"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.血糖控制目标值：对2型糖尿病合并慢性肾脏病患者的血糖控制目标应遵循个体化原则，尽量避免低血糖的发生。《中国成人2型糖尿病HbA1c控制目标的专家共识)建议对2型糖尿病合并中重度慢性肾脏病患者的HbA1c可适当放宽控制在7.0%~9.0%，以此一方面避免血糖水平控制过低而出现低血糖，另一方面避免血糖水平过高而出现代谢异常及感染。当慢性肾脏病导致红细胞寿命缩短时,HbA1c检测结果可能被低估。在晚期慢性肾脏病患者，使用糖化白蛋白可更可靠地反映血糖控制水平，同时应监测空腹及餐后血糖以更全面地了解血糖控制情况。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "中重度", "subject_type": "分期分型", "object": {"@value": "中重度慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "中重度慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "中重度慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "中重度慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "血糖水平过高", "subject_type": "发病机制", "object": {"@value": "代谢异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "血糖水平过高", "subject_type": "发病机制", "object": {"@value": "感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "晚期", "subject_type": "分期分型", "object": {"@value": "晚期慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "晚期慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "晚期慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "糖化白蛋白", "subject_type": "检查指标", "object": {"@value": "晚期慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "晚期慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(7)联合用药：糖尿病肾病患者在血压控制不佳时，可在ACEI/ARB的基础上选择其他降压药物联合使用。一些早期小型临床研究结果表明，ACEI联合ARB在糖尿病肾病患者中具有较高的耐受性和有效率，可使糖尿病患者的尿蛋白水平显著降低，有效降低了患者舒张压。然而，较新的研究表明ACEI与ARB联合治疗疗效并不优于单药治疗，联合ARB及ACEI后，糖尿病患者血清肌酐水平、ESRD发生及死亡率方面并无明显差异。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ACEI", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ARB", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ACEI", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ARB", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿蛋白", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "舒张压", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ACEI", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ARB", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ARB", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ACEI", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血清肌酐", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "·糖尿病合并多脏器功能不全如肝肾心肺功能不全等；", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝肾心肺功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肝肾心肺功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "肝肾心肺功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肺", "subject_type": "患病部位", "object": {"@value": "肝肾心肺功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "目前用于临床的胰岛素包括动物胰岛素、人胰岛素和胰岛素类似物。由于潜在免疫原性等问题，动物胰岛素在大多数地区使用逐渐减少，人胰岛素和胰岛素类似物使用逐渐增多。人胰岛素与人体自身分泌的胰岛素结构完全相同，胰岛素类似物通过改变胰岛素结构而改变胰岛素药代动力学特性。短期研究表明，胰岛素类似物与人胰岛素相比，控制HbA1c的能力相似，但使用更方便，在减少低血糖发生的潜在危险方面胰岛素类似物优于人胰岛素，这一优势主要表现在1型糖尿病患者。目前尚缺乏胰岛素类似物对患者长期终点事件，如死亡率、糖尿病相关微血管和大血管并发症等方面的证据。多项meta分析及临床研究显示，在2型糖尿病患者中，胰岛素类似物在HbA1c达标率、胰岛素剂量、体重、日问低血糖、严重低血糖和不良反应方面与人胰岛素相当，长效胰岛素类似物对夜间低血糖的改善优于NPH。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "人胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素类似物", "subject_type": "药品名称", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "人胰岛素", "subject_type": "药品名称", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素类似物", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素类似物", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "人胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "长效胰岛素类似物", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "NPH", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "指南均未推荐在1型糖尿病患者中使用。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "5.单药治疗的降糖疗效：一项双盲、安慰剂对照、剂量效应研究显示，在减去安慰剂效应后，不同剂量的二甲双胍单药治疗可使FPG降低1.05~4.33mmol/L，HbA1c下降0.9%~2.o%。另有研究显示，二甲双胍可使PPG降低2.58mmol/L。中国新诊断T2DM患者中，二甲双胍可使HbA1c降低1.8%(可能含安慰剂效应)(Ⅰ级)。在新诊断的经过短期胰岛素治疗后的中国T2DM患者中开展的随机分组、前瞻性对照研究结果显示，二甲双胍(2000mg/d)的疗效与甘精胰岛素的降糖疗效相当。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "·艾塞那肽有罕见肾功能改变报告，不推荐用于终末期肾病或严重肾功能不全患者；利拉鲁肽由于经验有限，也不推荐用于肾脏终末期患者。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "肾功能改变", "subject_type": "不良反应", "object": {"@value": "艾塞那肽"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "终末期", "subject_type": "分期分型", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.在治疗NAFLD方面的作用：中华医学会肝病学分会脂肪肝和酒精性肝病学组布《中国非酒精性脂肪性肝病诊疗指南(2010年修订版)》提出：除非存在明显的肝损害(如血清转氨大于3倍正常值上限)、肝功能不全或失代偿期肝硬化等情况，否则NAFLD患者可安全使用胰岛素增敏剂(二甲双胍和噻唑烷二酮类)等药物(V级)。有14项临床研究评价了二甲双胍对NAFLD患者肝脏组织学、血清酶学和IR等指标的改善情况，所有研究均显示HOMA-IR明显改善，13项研究显示血清酶学(谷丙转氨酶、谷草转氨酶)明显下降；5项研究显示二甲双胍对肝脏炎症、脂肪变性和纤维化有改善。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "脂肪肝"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "酒精性肝病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "酒精性", "subject_type": "分期分型", "object": {"@value": "酒精性肝病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "非酒精性脂肪性肝病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "非酒精性脂肪性", "subject_type": "分期分型", "object": {"@value": "非酒精性脂肪性肝病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血清转氨", "subject_type": "检查指标", "object": {"@value": "肝损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "失代偿期肝硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "失代偿期", "subject_type": "分期分型", "object": {"@value": "失代偿期肝硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素增敏剂", "subject_type": "药品名称", "object": {"@value": "NAFLD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "NAFLD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "噻唑烷二酮类", "subject_type": "药品名称", "object": {"@value": "NAFLD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "NAFLD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "临床问题6：DPP-4i是否可用于超重/肥胖2型糖尿病患者的降糖治疗? ", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4i", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "Huffman等对超重者进行了6个月CRD干预(能量摄入减少25%)，发现与非CRD相比，CRD组的胰岛素敏感性有明显改善，并认为这是降低体重的原因。Yoshimura等对内脏脂肪面积≥100cm2的成人进行12周CRD(CRD目标：25kcal/kg，基线能量摄入约为30kcal/kg)干预后，有效降低了体重、脂肪组织重量、内脏脂肪面积以及动脉粥样硬化的发生风险。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "CRD干预", "subject_type": "非药治疗", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "动脉", "subject_type": "患病部位", "object": {"@value": "动脉粥样硬化"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "由此可见，胰岛素早相分泌异常不仅是2型糖病的早期表现，并将持续整个病程，同时也是餐后高血糖的主要原因。《中国2型糖尿病患者餐后高血糖管理专家共识》建议，短效人胰岛素和速效胰岛素类似物均可用于补充餐时胰岛素的不足以控制餐后高血糖。", "spo_list": [{"Combined": false, "predicate": "发病机制", "subject": "胰岛素早相分泌异常", "subject_type": "发病机制", "object": {"@value": "2型糖病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "短效人胰岛素", "subject_type": "药品名称", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "速效胰岛素类似物", "subject_type": "药品名称", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)HUA与神经退行性疾病：阿尔茨海默病是最常见的痴呆类型，轻度认知功能障碍和阿尔茨海默病患者血尿酸水平较正常人群低，高尿酸饮食可延缓轻度认知功能障碍患者转变为阿尔茨海默病的进程。血尿酸水平升高有助于减少阿尔茨海默病的发生，保护阿尔茨海默病患者的认知功能损伤。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血尿酸水平", "subject_type": "检查指标", "object": {"@value": "轻度认知功能障碍"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸水平", "subject_type": "检查指标", "object": {"@value": "阿尔茨海默病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "高尿酸饮食", "subject_type": "非药治疗", "object": {"@value": "轻度认知功能障碍"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸水平", "subject_type": "检查指标", "object": {"@value": "阿尔茨海默病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "认知功能损伤", "subject_type": "临床表现", "object": {"@value": "阿尔茨海默病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(二)肾功能不全", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "七、T2DM患者血脂管理中药物不良事件的监测和处理", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.慢性疾病终末期(如心功能NYHA Ⅲ-Ⅳ级、慢性肾功能不全、恶性肿瘤伴转移、中重度认知功能障碍等)患者的HbA1c可放宽至<8.5%。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心功能NYHA Ⅲ-Ⅳ级"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "心功能NYHA Ⅲ-Ⅳ级"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "Ⅲ-Ⅳ级", "subject_type": "分期分型", "object": {"@value": "心功能NYHA Ⅲ-Ⅳ级"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "慢性肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "慢性肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "恶性", "subject_type": "分期分型", "object": {"@value": "恶性肿瘤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "转移", "subject_type": "分期分型", "object": {"@value": "恶性肿瘤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "恶性肿瘤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "认知功能障碍"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "每天2次以上胰岛素注射时原则上不联用胰岛素促泌剂(对于肥胖且胰岛素用量较大，已联合上述药物治疗效果不满意者，可试用GLP-1受体激动剂)。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "每天2次", "subject_type": "用药频率", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "冲击波碎石禁用于结石远端器质性梗阻、肾功能不全、未获控制的尿路感染。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "尿路", "subject_type": "患病部位", "object": {"@value": "尿路感染"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病微血管并发症治疗的推荐意见见表3。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "在限制总能量、减轻体重的前提下，宏量营养素比例和质量选择对PCOS患者的生育、代谢、心理的影响存在着细微差别。低碳水化合物或低血糖指数饮食可更明显降低胰岛素抵抗、纤维蛋白原、总胆固醇和高密度脂蛋白胆固醇，低血糖指数饮食明显改善月经周期和生活质量，高蛋白膳食可明显改善抑郁和增强自尊；反之，高碳水化合物饮食明显增加游离睾酮指数。有研究显示，肥胖PCOS患者使用限能量代餐可降低患者BMI，改善代谢及激素指标，增加受孕几率。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "限能量代餐", "subject_type": "非药治疗", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.加强公共政策与立法，营造健康支持性环境。将健康融入所有政策，落实部门职责。将糖尿病等慢性病防控纳入《基本医疗卫生法》制订，推动营养改善条例、公共场所控烟条例等立法进程。制订可落实、可持续发展的国家糖尿病综合防治方案，开展全民健康生活方式行动，普及合理膳食、戒烟限酒、适量运动，开展“三减三健”专项活动，促进健康行为形成。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "合理膳食", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "戒烟限酒", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "适量运动", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.心血管保护作用机制：二甲双胍可能通过减少心血管疾病的危险因素而达到心血管保护。心血管疾病的危险因素包括血脂异常、IR、肥胖、高血压、NAFLD等。控制危险因素是心血管保护的重要方式之一。二甲双胍目前已经被证实可以降低血糖、改善NAFLD和IR(尤其是肝脏和肌肉)、减轻体重、改善血脂(主要是改善TG、LDL-C及TC水平，对HDL-C改变不明显)和抗凝等此外，二甲双胍可以直接改善血管内皮细胞功能，增加血流量。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "NAFLD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "IR"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "利司那肽治疗T2DM合并ACS患者的心血管事件评估(ELIXA)研究是一项随机、双盲、安慰剂对照的临床试验，纳入6068例在既往180d内发生过ACS的T2DM患者，中位随访时间为25个月。结果显示，在常规降糖治疗基础上，与安慰剂组相比，利司那肽组首要心血管事件复合终点(3终点MACE+不稳定性心绞痛住院)的风险达到非劣效性标准( HR 1.02，95%CI 0.89~1.17)，且不增加心力衰竭住院风险。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "利司那肽", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利司那肽", "subject_type": "药品名称", "object": {"@value": "ACS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利司那肽", "subject_type": "药品名称", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "不稳定性", "subject_type": "分期分型", "object": {"@value": "不稳定性心绞痛"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "不稳定性心绞痛"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "GLP-1受体激动剂利拉鲁肽是目前在中国上市的降糖药物中唯一被CVOT证实具有心血管获益的降糖药物。利拉鲁肽在糖尿病患者中的心血管结局评估(LEADER)研究纳入9340例伴有心血管疾或心血管危险因素的T2DM患者，其中81.3%的患者既往有心血管病史(包括心肌梗死、卒中或短暂性脑缺血发作、曾行血运重建术、冠状动脉或颈动脉或下肢动脉狭窄≥50%)，中位随访时间为3.8年。结果显示，在常规治疗基础上，与安慰剂相比利拉鲁肽可使3终点MACE风险降低13%(P<0.001)-心血管死亡风险降低22%(P=0.007)，扩展的心血管事件复合终点(心血管死亡、非致死性心肌梗死、非致死性卒中、血运重建、不稳定性心绞痛住院或心力衰竭住院)风险降低12%(P=0.005)，且不增加心力衰竭住院风险。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "利拉鲁肽", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脑", "subject_type": "患病部位", "object": {"@value": "短暂性脑缺血发作"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "短暂性", "subject_type": "分期分型", "object": {"@value": "短暂性脑缺血发作"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "冠状动脉", "subject_type": "患病部位", "object": {"@value": "冠状动脉或颈动脉或下肢动脉狭窄"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "颈动脉", "subject_type": "患病部位", "object": {"@value": "冠状动脉或颈动脉或下肢动脉狭窄"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢动脉", "subject_type": "患病部位", "object": {"@value": "冠状动脉或颈动脉或下肢动脉狭窄"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管死亡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管死亡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "非致死性心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "非致死性", "subject_type": "分期分型", "object": {"@value": "非致死性心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "非致死性", "subject_type": "分期分型", "object": {"@value": "非致死性卒中"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "不稳定性", "subject_type": "分期分型", "object": {"@value": "不稳定性心绞痛"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "不稳定性心绞痛"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "高血压与高血糖并存可使ASCVD发生和发展风险显著增加，从而增加T2DM患者的病死率。研究显示，控制高血压可显著降低ASCVD发生和发展的风险，降压治疗的心血管获益主要源自血压控制本身。因此，对于大多数T2DM合并高血压患者，血压控制目标为<140/80mmHg；对于年轻、没有并发症、合并白蛋白尿或糖尿病慢性肾脏病(CKD)患者，可将收缩压控制在<130mmHg。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "收缩压", "subject_type": "检查方法", "object": {"@value": "白蛋白尿"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "收缩压", "subject_type": "检查方法", "object": {"@value": "糖尿病慢性肾脏病(CKD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "糖尿病慢性肾脏病(CKD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "糖尿病慢性肾脏病(CKD)"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.餐后高血糖的控制目标：控制餐后血糖对HbA1c达标及减少血糖波动非常重要。设定HbA1c目标值应根据患者年龄、病程、预期寿命、并发症严重程度、低血糖发生风险等因素个体化确定，与此相对应的PPG控制目标也应遵循个体化原则。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "餐后血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "PPG", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "既往的研究已充分证实，合并血脂异常可进一步增加T2DM患者的大血管和微血管并发症风险。因此，T2DM患者除了重视血糖控制外，还应重视血脂管理。经过积极的生活方式干预仍不能改善血脂水平者(基于ASCVD危险程度制定的目标)，需加用调脂药物治疗。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂水平", "subject_type": "检查方法", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "调脂药物", "subject_type": "药品名称", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "格列本脲本身及其代谢产物均具有降糖活性，肾功能不全的T2DM患者使用格列本脲容易发生严重的低血糖事件；格列美脲的代谢产物在GFR降低的患者中没有额外蓄积风险；其他常用的磺脲类药物如格列喹酮、格列齐特及格列吡嗪，代谢产物均为非活性物质，尤其是格列喹酮，其代谢产物只有5%经肾脏排泄，受肾功能的影响很小，其可用于轻、中度肾功能不全的糖尿病患者。ADVANCE研究发现，格列齐特缓释片具有肾脏保护作用，可降低患者蛋白尿和肾脏事件风险。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "格列本脲", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "蛋白尿", "subject_type": "不良反应", "object": {"@value": "格列齐特缓释片"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "肾脏事件", "subject_type": "不良反应", "object": {"@value": "格列齐特缓释片"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "T2DM心血管结局(HEART2D)研究显示，在急性心肌梗死后的T2DM患者中，餐时胰岛素或基础胰岛素治疗2.7年后，首要心血管事件复合终点(3终点MACE+冠状动脉血运重建或ACS住院)的风险相似( HR 0.98，95%CI 0.88~1.21)。事后亚组分析提示，在年龄>65.7岁亚组中，与基础胰岛素组相比，餐时胰岛素组首次心血管事件的发生风险更低(HR 0.69，95%CI 0.49~0.96)，表现为发生比例更低、时间更晚。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "急性", "subject_type": "分期分型", "object": {"@value": "急性心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "急性心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "餐时胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "基础胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "2.7年", "subject_type": "持续时间", "object": {"@value": "餐时胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "2.7年", "subject_type": "持续时间", "object": {"@value": "基础胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(5)预混胰岛素类似物应在餐前即刻注射或餐后立即注射。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "餐前即刻注射", "subject_type": "用药方法", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "餐后立即注射", "subject_type": "用药方法", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "4.糖尿病神经根神经丛病：也称糖尿病性肌萎缩或痛性肌萎缩，为少见的糖尿病并发症，常见于腰骶神经根神经丛分布区。急性或亚急性起病，表现为受累神经支配区的疼痛和感觉障碍，相继出现肌肉无力和萎缩，以下肢近端为主，可以单侧或双侧受累，诊断时需要首先除外其他原因的神经根或神经丛病变。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "神经根", "subject_type": "患病部位", "object": {"@value": "糖尿病神经根神经丛病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经丛", "subject_type": "患病部位", "object": {"@value": "糖尿病神经根神经丛病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "腰骶神经根神经丛分布区", "subject_type": "患病部位", "object": {"@value": "糖尿病神经根神经丛病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "糖尿病性", "subject_type": "分期分型", "object": {"@value": "糖尿病性肌萎缩"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肌", "subject_type": "患病部位", "object": {"@value": "糖尿病性肌萎缩"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "腰骶神经根神经丛分布区", "subject_type": "患病部位", "object": {"@value": "糖尿病性肌萎缩"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "痛性", "subject_type": "分期分型", "object": {"@value": "痛性肌萎缩"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肌", "subject_type": "患病部位", "object": {"@value": "痛性肌萎缩"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "腰骶神经根神经丛分布区", "subject_type": "患病部位", "object": {"@value": "痛性肌萎缩"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "腰骶神经根神经丛分布区", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经根", "subject_type": "患病部位", "object": {"@value": "神经根或神经丛病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经丛", "subject_type": "患病部位", "object": {"@value": "神经根或神经丛病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "·新诊断2型糖尿病需进行慢性并发症筛查或评估，或血糖较高需考虑胰岛素强化治疗；", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2型糖尿病合并慢性肾脏病患者口服降糖药用药原则中国专家共识", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.糖尿病患者手术当日停用口服降糖药和非胰岛素注射剂。磺脲类和格列奈类口服降糖药可能造成低血糖，术前应停用至少24小时；二甲双胍有引起乳酸酸中毒的风险，肾功能不全者术前停用24~48小时。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "非胰岛素注射剂", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "格列奈类口服降糖药"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列奈类口服降糖药"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "乳酸酸中毒", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.概述：控制高血糖与微血管、大血管病变发生的风险下降相关。临床研究证实，糖尿病患者早期进行积极有效的降糖治疗，能够显著降低血管并发症的发生风险，而在病程较长的患者中，强化降糖并未带来心血管获益。所以糖尿病患者在早期即维持良好的血糖控制至关重要。随着病情进展，T2DM患者胰岛β细胞功能逐渐减退，胰岛素补充或替代治疗成为T2DM高血糖管理的重要手段。对于使用1~2种口服药血糖控制不佳的患者，即可以考虑联合基础胰岛素注射以进一步改善血糖控制。对于口服降糖药与基础胰岛素联合使用后血糖仍无法达标的患者，可以使用基础胰岛素联合1~3次餐时胰岛素治疗进一步控制血糖。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "微血管、大血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "微血管、大血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "1~3次", "subject_type": "用药频率", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "临床研究显示，相对于餐前血糖而言，餐后血糖的良好控制可更好地减少并发症，尤其是巨大儿出生；相对于餐后2h血糖，控制好餐后1h血糖，产科结局更好。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "餐前血糖", "subject_type": "检查指标", "object": {"@value": "巨大儿"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "餐后血糖", "subject_type": "检查指标", "object": {"@value": "巨大儿"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "一般情况下，不推荐磺脲类药物联合胰岛素治疗T2DM，但胰岛细胞尚有部分分泌功能的T2DM患者可考虑使用磺脲类药物联合基础胰岛素治疗。当单一或联合口服降糖药无法满意控制血糖时，口服降糖药物(包括磺脲类药物)联合基础胰岛素可以作为一种胰岛素起始的治疗方案。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "基础胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "基础胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "②DPP-4抑制剂在肾功能不全患者中的应用：", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "研究表明，随着HbA1c水平的升高，发生CVD的危险性相对增加，而且糖尿病病史越长的患者治疗后CVD危险性减低越小；流行病学调查结果的meta分析显示，HbA1c每增加1%，2型糖尿病心血管事件的相对危险性为1.18，1型糖尿病为1.15；ACCORD亚组分析也提示，既往无CVD且HbA1c<8%的患者强化治疗后CVD的发生及其死亡率明显下降，这与总体患者(平均病程10年，35%发生过CVD)的研究结果恰恰相反。另一方面，DCCT-EDIC经过后续8年的随访证实1型糖尿病患者早期强化治疗对微血管有持久的保护作用，并延缓动脉粥样硬化的发展；UKPDS-80经过后续10年的长期随访发现对新诊断的2型糖尿病患者，强化降糖治疗不仅能减少微血管并发症的发生，还能显著降低患者的心肌梗死发生率和总死亡率。所以，观察到严格控制血糖对大血管的保护作用可能需要较长的时间。总之，不管从病理生理还是流行病学的角度，在糖尿病诊断时就严格控制血糖，同时控制体重、血脂、血压，抗血小板治疗，全面降低CVD危险因素会延缓慢性并发症的发生、发展。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "CVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "动脉", "subject_type": "患病部位", "object": {"@value": "动脉粥样硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1型糖尿病和2型糖尿病间的鉴别可参考表1。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "上述研究数据表明，我国T2DM患者合并ASCVD的情况非常普遍，已日益成为糖尿病管理的一个巨大挑战，值得临床医生给予高度重视。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病微血管并发症预防的推荐意见见表2。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)一线备选：尽管二甲双胍被作为一线用药，但当患者无法耐受二甲双胍治疗或是存在禁忌证时，可考虑将磺脲类药物作为一线用药。该共识还指出，对于新诊断的糖化血红蛋白>7.5%的2型糖尿病患者，可选择作用机制互补的两种降糖药物联合应用，结合中国国情和患者特点，磺脲类药物联合二甲双胍是推荐的联合治疗方案之一。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "二甲双胍应用于临床已有50多年的历史，是目前全球应用最广泛的口服降糖药之一。近年来，虽然有多个新型降糖药物上市，但二甲双胍仍是全球使用量迅速增加的经典口服降糖药物。二甲双胍有良好的单药/联合治疗的疗效和安全性证据、良好的卫生经济学效益证据，以及心血管并发症预防等方面明确的临床证据。因此，该药已经成为全球控制糖尿病的核心药物。二甲双胍在我国已经有20多年的临床应用经验。1995年，美国食品药品监督管理局(FDA)正式批准二甲双胍用于治疗T2DM。2004年，欧盟正式批准二甲双胍用于治疗10岁及上T2DM患儿。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病周围神经病变(diabetic peripheral neuropathy，DPN)可以通过以下几种方法得到诊断。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "糖尿病周围神经病变(diabetic peripheral neuropathy，DPN)"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "碳酸氢钠(小苏打)口服：每次0.5~1g，每日3次。在CKD患者中碳酸氢钠可同时改善代谢性酸中毒，因此具有双重功效。但也需要注意钠负荷诱发患者充血性心力衰竭和水肿的可能。枸橼酸合剂口服时应注意监测CKD患者的血钾水平，避免发生高钾血症。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "碳酸氢钠(小苏打)"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "每次0.5~1g", "subject_type": "用药剂量", "object": {"@value": "碳酸氢钠(小苏打)"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日3次", "subject_type": "用药频率", "object": {"@value": "碳酸氢钠(小苏打)"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "碳酸氢钠", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "枸橼酸合剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "高钾血症", "subject_type": "不良反应", "object": {"@value": "枸橼酸合剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血钾", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.胃肠道反应与剂量的关系及处理原则：二甲双胍引起的胃肠道反应发生多出现在治疗的早期(绝大多数发生于前10周)，多数患者随着治疗时间的延长，可逐渐耐受或症状消失。国外报道，即使二甲双胍较大剂量(1000mg/d)起始治疗，其胃肠道反应发生率为28%，在1000mg增至2000mg/d时胃肠道反应差异无统计学意义。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "胃肠道反应", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道反应", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道反应", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1000mg增至2000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "2.高血压：高血压的定义为平均收缩压或舒张压大于同年龄、性别和身高血压值的第95百分位数[若第95百分位数高于130/80mmHg(17.3/10.6kPa，1mmHg=0.133kPa) ，则标准为>130/80 mmHg(17.3/10.6kPa) ]。高血压应该非同日复测3次血压证实。如为90~95百分位数则为正常高限血压。TODAY研究发现，在633例平均病程7个月的2型糖尿病青少年患者中13.6%存在高血压，当随访至3.9年时，这一比例上升到33.8%*。高血压的起始治疗包括减轻体重，低盐饮食，加强锻炼。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "复测3次血压", "subject_type": "检查方法", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "低盐饮食", "subject_type": "非药治疗", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "加强锻炼", "subject_type": "非药治疗", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "减轻体重", "subject_type": "非药治疗", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "5.定量感觉测定：可以定量评估深感觉和痛温觉的异常，常用于DPN的临床研究；对于痛觉纤维的评估，有助于小纤维神经病变的判断，对糖尿病自主神经病的诊断有辅助作用。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "定量感觉测定", "subject_type": "检查方法", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "定量感觉测定", "subject_type": "检查方法", "object": {"@value": "小纤维神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "定量感觉测定", "subject_type": "检查方法", "object": {"@value": "糖尿病自主神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "小纤维神经", "subject_type": "患病部位", "object": {"@value": "小纤维神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "自主神经", "subject_type": "患病部位", "object": {"@value": "糖尿病自主神经病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "因此，本共识建议将免散瞳眼底照相机作为基层医疗卫生机构筛查DR的首选设备进行配置，在无相关技术及设备的情况下，建议转诊至上一级医院进行检查。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "免散瞳眼底照相机", "subject_type": "检查方法", "object": {"@value": "DR"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "临床应用共识还强调，DPP-4抑制剂不能用于1型糖尿病或糖尿病酮症酸中毒的患者；不推荐用于妊娠期、哺乳期妇女以及儿童。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "推荐6：T2DM患者ASCVD极高危人群调脂的主要目标为LDL-C<1.8mmol/L，次要目标Non-HDL-C<2.6mmol/L，其他目标TG<1.7mmol/L。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "Non-HDL-C", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "TG", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "Non-HDL-C", "subject_type": "检查指标", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "TG", "subject_type": "检查指标", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "HUA常伴随其他系统疾病，如其他代谢性疾病、肾脏疾病、心脑血管疾病等。治疗合并这些疾病的HUA时应遵循多学科联合治疗原则。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心脑血管", "subject_type": "患病部位", "object": {"@value": "心脑血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.2 每日2次预混胰岛素(包括预混人胰岛素和预混胰岛素类似物)治疗的SMBG方案每日2次预混胰岛素治疗的患者在血糖达标前每周监测3天空腹和晚餐前血糖，每2周复诊1次，复诊前1天加测5个时间点血糖；在血糖达标后每周监测3次血糖，即空腹、晚餐前和晚餐后血糖，每月复诊1次，复诊前1天加测5个时间点血糖(见表3)。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "每日2次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日2次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "GLP-1受体激动剂适用于成人2型糖尿病患者。艾塞那肽是在国内最早上市的GLP-1受体激动剂，用于改善2型糖尿病患者的血糖控制，适用于单用二甲双胍、磺脲类，以及二甲双胍合用磺脲类，而血糖仍控制不佳的患者(表1)。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "GLP-1受体激动剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "艾塞那肽", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "长效胰岛素类似物在手术当日早晨予常规剂量的5 0%~100%；中效胰岛素如为晚间注射，术前1天予常规剂量的75%，手术当日早晨予常规剂量的50%~75%；预混胰岛素在手术当日早晨应更换为基础胰岛素，剂量为预混胰岛素中的中效成分的50%~75%。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "中效胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "d.沙格列汀和阿格列汀上市后有报告严重超敏反应(包括速发过敏反应和血管性水肿)。如果疑有沙格列汀严重超敏反应，则停止使用，评估是否还存在其他可能的原因，并改用别的方案治疗糖尿病。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "严重超敏反应", "subject_type": "不良反应", "object": {"@value": "沙格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "速发过敏反应", "subject_type": "不良反应", "object": {"@value": "沙格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "血管性水肿", "subject_type": "不良反应", "object": {"@value": "沙格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "严重超敏反应", "subject_type": "不良反应", "object": {"@value": "阿格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "速发过敏反应", "subject_type": "不良反应", "object": {"@value": "阿格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "血管性水肿", "subject_type": "不良反应", "object": {"@value": "阿格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "严重超敏反应", "subject_type": "不良反应", "object": {"@value": "沙格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "沙格列汀", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.饮食干预与PCOS：(1)限制总能量摄入：超重和肥胖的PCOS患者在减重时应以CRD为首选治疗。随机对照试验表明，CRD可改善肥胖PCOS女性的代谢及激素水平，每日饮食总能量中减少500~1000kcal，即在6~12个月减少7%~10%的原体重。(2)宏量营养素和血糖指数的选择：国内外研究显示，在限制总能量的基础上，高蛋白/低碳水化合物饮食(蛋白质30%、碳水化合物40%、脂肪30%，MHCD)和低蛋白/高碳水化合物饮食(蛋白质15%、碳水化合物55%、脂肪30%，CHCD)相比，均可降低体重和雄激素水平，MHCD明显增加胰岛素敏感性、减轻高胰岛素血症继而减轻胰岛素抵抗；低血糖指数饮食亦可通过降低PCOS患者(无论是否肥胖)胰岛素、睾酮水平，改善多毛和痤疮。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "饮食干预", "subject_type": "非药治疗", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "CRD", "subject_type": "非药治疗", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "CRD", "subject_type": "非药治疗", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "胰岛素", "subject_type": "检查指标", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "睾酮", "subject_type": "检查指标", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "快速建议指南推荐DPP-4抑制剂作为2型糖尿病患者的二线和三线治疗选择之一，指出在当二甲双胍或者其他降糖药物单药治疗后，如糖化血红蛋白水平仍未达标，可联合此类药物。2017版指南也同样将DPP-4抑制剂列为与二甲双胍进行二联或三联治疗的选择之一。在这一点上，两个指南并没有分歧，然而。从最新的国内研究证据来看，在二甲双胍高剂量(2000毫克/天)单药治疗的基础上，加用DPP-4抑制剂只能使糖化血红蛋白进一步下降约0-2%，而减重作用反而更差一些，而在欧美人群中进行的研究中，糖化血红蛋白进一步下降了约0.5%，这是否是降糖药物的又一个中国特色呢(前一个中国特色是α-糖苷酶抑制剂的“西方不亮东方亮”——本刊注)?不过，DPP-4抑制剂可以带来多重获益。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2000毫克/天", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "糖化血红蛋白", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "老年人大多有不同程度的肝肾功能减退，或常患多种慢性疾病，需服用多种药物，需注意药物间的相互作用和不良反应；调脂药物剂量的选择需要个体化，起始剂量不宜太大；当老年患者年龄>75岁时，不推荐高强度他汀治疗，推荐中等强度他汀治疗，并根据治疗效果调整调脂药物剂量和监测肝肾功能、肌酸激酶。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝肾功能减退"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肝肾功能减退"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "调脂药物", "subject_type": "药品名称", "object": {"@value": "肝肾功能减退"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "中等强度他汀", "subject_type": "药品名称", "object": {"@value": "肝肾功能减退"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "调脂药物", "subject_type": "药品名称", "object": {"@value": "肝肾功能减退"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肝肾功能", "subject_type": "检查方法", "object": {"@value": "肝肾功能减退"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肌酸激酶", "subject_type": "检查指标", "object": {"@value": "肝肾功能减退"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.在积极使用胰岛素的同时，应合理使用胰岛素，避免过度应用。对于肥胖(体重指数>28kg/m2)的患者，应在口服药充分治疗的基础上起始胰岛素治疗。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "HUA促进缺血性卒中发生，增加卒中后早期死亡及复发，对HUA进行长期管理，有效降低血尿酸水平可以减少缺血性卒中的发生及不良预后，其治疗起始目标和最终目标参照相关章节。仅对急性缺血性卒中溶栓患者建议短期内将血尿酸保持在较高水平有助于改善临床症状及预后。", "spo_list": [{"Combined": false, "predicate": "患病病因", "subject": "HUA", "subject_type": "患病病因", "object": {"@value": "缺血性卒中"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸水平", "subject_type": "检查指标", "object": {"@value": "缺血性卒中"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸", "subject_type": "检查指标", "object": {"@value": "急性缺血性卒中"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "女性生殖道感染大部分发生在用药的初始4个月内，最常见的是外阴阴道真菌感染、阴道念珠菌病和外阴阴道炎；男性生殖道感染大部分发生在用药第一年内，最常见的是念珠菌性龟头炎和阴茎包皮炎。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "生殖道", "subject_type": "患病部位", "object": {"@value": "生殖道感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "外阴阴道", "subject_type": "患病部位", "object": {"@value": "外阴阴道真菌感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "阴道", "subject_type": "患病部位", "object": {"@value": "阴道念珠菌病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "外阴阴道", "subject_type": "患病部位", "object": {"@value": "外阴阴道炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "生殖道", "subject_type": "患病部位", "object": {"@value": "生殖道感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "龟头", "subject_type": "患病部位", "object": {"@value": "念珠菌性龟头炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "阴茎包皮", "subject_type": "患病部位", "object": {"@value": "阴茎包皮炎"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "格列美脲的代谢产物仍有降糖活性，其代谢产物及原型的60%经肾脏排泄。格列美脲用于CKD1~2期患者无需调整剂量；3a期减量；3b~5期禁用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "格列美脲", "subject_type": "药品名称", "object": {"@value": "CKD1~2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~2期", "subject_type": "分期分型", "object": {"@value": "CKD1~2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3a期", "subject_type": "分期分型", "object": {"@value": "CKD1~2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3b~5期", "subject_type": "分期分型", "object": {"@value": "CKD1~2期"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(4)格列喹酮与二肽基肽酶-Ⅳ抑制剂(DPP-4i)联合：格列喹酮与西格列汀联合治疗初诊2型糖尿病患者的研究结果显示：联合用药治疗后患者平均血糖FPG6.5mmol/L、PPG7.3mmol/L、HbA1c6.2%，降糖效果优于单用西格列汀(P<0.01)，无低血糖发生，且能够改善胰岛素抵抗。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西格列汀", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "平均血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.2 型糖尿病合并肾功能不全患者", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2 型", "subject_type": "分期分型", "object": {"@value": "2 型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "中国成人2型糖尿病HbA1c控制目标的专家共识", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "尽管ADA进一步提升了老年人HbA1c控制水平，但还缺乏老年糖尿病患者优化血糖管理是否能获益的研究证据。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "围术期血糖监测频率正常饮食的患者监测空腹血糖、三餐后血糖和睡前血糖。禁食患者每4~6小时监测一次血糖。术中血糖波动风险高，低血糖表现难以发现，应1~2小时监测一次血糖。危重患者、大手术或持续静脉输注胰岛素的患者，每0.5~1小时监测一次。体外循环手术中，降温复温期间血糖波动大，每15分钟监测一次。血糖≤70mg/dl(3.9mmol/L)时每5~15分钟监测一次直至低血糖得到纠正。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "持续", "subject_type": "持续时间", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉输注", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "中国20岁以上人口的2型糖尿病的患病率已经达到9.7%。传统降糖药物在2型糖尿病的防治中发挥了重要作用，但仍存在低血糖、体重增加、增加心血管风险以及药物继发失效使血糖控制进行性恶化等局限性。二肽基肽酶-4(dipeptidyl peptidase-4，DPP-4)抑制剂是近年研发的口服降糖药，因作用机制独特、疗效确定、低血糖发生率少、对体重中性作用或轻度降低、心血管安全性良好等特点受到普遍关注，临床应用越来越广泛。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "二肽基肽酶-4(dipeptidyl peptidase-4，DPP-4)抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二肽基肽酶-4(dipeptidyl peptidase-4，DPP-4)抑制剂"}, "object_type": {"@value": "药品名称"}}]}
{"text": "2.降压药物的选择：ACEI或ARB在糖尿病肾病中有控制血压、减少蛋白尿、延缓肾功能进展的作用，是目前治疗糖尿病肾病的药物中临床证据最多的，被推荐作为治疗糖尿病肾病的一线药物。糖尿病肾病或糖尿病合并高血压的患者首选使用其中一种，不能耐受时以另一种替代，使用期间应监测血清肌酐及血钾水平。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "ACEI", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ARB", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血清肌酐", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血钾水平", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血清肌酐", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血钾水平", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血清肌酐", "subject_type": "检查指标", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血钾水平", "subject_type": "检查指标", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)神经-缺血性溃疡：同时具有周围神经病变和周围血管病变，糖尿病足患者以此类居多。患者除了有神经性溃疡症状外还有下肢发凉感、间敏性跛行、静息痛等，足背动脉搏动减弱或消失，足部温减低，在进行清创换药时创面渗血少。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围血管", "subject_type": "患病部位", "object": {"@value": "周围血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "下肢发凉感", "subject_type": "临床表现", "object": {"@value": "神经性溃疡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "间敏性跛行", "subject_type": "临床表现", "object": {"@value": "神经性溃疡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "静息痛", "subject_type": "临床表现", "object": {"@value": "神经性溃疡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "足背动脉搏动减弱或消失", "subject_type": "临床表现", "object": {"@value": "神经性溃疡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "足部温减低", "subject_type": "临床表现", "object": {"@value": "神经性溃疡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "创面渗血少", "subject_type": "临床表现", "object": {"@value": "神经性溃疡"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "由于DPP-4i具有较好的有效性和安全性，在二线治疗时仍未使用DPP-4i治疗的患者，推荐DPP-4i作为2型糖尿病患者的三线治疗选择之一。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4i", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "神经电生理检查能够确认周围神经病变，并辅助判断其类型以及严重程度；对于无症状的糖尿病患者，电生理检查有助于发现其亚临床周围神经病变。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "神经电生理检查", "subject_type": "检查方法", "object": {"@value": "周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "电生理检查", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "电生理检查", "subject_type": "检查方法", "object": {"@value": "亚临床周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "亚临床", "subject_type": "分期分型", "object": {"@value": "亚临床周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "亚临床周围神经病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)抗血小板药物治疗：在糖尿病足患者，氯吡格雷是有适应证的抗血小板药物，与阿司匹林相比，氯吡格雷联合阿司匹林的抗血小板治疗能显著降低其全因死亡率(RR=0.73，95%CI：0.58~0.93)和心血管事件(RR=0.81，95%CI：0.67~0.98)发生，但严重出血的风险轻度增加。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "氯吡格雷", "subject_type": "药品名称", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿司匹林", "subject_type": "药品名称", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "心血管事件", "subject_type": "不良反应", "object": {"@value": "氯吡格雷"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "出血", "subject_type": "不良反应", "object": {"@value": "氯吡格雷"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "心血管事件", "subject_type": "不良反应", "object": {"@value": "阿司匹林"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "出血", "subject_type": "不良反应", "object": {"@value": "阿司匹林"}, "object_type": {"@value": "药品名称"}}]}
{"text": "老年糖尿病患者的饮食管理应当保证所需热量供给、合理调配饮食结构(适当限制甜食，多进食能量密度高且富含膳食纤维、升血糖指数低的食物)和进餐模式(少吃多餐、慢吃、后吃主食)，以保持良好的营养状况、改善生活质量。老年糖尿病患者的饮食结构中，碳水化合物供能应占50%~60%，没有肾脏病限制时，蛋白质的摄入量应为1.0~1.3g·kg-1·d-1，推荐以蛋、奶制品、动物肉类和大豆蛋白等优质蛋白为主。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "SGLT-2抑制剂通过抑制近端肾小管钠-葡萄糖重吸收、促进尿糖排泄降低血糖浓度。磺脲类药物联合SGLT-2抑制剂可进一步降低患者血糖，并减轻患者体重，但两者联用应注意低血糖风险。一项为期48周的随机、双盲、对照研究结果显示，格列美脲治疗血糖控制不佳的T2DM患者，联合使用达格列净(dapagliflozin)2.5mg/d、5mg/d、10mg/d后，HbA1c分别进一步下降0.41%、0.56%和0.73%，体重降幅分为1.36kg、1.54kg、2.41kg，低血糖发生率为9.7%~11.3%。一项为期24周随机双盲试验和28周开放标签延长期试验的研究结果显示，与安慰剂比较，鲁格列净(Luseogliflozin)联合磺脲类药物可进一步降低患者HbA1c0.63%，低血糖事件发生率为10.7%。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "减轻患者体重", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "减轻患者体重", "subject_type": "不良反应", "object": {"@value": "SGLT-2抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "SGLT-2抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列美脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列美脲", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2.5mg/d", "subject_type": "用药剂量", "object": {"@value": "达格列净(dapagliflozin)"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "5mg/d", "subject_type": "用药剂量", "object": {"@value": "达格列净(dapagliflozin)"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "10mg/d", "subject_type": "用药剂量", "object": {"@value": "达格列净(dapagliflozin)"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "达格列净(dapagliflozin)"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "达格列净(dapagliflozin)", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "鲁格列净(Luseogliflozin)"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病肾病@3.1 糖尿病肾病糖尿病肾病的主要病理改变表现为肾小球基底膜增厚、肾小球系膜区细胞外基质沉积，最终肾小球硬化伴或不伴肾小管间质纤维化。肾小球受累临床主要表现为进行性肾小球滤过率降低和尿白蛋白排泄增多。随着病程的进展出现严重肾小球硬化时，肾脏会逐步缩小。微量白蛋白尿是糖尿病肾病的早期临床表现，也是诊断糖尿病肾病的重要依据。糖尿病肾病自然病程分为5期：急性肾小球高滤过期、正常白蛋白尿期(尿蛋白排泄正常或间歇性白蛋白尿)、早期糖尿病肾病期(持续微量白蛋白尿)、临床糖尿病肾病期(显性白蛋白尿，部分进展为肾病综合征)、肾衰竭期。糖尿病肾病是糖尿病患者肾功能衰竭的主要原因。糖尿病肾病最新进展研究表明，肾小管损伤也应包括在糖尿病肾病概念中，其在疾病的早期即可出现，且可先于肾小球病变。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "肾小球基底膜增厚", "subject_type": "临床表现", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "肾小球系膜区细胞外基质沉积", "subject_type": "临床表现", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾小管", "subject_type": "患病部位", "object": {"@value": "肾小管间质纤维化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾小球", "subject_type": "患病部位", "object": {"@value": "肾小球硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "肾脏会逐步缩小", "subject_type": "临床表现", "object": {"@value": "肾小球硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "微量白蛋白尿", "subject_type": "临床表现", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "急性肾小球高滤过期", "subject_type": "分期分型", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "正常白蛋白尿期", "subject_type": "分期分型", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "早期糖尿病肾病期", "subject_type": "分期分型", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "临床糖尿病肾病期", "subject_type": "分期分型", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "肾衰竭期", "subject_type": "分期分型", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "肾小管损伤", "subject_type": "临床表现", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "肾小球病变", "subject_type": "临床表现", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "SGLT2i可应用于成人T2DM，当饮食和运动不能使血糖得到满意控制或二甲双胍不能耐受时，可单独使用。也可与其他口服降糖药物及胰岛素联合使用。由于SGLT2i的药理作用依赖一定水平的eGFR，故对患者eGFR的要求>60或45ml/(min·1.73m2)，在中国人群中已完成SGLT2i在新诊断成人T2DM中单药治疗、在二甲双胍单药治疗效果不佳或二甲双胍联合磺脲类药物治疗效果不佳人群中两药或三药联合治疗的3期临床研究。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "SGLT2i", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "SGLT2i", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "中国一项察性研究结果显示，递法明组的单纯型糖尿病网膜病变患者改善情况优于常规组(P<0.05)。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "递法明", "subject_type": "药品名称", "object": {"@value": "糖尿病网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "单纯型", "subject_type": "分期分型", "object": {"@value": "糖尿病网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病网膜病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "维格列汀的适应证适用于治疗2型糖尿病。单药治疗：本品配合饮食控制和运动，用于改善2型糖尿病患者的血糖控制；当二甲双胍作为单药治疗用至最大耐受剂量仍不能有效控制血糖时，本品可与二甲双胍联合使用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "维格列汀", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "运动", "subject_type": "非药治疗", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食控制", "subject_type": "非药治疗", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2型糖尿病合并慢性肾脏病患者的预后较单纯2型糖尿病或单纯慢性肾脏病患者更差。临床实践中，应重视2型糖尿病合并慢性肾脏病患者口服降糖药的正确选择和规范使用。一旦GFR<60ml.min-1(1.73m2)-1，大多数口服降糖药的药代和药效动力学特征将发生改变，低血糖及其他不良反应风险显著增加。研究显示遵循指南可显著提高降糖达标率，显著降低低血糖风险，且入院率和治疗费用均显著下降。因而，对于2型糖尿病合并慢性肾脏病患者的口服降糖药治疗，尤应重视指南推荐和规范应用。临床实践中，应密切监测2型糖尿病合并慢性肾脏病患者的血糖，依据患者的肾功能分期合理选择降糖药物的种类并积极调整剂量，以便有效控制血糖，同时减少低血糖等多种不良风险。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾功能", "subject_type": "检查方法", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾功能", "subject_type": "检查方法", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(3)围手术期：①围手术期血糖控制目标参见本共识“二、住院患者的血糖控制目标”部分；对于缺血性心脏病高风险患者，存在自主神经病变或肾功能衰竭患者需慎重评估围手术期低血糖风险；根据患者的血糖情况、一般状况及手术的类型决定是否需要停用之前的口服降糖药物以及是否需要胰岛素治疗。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心脏", "subject_type": "患病部位", "object": {"@value": "缺血性心脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "自主神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "慢性尿酸盐肾病一旦确诊即开始非药物治疗者，疗效不佳者根据尿酸水平及合并症开始药物治疗。出现肾功能损害(G2期及以上)、尿酸性肾石症患者血尿酸超过480μmol即开始降尿酸治疗，治疗目标值<360μmol／L。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "慢性尿酸盐肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "G2期及以上", "subject_type": "分期分型", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "尿酸性肾石症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "推荐5：T2DM患者ASCVD高危人群调脂的主要目标为LDL-C<2.6mmol/L，次要目标Non-HDL-C<3.4mmol/L，其他目标TG<1.7mmo/L。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "Non-HDL-C", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "TG", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "Non-HDL-C", "subject_type": "检查指标", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "TG", "subject_type": "检查指标", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病自我管理指患者为应对病情所采取的行动和选择，包括使用一系列技能、知识和应对策略。自我管理的任务包括：(1)医疗或行为管理：照顾自己的健康问题、定期服药或医学检查、改变膳食和其他高危行为、使用仪器。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "自我管理", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "在临床中，T2DM患者一些常用的药物会影响患者的血脂水平，可能会对患ASCVD的风险产生影响。有些药物对血脂的影响可能显著，但大多数影响较小(附表5)。当T2DM患者同时服用多种药物时，其累积效应不容忽视。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.4 磺脲类药物可否用于T2DM之外的糖尿病患者? ", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)复方丹参滴丸：由丹参、三七、冰片等药物组成，其中丹参的有效成分为水溶性丹参素，可提高机体抗凝和纤溶活性，抑制血小板聚集和释放前列环素类物质，抗凝血和抑制血栓形成；阻断羟自由基的产生，阻止脂质过氧化，是一种有效的氧自由基清除剂，临床上用于糖尿病肾病、视网病变和神经病变的治疗。一项纳入19个研究的荟萃分析结果显示，在常规治疗的基础上加用复方丹参滴丸，可显著减少24h尿蛋白总量，但是对血肌肝和血糖无影响。在中国疗非增殖性糖尿病视网膜病变患者中进行的一项随机对照研究，24周时眼底荧光血管造影及眼底检查结果均显示，高剂量和中剂量复方丹参滴丸组的有效的患者比例显著高于安慰剂组，且无临床不良事件发生。此外，复方丹参滴丸可以改善血瘀型糖尿病周围神经病变的血瘀症状，提高周围神经传导速度包括尺神经、腓总神经、腓肠神经和胫后神经的运动传导速度和感觉传导速度，有治疗和延缓其发展的作用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "复方丹参滴丸", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "复方丹参滴丸", "subject_type": "药品名称", "object": {"@value": "视网病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网", "subject_type": "患病部位", "object": {"@value": "视网病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "复方丹参滴丸", "subject_type": "药品名称", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "非增殖性糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "24周时眼底荧光血管造影", "subject_type": "检查方法", "object": {"@value": "非增殖性糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "眼底检查", "subject_type": "检查方法", "object": {"@value": "非增殖性糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "复方丹参滴丸", "subject_type": "药品名称", "object": {"@value": "血瘀型糖尿病周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "血瘀型糖尿病周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "血瘀", "subject_type": "临床表现", "object": {"@value": "血瘀型糖尿病周围神经病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "如果在控制体重和糖尿病治疗下肝酶仍持续升高，则需考虑肝脏活检。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "肝酶", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.踝动脉-肱动脉血压比值，又称踝肱指数(ankle brachial index，ABI) ：ABI反映的是肢体的血运状况，正常值为0.9~1.3，0.71~0.89为轻度缺血，0.5-0.7为中度缺血，<0.5为重度缺血，重度缺血的患者容易发生下肢(趾)坏疽。如果踝动脉收缩压过高，如高于200mmHg(1mmHg= 0.133kPa) 或ABI>1.3，则应高度怀疑患者有下肢动脉钙化，部分ABI正常患者，可能存在假阴性，可采用平板运动试验或趾臂指数(TBI)测定来纠正。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "下肢(趾)坏疽", "subject_type": "临床表现", "object": {"@value": "缺血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "踝动脉收缩压", "subject_type": "检查指标", "object": {"@value": "下肢动脉钙化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "ABI", "subject_type": "检查方法", "object": {"@value": "下肢动脉钙化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢动脉", "subject_type": "患病部位", "object": {"@value": "下肢动脉钙化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "平板运动试验", "subject_type": "检查方法", "object": {"@value": "下肢动脉钙化"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "利格列汀的适应证利格列汀与二甲双胍和磺脲类药物联合使用，配合饮食控制和运动，可用于成年2型糖尿病患者的血糖控制。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "利格列汀", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利格列汀", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食控制", "subject_type": "非药治疗", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "运动", "subject_type": "非药治疗", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(二)糖尿病足的内科治疗 ", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "以降低餐后血糖为主的口服降糖药物，α-糖苷酶抑制剂能延缓碳水化合物在小肠上段的吸收，降低餐后高血糖和减少血糖波动，包括阿卡波糖、伏格列波糖和米格列醇。α-糖苷酶抑制剂可降低HbA1c约0.5%。在中国人群中开展的MARCH研究表明，新诊断T2DM患者使用阿卡波糖300mg/d，HbA1c降幅达1.1%(可能包括部分安慰剂效应)并可减低体重。荟萃分析结果显示，在二甲双胍治疗的基础上采用α-糖苷酶抑制剂，改善体重的效果与GLP-1受体激动剂相当。常见的不良反应为胃肠道反应(腹胀、腹泻、恶心、肠道排气增多等)。小剂量开始、逐渐加量可减少胃肠道不良反应。单独使用一般不发生低血糖，甚至可减少反应性低血糖，总体耐受性良好。与其他降糖药物联合使用时可进一步改善血糖并减少体重增加。与胰岛素促泌剂或胰岛素合用时，如果出现低血糖，应采取口服或静脉注射葡萄糖纠正。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "餐后血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "α-糖苷酶抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "α-糖苷酶抑制剂", "subject_type": "药品名称", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿卡波糖", "subject_type": "药品名称", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "伏格列波糖", "subject_type": "药品名称", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "米格列醇", "subject_type": "药品名称", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿卡波糖", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "300mg/d", "subject_type": "用药剂量", "object": {"@value": "阿卡波糖"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "葡萄糖", "subject_type": "药品名称", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "葡萄糖"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉注射", "subject_type": "用药方法", "object": {"@value": "葡萄糖"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(2) Texas分级法：Texas分级法是由美国Texas San Antonio大学Lavery等提出的(表3) ，此分级方法从病变程度和病因两个方面对糖尿病足溃疡及坏疽进行评估，更好地体现了创面感染和缺血的情况，相对于Wagner分级在评价创面的严重性和预测肢体预后情况上更好。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "创面感染", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "缺血", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "创面", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "足溃疡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "创面感染", "subject_type": "临床表现", "object": {"@value": "足溃疡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "缺血", "subject_type": "临床表现", "object": {"@value": "足溃疡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "创面", "subject_type": "临床表现", "object": {"@value": "足溃疡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "创面感染", "subject_type": "临床表现", "object": {"@value": "坏疽"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "缺血", "subject_type": "临床表现", "object": {"@value": "坏疽"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "创面", "subject_type": "临床表现", "object": {"@value": "坏疽"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.4.3 起始剂量预混胰岛素类似物每日1次起始剂量一般为10~12IU，晚餐前注射，根据早餐前血糖调整剂量；如果治疗后HbA1c或餐前血糖不达标，则早餐前加用预混胰岛素类似物3~6IU，根据晚餐前和空腹血糖调整早餐前和晚餐前剂量；如果治疗后HbA1c或午餐后血糖不达标，则午餐前加用预混胰岛素类似物3IU或将早餐前剂量按1：1分配到早、午餐前，根据午餐后或晚餐前血糖调整午餐前剂量。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "每日1次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "10~12IU", "subject_type": "用药剂量", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "晚餐前注射", "subject_type": "用药方法", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "3~6IU", "subject_type": "用药剂量", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "3IU", "subject_type": "用药剂量", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "黄嘌呤氧化酶抑制剂在降低血尿酸之外，改善内皮功能、减少氧化应激、调节心肌能量代谢，从而进一管事件的发生率。NSAIDs类药物可导致水钠潴留及肾功能损伤，增加心衰恶化与心衰住院风险，因而在急、慢性心衰患者中应尽量避免使用该类药物。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "水钠潴留", "subject_type": "不良反应", "object": {"@value": "NSAIDs类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "肾功能损伤", "subject_type": "不良反应", "object": {"@value": "NSAIDs类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "增加心衰恶化与心衰住院风险", "subject_type": "不良反应", "object": {"@value": "NSAIDs类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "急、慢性心衰"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "共识根据痛风是否发作、危险因素、SUA浓度等分为三种情况：第一种情况是当有痛风发作且发作频繁时(≥2次)或者痛风性关节炎只发作1次，但合并有其他相关危险因素(年龄<40岁、有痛风石或关节腔尿酸盐沉积证据、尿酸性肾结石或肾功能损害≥G2期、高血压、糖尿病、血脂异常、肥胖、卒中、冠心病、心力衰竭)中的—项，不论尿酸水平如何，都需要进行降尿酸治疗，尿酸控制目标值应<360μmol/L，如果出现痛风石、慢性痛风性关节炎、痛风性关节炎发作频繁，患者尿酸控制目标值应<300μmol/L；第二种情况是痛风性关节炎只发作1次，或者没有急性发作但合并有其他相关危险因素(尿酸性肾结石或肾功能损害≥G2期、高血压、糖尿病、血脂异常、卒中、冠心病、肥胖、心力衰竭)，当尿酸浓度超过480μmol/L，应启动降尿酸治疗，尿酸控制目标值同第一种况；第三种情况是如果没有危险因素，也没有痛风发作，但尿酸>540μmol/L，也建议启动降尿酸治疗，尿酸控制目标值应<420μmol/L。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "SUA", "subject_type": "检查指标", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "关节", "subject_type": "患病部位", "object": {"@value": "痛风性关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "尿酸性肾结石"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能损害≥G2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "G2期", "subject_type": "分期分型", "object": {"@value": "肾功能损害≥G2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "冠心病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "关节", "subject_type": "患病部位", "object": {"@value": "慢性痛风性关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "关节", "subject_type": "患病部位", "object": {"@value": "痛风性关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "关节", "subject_type": "患病部位", "object": {"@value": "痛风性关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "痛风性关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "尿酸性肾结石"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "尿酸性肾结石"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能损害≥G2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "G2期", "subject_type": "分期分型", "object": {"@value": "肾功能损害≥G2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "肾功能损害≥G2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "血脂异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "卒中"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "冠心病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "冠心病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "关节腔", "subject_type": "患病部位", "object": {"@value": "关节腔尿酸盐沉积"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "CT对尿酸性肾石症的诊断很有帮助，尿酸结石CT值为300～400HU，低于胱氨酸结石，但高于血块、肿瘤等病变。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "CT", "subject_type": "检查方法", "object": {"@value": "尿酸性肾石症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "尿酸性肾石症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "CT值", "subject_type": "检查方法", "object": {"@value": "尿酸结石"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "新诊断的糖尿病患者HbA1c≥6.5%；而应激性高血糖患者的HbA1c水平一般不高；血糖的水平通常随导致血糖升高的急危重症的出现或缓解而升高或恢复正常。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "HbA1", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c水平", "subject_type": "检查指标", "object": {"@value": "应激性高血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "西格列汀的适应证单药治疗：本品配合饮食控制和运动，用于改善2型糖尿病患者的血糖控制；联合治疗：当单独使用盐酸二甲双胍血糖控制不佳时，可与盐酸二甲双胍联合使用，在饮食和运动基础上改善2型糖尿病患者的血糖控制。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "西格列汀", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西格列汀", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食控制", "subject_type": "非药治疗", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "运动", "subject_type": "非药治疗", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "盐酸二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食", "subject_type": "非药治疗", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "运动", "subject_type": "非药治疗", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.HUA与心血管疾病：HUA是心血管疾病的独立危险因素，同时与许多传统的心血管危险因素相互作用参与心血管疾病的发生、发展及转归。对于HUA合并高血压、冠心病、心力衰竭(心衰)等患者，若血尿酸>480μmol／L，应起始药物降尿酸治疗，可有效防治与其相关的心血降低心血管疾病，降低心血管事件发生率。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心衰"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "HUA", "subject_type": "患病病因", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.感觉检查：应仔细检查患者有无振动觉、痛觉、触压觉、温度觉减退以及痛觉过敏，DPN的感觉障碍通常以下肢远端更为明显，严重者可有感觉共济失调。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "感觉检查", "subject_type": "检查方法", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "振动觉、痛觉、触压觉、温度觉减退", "subject_type": "临床表现", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "痛觉过敏", "subject_type": "临床表现", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "感觉障碍", "subject_type": "临床表现", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "感觉共济失调", "subject_type": "临床表现", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢远端", "subject_type": "患病部位", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "一、T2DM合并ASCVD的流行病学", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "磺脲类药物通过刺激胰岛β细胞分泌胰岛素，增加体内胰岛素水平来发挥降糖作用，可使HbA1c降低1.0%~1.5%；磺脲类药物也可引起体重增加。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "肥胖是多种慢性疾病特别是心脑血管疾病发生、进展的危险因素，因此应该高度重视。一般认为磺脲类药物治疗可引起体重增加。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心脑血管", "subject_type": "患病部位", "object": {"@value": "心脑血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "基础胰岛素是胰岛素治疗方案中常用的胰岛素类型，具有低血糖风险低，使用简单方便等优点，既可与口服降糖药物联用作为起始方案，又可与餐时胰岛素组成强化治疗方案。然而，临床研究显示，中国2型糖尿病患者起始基础胰岛素治疗较晚，起始剂量偏低且在起始治疗后剂量调整不足，是导致起始胰岛素治疗后血糖控制不满意的重要原因。为此，国内多位内分泌学专家在2017年初联合发布了《成人2型糖尿病基础胰岛素临床应用中国专家指导建议》，以规范基础胰岛素在临床上的合理使用。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖控制", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.餐后高血糖与多项心血管疾病的危险因素相关：餐后高血糖升高渗透压，可增加血小板反应性，激活血小板，与餐后高凝状态相关。餐后高血糖可减少心肌血容量及心肌血流。研究显示，糖尿病患者餐后心肌血容量及心肌血流较正常对照者下降。餐后高血糖及血糖波动与颈动脉内-中膜厚度(CIMT)增加相关。降低餐后高血糖、减少血糖波动有可能延缓或减轻CIMT进展。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "颈动脉内-中膜厚度(CIMT)增加", "subject_type": "患病病因", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "围术期血糖管理对于减少血糖异常相关的并发症、促进患者术后快速康复、改善手术患者预后具有重要意义。术前筛查糖化血红蛋白有助于识别围术期高血糖相关不良事件的高危人群。“合理、有效、安全”是血糖管理的宗旨，围术期血糖目标值定为140mg/dl(7.8mmol/L)~180mg/dl(10.0mmol/L)兼顾了血糖管理的有效性和安全性，较为合理。血糖>180mg/dl(10.0mmol/L)即可启动胰岛素治疗，短效胰岛素持续静脉泵注便于及时调整剂量，减少血糖波动，是高危患者围术期血糖控制的首选方案。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "糖化血红蛋白", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "持续", "subject_type": "持续时间", "object": {"@value": "短效胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉泵注", "subject_type": "用药方法", "object": {"@value": "短效胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(4)新药治疗：NSAIDs、秋水仙碱或糖皮质激素治疗无效的难治性急性痛风，或者当患者使用上述药物有禁忌时，可以考虑IL-1受体拮抗剂治疗。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "IL-1受体拮抗剂", "subject_type": "药品名称", "object": {"@value": "难治性急性痛风"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)慢性尿酸盐肾病：慢性尿酸盐肾病发病机制是持续HUA尿酸钠结晶沉积在肾髓质间质组织，激活局部肾素-血管紧张素一醛固酮系统，损伤内皮细胞，引起肾小球高压力、慢性炎症反应、间质纤维化等病理改变。HUA患者出现肾小管功能障碍，如夜尿增多、低比重尿、小分子蛋白等，提示存在慢性尿酸盐肾病。尿酸升高水平与肾功能损伤程度可不匹配，排除其他慢性肾脏病后可考虑诊断，但通常很难与合并HUA的其他慢性肾脏病鉴别，确诊往往需要肾活检证实肾组织中有尿酸盐结晶沉积。晚期慢性尿酸盐肾病可导致肾小球滤过率下降和慢性肾衰竭。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "慢性尿酸盐肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "慢性尿酸盐肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "持续HUA尿酸钠结晶沉积在肾髓质间质组织", "subject_type": "发病机制", "object": {"@value": "慢性尿酸盐肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "激活局部肾素-血管紧张素一醛固酮系统", "subject_type": "发病机制", "object": {"@value": "慢性尿酸盐肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "损伤内皮细胞", "subject_type": "发病机制", "object": {"@value": "慢性尿酸盐肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "引起肾小球高压力、慢性炎症反应、间质纤维化等病理改变", "subject_type": "发病机制", "object": {"@value": "慢性尿酸盐肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "夜尿增多", "subject_type": "临床表现", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "低比重尿", "subject_type": "临床表现", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "小分子蛋白", "subject_type": "临床表现", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "慢性尿酸盐肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "慢性肾衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "晚期慢性尿酸盐肾病", "subject_type": "患病病因", "object": {"@value": "慢性肾衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2. 痛风患者管理：(1)痛风性关节炎患者首先遵循HUA管理原则；(2)医师须告知患者生活中避免可能的诱发因素，提出正确的预防措施，并制定个体化的急性发作时紧急处理方案；(3)痛风急性发作缓解后再考虑开始药物降尿酸治疗，已接受降尿酸药物治疗者急性期无需停药，初始药物降尿酸治疗者应给予预防痛风急性发作的药物。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "关节", "subject_type": "患病部位", "object": {"@value": "痛风性关节炎"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)不良反应：GLP-1受体激动剂的主要不良反应为恶心、呕吐、腹泻、消化不良、食欲下降、低血糖等。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "恶心", "subject_type": "不良反应", "object": {"@value": "GLP-1受体激动剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "呕吐", "subject_type": "不良反应", "object": {"@value": "GLP-1受体激动剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "腹泻", "subject_type": "不良反应", "object": {"@value": "GLP-1受体激动剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "消化不良", "subject_type": "不良反应", "object": {"@value": "GLP-1受体激动剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "食欲下降", "subject_type": "不良反应", "object": {"@value": "GLP-1受体激动剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "GLP-1受体激动剂"}, "object_type": {"@value": "药品名称"}}]}
{"text": "T2DM和ASCVD患者常合并心力衰竭。对于合并心力衰竭的T2DM患者，制定降糖治疗方案时，应关注某些降糖药物对心力衰竭的潜在不良影响。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "基层医疗卫生机构在糖尿病及其并发症的防控中担任重要角色。我国87%的糖尿病患者就诊于县级及以下医疗机构，而农村人群糖尿病的知晓率、治疗率及控制率均低于城市人群(24.6%vs38.7%，21.5%vs32.7%，38.6%vs40.8%)。然而，基层医疗卫生机构尚缺乏完整和规范的糖尿病微血管并发症筛查、防治及管理流程。以DR为例，50%以上就诊于基层医疗卫生机构的糖尿病患者未被告知应定期接受眼底检查，近70%的糖尿病患者未接受规范的眼科治疗，90%具有激光治疗指征的DR患者未接受激光治疗。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "眼底检查", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "激光治疗", "subject_type": "非药治疗", "object": {"@value": "DR"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "在当地医院缺乏有资质的眼科医师时，免散瞳眼底照相可以作为DR筛查的有效措施；但应由有经验的眼科医师或经过认证的智能远程系统辅助读片。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "免散瞳眼底照相", "subject_type": "检查方法", "object": {"@value": "DR"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "临床问题5：DPP-4i是否可用于65岁以上的2型糖尿病患者的降糖治疗? ", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4i", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "推荐20：治疗性生活方式改变不仅是治疗T2DM患者血脂异常的基础，更是预防T2DM患者血脂异常的根本手段。 ", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "治疗性生活方式改变", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病治疗相关的周围神经病较为少见。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "周围神经病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "对依从性差的患者，尤其是在中国农村地区的患者，宜选择低血糖风险低、对体重影响小及廉价的1日1次磺脲类促泌剂(4级)。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "1日1次", "subject_type": "用药频率", "object": {"@value": "磺脲类促泌剂"}, "object_type": {"@value": "药品名称"}}]}
{"text": "由于老年人群的特殊性，在使用胰岛素进行降糖治疗前应该认真考虑低血糖的风险。一项在身体状况良好的健康老年人(平均年龄66岁)中进行的研究结果显示，无论是胰岛素泵还是一天多次皮下注射的方法使HbA1c维持在7%的水平达12个月的时间，低血糖发生率很低(A)。在一系列临床试验中与年轻患者(平均年龄53岁)相比，老年2型糖尿病患者(平均年龄69岁)加用长效胰岛素对于达到HbA1c目标同样有效，并且没有增加低血糖的发生率(A)。年龄超过75岁或者存在多种合并症的老年人中相关的研究数据还比较少。与人胰岛素相比，胰岛素类似物发生低血糖的风险性相对低(A)，但价格也更高。胰岛素的使用会导致体重增加(A)，尤其在每日用量40u以上者，可考虑联合口服降糖药(二甲双胍、糖苷酶抑制剂)。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "长效胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "长效胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "人胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日", "subject_type": "用药频率", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "40u以上", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "糖苷酶抑制剂"}, "object_type": {"@value": "药品名称"}}]}
{"text": "4.1 用药原则积极控制血糖、血压、血脂仍是糖尿病治疗的基础。微循环障碍贯穿糖尿病病程的始终，改善糖尿病微循环用药应遵循“早期、个体化、合理联合、重视安全”的原则。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血脂", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "微循环障碍", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)是一种新型的口服降糖药物，该类药物在国外多个国家已经上市并得到越来越广泛的临床应用，即将在中国上市的SGLT2i主要有达格列净(dapagliflozin) 、坎格列净(canagliflozin) 和恩格列净(empagliflozin)。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)"}, "object_type": {"@value": "药品名称"}}]}
{"text": "4 糖尿病微循环障碍的药物治疗", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "微循环障碍", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "由此可见，胰岛素促泌剂肯定存在低血糖风险，但是胰岛素的低血糖风险更大。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "磺脲类药物可引起患者体重增加，但超重或肥胖并不是其治疗的禁忌证。不同磺脲类药物单药治疗对患者体重的影响存在差异，改良剂型对患者体重的影响较小。临床研究显示，传统磺脲类药物(如氯磺丙脲、格列本脲)对肥胖患者体重影响较大，治疗3年平均约增加3~5kg；新的品种(如格列美脲)和剂型(如格列齐特缓释片)对患者体重影响较小(平均增加0.4~0.6kg)。由于二甲双胍、阿卡波糖、钠-葡萄糖协同转运蛋白2(sodium-glucose co-transporter 2，SGLT-2)抑制剂等具有减轻体重的作用，对于超重或肥胖患者，磺脲类药物与此类药物联合使用，可减少磺脲类药物带来的体重增加的风险。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "减轻体重", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "减轻体重", "subject_type": "不良反应", "object": {"@value": "阿卡波糖"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "减轻体重", "subject_type": "不良反应", "object": {"@value": "钠-葡萄糖协同转运蛋白2(sodium-glucose co-transporter 2，SGLT-2)抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "老年前患糖尿病的患者合并大血管、微血管病变的比例远高于老年后患糖尿病者，这部分患者胰岛β细胞功能多很差，平常血糖波动幅度大，如长期未能得到良好管理和治疗，会存在不同程度的脏器功能损害，在治疗选择上要充分考虑到可能对降糖药应用的影响(C)。", "spo_list": [{"Combined": false, "predicate": "发病机制", "subject": "胰岛β细胞功能多很差", "subject_type": "发病机制", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "大血管、微血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "大血管、微血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛β细胞功能多很差", "subject_type": "发病机制", "object": {"@value": "大血管、微血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "大血管、微血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脏器", "subject_type": "患病部位", "object": {"@value": "脏器功能损害"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(5)α-糖苷酶抑制剂：α-糖苷酶抑制剂通过延缓碳水化合物在小肠上段的吸收而降低餐后血糖，适用于饮食结构以碳水化合物为主且餐后血糖升高的患者，可降低HbA1c0.5%~0.8%，不增加体重且有减轻体重的趋势。主要代表药物有阿卡波糖、伏格列波糖等。阿卡波糖口服后很少部分被吸收，随着肾功能的降低，阿卡波糖及其代谢产物的血药浓度显著增加。阿卡波糖可用于CKD1~3期患者；4~5期禁用。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "阿卡波糖"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿卡波糖", "subject_type": "药品名称", "object": {"@value": "CKD1~3期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~3期", "subject_type": "分期分型", "object": {"@value": "CKD1~3期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "4~5期", "subject_type": "分期分型", "object": {"@value": "CKD1~3期"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "有研究显示，非诺贝特与他汀类药物(尤其是阿托伐他汀)具有促进尿酸排泄作用。伴有高脂血症的患者，可考虑使用非诺贝特或他汀类药物，但两者的降尿酸作用都较弱。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "非诺贝特", "subject_type": "药品名称", "object": {"@value": "高脂血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类药物", "subject_type": "药品名称", "object": {"@value": "高脂血症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "·病程长的糖尿病需进行慢性并发症筛查或评估；", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "慢性并发症筛查或评估", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "DPP-4抑制剂：SAVOR-TIMI53研究显示，对于伴有心血管事件病史或心血管危险因素的T2DM患者，沙格列汀可增加心力衰竭住院风险。EXAMINE研究事后分析显示，对于无心力衰竭病史、近期发生过ACS的T2DM患者，阿格列汀增加心力衰竭住院风险( HR 1.76，P=0.026)。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "沙格列汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿格列汀", "subject_type": "药品名称", "object": {"@value": "ACS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿格列汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "HLA-B*5801基因阳性，应用噻嗪类利尿剂和肾功能不全是别嘌醇发生不良反应的危险因素。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病患者足踝以下部位的感染，糖尿病足感染依据感染范围和症状分为轻中重度(表1)。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "足踝以下部位的感染", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足感染"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.计划妊娠的糖尿病患者住院血糖管理", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "本共识建议，T2DM合并ASCVD患者的血糖控制目标应该遵循个体化原则-综合考虑患者的年龄、糖尿病病程、ASCVD病史、其他并发症或合并症、低血糖风险等因素，充分平衡严格血糖控制的利弊得失。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.2. 改善糖尿病微循环障碍的药物改善糖尿病微循环障碍的药物主要包括血管扩张药物、影响血液流变学的药物、保护血管内皮的药物以及部分中药制剂等(改善微循环障碍药物的临床推荐意见见表1；常用改善糖尿病微循环障碍药物的简要说明见表2和药品说明书)。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "微循环障碍", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "微循环障碍", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "微循环障碍", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "二、T2DM合并CKD的诊断与分期", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "血糖≤50mg/dl(2.8mmol/L)时出现认知功能障碍，长时间≤40mg/dl(2.2mmol/L)的严重低血糖可造成脑死亡。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "认知功能障碍"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脑", "subject_type": "患病部位", "object": {"@value": "脑死亡"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "DPP-4抑制剂的主要不良反应有鼻咽炎，头痛、上呼吸道感染、低血糖等，低血糖的发生率比磺脲类低。其他一些很少见的不良反应有超敏反应、血管神经性水肿、肝酶升高、腹泻、咳嗽、淋巴细胞绝对计数降低等。最近完成的临床研究结果显示，沙格列汀可明显增加心力衰竭住院的风险，但不增加相关的死亡率。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "鼻咽炎", "subject_type": "不良反应", "object": {"@value": "DPP-4抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "头痛", "subject_type": "不良反应", "object": {"@value": "DPP-4抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "上呼吸道感染", "subject_type": "不良反应", "object": {"@value": "DPP-4抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "DPP-4抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "沙格列汀", "subject_type": "患病病因", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1. 痛风性关节炎：中青年男性多见，常首发于第一跖趾关节，或踝、膝等关节。起病急骤，24h内发展至高峰。初次发病常累及单个关节，持续数天至数周可完全自然缓解，反复发作则受累关节逐渐增多，症状持续时间延长，两次关节炎发作间歇期缩短。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "关节", "subject_type": "患病部位", "object": {"@value": "痛风性关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "第一跖趾关节", "subject_type": "患病部位", "object": {"@value": "痛风性关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "踝", "subject_type": "患病部位", "object": {"@value": "痛风性关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "膝", "subject_type": "患病部位", "object": {"@value": "痛风性关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "关节", "subject_type": "患病部位", "object": {"@value": "痛风性关节炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "关节", "subject_type": "患病部位", "object": {"@value": "关节炎"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "短效磺脲类促泌剂通过与胰岛β细胞膜上的磺脲类受体结合，促进胰岛素分泌，增加体内胰岛素水平而降低血糖。常用的短效磺脲类药物包括格列吡嗪和格列喹酮，降低HbA1c约1.0%。磺脲类药物可导致低血糖，更易在老年及肝、肾功能不全的患者中发生。磺脲类药物可增加体重。肾功能不全的患者可考虑选用格列喹酮。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝、肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肝、肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "增加体重", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "9.联合α糖苷酶抑制剂的疗效：二甲双胍与α糖苷酶抑制剂联合，可兼顺FPG和PPG，超重的T2DM患者在二甲双胍疗效不佳时，加用阿卡波糖能更好地控制HbA1c、FPG和体重。一项在中国T2DM人群中的对照研究显示，二甲双胍和阿卡波糖联用的降糖效果劣于二甲双胍和磺脲类联用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿卡波糖", "subject_type": "药品名称", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿卡波糖", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿卡波糖", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "磺脲类药物促进胰岛素分泌，α-糖苷酶抑制剂抑制肠道碳水化合物吸收，二者联合，机制互补，可更好地控制T2DM患者的空腹血糖和餐后血糖。一项交叉设计临床对照研究，磺脲类药物联合阿卡波糖可使患者HbA1c下降2.2%，空腹血糖(fasting plasma glucose，FPG)下降2.8mmol/L，餐后血糖(postprandial plasma glucose，PPG)下降5.3mmol/L，甘油三酯下降35.7mg/dl。随机、双盲、安慰剂对照研究显示，与阿卡波糖、格列本脲单药治疗相比，格列本脲联合阿卡波糖可显著降低患者的餐后血糖，且较格列本脲单药治疗显著降低患者血清胰岛素水平。对于新诊断T2DM患者，格列吡嗪控释片联合阿卡波糖治疗8周较格列吡嗪控释片单药治疗，患者的体质指数(body mass index，BMI)、腰围及HbA1c变化无统计学差异，但前者可显著改善患者HOMA-IR，降低餐后血糖增量，且有效减少血糖波动(日间血糖变异度与日内血糖变异度)。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "α-糖苷酶抑制剂", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列吡嗪控释片", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "8周", "subject_type": "持续时间", "object": {"@value": "格列吡嗪控释片"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿卡波糖", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "8周", "subject_type": "持续时间", "object": {"@value": "阿卡波糖"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "空腹血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "餐后血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "体质指数(body mass index，BMI)", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HOMA-IR", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "餐后血糖增量", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "日间血糖变异度", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "日内血糖变异度", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.4 1-2-3次方案1-2-3次方案是指，对于采用生活方式干预及两种或两种以上口服降糖药最大有效剂量治疗血糖仍不达标(HbA1c≥7.0%)的患者，起始每日1次预混胰岛素类似物注射，血糖控制仍不达标时，可逐渐增加到每日2次、每日3次的方案。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "每日1次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日2次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日3次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "肾功能正常的糖尿病患者，推荐蛋白质摄入量占总能量的15%~20%。植物来源蛋白质，尤其是大豆蛋白更有助于降低血脂水平。高蛋白膳食在短期内有助于减轻体重，但不建议超重或肥胖人群长期食用。乳清蛋白有助胰岛素分泌，改善糖代谢，并在短期内减轻体重。2型糖尿病患者摄入蛋白质能增加胰岛素应答，但不升高血糖浓度。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "还具有减重、降压、降尿酸、减少蛋白尿等与心血管疾病相关危险因素的作用，目前也有一些研究证实此类药物确实能够降低心血管事件风险。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "个别学者对DPN诊断进行分层，第1层指有DPN的症状或体征(踝反射、压力觉、振动觉、针刺觉、温度觉任意1项体征为阳性)，同时存在神经传导功能异常，可确诊；第2层指有DPN的症状及1项体征为阳性，或无症状但有2项及以上体征为阳性，可临床诊断；第3层指有DPN的症状但无体征或无症状但有1项体征阳性，为疑似诊断；第4层指无症状和体征，仅存在神经传导功能异常，为亚临床诊断。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "踝反射", "subject_type": "检查方法", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "压力觉", "subject_type": "检查方法", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "振动觉", "subject_type": "检查方法", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "针刺觉", "subject_type": "检查方法", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "温度觉", "subject_type": "检查方法", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "神经传导功能异常", "subject_type": "临床表现", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.糖尿病前期：空腹血糖受损(IFG)或糖耐量受损(IGT)统称为糖调节受损(IGR，即糖尿病前期)。若FPG6.1~<7.0mmoL/L，2hPG<7.8mmol/L诊断为IFG；FPG<7.0mmoL/L，2hPG7.8~<11.1mmol/L诊断为IGT(表1)。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "前期", "subject_type": "分期分型", "object": {"@value": "糖尿病前期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "前期", "subject_type": "分期分型", "object": {"@value": "糖调节受损(IGR，即糖尿病前期)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "IFG"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "2hPG", "subject_type": "检查指标", "object": {"@value": "IFG"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "IGT"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "2hPG", "subject_type": "检查指标", "object": {"@value": "IGT"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "同时，在每次进行肠内营养时，给予短效或速效胰岛素皮下注射；③肠外营养，全胃肠外静脉营养液中添加短效或速效胰岛素；同时，每4h给予短效或速效胰岛素皮下注射。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "皮下注射", "subject_type": "用药方法", "object": {"@value": "短效或速效胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每4h", "subject_type": "用药频率", "object": {"@value": "短效或速效胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "皮下注射", "subject_type": "用药方法", "object": {"@value": "短效或速效胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "慢性肾脏病(G4～5期)患者的痛风急性发作时不宜用NSAIDs，可给予糖皮质激素短期口服或关节内注射。也可根据eGFR酌情采用低剂量秋水仙碱治疗(见痛风急性发作期治疗)。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "G4～5期", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "糖皮质激素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "关节内注射", "subject_type": "用药方法", "object": {"@value": "糖皮质激素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "围术期血糖测量方法床旁快速血糖仪测量指血(毛细血管血)血糖用于血流动力学稳定的患者。血糖仪需定期校准。严重低血糖时血糖仪所测得的数值可能偏高，应与中心实验室测量的静脉血结果进行对照。动脉或静脉血气分析是围术期血糖监测的金标准。在低血压、组织低灌注、贫血以及高血脂、高胆红素血症等代谢异常的情况下，指血血糖准确性下降，应使用动脉血气监测血糖。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "贫血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血脂"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高胆红素血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "指血血糖", "subject_type": "检查指标", "object": {"@value": "贫血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "动脉血气", "subject_type": "检查方法", "object": {"@value": "贫血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "指血血糖", "subject_type": "检查指标", "object": {"@value": "高血脂"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "动脉血气", "subject_type": "检查方法", "object": {"@value": "高血脂"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "指血血糖", "subject_type": "检查指标", "object": {"@value": "高胆红素血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "动脉血气", "subject_type": "检查方法", "object": {"@value": "高胆红素血症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)双胍类：目前，国内外指南均一致推荐二甲双胍作为T2DM控制血糖的一线用药，其主要药理作用是通过减少肝糖输出和改善外周胰岛素抵抗而降低血糖。二甲双胍可使HbA1c降低1%~2%，并可减轻体重且不增加低血糖风险。英国前瞻性糖尿病研究(UKPDS)显示，二甲双胍可降低肥胖T2DM患者心血管事件和死亡风险。二甲双胍直接以原形经肾脏排泄，当肾功能损害时易发生二甲双胍与乳酸在体内蓄积，从而增加乳酸性酸中毒风险。二甲双胍用于CKD3a期患者时减量，当GFR<45ml/(min·1.73m2)停用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "乳酸性酸中毒", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "CKD3a期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3a期", "subject_type": "分期分型", "object": {"@value": "CKD3a期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "CKD3a期"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "·糖尿病妊娠或妊娠糖尿病(详见“糖尿病妊娠及妊娠糖尿病住院患者的血糖管理”部分)；", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病妊娠"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "妊娠糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "对老年患者来说这类药物的低血糖风险相对较大，格列本脲的低血糖风险最大，不宜用于老年患者(A)。对于肝肾功能正常的老年糖尿病患者可考虑选择每日1次的磺脲类药物，或根据血糖谱的特点选择中短效的磺脲类药物。缓释(格列齐特)和控释(格列吡嗪)的包装剂型，每天服用1次，且体内药物浓度平缓，低血糖发生少，推荐老年患者选用(A)。有轻中度肾功能不全的患者，可考虑选择格列喹酮。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列本脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日1次", "subject_type": "用药频率", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "缓释(格列齐特)"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每天服用1次", "subject_type": "用药频率", "object": {"@value": "缓释(格列齐特)"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "控释(格列吡嗪)"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每天服用1次", "subject_type": "用药频率", "object": {"@value": "控释(格列吡嗪)"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)HUA与高血压：HUA与高血压之间存在独立的相互关系，血尿酸水平是高血压发病、长期血压变化及预后的独立预测因子。血尿酸水平每增加60μmol／L，高血压发生的风险增加15％～23％。对于高尿酸合并高血压患者降压药物的选择详见HUA与代谢综合征部分。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血尿酸水平", "subject_type": "检查指标", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "国外资料显示在所有的非外伤性低位截肢手术中，糖尿病患者占40%~60%，在糖尿病相关的低位远端截肢中，有85%是发生在足部溃疡后。", "spo_list": [{"Combined": false, "predicate": "临床手术", "subject": "非外伤性低位截肢手术", "subject_type": "临床手术", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "低位远端截肢", "subject_type": "临床手术", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足部", "subject_type": "患病部位", "object": {"@value": "足部溃疡"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "临床问题12：GLP-1RA是否可用于超重/肥胖2型糖尿病患者的降糖治疗? ", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "GLP-1RA", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "评估罗格列酮对糖尿病患者心血管结局和血糖控制影响(RECORD)研究是一项开放标签的RCT研究，4447例二甲双胍或SUs单药治疗血糖控制不佳的T2DM患者随机分为两组：在原有治疗基础上联合罗格列酮或在原有治疗基础上联合SUs或双胍类，平均随访时间为5.5年。结果显示与二甲双胍联合SUs治疗组相比，罗格列酮联合二甲双胍或SUs组的首要心血管终点事件(心血管疾病住院或心血管死亡)风险达到非劣效性标准(HR为0.99.95%CI为0.85~1.16)；心力衰竭住院或死亡的相对风险显著增加(HR2.10，95%CI 1.35~3.27)", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "罗格列酮", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "SUs", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管死亡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "阿托伐他汀具有较弱的降尿酸作用，并HUA冠心病二级预防可优先使用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "阿托伐他汀", "subject_type": "药品名称", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿托伐他汀", "subject_type": "药品名称", "object": {"@value": "冠心病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "降糖治疗的目标不仅仅是单纯控制血糖，更重要的是减少糖尿病并发症(特别是心血管事件)、降低死亡风险，从而改善患者的远期预后。生活方式干预是T2DM患者降糖治疗的基础性措施，应贯穿于降糖治疗的始终。如果单纯生活方式干预不能使血糖达标，应开始药物治疗。对于合并ASCVD的T2DM患者，尤应注意心血管安全性问题，并且优先考虑选择具有心血管获益证据的降糖药物。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "SGLT2i单独使用时不增加低血糖发生的风险，联合胰岛素或磺脲类药物时，可增加低血糖发生风险，SGLT2i其主要的不良反应为生殖泌尿道感染，多数为轻度到中度感染，抗感染治疗有效。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "SGLT2i"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "5.肝功能不全的T2DM患者使用注意事项：二甲双胍不经过肝脏代谢，无肝脏毒性。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "四、T2DM合并ASCVD患者的降糖药物治疗", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2016年，ADA糖尿病指南指出，如果肾功能正常，二甲双胍可用于病情稳定的CHF患者。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "CHF"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "数据显示，伴微血管并发症的糖尿病患者年直接医疗费用是无并发症患者的3.18倍，因此，微血管并发症的防治是2型糖尿病管理中非常重要的环节。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "微血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "微血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "推荐意见DPP-4i可用于超重/肥胖2型糖尿病患者的降疗。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4i", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "甘精胰岛素初始干预转归(ORIGIN)研究采用随机、双盲、2×2析因设计，纳入12537例有心血管高危因素的IFG、IGT或T2DM患者，随机分为甘精胰岛素或常规治疗，中位随访时间为6.2年。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "IFG"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "甘精胰岛素", "subject_type": "药品名称", "object": {"@value": "IFG"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "IGT"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "甘精胰岛素", "subject_type": "药品名称", "object": {"@value": "IGT"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "甘精胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "长期观察结果发现，微量白蛋白尿的患者在10年中仅有30%~45%转变为大量白蛋白尿，有30%转变为尿白蛋白阴性，该现象在2型糖尿病患者中更为显著。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "尿白蛋白", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.OGTT：如果FPG无法确诊糖尿病，推荐采用OGTT进行糖尿病筛查：依据FPG和糖负荷后2h血糖(2hPG)水平进行诊断。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "OGTT", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "糖负荷后2h血糖(2hPG)", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "HUA引起心、脑、肾等多器官损害的机制包括促进氧自由基生成、损伤血管内皮细胞、上调内皮素并下调一氧化氮合酶的表达，导致血管舒缩功能失调；引起LDL-C氧化修饰，导致动脉粥样硬化；损害线粒体、溶酶体功能，引起肾小管上皮细胞和心肌细胞凋亡等；激活肾素-血管紧张素-醛固酮系统，导致血管重构、器官受损；促进炎性反应，导致血小板聚集黏附。", "spo_list": [{"Combined": false, "predicate": "发病机制", "subject": "促进氧自由基生成", "subject_type": "发病机制", "object": {"@value": "动脉粥样硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "损伤血管内皮细胞", "subject_type": "发病机制", "object": {"@value": "动脉粥样硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "上调内皮素并下调一氧化氮合酶的表达", "subject_type": "发病机制", "object": {"@value": "动脉粥样硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "导致血管舒缩功能失调", "subject_type": "发病机制", "object": {"@value": "动脉粥样硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脑", "subject_type": "患病部位", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "动脉", "subject_type": "患病部位", "object": {"@value": "动脉粥样硬化"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.有严重低血糖病史，或预期寿命较短，或有显著微血管或大血管并发症的患者，可放宽血糖目标值：HbA1c<7.5%~8.0%。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)2型糖尿病预防用药：二甲双胍是第一个被证明能预防糖尿病或延缓糖尿病发生的药物，能有效降低糖尿病前期人群发生2型糖尿病的风险，且具有良好的耐受性和长期有效性。不过在我国，预防糖尿病还不是二甲双胍的适应证，所以该共识也无法给出明确建议。但是，共识中提到，基于各国的大型研究结果，国际糖尿病联盟(IDF)2012年全球2型糖尿病指南推荐，预防糖尿病最好起始生活方式干预；对于空腹血糖受损(IFG)、年龄<60岁的肥胖人群，可给予二甲双胍干预；并建议糖尿病前期人群应起始生活方式干预，对生活方式不能有效控制血糖的患者，给予二甲双胍可有效预防糖尿病(属于超药品说明书用药——本刊注)，接受二甲双胍干预的患者应限于有预防糖尿病意愿、有很好的治疗依从性并有条件按照医嘱定期接受糖代谢评估的糖尿病前期个体。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "空腹血糖受损(IFG)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "糖代谢评估", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "SGLT-2抑制剂恩格列净是第一个通过CVOT证实具有明确心血管获益的新型降糖药物，但目前尚未在我国上市。恩格列净心血管事件结局(EM-PA-REG OUTCOME)研究纳入7020例伴有心血管疾病的T2DM患者，中位随访时间为3.1年。结果显示，在常规治疗基础上，与安慰剂相比，恩格列净可显著降低3终点的主要心血管不良事件(3终点MACE，包括心血管死亡、非致死性心肌梗死或非致死性卒中)风险14%(P=0.04)，降低心血管死亡风险38%(P<0.001)，降低心力衰竭住院风险35%(P=0.002)。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "非致死性心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "非致死性", "subject_type": "分期分型", "object": {"@value": "非致死性心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "非致死性", "subject_type": "分期分型", "object": {"@value": "非致死性卒中"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管死亡"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.糖尿病自主神经病：以自主神经病变为首发症状，一般隐袭起病，缓慢发展，表现有排汗异常、胃肠道症状、性功能减退、排尿困难、直立性低血压以及静息时心动过速等。由于小纤维受累，发生心绞痛或心肌梗死时可无心前区疼痛的表现，发生严重心律失常时猝死的风险增加。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "自主神经", "subject_type": "患病部位", "object": {"@value": "糖尿病自主神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "排汗异常", "subject_type": "临床表现", "object": {"@value": "糖尿病自主神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "胃肠道症状", "subject_type": "临床表现", "object": {"@value": "糖尿病自主神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "性功能减退", "subject_type": "临床表现", "object": {"@value": "糖尿病自主神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "排尿困难", "subject_type": "临床表现", "object": {"@value": "糖尿病自主神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "直立性低血压", "subject_type": "临床表现", "object": {"@value": "糖尿病自主神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "静息时心动过速", "subject_type": "临床表现", "object": {"@value": "糖尿病自主神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "自主神经", "subject_type": "患病部位", "object": {"@value": "自主神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "小纤维", "subject_type": "患病部位", "object": {"@value": "心绞痛"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "小纤维", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心绞痛"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "严重心律失常"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)儿童及青少年糖尿病患者：推荐理想的HbA1c控制在7%以下，强调糖尿病血糖控制应权衡利弊，实行个体化，低血糖风险较高或尚无低血糖风险意识的患儿可适当放标准。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "共识在总结国内外痛风治疗指南和大量痛风及HUA治疗临床研究的基础上，对降尿酸药物治疗的指征、SUA控制的目标以及药物的选择给出了清晰的建议。并强调了痛风治疗的长期性和SUA定期复查的重要性。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "SUA", "subject_type": "检查指标", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "SUA", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "SUA", "subject_type": "检查指标", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(四)糖尿病肾病的临床分期和病理分级", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.远端对称性多发性周围神经病：是DPN最常见的类型。主要表现为隐袭起病，缓慢发展，临床表现对称，多以肢体远端感觉异常为首发症状，可呈现手套.袜套样感觉障碍，早期即可有腱反射减低，尤以双下肢为著，可伴有自主神经受损表现。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "远端对称性多发性", "subject_type": "分期分型", "object": {"@value": "远端对称性多发性周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "远端对称性多发性周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "自主神经", "subject_type": "患病部位", "object": {"@value": "自主神经受损"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "二甲双胍：现有国内外糖尿病指南中均推荐二甲双胍作为2型糖尿病患者控制高血糖的首选或一线用药。它较少的低血糖风险对于老年人有一定的益处，但是药物带来的胃肠道反应与体重减轻对于瘦弱的老年患者可能不利。双胍类药物本身没有肾毒性，因以原型从肾脏排出，如果估算的肾小球滤过率(eGFR)在45~60ml/min之间，则二甲双胍应该减量，如果eGFR<45ml/min二甲双胍则不能使用(A)。双胍类药物禁用于肝功能不全、心力衰竭、缺氧或接受大手术的患者，以避免乳酸性酸中毒的发生。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "乳酸性酸中毒", "subject_type": "不良反应", "object": {"@value": "双胍类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "双胍类药物", "subject_type": "药品名称", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "双胍类药物", "subject_type": "药品名称", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "双胍类药物", "subject_type": "药品名称", "object": {"@value": "缺氧"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "推荐意见推荐DPP-4i作为2型糖尿病患者的三线治疗选择之一。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4i", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.碳水化合物与肥胖：一项队列研究表明.青少年女性膳食中血糖指数(glycemic-index)每升高1SD，BMI和腰围分别增加0.77kg/m2和1.45cm；而膳食纤维摄入最每增加1SD，会导致青少年女性BMI值降低0.44kg/m2和青少年男性腰降低1.45cm。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖指数(glycemic-index)", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.糖尿病合并肝肾功能不全者：SGLT2i在中度肾功能不全[45≤eGFR<60ml/(min·1.73m2)]的患者可减量使用。轻中度肝功能不全时也可使用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "SGLT2i", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝肾", "subject_type": "患病部位", "object": {"@value": "肝肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "研究显示，DSME处万可改善治疗质量。为了指导广大医护工作者更加规范、科学地运用指南，结合个体化需求，选择合适时机，量化确定自我管理的内容、目标、预期效果，与患者一起制定实施计划，确定复诊时间，以提高患者生活质量，中华医学会糖尿病学分会糖尿病教育与管理学组组织专家编写“中国2型糖尿病自我管理处方专家共识”。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "建议GLP-1RA用于伴有非酒精性脂肪肝2型糖尿病患者的降糖治疗。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "GLP-1RA", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "非酒精性脂肪肝"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "高尿酸血症(HUA)的流行总体呈现逐年升高的趋势，常与高血压、高脂血症、2型糖尿病、肥胖、胰岛素抵抗等传统的代谢性心血管危险因素伴发，因此长期以来HUA仅仅被认为是代谢异常的一种标志。但近年来多个前瞻性大规模临床结果显示，HUA是心血管疾病、糖尿病的独立危险因素，也是全因死亡、总心血管事件和缺血性卒中的独立危险因素。HUA可增加糖尿病肾病的风险，是急慢性肾衰竭的强有力的预测因素。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "急慢性肾衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "一项为期52周的随机、双盲试验评估了利格列汀的疗效及安全性。受试者为既往接受其他降糖药治疗的T2DM患者，GFR<30ml/(min·1.73m2)，分别给予利格列汀或安慰剂，结果显示与安慰剂组相比，利格列汀降低HbA1c达0.6%，但利格列汀组低血糖发生率高于安慰剂组。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利格列汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利格列汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "利格列汀"}, "object_type": {"@value": "药品名称"}}]}
{"text": "2.内分泌科住院糖尿病患者的血糖管理", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "转往基层医疗卫生机构：①患者在当地中心医院或三级甲等医院完成糖尿病微血管并发症的筛查项目；②治疗方案确定且血糖基本控制稳定；③糖尿病微血管并发症患者的症状和体征得到控制或改善，医患双方均同意转回基层医疗卫生机构。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病足是目前非创伤性截肢的主要原因。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "胰岛素皮下注射适合病情稳定的非重症患者，常用于术前术后过渡；注意避免短时问内反复给药造成降糖药效叠加。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "皮下注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "6.二甲双胍联合磺脲类药物的疗效：二甲双胍可改善IR，减少肝糖输出；磺脲类药物可促进胰岛素分泌，两类药物联合，作用机制互补，具有更全面针对T2DM病理生理缺陷的特点。一项随机、双盲、平行对照研究显示，二甲双胍联合格列本脲治疗组比单用二甲双胍或单用格列本脲组能更好地控制FPG和HbA1c(I级)。磺脲类药物血糖控制不佳的患者治疗18周后，格列吡嗪/二甲双胍复合制剂治疗组的血糖达标率(HbA1c<7.0%)为36.3%，分别是单用二甲双胍治疗组(8.9%)和单用格列吡嗪治疗组(9.9%)的4.1和3.7倍，同时复合制剂治疗组FPG水平控制更好(I级)。在中国T2DM患者中开展的一项随机、平行对照研究显示，二甲双胍联合格列喹酮治疗组的HbA1c降低幅度(1.7%)高于二甲双胍联合阿卡波糖治疗组(0.9%)，且两组低血糖、体重增加比较，差异无统计学意义(I级)。另有随机、双盲、双模拟、平行对照研究显示，与相同剂量的格列本脲相比，在二甲双胍的基础上联合含有格列本脲的中药固定复方制剂降糖效果相当，但低血糖发生的风险减低(I级)。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "IR", "subject_type": "发病机制", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "18周", "subject_type": "持续时间", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿卡波糖", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列喹酮"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "格列喹酮"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "阿卡波糖"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "阿卡波糖"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列本脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列本脲"}, "object_type": {"@value": "药品名称"}}]}
{"text": "超出说明书范围，如与其他2种及以上的不同类别降糖药物联合使用；或在1型糖尿病患者中使用即属超药物说明书使用。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "对于T2DM合并ASCVD患者，血糖管理的总原则是必须兼顾降糖有效性和心血管安全性，并且优先考虑选择具有心血管获益证据的降糖药物。英国糖尿病前瞻性研究(UKPDS)及其后续的10年随访研究显示，在新诊断的T2DM患者中，严格血糖控制(HbA1c<7.0%)对降低心血管事件的远期风险非常重要。然而，退伍军人糖尿病研究(VADT)、控制糖尿病患者心血管风险行动研究(ACCORD)、糖尿病与血管疾病行动研究(AD-VANCE)等随机对照临床试验(RCTs)均显示，在年龄较大、病程较长或合并ASCVD的T2DM患者中，强化降糖治疗并不能显著降低心血管事件风险。此外，对于合并ASCVD的T2DM患者，一旦发生低血糖还可能诱发心律失常、心肌梗死、卒中、猝死等。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "血管", "subject_type": "患病部位", "object": {"@value": "血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "低血糖", "subject_type": "患病病因", "object": {"@value": "心律失常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "低血糖", "subject_type": "患病病因", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "低血糖", "subject_type": "患病病因", "object": {"@value": "卒中"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "低血糖", "subject_type": "患病病因", "object": {"@value": "猝死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心律失常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "近年研究认为采用营养代餐方法能兼顾体重减轻和营养均衡。Wadden等对Look AHEAD研究(纳入5145例肥胖合并糖尿病的患者)进行了后续分析，该后续分析考察了接受食支持和教育以及强化生活方式干预的减重情况。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "接受食支持和教育", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "接受食支持和教育", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.合理的联合用药，避免药物不良反应的产生和叠加。单独使用胰岛素的主要不良反应是低血糖和体重增加。推荐采用胰岛素/口服药联合方案，以增加降糖疗效，同时减少低血糖和体重增加的不良反应。二甲双胍与胰岛素联用可减少体重增加，减少外源性胰岛素用量。α-葡萄糖苷酶抑制剂与胰岛素联用在有效改善血糖的同时，减少胰岛素使用剂量，减少体重增加的幅度和趋势。因此，在无禁忌证的2型糖尿病患者中均可采用二甲双胍或α糖苷酶抑制剂与胰岛素联用。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "α糖苷酶抑制剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "T2DM患者常为混合型血脂异常，临床可能需要他汀类与贝特类药物联合应用，两药联用可能会增加不良反应的几率。Meta分析共纳人13项非诺贝特他汀联用随机对照临床研究中的7712例受试者数据，结果显示，联合治疗组尽管肝酶升高发生率有所升高，但因肝功能异常停药的患者比例并未增加，且CK升高、因肌病停药发生率在联合治疗组和单药组间无统计学差异，说明他汀与非诺贝特联用耐受性良好。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝特类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "混合型", "subject_type": "分期分型", "object": {"@value": "混合型血脂异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类", "subject_type": "药品名称", "object": {"@value": "混合型血脂异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝特类药物", "subject_type": "药品名称", "object": {"@value": "混合型血脂异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "肝酶升高", "subject_type": "不良反应", "object": {"@value": "非诺贝特"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "肝酶升高", "subject_type": "不良反应", "object": {"@value": "他汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肌", "subject_type": "患病部位", "object": {"@value": "肌病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "若低预混胰岛素每2次治疗，HbA1c≥7.0%，早餐后血糖<10.0毫摩尔/升，可考虑调整为低预混胰岛素类似物每日3次；若早餐后血糖≥10.0毫摩尔/升，则可考虑调整为中预混胰岛素类似物每日3次治疗；中预混胰岛素类物每日3次治疗者，如餐后血糖控制好而空腹血糖>6毫摩尔/升，可考虑将晚餐前调整为低预混胰岛素类似物。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "每日3次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日3次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日3次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素类物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "但肝功能受损者使用二甲双胍时应谨慎，因为肝功能受损会明显限制其对乳酸盐的清除能力。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能受损"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "儿童青少年2型糖尿病诊治专家共识尚需在我国更多的临床实践中不断完善，并逐步建立指南。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "7.二甲双胍联合TZDs的疗效：二甲双胍联合TZDs能更好地降低HbA1c，显著改善胰岛功能和IR，但联合治疗药物的不良反应(体重增加、升高LDL-C)高于单用二甲双胍；罗格列酮/二甲双胍的复合制剂与单用二甲双胍比较，复合制剂降低HbA1c和FPG更显著。故IR严重的患者可考虑二甲双胍联合TZDs药物的治疗方案(I级)。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "升高LDL-C", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "TZDs"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "升高LDL-C", "subject_type": "不良反应", "object": {"@value": "TZDs"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "升高LDL-C", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "IR"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "TZDs", "subject_type": "药品名称", "object": {"@value": "IR"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "美国大学组糖尿病研究项目(UGDP)研究提出，甲苯磺丁脲可能增加2型糖尿病患者心血管死亡风险。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "甲苯磺丁脲", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4. 关节B超检查：关节腔内可见典型的“暴雪征“和“双轨征”，具有诊断价值。关节内点状强回声及强回声团伴声影是痛风石常见表现。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "关节内点状强回声及强回声团伴声影", "subject_type": "临床表现", "object": {"@value": "痛风石"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "二、心血管疾病合并糖尿病患者口服降糖药物选择", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "六、糖尿病足预后 ", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)别嘌醇：适应证：①慢性原发性或继发性痛风的治疗；②伴或不伴痛风症状的高尿酸血症的CKD患者；③反复发作性尿酸结石患者；④预防白血病、淋巴瘤或其他肿瘤在化疗或放疗后继发的组织内尿酸盐沉积、肾结石等。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "别嘌醇", "subject_type": "药品名称", "object": {"@value": "继发性痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "化疗", "subject_type": "非药治疗", "object": {"@value": "肿瘤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "放疗", "subject_type": "非药治疗", "object": {"@value": "肿瘤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾结石"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.降尿酸治疗初期痛风急性发作的预防：由于血尿酸水平波动易诱发痛风急性发作，痛风患者初始降尿酸治疗时应使用药物预防痛风发作。首选口服小剂量秋水仙碱，推荐剂量0.5～1.01.0mg／d，轻度肾功能不全无需调整剂量，定期监测肾功能；中度肾功能不全患者剂量减半，0.5mg隔日1次口服或酌情递减；重度肾功能不全或透析患者避免使用。秋水仙碱无效时采用NSAIDs，使用时关注胃肠道、心血管、肾损伤等不良反应。对于有冠心病等慢性心血管疾病者，应权衡利弊，慎重选用NSAIDs。秋水仙碱和NSAIDs疗效不佳或存在使用禁忌时改用小剂量泼尼松或泼尼松龙(≤10mg／d)，同时注意监测和预防骨质疏松等不良反应。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "慢性心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "秋水仙碱"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "0.5～1.01.0mg／d", "subject_type": "用药剂量", "object": {"@value": "秋水仙碱"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道、心血管、肾损伤", "subject_type": "不良反应", "object": {"@value": "NSAIDs"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "骨质疏松", "subject_type": "不良反应", "object": {"@value": "泼尼松"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "≤10mg／d", "subject_type": "用药剂量", "object": {"@value": "泼尼松"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "骨质疏松", "subject_type": "不良反应", "object": {"@value": "泼尼松龙"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "≤10mg／d", "subject_type": "用药剂量", "object": {"@value": "泼尼松龙"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(4)对于中预混胰岛素类似物每日3次治疗患者，如果餐后血糖控制好而空腹血糖>6mmol/L时，可考虑将晚餐前调整为低预混胰岛素类似物。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "每日3次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "3.2 糖尿病视网膜病变糖尿病视网膜病变的病理特征是周细胞丢失、视神经视网膜异常和血管新生。糖尿病视网膜病变的主要临床表现为微血管瘤、出血斑点、硬性渗出、棉绒斑、静脉串珠状、视网膜内微血管异常(intraretinal microvascular abnormality，IRMA)以及黄斑水肿等。广泛出血会引起视网膜或视盘的新生血管、视网膜前出血、玻璃体积血及牵拉性视网膜脱离，微血管瘤出现最早期。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "周细胞丢失", "subject_type": "临床表现", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "视神经视网膜异常", "subject_type": "临床表现", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "血管新生", "subject_type": "临床表现", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "微血管瘤", "subject_type": "临床表现", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "出血斑点", "subject_type": "临床表现", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "硬性渗出", "subject_type": "临床表现", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "棉绒斑", "subject_type": "临床表现", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "静脉串珠状", "subject_type": "临床表现", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "视网膜内微血管异常(intraretinal microvascular abnormality，IRMA)", "subject_type": "临床表现", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "黄斑水肿", "subject_type": "临床表现", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "视网膜或视盘的新生血管"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视盘", "subject_type": "患病部位", "object": {"@value": "视网膜或视盘的新生血管"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "视网膜前出血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "玻璃体", "subject_type": "患病部位", "object": {"@value": "玻璃体积血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "牵拉性视网膜脱离"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "肥胖与糖尿病外科手术的开展必须得到多学科协作的支持，可参考《上海市2型糖尿病外科手术管理规范》，即“手术应在三级综合性医疗单位开展，二级医院原则上不能开展，具备条件的二级医院可向省级医师协会申请并接受审核。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病肾病的诊断分为病理诊断和临床诊断。肾脏病理被认为是诊断金标准。糖尿病主要引起肾小球病变，表现为肾小球系膜增生、基底膜增厚和K-W(Kimmelstiel-Wilson)结节等，是病理诊断的主要依据。糖尿病还可引起肾小管间质、肾微血管病变，如肾间质纤维化、肾小管萎缩、出球动脉透明变性或肾微血管硬化等，这些改变亦可由其他病因引起，在诊断时仅作为辅助指标。目前糖尿病肾病临床诊断的依据有尿白蛋白和糖尿病视网膜病变。糖尿病肾病早期可表现为尿白蛋白阴性，症状不明显，易被忽略，但目前仍缺乏比尿微量白蛋白更可靠敏感的糖尿病肾病早期检测指标。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾小球", "subject_type": "患病部位", "object": {"@value": "肾小球病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "肾小球系膜增生", "subject_type": "发病机制", "object": {"@value": "肾小球病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "基底膜增厚", "subject_type": "发病机制", "object": {"@value": "肾小球病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "K-W(Kimmelstiel-Wilson)结节", "subject_type": "发病机制", "object": {"@value": "肾小球病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿白蛋白", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿白蛋白", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿微量白蛋白", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "糖尿病", "subject_type": "患病病因", "object": {"@value": "肾小管间质、肾微血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "糖尿病", "subject_type": "患病病因", "object": {"@value": "肾间质纤维化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "糖尿病", "subject_type": "患病病因", "object": {"@value": "出球动脉透明变性"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "糖尿病", "subject_type": "患病病因", "object": {"@value": "肾微血管硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "糖尿病", "subject_type": "患病病因", "object": {"@value": "肾小管萎缩"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾小管间质", "subject_type": "患病部位", "object": {"@value": "肾小管间质、肾微血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾微血管", "subject_type": "患病部位", "object": {"@value": "肾小管间质、肾微血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾间质", "subject_type": "患病部位", "object": {"@value": "肾间质纤维化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾小管", "subject_type": "患病部位", "object": {"@value": "肾小管萎缩"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾微血管", "subject_type": "患病部位", "object": {"@value": "肾微血管硬化"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)国家分级诊疗制度中关于不同等级医院的分工：2015年9月，国务院办公厅印发《国务院办公厅关于推进分级诊疗制度建设的指导意见(国办发(2015)70号)》，部署加快推进分级诊疗制度建设，形成科学有序的就医秩序，全面提高人民卫生服务水平，进一步保障和改善民生。分级诊疗模式可概括为16个字：基层首诊、双向转诊、急慢分治、上下联动。基层医疗卫生机构具备常见慢性病的诊疗能力，是实施分级诊疗的重要基础。在糖尿病患者的长期管理中，加强基层医疗卫生机构医师和护士糖尿病专业知识的规范化培训，以患者的需求为中心，充当糖尿病首诊、知识宣教、长期随访的主力军。二级医院组建糖尿病专业管理团队，全面管理糖尿病患者的血糖、血压、血脂，着力于糖尿病的诊断、并发症的筛查及慢性并发症的诊治，发挥承上启下作用。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血脂", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(四)糖尿病足创面处理", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "创面", "subject_type": "临床表现", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "四、T2DM患者的ASCVD危险度评估和治疗目标 ", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "9.二甲双胍联合α-糖苷酶抑制剂的疗效：二甲双胍与α-糖苷酶抑制剂联合，可兼顾FPG和PPG。超重的T2DM患者在二甲双胍疗效不佳时，加用阿卡波糖能更好控制HbA1c、FPG和体重。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿卡波糖", "subject_type": "药品名称", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿卡波糖", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2007年NKF指南荟萃大量研究后指出，在大量白蛋白尿者中，糖尿病视网膜病变对糖尿病性肾小球肾病的阳性预测值为67%~100%，阴性预测值为20%~84%，灵敏度为26%~85%，特异度为13%~100%；在微量白蛋白尿者中，阳性预测值为45%左右，但阴性预测值接近100%，灵敏度为100%，特异度为46%~62%。Meta分析结果表明糖尿病视网膜病变预测2型糖尿病肾病的灵敏度为0.65(95%CI：0.62~0.68)，特异度为0.75(95%CI：0.73~0.78)，阳性为0.72(95%CI：0.68~0.75)，阴性预测值为0.69(95%CI：0.67~0.72)，提示糖尿病视网膜病变是2型糖尿病肾病诊断和筛查的有用指标。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾小球", "subject_type": "患病部位", "object": {"@value": "糖尿病性肾小球肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病性肾小球肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "2型糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "2型糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "流行病学调查显示各地成年人慢性肾脏病的患病率存在差异,为9.0%~14.0%。近期中国慢性肾脏病流行病学调查显示，我国成年人中慢性肾脏病患病率为10.8%，据此估算18岁以上人群慢性肾脏病患者人数约1.195亿。一项中国健康与养老追踪调查研究表明，45岁以上中年及老年人群中，慢性肾脏病患病率达到11.5%，且城市患病率高于农村。另一方面，糖尿病的患病率也很高。2010年中国糖尿病流行病学调查显示成人糖尿病患病率已达11.6%，据此估计我国糖尿病患者人数约1.139亿。糖尿病与慢性肾脏病关系密切，糖尿病患者慢性肾脏病发生风险较非糖尿病患者增加2.6倍。在发达国家,糖尿病已是导致慢性肾脏病的主要病因,美国流行病学调查显示,年龄≥20岁的2型糖尿病患者有39.7%合并慢性肾脏病。而且在发展中国家,糖尿病正逐渐成为慢性肾脏病的主要致病原因。我国住院糖尿病患者的回顾性研究表明，52.25%的糖尿病患者合并肾脏并发症,上海市区30岁以上2型糖尿病患者慢性肾脏病患病率可达63.9%，提示糖尿病合并慢性肾脏病也是我国糖尿病研究和治疗领域面临的重大问题。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "糖尿病", "subject_type": "患病病因", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "糖尿病", "subject_type": "患病病因", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.手术类型与围术期高血糖风险相关。手术越大、应激越强，血糖增高越明显。与区域麻醉比较，全身麻醉特别是吸入性麻醉药刺激血糖升高的作用更显著，但目前并没有证据证明糖尿病患者必须首选区域麻醉。", "spo_list": [{"Combined": false, "predicate": "临床手术", "subject": "区域麻醉", "subject_type": "临床手术", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "全身麻醉", "subject_type": "临床手术", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "区域麻醉", "subject_type": "临床手术", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "吸入性麻醉药", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "西洛他唑是一种强效磷酸二酯Ⅲ抑制剂，2007年被泛大西洋协作组织(TASC) Ⅱ指南推荐作为治疗间歇性跛行的一线药物。在糖尿病足的治疗中，西洛他唑既可以抑制血小板的聚集，防止血栓形成；另一方面，也能够通过扩张血管的作用，增加狭窄动脉的血流量，改善患肢取血状态。西洛他唑的应用可以大幅延迟糖尿病患者截肢的发生，并且改善糖尿病足患者下肢动脉缺血的情况。一般来讲，24周的西洛他唑(100mg，2次/d)治疗可以有效预防糖尿病足者发生溃疡；经8周的西洛他唑(100mg，2次/d)治疗，2型糖尿病下肢缺血患者的经皮氧分压、间歇性跛行、肢体冷感以及疼痛感等显著改善且优于阿司匹林，给予西洛他唑100mg与50mg，2次/d，其无痛性跛行距离均有较好的改善(WMD=31.4lm，95%CI：22.38~40.45m，P<0.00001； WMD=19.89m，95%CI：9.44~30.34m，P=0.0002)，最大跛行距离也有明显改善(WMD=43.12m，95% CI：18.28~67.96m，P=0.0007；WMD=32.00m，95%CI：14.17~49.83m，P=0.0004)，提示西洛他唑能够改善下肢动脉粥样硬化性病变(LEAD) 患者的步行距离，但目前没有足够的证据证明服用西洛他唑能够降低全因病死率和心血管事件或者改善患者的生活质量。此外，经血管腔内微创治疗(球囊扩张及支架植入) 的LEAD患者，西洛他唑治疗较噻氯匹啶有更少的再闭塞发生(OR=0.32，95%CI：0.13~0.76，P=0.01)，且西洛他唑治疗是预防血管再狭窄的独立预测因子。西洛他唑的不良反应主要有头痛、腹泻、大便异常、头晕以及心悸，但症状轻微可以忍受，严重不良事件包括心血管事件及死亡率与安慰剂相比并没有增加，但长期有效性尚不明确。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "西洛他唑", "subject_type": "药品名称", "object": {"@value": "间歇性跛行"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西洛他唑", "subject_type": "药品名称", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "血栓", "subject_type": "临床表现", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "血小板的聚集", "subject_type": "发病机制", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西洛他唑", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西洛他唑", "subject_type": "药品名称", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西洛他唑", "subject_type": "药品名称", "object": {"@value": "下肢动脉缺血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "截肢", "subject_type": "临床手术", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢动脉", "subject_type": "患病部位", "object": {"@value": "下肢动脉缺血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "24周", "subject_type": "持续时间", "object": {"@value": "西洛他唑"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西洛他唑", "subject_type": "药品名称", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "2次/d", "subject_type": "用药频率", "object": {"@value": "西洛他唑"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "100mg", "subject_type": "用药剂量", "object": {"@value": "西洛他唑"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "8周", "subject_type": "持续时间", "object": {"@value": "西洛他唑"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西洛他唑", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西洛他唑", "subject_type": "药品名称", "object": {"@value": "下肢缺血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西洛他唑", "subject_type": "药品名称", "object": {"@value": "下肢动脉粥样硬化性病变(LEAD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西洛他唑", "subject_type": "药品名称", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "100mg", "subject_type": "用药剂量", "object": {"@value": "西洛他唑"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "50mg", "subject_type": "用药剂量", "object": {"@value": "西洛他唑"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "2次/d", "subject_type": "用药频率", "object": {"@value": "西洛他唑"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿司匹林", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "间歇性跛行", "subject_type": "临床表现", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "肢体冷感", "subject_type": "临床表现", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "疼痛感", "subject_type": "临床表现", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "经皮氧分压", "subject_type": "检查方法", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢", "subject_type": "患病部位", "object": {"@value": "下肢缺血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿司匹林", "subject_type": "药品名称", "object": {"@value": "下肢缺血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "经皮氧分压", "subject_type": "检查方法", "object": {"@value": "下肢缺血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢动脉", "subject_type": "患病部位", "object": {"@value": "下肢动脉粥样硬化性病变(LEAD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "经血管腔内微创治疗(球囊扩张及支架植入)", "subject_type": "临床手术", "object": {"@value": "LEAD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西洛他唑", "subject_type": "药品名称", "object": {"@value": "LEAD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "噻氯匹啶", "subject_type": "药品名称", "object": {"@value": "LEAD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "血管再狭窄", "subject_type": "临床表现", "object": {"@value": "LEAD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "再闭塞", "subject_type": "不良反应", "object": {"@value": "西洛他唑"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "再闭塞", "subject_type": "不良反应", "object": {"@value": "噻氯匹啶"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "头痛", "subject_type": "不良反应", "object": {"@value": "西洛他唑"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "腹泻", "subject_type": "不良反应", "object": {"@value": "西洛他唑"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "大便异常", "subject_type": "不良反应", "object": {"@value": "西洛他唑"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "头晕", "subject_type": "不良反应", "object": {"@value": "西洛他唑"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "心悸", "subject_type": "不良反应", "object": {"@value": "西洛他唑"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "心血管事件", "subject_type": "不良反应", "object": {"@value": "西洛他唑"}, "object_type": {"@value": "药品名称"}}]}
{"text": "因此，DPP-4抑制剂是否能够用于1型糖尿病的治疗尚需要更多的临床研究证实，也没有相应的适应证，国内外指南也未推荐使用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "在口服降糖药物中，胰岛素促泌剂均可引起低血糖，其中磺脲类药物尤为常见，格列奈类药物因其药理作用时间短，相对较少见。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "磺脲类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "格列奈类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列奈类"}, "object_type": {"@value": "药品名称"}}]}
{"text": "1.心血管保护作用：二甲双胍通过有效改善糖尿病和非糖尿病患者的IR，降低基础和负荷后胰岛素水平，起到直接或间接的心血管保护作用(Ⅰ级)。UKPDS显示，使用二甲双胍的肥胖T2DM患者的全因死亡风险相对下降35%，心肌梗死风险下降39%；UKPDS10年随访显示，二甲双胍治疗组大血管并发症及死亡风险的获益具有延续效应，且降低死亡和心肌梗死的作用优于磺脲类和胰岛素。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "IR", "subject_type": "发病机制", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "IR", "subject_type": "发病机制", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "在冠心病一级、二级预防的药物治疗方面，应考虑阿司匹林和阿托伐他汀等药物对血尿酸的影响。阿司匹林对于尿酸代谢的影响具有剂量特异性：大剂量阿司匹林(>3g/d)可明显抑制肾小管对尿酸的重吸收，促进尿酸排泄；中等剂量阿司匹林(<1～2g／d)抑制肾小管对尿酸的排泄，从而引起血尿酸水平升高。小剂量阿司匹林(75~325mg／d)轻度升高血尿酸，但考虑到75～325mg／d阿司匹林抗血小板作用相关的心、脑血管获益，对合并HUA的患者不建议停用，建议碱化尿液、多饮水，同时监测血尿酸水平。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "阿司匹林", "subject_type": "药品名称", "object": {"@value": "冠心病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿托伐他汀", "subject_type": "药品名称", "object": {"@value": "冠心病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": ">3g/d", "subject_type": "用药剂量", "object": {"@value": "阿司匹林"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "<1～2g／d", "subject_type": "用药剂量", "object": {"@value": "阿司匹林"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "75~325mg／d", "subject_type": "用药剂量", "object": {"@value": "阿司匹林"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "75～325mg／d", "subject_type": "用药剂量", "object": {"@value": "阿司匹林"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸", "subject_type": "检查指标", "object": {"@value": "冠心病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "碱化尿液", "subject_type": "非药治疗", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "多饮水", "subject_type": "非药治疗", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "监测血尿酸水平", "subject_type": "非药治疗", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)磺脲类：第一代磺脲类药物(如氯磺丙脲、妥拉磺脲、甲苯磺丁脲)的药物原型及其活性代谢产物主要依赖肾脏排泄，应用于CKD患者时半衰期延长，低血糖风险明显增加，因此禁用于该类患者，目前此类药物在临床上已基本被淘汰。第二代磺脲类药物包括格列本脲、格列吡嗪、格列奇特、格列喹酮和格列美脲等。格列本脲和格列美脲的代谢产物仍有降糖活性，尤其是格列本脲的半衰期较长，其活性代谢产物可在CKD患者体内积聚，可能引起严重的低血糖反应，且持续时间可超过24h。因而格列本脲仅可用于CKD1~2期的患者；格列美脲用于CKD3~4期的患者时，应从小剂量开始用药，即起始剂量为每日1mg；由于还未积累关于透析患者的用药经验，在透析患者禁用。格列吡嗪和格列齐特的代谢产物均无降糖活性，虽然主要经肾脏排泄，但低血糖风险小于前两者。格列喹酮的代谢产物无降糖作用且大部分从粪便排泄，仅5%由肾脏排泄，受肾功能影响较小。因而格列吡嗪、格列齐特和格列喹酮于CKD1~3期患者无需调整剂量。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "第一代磺脲类药物", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "第一代磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "氯磺丙脲", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "氯磺丙脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "妥拉磺脲", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "妥拉磺脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "甲苯磺丁脲", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "甲苯磺丁脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列本脲", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列美脲", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列本脲", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列本脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列本脲", "subject_type": "药品名称", "object": {"@value": "CKD1~2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~2期", "subject_type": "分期分型", "object": {"@value": "CKD1~2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列美脲", "subject_type": "药品名称", "object": {"@value": "CKD3~4期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "每日1mg", "subject_type": "用药剂量", "object": {"@value": "格列美脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3~4期", "subject_type": "分期分型", "object": {"@value": "CKD3~4期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "透析", "subject_type": "非药治疗", "object": {"@value": "CKD3~4期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "透析", "subject_type": "非药治疗", "object": {"@value": "CKD3~4期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列吡嗪"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列齐特"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列吡嗪", "subject_type": "药品名称", "object": {"@value": "CKD1~3期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列齐特", "subject_type": "药品名称", "object": {"@value": "CKD1~3期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "CKD1~3期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~3期", "subject_type": "分期分型", "object": {"@value": "CKD1~3期"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.二甲双胍在治疗NAFLD方面的作用：中华医学会肝病学分会脂肪肝和酒精性肝病学组颁布《中国非酒精性脂肪性肝病诊疗指南(2010年修订版)》提出，除非存在明显的肝损害(如血清转氨酶大于3倍正常值上限)、肝功能不全或失代偿期肝硬化等情况，NAFLD患者可安全使用二甲双胍(V级)。有14项临床研究评价了二甲双胍对NAFLD患者肝脏组织学、血清酶学和IR等指标的改善情况。所有研究均显示，HOMAI-IR明显改善，13项研究显示血清酶学(ALT、AST)明显下降，5项研究显示二甲双胍对肝脏炎症、脂肪变性和纤维化有显著改善。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "NAFLD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "脂肪肝"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "酒精性肝病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "酒精性", "subject_type": "分期分型", "object": {"@value": "酒精性肝病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "非酒精性脂肪性肝病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "非酒精性脂肪性", "subject_type": "分期分型", "object": {"@value": "非酒精性脂肪性肝病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血清转氨酶", "subject_type": "检查指标", "object": {"@value": "肝损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "失代偿期肝硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "失代偿期", "subject_type": "分期分型", "object": {"@value": "失代偿期肝硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "NAFLD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "NAFLD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血清酶学", "subject_type": "检查方法", "object": {"@value": "NAFLD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "IR", "subject_type": "发病机制", "object": {"@value": "NAFLD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肝脏炎症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "脂肪变性和纤维化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝脏", "subject_type": "患病部位", "object": {"@value": "肝脏炎症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "6.二甲双胍与乳酸酸中毒：目前，尚无确切的证据支持二甲双胍的使用与乳酸酸中毒有关，肝、肾功能正常者长期应用并不增加乳酸酸中毒风险。COSMIC研究是一项随机、开放标签、活性对照、平行分组研究，结果显示，使用二甲双胍的乳酸酸中毒发生率与其他降糖治疗比较，差异无统计学意义(I级)。荟萃分析显示，在肾功能正常的患者中使用二甲双胍不增加乳酸酸中毒风险，且二甲双胍发生乳酸酸中毒的概率并不比其他口服降糖药物高。因为二甲双胍直接以原形经肾脏排泄，所以有肾功能损害时易发生二甲双胍与乳酸在体内蓄积，有可能会增加乳酸酸中毒风险。建议肾功能受损[eGFR<45ml/(min·1.73m2)]和低氧血症患者应避免使用二甲双胍。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "eGFR", "subject_type": "检查指标", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.规律早餐与BMI：横断面研究表明，不爱吃早餐的群体发生超重和肥胖的比例更大。芬兰一项出生队列研究发现，相对于规律进食早餐的青少年，很少吃早餐的群体更容易吸烟、喝酒、咖啡以及含有咖啡因的碳酸饮料，并且很少锻炼，BMI值更高。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "规律早餐", "subject_type": "非药治疗", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "规律早餐", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "患者单药治疗的一线首选药物和联合治疗的基本用药，如无禁忌证且能够耐受，二甲双胍应一直保留在T2DM患者的降糖治疗方案中。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "长效制剂有利拉鲁肽，每天一次；艾塞那肽周制剂，每周一次；阿必鲁肽(albiglutide)，每周一次；dulaglutide，每周一次。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "每天一次", "subject_type": "用药频率", "object": {"@value": "利拉鲁肽"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每周一次", "subject_type": "用药频率", "object": {"@value": "艾塞那肽周制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每周一次", "subject_type": "用药频率", "object": {"@value": "阿必鲁肽(albiglutide)"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每周一次", "subject_type": "用药频率", "object": {"@value": "dulaglutide"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(二)T2DM合并超重或肥胖管理流程见图1", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "TZDs：可引起水钠潴留和血容量扩张，诱发或加重心力衰竭，故急性心力衰竭、NYHA心功能Ⅱ~IV级的慢性心力衰竭患者禁用。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "水钠潴留", "subject_type": "不良反应", "object": {"@value": "TZDs"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "血容量扩张", "subject_type": "不良反应", "object": {"@value": "TZDs"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "诱发或加重心力衰竭", "subject_type": "不良反应", "object": {"@value": "TZDs"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "急性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "急性", "subject_type": "分期分型", "object": {"@value": "急性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "Ⅱ~IV级", "subject_type": "分期分型", "object": {"@value": "NYHA心功能Ⅱ~IV级"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "慢性心力衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "促泌剂可发生低血糖和体重增加的不良反应，因此，除基础胰岛素外，不建议胰岛素和促泌剂联合使用。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "促泌剂"}, "object_type": {"@value": "药品名称"}}]}
{"text": "目前，临床研究数据尚未证实此类药物与膀胱癌风险存在因果关系，上市后至今尚无相关肿瘤病例报告；FDA和EMA根据不良事件报告系统的数据，已加强提醒在使用SGLT-2抑制剂过程中，注意骨折风险(坎格列净)、足趾截肢风险(坎格列净)及急性肾损伤风险(达格列净、坎格列净)，但它们之间是否存在因果关系仍需要进一步研究。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "膀胱", "subject_type": "患病部位", "object": {"@value": "膀胱癌"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "SGLT-2抑制剂", "subject_type": "药品名称", "object": {"@value": "肿瘤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足趾", "subject_type": "患病部位", "object": {"@value": "足趾截肢"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "急性肾损伤"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.老年2型糖尿病患者", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "目前普遍认为长期使用磺脲类药物可致患者体重明显增加，但不同磺脲类药物对体重的影响存在差异。剂型改良后的磺脲类药物及格列美脲对体重影响较小。随机对照研究结果显示，2型糖尿病患者使用格列吡嗪单药治疗1年体重增加2.6kg。GUIDE研究中随机分为格列齐特缓释片组和格列美脲组治疗27周，体重增加分别为0.5kg和0.6kg。荟萃分析结果显示，磺脲类药物单药治疗平均约增加体重2kg，但磺脲类药物与二甲双胍、SGLT-2抑制剂、GLP-1受体激动剂等药物联合时，这一不良反应可能会被完全或部分抵消。ZODIAC-39队列研究显示，不同磺脲类药物联合二甲双胍治疗5年，格列本脲组体重增加3.3kg，格列齐特组体重增加3.9kg，格列美脲组体重增加0.1kg。LEAD-1研究显示，之前使用格列美脲单药治疗的T2DM患者换为格列美脲联合利拉鲁肽1.2mg/d或1.8mg/d治疗后，体重变化分别为+0.3kg和-0.2kg。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "体重明显增加", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "格列吡嗪"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "1年", "subject_type": "持续时间", "object": {"@value": "格列吡嗪"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列吡嗪", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "格列齐特缓释片"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "27周", "subject_type": "持续时间", "object": {"@value": "格列齐特缓释片"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "格列美脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "27周", "subject_type": "持续时间", "object": {"@value": "格列美脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "增加体重", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "5年", "subject_type": "持续时间", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "5年", "subject_type": "持续时间", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "格列本脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "格列齐特"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "格列美脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列美脲", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1.2mg/d", "subject_type": "用药剂量", "object": {"@value": "利拉鲁肽"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1.8mg/d", "subject_type": "用药剂量", "object": {"@value": "利拉鲁肽"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利拉鲁肽", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "转往上级医院：①基层医疗卫生机构缺乏糖尿病微血管并发症筛查设备；②糖尿病微血管并发症患者需调整治疗方案；③糖尿病患者出现严重微血管并发症或病情进一步恶化，基层医疗卫生机构缺乏进一步改善微血管并发症的治疗手段，医患双方均同意转往上级医院就诊。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "微血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "微血管并发症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "中国成人2型糖尿病发生的病理生理特点与欧美国家存在差异，β细胞胰岛素分泌功能下降比胰岛素敏感性降低更明显，且糖尿病肾病发生率更高(2c级，2b级)。因此根据中国2型糖尿病患者自身特点，进行合理的降糖治疗，努力控制其他多种血管病变危险因素，降低血管并发症风险和提高患者生活质量是目前亟需解决的问题。尽管随着糖尿病防治进展，新降糖药物不断问世，而多数权威指南仍将胰岛素促泌剂作为成人2型糖尿病治疗的一线药物。英国糖尿病前瞻性研究(UKPDS)及其后续研究与糖尿病和心血管疾病行动(ADVANCE)等多个大型临床研究证实，磺脲类促泌剂或以其为基础的降糖治疗可显著提高2型糖尿病患者的血糖达标率，降低糖尿病血管并发症风险(1b级)。由于胰岛素促泌剂的发展，其种类逐渐增多，为了针对中国成人2型糖尿病患者的自身特点，更有效指导临床正确使用胰岛素促泌剂，中华医学会内分泌分会组织专家对胰岛素促泌剂在中国成人2型糖尿病的临床应用进行了多次认真的讨论并达成了共识。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "β细胞胰岛素分泌功能下降比胰岛素敏感性降低更明显", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "血管", "subject_type": "患病部位", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "血管", "subject_type": "患病部位", "object": {"@value": "血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类促泌剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "血管", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)药物选择：从磺脲类药物的降糖机制不难看出，患者需要有一定的胰岛功能才能起效，所以糖尿病病程较短且能够坚持饮食和运动干预的患者使用磺脲类药物的疗效会更好。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "饮食和运动干预", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病专科医师或专科护士应该充分了解上述5个方面的内容，对患者进行完善的评估，也可根据实际条件进行项目选择。第1、2条是合理选用降糖药的基础，规避滥用药；第3、4条是综合治疗、全面控制心血管风险、保护脏器功能的基础，第5条有助于评估患者的自我管理能力，综合考虑为患者制定量身打造的治疗方案。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管风险"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(4)噻唑烷二酮类：噻唑烷二酮类为胰岛素增敏剂，主要通过增加靶细胞对IS而降低血糖，可降低HbA1c1.0%~1.5%。主要代表药物为吡格列酮和罗格列酮，均经肝脏代谢，不增加低血糖风险。该类药物的常见不良反应是液体潴留，因而对于重度心力衰竭患者应慎用。此外，绝经后妇女服用该类药物发生骨折及骨质疏松的风险增加，因此慎用于潜在骨疾病的患者(如肾性骨营养不良)。吡格列酮用于CKD1~3a期患者时，无需调整剂量；3b~5期患者用药经验有限，需谨慎用药。罗格列酮因增加心血管风险的安全性问题引起了国内外的警惕，目前美国食品药品监督管理局(FDA)已严格限制其使用。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "吡格列酮"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "罗格列酮"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "骨", "subject_type": "患病部位", "object": {"@value": "肾性骨营养不良"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "吡格列酮", "subject_type": "药品名称", "object": {"@value": "CKD1~3a期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~3a期", "subject_type": "分期分型", "object": {"@value": "CKD1~3a期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3b~5期", "subject_type": "分期分型", "object": {"@value": "CKD1~3a期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "增加心血管风险", "subject_type": "不良反应", "object": {"@value": "罗格列酮"}, "object_type": {"@value": "药品名称"}}]}
{"text": "目前有多种药物在临床上用于DPN的治疗，包括具有抗氧化应激作用的药物(如α-硫辛酸)，改善代谢紊乱类药物(如醛糖还原酶抑制剂)以及各种改善微循环的药物等。但是，临床研究显示当DPN发生后，目前尚无药物能够逆转周围神经病变的进展。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "α-硫辛酸", "subject_type": "药品名称", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "醛糖还原酶抑制剂", "subject_type": "药品名称", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "周围神经病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "国内报道二甲双胍的胃肠道反应发生率为15%，且二甲双胍的胃肠道反应与患者的体重、二甲双胍剂量没有明显的相关性。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "胃肠道反应", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道反应", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "四、糖尿病足的辅助检查 ", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "DPP-4抑制剂是一种新型的口服降糖药，疗效确切，安全性良好。中国FDA批准的适应证主要为单药或与二甲双胍联用，或与二甲双胍和磺脲类药物联用。临床应用应该以药物说明书为基础，但临床证据和国内外权威指南支持与多种传统降糖药双药以上的联合使用。暂不主张在1型糖尿病患者中应用DPP-4抑制剂，因为需要更充分的临床证据。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "DPP-4抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "但是，由于我国糖尿病足具有自身的特点，因此，中国医疗保健国际交流促进会组织全国足病相关专家起草了糖尿病足诊治指南。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "足病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病足的治疗策略：一级预防——防止或延缓神经病变、周围血管病变的发生；二级预防——缓解症状，延缓神经病变、周围血管病变的进展；三级预防——血运重建，溃疡综合治疗，降低截肢率和心血管事件发生率。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围血管", "subject_type": "患病部位", "object": {"@value": "周围血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围血管", "subject_type": "患病部位", "object": {"@value": "周围血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "目前，明确具有心血管获益的降糖药物包括二甲双胍、恩格列净及利拉鲁肽。二甲双胍是T2DM降糖治疗的一线药物，其心血管安全性证据来自UKPDS及其后续的10年随访研究。UKPDS研究纳人1704例合并超重或肥胖的新诊断T2DM患者，随机分为给予传统治疗(饮食控制为主，n=411)、二甲双胍强化降糖治疗(n=342)或其他药物(SUs或胰岛素)强化降糖治疗(n=951)，中位随访时间为10.7年。结果显示，与传统治疗相比，二甲双胍可显著降低心血管事件风险，其中心肌梗死风险下降39%(P=0.010)，心血管事件复合终点(心肌梗死、猝死、心绞痛、卒中或周围血管疾病)风险下降30%(P=0.020)；二甲双胍与其他药物的两种强化降糖治疗方案之间相比，心血管事件风险差异无统计学意义。UKPDS研究结束后继续随访10年仍发现，二甲双胍的心血管获益具有延续效应，与传统治疗相比，其心肌梗死风险下降33%(P=0.005)。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食控制", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "SUs", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心绞痛"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围血管", "subject_type": "患病部位", "object": {"@value": "周围血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.1 DPP-4抑制剂联合二甲双胍大多数DPP-4抑制剂最常见的联合用药指征是用于二甲双胍不能取得良好血糖控制的患者，主要原因在于二甲双胍是国内外指南推荐治疗2型糖尿病的一线用药。此外，这2种药物联合使用可优势互补，针对了2型糖尿病最重要的病理生理基础，即DPP-4抑制剂改善β细胞功能，二甲双胍改善胰岛素抵抗。众多的研究已经证实这种联治疗的有效性和安全性。DPP-4抑制剂联合二甲双胍可以进一步降低患者HbA1c0.5%~1.1%。DPP-4抑制剂联合二甲双胍的低血糖发生率与安慰剂组相似，胃肠道反应与二甲双胍单药治疗相比无显著差异。目在中国获批与二甲双胍联合应用的DPP-4抑制剂有沙格列汀、维格列汀、阿格列汀、西格列汀。利格列汀获得了FDA和EMA的批准用于与二甲双胍的联合治疗。目前国外已有DPP-4抑制剂与二甲双胍的复合制剂，可直接用于需要二者联合使用的患者。对于二甲双胍单药治疗不满意的患者联合DPP-4抑制剂的低血糖发生率明显低于联合磺脲类药物，且具有体重控制方面的优势。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "DPP-4抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "DPP-4抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道反应", "subject_type": "不良反应", "object": {"@value": "DPP-4抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道反应", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道反应", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(6)住院期间：①根据院内血糖监测情况、年龄，及入院后完善的检查，包括HbA1c、胰岛功能及其相关抗体、肝肾功能、慢性并发症情况、心血管系统及其相关代谢指标等健康状态评估后确定院内血糖控制目标。2根据上述情况及糖尿病分型完善降糖及综合治疗方案。③制订并实施饮食、运动治疗方案。④全程糖尿病健康指导，包括：饮食、运动、血糖监测、胰岛素注射技术、预防低血糖和糖尿病急性并发症、足保护、体重管理等。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "健康指导", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "足保护", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "体重管理", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖监测", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "档案建立及远期随访：所有因糖尿病住院的孕妇都应常规建立随访档案，制订随访计划，定期到内分泌门诊随访血糖状况。推荐所有GDM妇女在产后6~12周进行口服葡萄糖耐量试验(OGTT)检查，明确有无糖代谢异常，以后每3年随访1次。同时，建议对糖尿病患者的子代进行生长发育状况的随访，并进行健康生活方式的指导。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "口服葡萄糖耐量试验(OGTT)检查", "subject_type": "检查方法", "object": {"@value": "GDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生长发育状况的随访", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "健康生活方式的指导", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.二甲双胍的最小、最大及最佳使用剂量：临床研究显示，在500~2000mg/d的剂量范围内，二甲双胍的降糖效果与剂量呈正相关。500mg/d二甲双胍可降低HbA1c 0.6%(减去安慰剂效应后，以下同)，2000 mg/d可降低HbA1c 2.0%，且与1000mg或1500mg比较，胃肠道反应差异无统计学意义。UKPDS研究中，二甲双胍强化治疗剂量中位数达到2550 mg/d，缓释剂型推荐最大用量为2000 mg/d，普通片推荐成人可用的最大剂量为2550 mg/d。综上所述，二甲双胍起效的最小推荐剂量为500mg/d，成人可用的最大剂量为2550mg/d，最佳有效剂量为2000mg/d。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "500~2000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "500mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2000 mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1000mg", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1500mg", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道反应", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2000 mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2550 mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2550 mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "500mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2550mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "近年来，随着对住院高血糖管理认识的不断深化和证据积累，血糖控制目标已由强化血糖控制发展至多样化的个体化目标。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(3)制订妊娠计划与患者教育：住院期间，应对计划妊娠的糖尿病患者及其家属进行教育，帮助患者及其家属明确糖尿病与妊娠间的相互影响，帮助患者制订以家庭为单位的妊娠计划，并制定完善的孕期随访计划。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "制订以家庭为单位的妊娠计划", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "制定完善的孕期随访计划", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.蛋白质：由于CRD降低了摄入的总能量，必然导致产热的宏量营养素摄入降低，应适当提高蛋白质供给量比例(1.2~1.5g/kg，或15%~20%)，这样就能在减重过程中维持氮平衡，同时具有降低心血管疾病风险、增加骨矿物质含量等作用。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "·糖尿病合开各种严重慢性开发症如各种神经病变、视网膜病变、肾病、糖尿病足溃疡伴或不伴感染等；", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足溃疡"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.剂型：目前国内外主要有单一成分的二甲双胍普通片(250mg/片，500mg/片或850rag/片)、二甲双胍缓释片或胶囊(500mg/片或500mg/胶囊)、二甲双胍肠溶片或胶囊(250mg/片或250mg/胶囊)、二甲双胍粉剂，以及与其他口服降糖药[如磺脲类药物或DPP-4抑制剂]组成的复方制剂。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "DPP-4抑制剂"}, "object_type": {"@value": "药品名称"}}]}
{"text": "对于临床中使用口服药联合预混胰岛素治疗的患者，若其血糖控制不满意且患者病程较短，有一定残存胰岛β细胞功能，也可尝试调整为基础胰岛素与口服降糖药联合治疗。研究发现，在血糖控制不满意，病程<10年，预混胰岛素剂量<50U/d的患者中，将预混胰岛素转换为基础胰岛素联合口服药治疗方案后，能够显著改善血糖，并较继续使用并优化预混胰岛素低血糖发生的风险低。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "<50U/d", "subject_type": "用药剂量", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "6.二甲双胍与乳酸酸中毒：目前尚无确切的证据支持二甲双胍的使用与乳酸酸中毒有关，肝肾功能正常患者长期应用不增加乳酸酸中毒风险。COSMIC研究显示，使用二甲双胍的乳酸酸中毒发生率与其他降糖治疗差异无统计学意义(Ⅰ级)。荟萃分析显示，在肾功能正常的患者中使用二甲双胍不增加乳酸酸中毒风险，且二甲双胍发生乳酸酸中毒的概率并不比其他口服降糖药物高。因二甲双胍直接以原形经肾脏排泄，因此有肾功能损害时易发生二甲双胍与乳酸在体内蓄积，有可能会增加乳酸酸中毒风险。建议肾功能受损[eGFR<45ml/(min·1.73m2)]和低氧血症患者应避免使用。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "乳酸酸中毒", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "乳酸酸中毒", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "乳酸酸中毒", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "eGFR", "subject_type": "检查指标", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能受损"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "大量证据表明，围术期血糖异常(包括高血糖、低血糖和血糖波动)增加手术患者的死亡率，增加感染伤口不愈合以及心脑血管事件等并发症的发生率，延长住院时间，影响远期预后。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "⑤超重或肥胖患者：胰岛素抵抗会导致胰岛素需要量增加，必要时可联合二甲双胍(10岁以下儿童禁用)。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.兼有降尿酸作用的其他药物：氯沙坦不但能降血压，同时能促进尿酸排泄。高血压患者，可考虑使用氯沙坦，但单独使用的降尿酸作用较弱。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "氯沙坦", "subject_type": "药品名称", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "GLP-1受体激动剂主要通过激活GLP-1受体发挥作用，因其降糖作用具有葡萄糖浓度依赖性，因此低血糖发生率极低。利拉鲁肽无论单药或联合治疗，均能显著降低HbA1c1.1%~1.6%，降低体重1.0-3.2kg，持久地缩小患者腰围，且基线体重、腰围值越大，降低体重、缩小腰围的效果越显著。LEAD-2研究中，利拉鲁肽1.2mg或1.8mg治疗使患者内脏脂肪分别减少17.1%和16.4%。另一种GLP-1受体激动剂艾塞那肽，与利拉鲁肽头对头比较的临床研究显示，降糖效果略差，减重效果类似。此外，利拉鲁肽(3.0mg/d)在美国、加拿大、欧盟已经被正式批准作为减肥药。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "GLP-1受体激动剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1.2mg", "subject_type": "用药剂量", "object": {"@value": "利拉鲁肽"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1.8mg", "subject_type": "用药剂量", "object": {"@value": "利拉鲁肽"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "3.0mg/d", "subject_type": "用药剂量", "object": {"@value": "利拉鲁肽"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(1)碳酸氢钠：适用于慢性肾功能不全合并HUA和/或痛风患者。起始剂量0.5～1.0g口服，3次／d，与其他药物相隔1～2h服用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "碳酸氢钠", "subject_type": "药品名称", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "碳酸氢钠", "subject_type": "药品名称", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "慢性肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "该共识建议，对于2型糖尿病患者，以下情况应给予胰岛素治疗(暂不考虑口服降糖药治疗)：(1)急性并发症或严重慢性并发症；(2)应激情况(感染、外伤、手术等)；(3)严重合并症，肝肾功能不全； (4)妊娠期间。而以下情况可给予胰岛素单药治疗，亦可给予口服药和胰岛素联合应用：(1)新诊断2型糖尿病患者，糖化血红蛋白(HbA1c)≥9.0%且糖尿病症状明显；(2)在采用有效的生活方式干预及2种或2种以上口服降糖药次大剂量治疗3个月后血糖仍不达标(HbA1c≥7.0%)患者；(3)病程中出现无确切诱因的体重下降者。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "糖化血红蛋白(HbA1c)", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肝肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "快速建议指南推荐复方制剂(DPP-4抑制剂和二甲双胍)用于2型糖尿病患者的起始降糖治疗，指出对于糖化血红蛋白>7.5%的首次治疗患者，推荐使用复方制剂(DPP-4抑制剂和二甲双胍)进行起始治疗。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "糖化血红蛋白", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "·糖尿病患者需要接受胰岛细胞移植或干细胞治疗者。", "spo_list": [{"Combined": false, "predicate": "临床手术", "subject": "胰岛细胞移植", "subject_type": "临床手术", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "干细胞治疗", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)神经性溃疡：神经性溃疡患者通常有患足麻木、感觉异常、皮肤干燥，但皮温正常，足背动脉搏动良好。病情严重者可发展为神经性关节病 (Charcot关节病)。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "患足麻木", "subject_type": "临床表现", "object": {"@value": "神经性溃疡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "感觉异常", "subject_type": "临床表现", "object": {"@value": "神经性溃疡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "皮肤干燥", "subject_type": "临床表现", "object": {"@value": "神经性溃疡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "关节", "subject_type": "患病部位", "object": {"@value": "神经性关节病 (Charcot关节病)"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "在DPN诊断过程中，需要与多种其他病因导致的周围神经病进行鉴别，特别是当临床存在明显的肢体无力或神经电生理显示传导速度明显减慢时，诊断DPN应该慎重。临床常需要与其鉴别的疾病包括：慢性炎性脱髓鞘性多发性神经根周围神经病、营养缺乏、中毒、异常球蛋白血症、肝功能不全、肾功能不全、甲状腺功能减退、恶性肿瘤、结缔组织病、感染性疾病以及遗传病等。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "明显的肢体无力", "subject_type": "临床表现", "object": {"@value": "周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "神经电生理", "subject_type": "检查方法", "object": {"@value": "周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "明显的肢体无力", "subject_type": "临床表现", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "神经电生理", "subject_type": "检查方法", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性炎性脱髓鞘性多发性", "subject_type": "分期分型", "object": {"@value": "慢性炎性脱髓鞘性多发性神经根周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经根周围神经", "subject_type": "患病部位", "object": {"@value": "慢性炎性脱髓鞘性多发性神经根周围神经病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "甲状腺", "subject_type": "患病部位", "object": {"@value": "甲状腺功能减退"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "结缔组织", "subject_type": "患病部位", "object": {"@value": "结缔组织病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "《中国肥胖和2型糖尿病外科治疗指南(2014)》中将建议手术年龄定为16~65岁。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "CKD的GFR分期：可用血清肌酐估算公式或其他指标(如胱抑素C或清除率测定)对GFR进行初步评估进行分期。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血清肌酐", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "胱抑素C", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "清除率测定", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.空腹静脉血浆血糖(FPG)：FPG是评价糖代谢状态和血糖控制水平最常用的指标，要求受试者至少空腹8h后，在次日上午取血。仅通过FPG筛查糖尿病的优点是简便、易行，但存在漏诊的可能性。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)目前缺少在T2DM患者中评估心血管安全性的CVOT证据的降糖药物", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "餐后高血糖和低血糖是引起糖尿病患者血糖波动的两个重要原因。常用降糖药对餐后高血糖和低血糖的影响见表3。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "在T2DM患者中进行的终止糖尿病患者动脉粥样硬化研究(SANDS)、依折麦布/辛伐他汀疗效国际试验(IMPROVE-IT)研究显示，选择性胆固醇吸收抑制剂依折麦布联合他汀治疗进一步降低主要心血管终点事件风险(HR：0.936，P=0.016)，且安全性良好。PCSK9抑制剂是一类新型的降胆固醇治疗药物，Meta分析结果显示，PCSK9抑制剂可降低心肌梗死(OR：0.49，P=0.03)和全因死亡率(OR：0.45，P=0.015)。胆固醇吸收抑制剂依折麦布和PCSK9抑制剂可作为他汀不耐受或单药治疗LDL-C不能达标时的联合用药(建议；A级证据)，但其长期以及在糖尿病患者中的疗效和安全性仍有待进一步的探讨。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "依折麦布", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "辛伐他汀", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "依折麦布", "subject_type": "药品名称", "object": {"@value": "动脉粥样硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "辛伐他汀", "subject_type": "药品名称", "object": {"@value": "动脉粥样硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀", "subject_type": "药品名称", "object": {"@value": "心血管终点事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "PCSK9抑制剂", "subject_type": "药品名称", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "PCSK9抑制剂", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胆固醇吸收抑制剂", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "依折麦布", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "选择性胆固醇吸收抑制剂", "subject_type": "药品名称", "object": {"@value": "心血管终点事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "依折麦布", "subject_type": "药品名称", "object": {"@value": "心血管终点事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管终点事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "不耐受", "subject_type": "不良反应", "object": {"@value": "他汀"}, "object_type": {"@value": "药品名称"}}]}
{"text": "DCCT及其后续的糖尿病干预和并发症流行病学研究(EDIC)、英国2型糖尿病前瞻性研究(UKPDS)及美国退伍军人合作研究(VAC)分别验证了在1型糖尿病和2型糖尿病患者中，严格控制血糖可减少糖尿病肾病的发生或延缓其病程进展。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "10.二甲双胍联合DPP-4抑制剂的疗效：二甲双胍与DPP-4抑制剂的联合治疗，可针对T2DM不同的病理生理缺陷，发挥机制互补、协同增效的降糖作用。一项随机、双盲、对照研究显示，二甲双胍单药控制不佳的T2DM患者加用DPP-4抑制剂可有效改善血糖水平，且耐受性良好(I级)。中国多中心、前瞻性、随机、对照研究显示，1000mg二甲双胍联合维格列汀与二甲双胍2000mg单药疗效和安全性相当；在新诊断T2DM患者中，1700mg/d二甲双胍单药治疗的降糖疗效非劣于1700mg二甲双胍联合西格列汀治疗(Ⅰ级)。建议遵循《中国2型糖尿病防治指南》的治疗原则，新诊断T2DM患者首选二甲双胍，可耐受的情况下加至最佳有效剂量(2000mg/d)；不达标的患者，可以联合DPP-4抑制剂。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1000mg", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2000mg", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西格列汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1700mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1700mg", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "随着社会生活水平的提高，以及国人膳食模式的变化，代谢综合征的流行呈现快速上升趋势，2000年至2001年的全国性横断面调查显示，男性和女性代谢综合征的惠病车分别为10.0%和23.3%。2011年美国Joslin糖尿病中心发布了合并糖尿病的肥胖患者临床营养指南，整部指南的目标人群实际是代谢综合征患者，其将体重管理置于营养管理的首要目标。与此同时，该指南还提出将膳食管理与胰岛素治疗相配合，同时需要考虑与营养有关的代谢并发症的控制。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "膳食管理", "subject_type": "非药治疗", "object": {"@value": "代谢并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "代谢并发症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(3)糖尿病周围神经病变(DPN)的诊断：DPN是指在排除其他原因的情况下，糖尿病患者出现周障碍相关的症状或体征，其中最常见及最具代尿病远端对称性多发性神经病变(DSPN)。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "糖尿病周围神经病变(DPN)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "尿病远端对称性多发性神经病变(DSPN)"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "贝前列腺素钠的剂量根据患者病变程度推荐为20~40μg/次，2~ 3次/d。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "2~ 3次/d", "subject_type": "用药频率", "object": {"@value": "贝前列腺素钠"}, "object_type": {"@value": "药品名称"}}]}
{"text": "60~70岁以恶性肿瘤排位最前，80~90岁心血管病、肺部感染升至最高。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肺部", "subject_type": "患病部位", "object": {"@value": "肺部感染"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "胰岛素促泌剂其他少见不良反应包括头晕、乏力、头痛、皮疹、恶心和胃肠道不良反应(呕吐、腹痛、腹泻等)。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "头晕", "subject_type": "不良反应", "object": {"@value": "胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "乏力", "subject_type": "不良反应", "object": {"@value": "胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "头痛", "subject_type": "不良反应", "object": {"@value": "胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "皮疹", "subject_type": "不良反应", "object": {"@value": "胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "恶心", "subject_type": "不良反应", "object": {"@value": "胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道不良反应", "subject_type": "不良反应", "object": {"@value": "胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "呕吐", "subject_type": "不良反应", "object": {"@value": "胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "腹痛", "subject_type": "不良反应", "object": {"@value": "胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "腹泻", "subject_type": "不良反应", "object": {"@value": "胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}]}
{"text": "由于DPP-4i不影响患者的体重，故建议DPP-4i用于超重/肥胖2型糖尿病患者的降糖治疗。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4i", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "血糖控制的目标应根据个体化原则，综合考虑患者的年龄、病程、预期寿命、伴发疾病、降糖治疗方案及患者意愿等情况制定。对于大多数非妊娠成年T2DM患者，合理的血糖控制目标为HbA1c<7%、FPG4.4~7.0mmol/L；对于病程较短、预期寿命较长、无严重并发症或低血糖风险低的患者可设定较为严格的血糖控制目标，HbA1c≤6.5%、FPG<6.1mmol/L；而对于有严重低血糖史、预期寿命较短、合并严重并发症的患者，血糖控制目标较为宽松，HbA1c<8.0%、FPG<8.0mmol/L或更高(表2)。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "中国2型糖尿病自我管理处方专家共识(2017年版)", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "自我管理", "subject_type": "非药治疗", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)肥胖：尤其是腹型肥胖与HUA关系密切一相关的轻度慢性炎症和胰岛素抵抗状态增加HUA和痛风的风险。减轻体重特别是减小腹围是非药物治疗降低尿酸水平的有效方法。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "腹", "subject_type": "患病部位", "object": {"@value": "腹型肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "慢性炎症", "subject_type": "患病病因", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "慢性炎症", "subject_type": "患病病因", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "11.联合GLP-1受体激动剂的疗效：目前中国临床应用的GLP-1受体激动剂主要包括利拉鲁肽和艾塞那肽。在二甲双胍治疗基础上加用GLP-1受体激动剂，可进一步降低FPG、HbA1c，血糖达标率更高：改善胰岛素β细胞功能：改善IR，降低体重和SBP，无严重低血糖事件(Ⅰ级)。在我国T2DM人群中开展的随机分组、对照性研究显示，利拉鲁肽联合二甲双胍与格列美脲联合二甲双胍相比降糖疗效相当，体重和血压显著降低，低血糖发生风险显著减少。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "GLP-1受体激动剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利拉鲁肽", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列美脲", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "利拉鲁肽"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列美脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "中国2型糖尿病患者餐后高血糖管理专家共识", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "国内外研究证明，对患者进行糖尿病DSME，包括健康饮食、规律运动、正确服药、充足的社会支持等，能提高患者对饮食控制、血糖监测、检查足部的依从性，有效降低患者的体重、血糖、糖化血红蛋白，提高生活质量。中华医学会糖尿病学会等学术组织积极推动各级医疗机构普及糖尿病教育，有些地区糖尿病DSME/S现已被纳人到医疗门诊及社区卫生服务中心常规诊疗项目。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "DSME", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "健康饮食", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "规律运动", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "社会支持", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖监测", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "糖化血红蛋白", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足部", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "DSME/S", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "加强健康教育，提高患者自我护理能力。积极控制高血压和高脂血症，改变生活方式，控制体重，避免吸烟和过度饮酒。早期发现空腹血糖受损以及糖耐量异常的患者，并进行积极干预。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "改变生活方式", "subject_type": "非药治疗", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "控制体重", "subject_type": "非药治疗", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "避免吸烟和过度饮酒", "subject_type": "非药治疗", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "改变生活方式", "subject_type": "非药治疗", "object": {"@value": "高脂血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "控制体重", "subject_type": "非药治疗", "object": {"@value": "高脂血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "避免吸烟和过度饮酒", "subject_type": "非药治疗", "object": {"@value": "高脂血症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "在一项长达104周的对照临床研究中，与西格列汀(100mg/d)单药治疗相比，二甲双胍(2000mg/d)单药治疗使受试者平均HbA1c水平维持在7%以下的时间增加了约24周。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "100mg/d", "subject_type": "用药剂量", "object": {"@value": "西格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2000mg/d", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}]}
{"text": "胰岛素促泌剂是临床应用最早、最广泛的口服降糖药之一，降糖疗效肯定、安全性高、价格低廉、可与其他口服降糖药联用，在2型糖尿病(T2DM)治疗中占有重要地位，是多数国际权威人T2DM防治指南中的一线降糖药物。为了强调其重要性及正确认识和评价这一大类降糖药、中华医学会内分泌学分会于2011年讨论通过了《中国成人2型糖尿病胰岛素促泌剂应用的专家共识》，并于2012年正式表发。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病(T2DM)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "被代谢消除是维格列汀在人体内的主要清除途径，约占给药剂量的69.0%；其主要代谢产物(LAY151)没有药理活性，约有23.0%的维格列汀原形药物从肾脏中排泄。与正常健康受试者相比，维格列汀在轻度、中度和重度肾功能不全患者中的AUC均值分别增加1.4、1.7和2倍。对于中度或重度肾功能不全患者，维格列汀的峰浓度无明显增加，由于半衰期(TI/2)延长致使暴露水平增加约2倍，因此，对于中、重度肾功能不全患者，维格列汀50mgqd就可以维持24h对DPP-4的抑制作用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "维格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "维格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "维格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "50mg", "subject_type": "用药剂量", "object": {"@value": "维格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "qd", "subject_type": "用药频率", "object": {"@value": "维格列汀"}, "object_type": {"@value": "药品名称"}}]}
{"text": "ACEI及ARB应用于糖尿病肾病的一级预防治疗存在争议。一项临床试验研究将伴有高血压的2型DM患者分为群多普利组、维拉帕米组、群多普利联合维拉帕米组及安慰剂组，发现群多普利组及群多普利+维拉帕米组两组患者微量白蛋白尿的出现明显延迟，提示ARB对2型糖尿病患者微量白蛋白尿的发生可能具有一级预防作用。糖尿病视网膜坎地沙坦临床试验-肾脏研究(DIRECT-Renal)和肾素-血管紧张素系统研究(RASS)的结果却表明ACEI或ARB改善微量白蛋白尿、保护肾脏的作用并不明显。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "ACEI", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ARB", "subject_type": "药品名称", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "群多普利", "subject_type": "药品名称", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "维拉帕米", "subject_type": "药品名称", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "群多普利", "subject_type": "药品名称", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "维拉帕米", "subject_type": "药品名称", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "群多普利", "subject_type": "药品名称", "object": {"@value": "2型DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "维拉帕米", "subject_type": "药品名称", "object": {"@value": "2型DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "群多普利", "subject_type": "药品名称", "object": {"@value": "2型DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "维拉帕米", "subject_type": "药品名称", "object": {"@value": "2型DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ARB", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "坎地沙坦", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ACEI", "subject_type": "药品名称", "object": {"@value": "白蛋白尿"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ARB", "subject_type": "药品名称", "object": {"@value": "白蛋白尿"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.2 哪些情况下磺脲类药物可以作为治疗T2DM的一线选择?", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(4)原发疾病的病情评估：年龄、预期寿命、是否存在器官功能不全、精神或智力障碍、心脑血管疾病既往史和(或)风险程度、是否需重症监护、是否需进行手术、手术的类型(急症、择期、整形等精细手术、或器官移植手术)；患者的营养状态、进食情况(禁食、正常摄食,或胃肠外营养)等。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心脑血管", "subject_type": "患病部位", "object": {"@value": "心脑血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "【应对】与胰岛素或磺脲类药物联用时，要注意调整胰岛素或磺脲类药物剂量，加强血糖监测，避免低血糖发生。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "2015年4月，美国FDA对沙格列汀和阿格列汀提出警示，要求在说明书中增加对心力衰竭风险的标示。TECOS研究显示，在有心血管病史的T2DM患者中，西格列汀不增加心力衰竭住院风险，维格列汀的相关研究证据尚不充分.。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "沙格列汀", "subject_type": "药品名称", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿格列汀", "subject_type": "药品名称", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西格列汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "维格列汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4. 高危人群管理：一级亲属中有HUA或痛风患者、久坐、高嘌呤高脂饮食等不良生活方式者，存在性疾病(如糖代谢异常、血脂紊乱、非酒精性脂肪肝等)、脑血管疾病(如高血压、冠心病、心力衰竭、卒中等)以及慢性肾脏病(定义及分期见附件5)等高危人群建立定期筛查方案，普及HUA和痛风医学知识，提高人群防治意识，定期监测血尿酸水平，尽早发现并诊治HUA或痛风。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "非酒精性脂肪肝"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脑血管", "subject_type": "患病部位", "object": {"@value": "脑血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸水平", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸水平", "subject_type": "检查指标", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "因此，当前各糖尿病指南中虽然建议T2DM患者需全面控制血脂，但LDL-C仍是首要的", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "附件3 1977年美国风湿病学会(ACR)急性痛风性关节炎分类标准", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "关节", "subject_type": "患病部位", "object": {"@value": "急性痛风性关节炎"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "相比于其他降糖药物类别，胰岛素的成员最多，临床应用也各不相同，所以需要分开介绍。在这里我们将分为1型糖尿病与2型糖尿病、餐时/基础/预混胰岛素来看看相应的指南/共识是怎么说的。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "预混胰岛素", "subject_type": "药品名称", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "预混胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)当调整为预混胰岛素类似物每日2次或每日3次治疗时，不建议同时使用胰岛素促泌剂(主要不良反应与胰岛素一致，为低血糖和体重增加)；", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "每日2次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日3次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "胰岛素促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "治疗前对糖尿病足患者进行正确的分类和分级，有助于选择合理的治疗方案和判断预后。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)如果预混胰岛素从每日2次增加至每日3次时，建议将预混人胰岛素改为预混胰岛素类似物；", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "每日2次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日3次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "推荐在痛风发作12h内尽早使用，超过36h后疗效显著降低。起始负荷剂量为1.0mg口服，1h后追加0.5mg，12h后按照0.5mg，1～3次／d。使用细胞色素P4503A4酶或磷酸化糖蛋白抑制剂者(如环孢素A、克拉霉素、维拉帕米、酮康唑等)避免使用秋水仙碱。秋水仙碱不良反应随剂量增加而增加，常见有恶心、呕吐，腹泻、腹痛等胃肠道反应，症状出现时应立即停药；少数患者可出现肝功能异常，转氨酶升高，超过正常值2倍时须停药，肾脏损害可见血尿、少尿、肾功能异常，肾功能损减量。eGFR35~49ml·min-1·1.73m-2时每日最大剂0.5mg；eGFR10~34ml·min-1·1.73m-2时每次最大剂0.5mg，隔日1次；eGFR<10ml·min-1·1.73m-2或透析患者禁用。秋水仙碱可引起骨髓抑制，使用时注意监测血常规。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "恶心", "subject_type": "不良反应", "object": {"@value": "秋水仙碱"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "呕吐", "subject_type": "不良反应", "object": {"@value": "秋水仙碱"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "腹泻", "subject_type": "不良反应", "object": {"@value": "秋水仙碱"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "腹痛", "subject_type": "不良反应", "object": {"@value": "秋水仙碱"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道反应", "subject_type": "不良反应", "object": {"@value": "秋水仙碱"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "骨髓抑制", "subject_type": "不良反应", "object": {"@value": "秋水仙碱"}, "object_type": {"@value": "药品名称"}}]}
{"text": "T2DM患者往往需要长期降胆固醇治疗，而不依从用药占据治疗失败的30%~50%，并导致各种不良后果，包括增加住院率和医疗费用等。因此，在T2DM患者就诊时应评估其生活方式干预及药物治疗的依从性，发现其(可能)存在的问题、障碍或不良反应，并将血脂水平及控制目标等信息持续向惠者反馈。必要时组建多学科治疗团队，包括内分泌代谢病科医师、心血管病科医师、脑血管病科医师、营养专家、运动医学专家、护师、药剂师等，以帮助患者解决依从性问题。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "胆固醇", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血脂水平", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脑血管", "subject_type": "患病部位", "object": {"@value": "脑血管病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(3)HbA1c<8.5%：如有预期寿命<5年、完全丧失自我管理能力等情况，HbA1c的控制标准可放宽至<8.5%，尚需避免严重高血糖(>16.7mmol/L)引发的糖尿病急性并发症和难治性感染等情况发生。消除糖尿(血糖水平<11.1mmol/L)是老年糖尿病患者治疗的一个重要目标，有利于改善高血糖渗透性利尿(引起血容量减少，夜尿多等)和营养负平衡(尿糖排出)。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病急性并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "难治性感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "严重高血糖(>16.7mmol/L", "subject_type": "患病病因", "object": {"@value": "难治性感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "严重高血糖(>16.7mmol/L", "subject_type": "患病病因", "object": {"@value": "糖尿病急性并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "糖尿", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖水平", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "高血糖渗透性利尿", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "血容量减少", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "夜尿多", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "营养负平衡", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "尿糖", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "TZDs主要通过增加靶细胞对胰岛素作用的敏感性而降低血糖，可使HbA1c下降1.0%~1.5%，引起体重增加(主要为水钠潴留)。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "TZDs"}, "object_type": {"@value": "药品名称"}}]}
{"text": "在生理非进食状态下胰岛β细胞持续分泌的胰岛素被称为基础胰岛素，约占胰岛素全天分泌总量的50%。基础胰岛素通过抑制肝脏中肝糖原分解和糖异生作用而减少肝糖输出控制基础血糖。经皮下注射的外源性基础胰岛素药物具有和内源性基础胰岛素相似的特性，能模拟正常人体的生理性基础胰岛素作用。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "皮下注射", "subject_type": "用药方法", "object": {"@value": "基础胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "1.制定个体化的治疗目标：(1)长期血糖控制目标：一般而言，以反映最近2~3个月血糖控制情况的HbA1c为主要目标，兼顾空腹和餐后血糖达标(具体可参照《中国成人2型糖尿病Hbh1c控制目标的专家共识》，表3)。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "Hbh1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "肥胖与糖尿病外科手术开展的适应证及禁忌证均应参照《中国肥胖和2型糖尿病外科治疗指南(2014)》。针对肥胖伴有2型糖尿病的治疗，该版指南强调了胰岛功能储备，即T2DM病程小于15年，且空腹血清C肽水平高于正常值下限的二分之一。对于体质量指数(body mass index，BMI)介于25.0~27.5kg/m2的患者，即使合并T2DM及其他肥胖相关疾病，也应慎重开展手术。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "空腹血清C肽水平", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.尿白蛋白：微量白蛋白尿是糖尿病肾病早期的临床表现，也是诊断糖尿病肾病的主要依据。其评价指标为尿白蛋白排泄率(UAE/AER)或ACR。个体间UAE的差异系数接近40%，与之相比ACR更加稳定且检测方法方便，只需要检测单次随机晨尿即可，故推荐使用ACR。尿白蛋白排泄异常的定义见表1，因尿白蛋白排泄受影响因素较多，需在3-6个月内复查，3次结果中至少2次超过临界值，并且排除影响因素如24h内剧烈运动、感染、发热、充血性心力衰竭、明显高血糖、怀孕、明显高血压、尿路感染，可作出诊断。然而，尿白蛋白对诊断2型糖尿病肾病的特异性不足，对预测病情的转归也存在局限性。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "白蛋白尿", "subject_type": "临床表现", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿白蛋白排泄率(UAE/AER)", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "ACR", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "充血性", "subject_type": "分期分型", "object": {"@value": "充血性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "充血性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿白蛋白", "subject_type": "检查指标", "object": {"@value": "2型糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "2型糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.药物治疗：尽管成人2型糖尿病有多种药物可供选择，但在儿童青少年，世界上大部分地区仅批准二甲双胍和胰岛素应用。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "磺脲类药物单药治疗血糖控制不佳时，联合噻唑烷二酮类药物治疗可以进一步改善血糖，减轻胰岛素抵抗。随机、双盲、安慰剂对照研究结果显示，患者使用罗格列酮4mg联合磺脲类药物和罗格列酮8mg联合磺脲类药物治疗24周，HbA1c分别下降1.04%和1.44%，空腹血糖分别下降1.2mmol/L和2.0mmol/L，血中胰岛素水平较基线分别下降23.3pmol/L和30.4pmol/L，但患者体重增加更明显。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "4mg", "subject_type": "用药剂量", "object": {"@value": "罗格列酮"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "24周", "subject_type": "持续时间", "object": {"@value": "罗格列酮"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加更明显", "subject_type": "不良反应", "object": {"@value": "罗格列酮"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "24周", "subject_type": "持续时间", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加更明显", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "8mg", "subject_type": "用药剂量", "object": {"@value": "罗格列酮"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "24周", "subject_type": "持续时间", "object": {"@value": "罗格列酮"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加更明显", "subject_type": "不良反应", "object": {"@value": "罗格列酮"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "24周", "subject_type": "持续时间", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加更明显", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "饮食管理处方内容包括：(1)糖尿病饮食治疗的基本原则：概述总热量控制、合理搭配饮食结构、体重管理、合理分餐、食物多样化、烹调方式、甜味剂等。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "饮食治疗", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "CCMR-3B研究真实地反映了当前我国T2DM患者血脂异常患病及控制情况，并提示临床上应加强对T2DM患者的血脂管理。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "a.西格列汀在上市后发现有严重超敏反应，包括过敏反应、血管性水肿和脱性皮肤损害，包括Stevens-Johnson综合征。如怀疑发生超敏反应，应停止使用。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "严重超敏反应", "subject_type": "不良反应", "object": {"@value": "西格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "过敏反应", "subject_type": "不良反应", "object": {"@value": "西格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "血管性水肿", "subject_type": "不良反应", "object": {"@value": "西格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "脱性皮肤损害", "subject_type": "不良反应", "object": {"@value": "西格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "Stevens-Johnson综合征", "subject_type": "不良反应", "object": {"@value": "西格列汀"}, "object_type": {"@value": "药品名称"}}]}
{"text": "1 我国糖尿病微血管并发症的流行病学现状及卫生经济负担 ", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "对于神经病变型，目前除治疗神经病变外，重要的是患肢减压，局部清创可促进溃疡愈合；而对于缺血型病变则可以通过药物治疗，运动锻炼和重建下肢血流的方法，取得一定疗效；即使混合型病变，如果血流得到改善，其神经病变也可得到部分缓解。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "神经病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)老年糖尿病患者：老年糖尿病患者病情复杂，病程较长，对低血糖的感知和耐受性差，慢性并发症常见，尤其是心血管疾病以及认知功能障碍等，因此，应加强对多重危险因素的管理。有研究显示，老年糖尿病患者的血糖波动存在性别差异，女性高于男性，此外，糖尿病病程、HbA1c水平也是老年2型糖尿病患者血糖波动的重要影响因素。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "以下情况可给予胰岛素单药治疗，亦可给予口服药和胰岛素联合应用：(1)新诊断2型糖尿病患者，HbA1c≥9.0%且糖尿病症状明显；(2)在采用有效的生活方式干预及2种或2种以上口服降糖药物次大剂量治疗3个月后血糖仍不达标(HbA1c≥7.0%)的患者；(3)病程中出现无明显诱因的体重下降者。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "47项RCTs研究的荟萃分析显示，与安慰剂或活性对照药相比，SUs不增加T2DM患者全因死亡、心血管死亡、心肌梗死及卒中的风险.。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "SUs", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管死亡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "尿酸性肾石症治疗可采用排石疗法、体外冲击波碎石和／或手术治疗。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "尿酸性肾石症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "排石疗法", "subject_type": "非药治疗", "object": {"@value": "尿酸性肾石症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "体外冲击波碎石", "subject_type": "非药治疗", "object": {"@value": "尿酸性肾石症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病已成为严重威胁国人健康的最重要的慢性非传染性疾病之一，但糖尿病控制状况在我国并不容乐观，甚至按纵向比较，血糖控制情况亦无显著改善。2011年公布现状调查显示口服药联合胰岛素治疗的患者中85%HbA1c控制未达标(≥7.o%)糖尿病相关治疗费用中约80%用于糖尿病并发症的治疗。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "目前在中国，西格列汀、维格列汀、阿格列汀和沙格列汀已获批了单药治疗的适应证，可用于饮食和运动治疗基础上不能良好控制血糖的2型糖尿病患者。国外研究也显示利格列汀对绝大多数2型糖尿病患者有明显降低血糖的效果。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "西格列汀", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "维格列汀", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿格列汀", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "沙格列汀", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食", "subject_type": "非药治疗", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "运动治疗", "subject_type": "非药治疗", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利格列汀", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.确诊时：为新确诊的糖尿病患者制定自我管理处方之前应进行全面的自我管理能力及其影响因素(如文化因素、健康信仰、经济状况、读写能力等)的评估，关注并解答糖尿病诊断相关问题并给予情感支持。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "给予情感支持", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.神经传导速度(nerve conduction velocity，NCV) ：过去被认为是DPN诊断的“金标准”，通常认为有两项或以上NCV减慢者结合其他症状体征及辅助检查可考虑存在DPN。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "神经传导速度(nerve conduction velocity，NCV)", "subject_type": "检查方法", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "NCV", "subject_type": "检查方法", "object": {"@value": "DPN"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.多饮水：建议患者每日饮水量2000ml以上，可促进尿酸排泄并预防尿路结石。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "多饮水", "subject_type": "非药治疗", "object": {"@value": "尿路结石"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "尿路结石"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "随着互联网技术的发展、医疗软件的开发利用以及智能手机、平板电脑等移动终端的普及，基于互联网的系统管理模式逐渐用于糖尿病患者血糖管理，通过信息技术合理配置医疗资源，提高医疗资源的利用率。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "生活方式干预作为基础治疗，是一种囊括营养、运动、认知-行为及心理多方面的综合干预模式。认知-行为及心理干预是通过调整超重和肥胖患者的生活环境及心理状态，帮助患者理解和认识体重管理、肥胖及其危害，从而做出行为改变。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "认知-行为及心理干预", "subject_type": "非药治疗", "object": {"@value": "超重"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "认知-行为及心理干预", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(5)药物相互作用：①氨氯吡咪、地高辛、吗啡、普鲁卡因胺、奎尼丁、奎宁、雷尼替丁、氨苯蝶啶、甲氧苄氨嘧啶和万古霉素等药物会影响肾功能或二甲双胍分布，因此建议密切监测血糖并调整二甲双胍和/或其他药物的剂量。②同时服用噻嗪类药物或其他利尿剂、糖皮质激素、吩噻嗪、甲状腺制剂、雌激素、口服避孕药、苯妥英、烟碱酸、拟交感神经药、钙离子通道阻滞剂和异烟肼等可引起血糖升高的药物时，也应密切监测血糖，这些药物停用后，则要密切注意低血糖。③二甲双胍有增加华法林的抗凝血倾向。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "口服避孕药"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "抗凝血", "subject_type": "不良反应", "object": {"@value": "华法林"}, "object_type": {"@value": "药品名称"}}]}
{"text": "根据NKF-K/DOQI指南、NHS等标准，强调白蛋白尿是2型糖尿病肾脏病变诊断的必要依据，但不能涵盖正常白蛋白尿的糖尿病肾病，忽略了GFR的诊断价值。考虑到ADA指南建议每年检测CKD，本共识提出糖尿病视网膜病变并CKD任何一期的诊断标准，避免遗漏那些白蛋白尿正常但eGFR下降的糖尿病肾病。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "2型糖尿病肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "eGFR", "subject_type": "检查指标", "object": {"@value": "白蛋白尿"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "eGFR", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(4)特殊情况：①尽管二甲双胍说明书上的禁忌一栏中列出了需要药物治疗的充血性心力衰竭，研究显示，二甲双胍本身并不会导致心衰，也不会对心衰患者造成不良影响，相反，甚至可能降低糖尿病患者心衰和死亡风险，提高伴心衰的糖尿病患者的存活率。所以，美国糖尿病协会(ADA)的糖尿病指南指出，如肾功能正常，二甲双胍可用于病情稳定的充血性心衰患者；欧洲版二甲双胍说明书中更是单春了慢性心衰的禁忌证。②年龄同样不是二甲双胍使用禁忌，而是要根据患者的肾功能情况而定，由于随着年龄增长，肾功能会逐渐下降，高龄患者使用二甲双胍时需定期监测肾功能。③二甲双胍可用于10岁及以上的2型糖尿病儿童青少年，且最高剂量不超过2000毫克/天，目前暂不推荐用于10岁以下的患儿④虽然国际多个学术组织推荐二甲双胍可用于妊娠糖尿病患者，但由于目前国内证据缺乏，我国药监部门尚未批准二甲双胍用于妊娠妇女。⑤尽管二甲双胍不经肝脏代谢，无肝脏毒性，但建议血清转氨酶超过3倍正常上限或有严重肝功能不全的患者避免使用二甲双胍，血清转氨酶轻度升高者使用时应密切监测肝功能。⑥二甲双胍本身不会对肾功能有影响，随着教育普及，公众对二甲双胍伤肾的错误认识已经得较普遍的纠正，近年来国内外的各大指南都将二甲双胍的使用范围放宽至轻中度肾功能不全患者，但中度肾功能不全患者应减少用量并停用治疗恶心、呕吐及脱水的药物。⑦肾功能正常者在造影前不必停用二甲双胍，但使用造影剂后应在医生的指导下停用48~72小时，复查肾功能正常后可继续用药；而肾功能异常者在使用造影剂及全身麻醉术前48小时时应暂停二甲双胍，之后还需停药48~72小时，复查肾功能正常后可继续用药。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "充血性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心衰"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心衰"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心衰"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "充血性心衰"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "慢性心衰"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2000毫克/天", "subject_type": "用药剂量", "object": {"@value": "二甲双胍"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "妊娠糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "造影剂", "subject_type": "药品名称", "object": {"@value": "肾功能异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "全身麻醉", "subject_type": "临床手术", "object": {"@value": "肾功能异常"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "大部分DPP-4抑制通过肾脏排泄，因此DPP-4抑制剂的暴露浓度会随着肾功能下降而相应的增加。药物说明书和国内外指南认为西格列汀、沙格列汀、维格列汀以及阿格列汀在轻度肾功能不全的患者中不需要调整剂量，但对于中到重度肾功能不全的患者需要减少剂量，利格列汀不需要调整剂量。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "维格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "沙格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "SGLT-2抑制剂在轻中度肝功能不全时也可使用。由于在重度肝功能不全的2型糖尿病患者中使用数据有限。欧美国家的药物说明书中均不推荐用于重度肝功能不全患者。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "SGLT-2抑制剂", "subject_type": "药品名称", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "DPP研究随访显示，生活方式干预组和二甲双胍治疗组与安慰剂组相比，10年内糖尿病病发生率分别降低了34%和18%(Ⅰ级)。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "②剂量调整方案：剂量调整是胰岛素治疗中至关重要的一环，起始基础胰岛素治疗后，需根据FPG，在避免低血糖的情况下及时调整胰岛素剂量。只有通过积极的剂量调整，才能获得有效的血糖控制。多数患者长效胰岛素类似物剂量达到约0.5U/(kg·d)前，可通过继续调整剂量控制血糖，而无需调整治疗方案。在血糖未达到设定的血糖目标值前，建议患者在医生指导下，根据FPG，每周调整2~6U基础胰岛素直至FPG达标。对于能进行血糖监测、感知低血糖、进行自我管理的患者，医生可指导其进行简便易行的自我胰岛素剂量调整，每3天调整2~3U直至FPG达标(表4)。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "0.5U/(kg·d)", "subject_type": "用药剂量", "object": {"@value": "长效胰岛素类似物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2~6U", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2~3U", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "由于GLP-1RA可显著降低患者体重，对于超重/肥胖的2型糖尿病患者，建议GLP-1RA用于超重/肥胖患者的降糖治疗。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "GLP-1RA", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "格列酮类：包括罗格列酮和吡格列酮，增加胰岛素敏感性作用明确，有延缓糖尿病进程和较长时间稳定血糖的临床疗效。但有增加体重、水肿、加重心力衰竭、骨折的风险，在老年人中的应用还存在一定的负面影响(A)。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "格列酮类", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "罗格列酮", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "吡格列酮", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "为进一步规范中国儿童青少年2型糖尿病的诊断、分型，治疗、随访，并发症和合并症的评估及治疗，由中华医学会儿科学分会内分泌遗传代谢学组组织专家讨论，并参考国内外的最新指南，包括美国糖尿病协会(American Diabetes Association)指南，美国儿科协会(American Academy of Pediatries)指南，国际儿童青少年糖尿病协会(International Society for Pediatric and Adolescent Diabetes)指南，美国临床内分泌协会(American Association of Clinical Endocrinolo gists) 指南，加拿大糖尿病协会(Canadian Diabetes Association)指南，中华医学会糖尿病学分会指南等，同时结合国内外流行病学调查、临床研究成果，制订如下共识。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "25项Ⅲ期临床试验的荟萃分析显示，与安慰剂或活性对照药相比，维格列汀不增加T2DM患者心脑血管事件风险，其中50mg/d组的相对风险为0.88(95%CI 0.37~2.11)、100mg/d组的相对风险0.84(95%CI 0.62~1.14).。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "50mg/d", "subject_type": "用药剂量", "object": {"@value": "维格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "100mg/d", "subject_type": "用药剂量", "object": {"@value": "维格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "维格列汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心脑血管", "subject_type": "患病部位", "object": {"@value": "心脑血管事件"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "多项研究表明，亚裔不仅胰岛β细胞胰岛素分泌储备能力较西方白种人低，糖脂毒性及氧化应激等对β细胞毒害作用亦更为显著。因此，中国2型糖尿病患者应适时启动胰岛素治疗。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "所有大样本随机对照研究都证实强化治疗使低血糖的发生率明显增加，虽然严重低血糖事件发生率少，但对UKPDS、前瞻性吡格列酮对大血管事件影响的临床研究(PROactive)、ADVANCE、VADT和ACCORD五大临床研究的meta分析显示强化治疗组的严重低血糖发生率为2.3%，常规治疗组为1.2%，可见，强化治疗增加低血糖发生率是不可避免的。但是，如前面所述，低血糖除了直接造成相应的严重临床后果外，频繁或严重的低血糖影响糖尿病患者的治疗。调查表明患者一旦出现频繁或严重的低血糖会明显降低患者对血糖控制达标的积极性。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "吡格列酮", "subject_type": "药品名称", "object": {"@value": "大血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "大血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.二甲双胍是否只是超重/肥胖T2DM患者的首选用药：回顾性和前瞻性临床研究结果均显示，二甲双胍在正常体重/超重/肥胖T2DM患者中的疗效相当(I级)。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "推荐GLP—1RA作为2型糖尿病患者的二线治疗择之一。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "GLP—1RA", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "中国糖尿病足诊治指南 ", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.糖尿病病史较短、预期寿命较长、没有并发症的患者，在不发生低血糖的情况下可考虑将HbA1c控制在6.5%以下。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "T2DM患者的脂代谢异常与胰岛素抵抗和腹型肥胖等代谢综合因素有关。导致患者血脂异常的主要原因是由于胰岛素作用不足、胰岛素抵抗等所致的极低密度脂蛋白(VLDL)、TG的产生过多和清除缺陷。T2DM患者的血脂谱以混合型血脂紊乱多见，其特征性的血脂谱包括：空腹和餐后TC水平升高，即使在空腹血糖和TG水平控制正常后往往还存在餐后高TG血症；HDL-C水平降低；血清TC水平和LDL-C正常或轻度升高，且LDL-C发生质变，小而致密的LDL-C水平升高。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "脂代谢异常", "subject_type": "发病机制", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "腹型肥胖", "subject_type": "患病病因", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素抵抗", "subject_type": "发病机制", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂谱", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "空腹和餐后TC水平", "subject_type": "检查指标", "object": {"@value": "高TG血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "空腹血糖", "subject_type": "检查指标", "object": {"@value": "高TG血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "TG水平", "subject_type": "检查指标", "object": {"@value": "高TG血症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "慢性肾脏病(CKD)是严重威胁人类健康的常见慢性病，病因多种多样，由糖尿病所引发的肾脏病称为糖尿病肾脏病(DKD)。T2DM常合并CKD，高血糖是CKD发展的主要原因之一，降糖治疗至关重要。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病(CKD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "糖尿病", "subject_type": "患病病因", "object": {"@value": "肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "糖尿病肾脏病(DKD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "高血糖", "subject_type": "患病病因", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)NSAIDs：包括非选择性环氧化酶(COX)抑制剂COX-2抑制剂两种，若无禁忌推荐早期足量使用NSAIDs速效制剂。非选择性COX抑制剂主要存在消化道溃道溃疡，胃肠道穿孔、上消化道出血等胃肠道不良反应，对于不耐受非选择性COX抑制剂的患者可选用COX-2抑制剂，其胃肠道不良反应可降低50％；活动性消化道溃疡／出血，或既往有复发性消化道溃疡／出血病史者为所有NSAIDs使用禁忌症。COX-2抑制剂可能引起心血管事件的危险性增加，合并心肌梗死、心功能不全者避免使用。NSAIDs中使用过程中需监测肾功能，严重慢性肾脏病(G4～5期)未透析患者不建议使用。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "消化道溃道溃疡", "subject_type": "不良反应", "object": {"@value": "非选择性COX抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道穿孔", "subject_type": "不良反应", "object": {"@value": "非选择性COX抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "上消化道出血", "subject_type": "不良反应", "object": {"@value": "非选择性COX抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "胃肠道不良反应", "subject_type": "不良反应", "object": {"@value": "非选择性COX抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "心血管事件", "subject_type": "不良反应", "object": {"@value": "COX-2抑制剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "消化道", "subject_type": "患病部位", "object": {"@value": "活动性消化道溃疡／出血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "消化道", "subject_type": "患病部位", "object": {"@value": "复发性消化道溃疡／出血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "G4～5期", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.对合并糖尿病的患者，术前还应了解糖尿病类型、病程、目前的治疗方案、低血糖发作情况，特别是有无糖尿病并发症。合并糖尿病酮症酸中毒、高渗综合症是非急诊手术的禁忌。病程长的糖尿病患者可能并发冠心病等心脑血管疾病，且心肌缺血症状往往不典型、容易漏诊，应引起警惕。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心脑血管", "subject_type": "患病部位", "object": {"@value": "心脑血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌缺血"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "伏格列波糖可用于CKD1~3期患者；4~5期禁用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "伏格列波糖", "subject_type": "药品名称", "object": {"@value": "CKD1~3期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~3期", "subject_type": "分期分型", "object": {"@value": "CKD1~3期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "4~5期", "subject_type": "分期分型", "object": {"@value": "CKD1~3期"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "④妊娠患者：合并妊娠时可采用短效胰岛素、中效胰岛素或长效胰岛素进行方案组合，或使用胰岛泵治疗。目前经国家食品药品监督管理总局(CFDA)批准可用于妊娠糖尿病和糖尿病合并妊娠患者的胰岛素类似物制剂是门冬胰岛素和地特胰岛素。与2型糖尿病患者妊娠期间的情况类似，由于激素水平的变化，妊娠中后期胰岛素需要量，尤其是日间胰岛素需要量会增加，而随着胎盘娩出，拮抗胰岛素的激素及破坏胰岛素的酶急剧减少或消失，胰岛素需要量会快速减少，一般分娩后2~3天胰岛素可减量至原量的1/3~1/2。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "胰岛素类似物制剂", "subject_type": "药品名称", "object": {"@value": "妊娠糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "门冬胰岛素", "subject_type": "药品名称", "object": {"@value": "妊娠糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "地特胰岛素", "subject_type": "药品名称", "object": {"@value": "妊娠糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素类似物制剂", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "门冬胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "地特胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "6.对于注射胰岛素的患者，必须进行自我血糖监测。监测的频率取决于治疗的目标和方式[具体可参考：中国血糖监测临床应用指南(2011年版)]。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "对于格列喹酮治疗平均年龄60岁老年患者、近4年半的回顾性分析中，格列喹酮单药及联合治疗1年后，HbA1c下降1.7%，PPG下降6.38mmol/L，FPG下降4.45mmo/L(P<0.01)；另一项针对老年患者的研究显示格列喹酮在降糖的同时可有效改善尿蛋白排泄率(UAE)、β细胞功能指数(HOMA-β)(P<0.001)。以上两项研究的安全性分析显示格列喹酮长期应用低血糖发生人次较少且均为轻度低血糖，进食或调整药物剂量后好转，无低血糖昏迷。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列喹酮"}, "object_type": {"@value": "药品名称"}}]}
{"text": "下肢缺血表现：皮肤营养不良、肌肉萎缩，皮肤干燥弹性差，皮温下降，色素沉着，肢端动脉搏动减弱或消失，患者可合并有下肢间歇跛行症状。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "下肢", "subject_type": "患病部位", "object": {"@value": "下肢缺血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "皮肤营养不良", "subject_type": "临床表现", "object": {"@value": "下肢缺血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "肌肉萎缩", "subject_type": "临床表现", "object": {"@value": "下肢缺血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "皮肤干燥弹性差", "subject_type": "临床表现", "object": {"@value": "下肢缺血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "皮温下降", "subject_type": "临床表现", "object": {"@value": "下肢缺血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "色素沉着", "subject_type": "临床表现", "object": {"@value": "下肢缺血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "肢端动脉搏动减弱或消失", "subject_type": "临床表现", "object": {"@value": "下肢缺血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢", "subject_type": "患病部位", "object": {"@value": "下肢间歇跛行"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.生活方式干预与PCOS：临床研究显示，PCOS患者对富含碳水化合物、高血糖指数食物以及高饱和脂肪的食物摄入均显著增加；同时具有总能量摄入过高以及久坐的特点。一项系统性综述表明，对于PCOS患者，在减轻体重、改善胰岛素抵抗及高雄激素血症等方面，生活方式干预(饮食、运动和行为干预)比药物治疗更有效。研究表明，超重或肥胖的PCOS患者轻度体重减轻(减少5%~10%)即可使血清睾酮浓度下降，也可恢复正常的排卵周期，并提高妊娠成功率。因此，对于超重和肥胖的PCOS患者，建议首先进行生活方式干预(饮食和运动)以减轻体重。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食", "subject_type": "非药治疗", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "运动", "subject_type": "非药治疗", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "行为干预", "subject_type": "非药治疗", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血清睾酮", "subject_type": "检查指标", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "饮食", "subject_type": "非药治疗", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "运动", "subject_type": "非药治疗", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "二、糖尿病足与下肢动脉病变的流行病学 ", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢动脉", "subject_type": "患病部位", "object": {"@value": "下肢动脉病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "总之，糖尿病患者的血糖控制目标要因人而异，像GPEDM倡导的“量体裁衣”(tailoring)式管理血糖，有些患者可适当放宽，不要因为过分强调HbA1c达标或正常化增加患者低血糖和死亡风险。HbA1c受检测方法和血红蛋白、红细胞转换、年龄等诸多因素的影响，也不能反映瞬时血糖水平及血糖波动，常规开展HbA1c测定还有困难，且目前国内尚缺乏检测方法的标准化，因此必须充分结合血糖监测才能真正了解糖代谢的控制情况。HbA1c的监测可依据病情每3~6个月进行一次。应该依据病情、治疗方案的不同结合患者的经济、文化、对治疗的依从性、医疗条件等多种因素，制定个体化的降糖策略，达到安全平稳降糖。必须强调血糖以外的CVD风险因素如血压、血脂、体重以及促凝状态等控制，戒烟及生活方式干预对防止、延缓或减少糖尿病并发症的发生同样十分重要。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "CVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "CVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "CVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "戒烟", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "为防止慢性肾脏病患者降尿酸治疗时诱发痛风发作，治疗同时需预防性使用秋水仙碱。eGFR<10ml·min-1.73m-2或透析患者禁用，可考虑短期应用小剂量糖皮激素。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "秋水仙碱", "subject_type": "药品名称", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病患者血脂目标水平为低密度脂蛋白<2.6mmol/L(100mg/dl)，高密度脂蛋白>0.91 mmol/L.(35mg/dl) 甘油三酯<1.7mmol/L(150 mg/dl)。如果LDL水平过高，应尽可能控制血糖并进行饮食控制(饮食胆固醇<200mg/d，饱和脂肪占总热卡<7%，脂肪占总热卡<30%)，6个月内进行空腹血脂复查。10岁以上患者，如在医学营养治疗和生活方式改变后，低密度脂蛋白>4.1 mmol/L(160mg/dl)，或>3.4mmol/L(130mg/dl)伴1个或多个心血管病危险因素时可加用他汀类药物理想状态应低于2.6mmol/L(100mg/dl)。甘油三酯：如空腹>4.5mmol/L(400mg/dl)或非空腹>11.3mmol/L(1000mg/dl)即可开始药物治疗，以达到空腹<4.5mmol/L(400mg/dl)的目标。苯氧芳酸类为治疗高甘油三酯血症的首选药物，目前显示是安全有效的，但对儿童患者仍需谨慎使用。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血脂", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "低密度脂蛋白", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "高密度脂蛋白", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "甘油三酯", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "苯氧芳酸类", "subject_type": "药品名称", "object": {"@value": "高甘油三酯血症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(1)HUA与缺血性卒中：血尿酸水平升高，尤其>420μmol／L是卒中的独立危险因素。HUA促进卒中发生，是我国人群缺血性卒中的独立危险因素。此外对非卒中患者的长期随访发现，血尿酸水平的增高可能时女性患者无症状性脑梗死及预期卒中的重要血清学指标，提示控制血尿酸水平对女性HUA患者预防卒中发生可能更重要的意义。", "spo_list": [{"Combined": false, "predicate": "患病病因", "subject": "HUA", "subject_type": "患病病因", "object": {"@value": "卒中"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脑", "subject_type": "患病部位", "object": {"@value": "无症状性脑梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸水平", "subject_type": "检查指标", "object": {"@value": "无症状性脑梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸水平", "subject_type": "检查指标", "object": {"@value": "卒中"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸水平", "subject_type": "检查指标", "object": {"@value": "卒中"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2型糖尿病合并慢性肾脏病口服降糖药用药原则中国专家共识(2015年更新版)", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "若一线降药物单药治疗3个月不能使血糖控制达标，需考虑两种降糖药物联合治疗。根据患者的不同情况，选择个体化的联合用药方案。对于T2DM合并ASCVD患者，可优先考虑联合具有明确心血管获益证据的降常药物(如利拉鲁肽或恩格列净)治疗，", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利拉鲁肽", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "恩格列净", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利拉鲁肽", "subject_type": "药品名称", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "恩格列净", "subject_type": "药品名称", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "5.血糖监测及控制目标：2型糖尿病自身血糖监测频次对血糖控制的影响虽弱于1型糖尿病，但是仍不可缺少。自身血糖监测的频次应基于血糖控制情况和自身条件个体化，血糖控制理想时，1周数次餐前餐后血糖测量即可，而控制不理想时，应增加测量频次，如每日三餐前后加凌晨的血糖。如果使用胰岛素，一定要注意无症状低血糖的检测。糖化血红蛋白一般每3个月测1次，如未达标则需要强化治疗。美国糖尿病协会建议对于所有儿童糖尿病患者，推荐HbA1c目标<7.5%。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖监测", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖监测", "subject_type": "检查指标", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.餐后高血糖与糖尿病微血管并发症发生的风险增高相关：餐后高血糖比HbA1c能更好地预测DR的发生发展。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "DR"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "西格列汀大约79.0%从尿中排泄，中度肾功能不全的患者使用西格列汀后其血浆曲线下面积(AUC)约增加2倍，重度肾功能不全和终末期肾病的患者大约增加4倍：同时西格列汀可以少量被透析清除，因此为了达到与正常肾功能患者相似的血浆浓度，中、重度和终末期肾病患者需要减少药物剂量。推荐西格列汀用于GFR≥50ml.min-1.(1.73m2)-1的慢性肾脏病患者时无需调整剂量；GFR在30~50ml.min-1.(1.73m2)-1时减量至50mg，每日1次(qd)；GFR<30ml.min-1.(1.73m2)-1时减量至25mg，qd。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西格列汀", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "终末期肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "终末期", "subject_type": "分期分型", "object": {"@value": "终末期肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西格列汀", "subject_type": "药品名称", "object": {"@value": "终末期肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾功能", "subject_type": "检查方法", "object": {"@value": "终末期肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "透析", "subject_type": "非药治疗", "object": {"@value": "终末期肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "终末期", "subject_type": "分期分型", "object": {"@value": "终末期肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "终末期肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "50mg", "subject_type": "用药剂量", "object": {"@value": "西格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "25mg", "subject_type": "用药剂量", "object": {"@value": "西格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日1次(qd)", "subject_type": "用药频率", "object": {"@value": "西格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "qd", "subject_type": "用药频率", "object": {"@value": "西格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西格列汀", "subject_type": "药品名称", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}]}
